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Abstract 
ANGLIA RUSKIN UNIVERSITY 
ABSTRACT 
FACULTY OF SCIENCE AND TECHNOLOGY 
DOCTOR OF PHILOSOPHY 
ZINC IS AN INTRACELLULAR SECONDARY MESSENGER IN PLATELETS 
NIAZ SHAHED AHMED 
JANUARY 2019 
  
Zinc (Zn2+) is an essential trace element which regulates intracellular processes in multiple cell 
types. Whilst Zn2+ has been shown to be released from intracellular compartments of a variety of cell 
types in response to external stimuli, its role in platelets has yet to be confirmed. This work aimed to 
determine whether agonist-evoked activation of platelets induced changes in cytosolic zinc 
concentrations ([Zn2+]i) contributing to modulation of activatory processes in platelets, in a manner 
consistent with a secondary messenger. 
Fluorometry was used to assess intracellular Zn2+ [Zn2+]i changes via zinc-specific fluorophores. 
Fluctuations in [Zn2+]i were modulated using Zn2+-specific chelators and ionophores. Light transmission 
aggregometry, flow cytometry and western blotting were employed to assess the influence of [Zn2+]i 
on platelet function. 
 
Stimulation by CRP-XL or U46619 evoked increases in intraplatelet Fluozin-3 (FZ-3) 
fluorescence consistent with [Zn2+]i elevation. Increases in FZ-3 fluorescence were abrogated by Zn2+ 
chelators and were distinct from agonist-evoked [Ca2+]i signals. Fluctuations of [Zn2+]i induced by CRP-
XL or U46619 were sensitive to changes in platelet redox states. Sustained increases of [Zn2+]i were 
induced by the Zn2+ ionophores, Clioquinol or Pyrithione, which resulted in significant platelet shape 
change, integrin αIIbβ3 upregulation, dense granule but not α granule secretion and phosphatidylserine 
exposure. Chelation of [Zn2+]i also resulted in the inhibition of agonist-induced platelet activity. 
Furthermore, elevation of [Zn2+]i was also found to occur in a similar manner to [Ca2+]i elevation from 
stores within platelets in addition to redox state modulation.   
  
In conclusion, this is the first description of agonist-dependent increases in platelet [Zn2+]i, 
indicative of a role as a secondary messenger. The Zn2+ release is sensitive to mediators of the platelet 
redox state, and so may be attributable to release from oxidised thiol groups on Zn2+ -binding proteins. 
Modulation of [Zn2+]i  indicated a role for Zn2+ in platelet activatory processes. The rise in [Zn2+]i in 
response to CRP-XL and U46619 demonstrates the physiological importance of Zn2+, implying the 
importance to Zn2+ in platelet activation during thrombus formation. 
 
Keywords: Platelets, zinc, intracellular, redox-sensitive, ionophores, platelet activation 
 
iii 
 
Publications: 
Articles 
Ahmed NS, Lopes Pires ME, Taylor KA, Pugh N. 2019. 
Agonist-Evoked Increases in Intra-Platelet Zinc Couple to Functional Responses. 
Thrombosis and Haemostasis,119(1):128-139 
 
Iegre J, Ahmed NS, Gaynord JS, Wu Y, Herlihy KM, Tan YS, Lopes-Pires ME, Jha R, Lau YH, Sore 
HF, Verma C, O' Donovan DH, Pugh N, Spring DR. 2018 
Stapled peptides as a new technology to investigate protein-protein interactions in human platelets. 
Chemical Science,9(20):4638-4643 
 
Oral Communications 
Ahmed NS. Pugh N. Functional role of intracellular Zn2+ in platelets. 10th Annual student research 
conference, Anglia Ruskin University, Cambridge, UK, July 2016. 
Ahmed NS. Pugh N. The role of Zn2+ in platelets. Research Seminar, Anglia Ruskin University, 
Cambridge, UK, May 2017 
Poster Communications 
Ahmed NS, Taylor KA, Pugh N. Modelling intracellular Zn2+ in platelets. 3rd European platelet network 
(EUPLAN) conference. Bad Homburg vor der Höhe, Germany, September 2016  
Ahmed NS, Pugh N. Zn2+ is an intracellular secondary messenger in platelets. Cambridge 
cardiovascular 5th annual research symposium. Cambridge, April 2018 
Ahmed NS. Pugh N. Zn2+ regulates platelet shape change. 11th Annual student research conference, 
Anglia Ruskin University, Cambridge, UK, July 2017 
Ahmed NS. Pugh N. Redox dependent intracellular Zn2+ elevation in platelets. 12th Annual student 
research conference, Anglia Ruskin University, Cambridge, UK, July 2018. 
iv 
 
 
Declaration 
I declare that this work has not previously been submitted for the acceptance of any other degree or 
diploma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
 
Commonly used abbreviations 
ADP           Adenosine diphosphate   
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PEG-SOD   Polyethylene glycol-Superoxide dismutase 
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Chapter 1  
1.0 Introduction 
Cardiovascular diseases (CVD) including coronary heart disease, stroke and myocardial 
infarction, are the leading causes of mortality in the UK (GBD 2013 Mortality and Causes of Death 
Collaborators, 2015). However, as a result of extensive cardiovascular research and public awareness, 
the mortality rates due to CVD have declined over the past 30 years (Bhatnagar et al., 2016; Smolina 
et al., 2012). For example, mortality rates as a result of myocardial infarctions have dropped by 
approximately 4.8% in men and 9.1% in women on average annually since 2002 (Smolina et al., 2012). 
CVD is attributable to inappropriate haemostasis, which is the physiological process whereby elements 
of the circulatory system interact with damaged endothelium to form a stable thrombus to stop 
bleeding and maintain the integrity of the circulatory system (Berndt et al., 2014; Clemetson, 2012; 
Reininger, 2008a, Faure et al., 1995, Asselin et al., 1997). Inappropriate activation of the haemostatic 
response can occur leading to cardiovascular diseases such as myocardial infarctions and stroke 
(Kowalska et al., 1994). 
1.1 Haemostasis and Thrombosis 
Vascular injury exposes sub-endothelial matrix proteins including collagen, and von 
Willebrand factor (VWF) within the vessel to the circulation (Ferhat-Hamida et al., 2015). These 
proteins initiate a series of reactions known as the ‘haemostatic response’ that culminates in clot 
formation and the cessation of bleeding, resulting in the formation of a thrombosis (Gogia and 
Neelamegham, 2015).  
Haemostasis is dependent on the vessel wall, protein components in the blood (coagulation 
factors) and blood cells known as platelets (Li et al., 2010). Platelets adhere to sites of vascular injury, 
which become exposed as a result of damage to the endothelium. Platelets interact with these regions 
via membrane receptors and undergo a process of activation which results in many cellular responses 
(Mammadova-Bach et al., 2015). These include upregulation of the fibrinogen-binding receptor, 
integrin αIIbβ3, which upregulates platelet-platelet interactions leading to thrombus formation (Chari-
Turaga and Naik, 2011). Activation also results in the release of α-and dense-granules (Cai et al., 2016, 
Asselin et al., 1997) which contain adhesive proteins, coagulation factors and soluble platelet agonists. 
These include ADP andATP which mediate further platelet activation as well as recruiting circulatory 
2 
 
platelets and enhancing stable adhesion of the subendothelium (Kuwahara et al., 2002; Rahman et al., 
2016; Watson et al., 2016).  
The haemostatic process is subdivided into several stages. Following vascular injury, myogenic 
reflexes induce vasoconstriction which results in the narrowing of the lumen of the blood vessel. This 
vasoconstriction is an immediate effect to minimise blood flow to the area of injury, thus reducing 
blood loss (Clemetson, 2012). Following vasoconstriction, platelets are recruited and undergo 
activation, which leads to platelet aggregation and formation of a platelet plug to stop blood loss 
(Berndt et al., 2014; Clemetson, 2012). Subsequently, the coagulation phase is initiated, which 
reinforces the stable platelet plug allowing a stable long lasting clot to form (Abdollahi et al., 2013). 
Once the clot has formed, and the healing process is complete, fibrinolysis occurs which dissolves the 
clot via enzymatic reactions (Palta et al., 2014).  
1.2 Platelet physiology 
Platelets are small (typically 2-3μm in diameter) discoid anuclear blood cells that are central 
to haemostasis and thrombus formation. Platelets circulate in a resting state and become activated 
following vascular injury to form a platelet plug to prevent excessive bleeding. Platelet activation in 
the context of a ruptured atherosclerotic plaque or narrowed arteries may result in an occlusive 
thrombus causing a myocardial infarction or ischaemic stroke. Platelets are generated from 
megakaryocytes (MKs) in the bone marrow (Machlus and Italiano, 2013). As megakaryocytes mature 
they migrate from the osteoblastic to the vascular niche in the bone marrow. MKs align with the 
venous sinusoid, where they project pro-platelet extensions into the circulation where platelets are 
released (Harker and Finch, 1969; Italiano et al., 1999; Jackson and Edwards, 1977; Nakeff and Maat, 
1974; Pease, 1956; Richardson et al., 2005). The lifespan of human platelets once released into the 
bloodstream generally ranges from 7-10 days (Aster, 1967). The normal circulating level of platelets 
ranges from 150x109/L to 400x109/L (Daly, 2011).  
Platelets undergo activation in response to several agonists such as collagen, thrombin, 
thromboxane A2 and ADP. These agonists induce downstream intracellular signalling via stimulation 
of specific platelet receptors. Figure 1.1 below illustrates a general overview of platelet activation via 
the major platelet agonists. A hallmark of platelet activation is phospholipase C-mediated elevation of 
intracellular Ca2+ ([Ca2+]i) via mobilisation from intracellular stores.  
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Figure 1.1. Schematic illustrating general overview of agonist evoked platelet activation. Major platelet agonists including 
collagen, thrombin, thromboxane A2 and adenosine diphosphate (ADP) induce activation via stimulation of their cognate 
receptors. The primary platelet collagen receptor is glycoprotein VI (GpVI), whereas thrombin, thromboxane A2 and ADP 
stimulate G protein-coupled receptors (GPCRs). Thrombin stimulates protease-activated receptor (PAR) 1 and 4; 
thromboxane A2 stimulates the thromboxane receptor (TP); ADP stimulates the Purinergic (P2Y) receptors P2Y1 and P2Y12. 
Activation by these agonists results in the mobilisation of Ca2+ from its store via the activation of phospholipase C. Elevation 
of [Ca2+]i is well documented as a hallmark of platelet activation. Many activatory processes are thought to be regulated by 
[Ca2+]I elevated in response to agonists.  
 
 
1.2.1 Initiation of platelet activation 
Platelet activation is a progressive process which is initiated by interactions with VWF, 
followed by collagen-induced activation via the GpVI receptor as illustrated by Figure 1.2 below. 
Platelet activation can also be evoked upon stimulation of G protein-coupled receptors (GPCRs) found 
on platelets such as protease-activated receptors (PAR) 1 and 4, thromboxane receptor (TP) and the 
Purinergic (P2Y) receptors P2Y1 and P2Y12. 
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Figure 1.2. Representation of platelet activation during haemostasis. 1) Circulating platelets are maintained in their resting 
state by the actions of nitric oxide (NO) and Prostacyclin (PGI2) which are released from the endothelial cells. 2) Vascular 
injury to blood vessel results in the exposure of the subendothelial matrix, where Von Willebrand factor (VWF) and collagen 
are present. Circulating platelets interact with the VWF via the membrane receptor complex, glycoprotein Ib/V/IX (GPIb-V-
IX). 3) Platelets become tethered to VWF, resulting in platelets transiently interacting (rolling) along the sub-endothelium. 
GpVI receptors on the platelet surface bind to the exposed collagen initiate intracellular signalling pathways leading to 
platelet activation. 4) Activated platelets undergo a shape change and granule release and begin externalising phosphatidyl-
serine (PS) on their surfaces. 5) The contents of the alpha and dense granules activate surrounding platelets. 6) Activated 
platelets are recruited to enable platelet aggregation. 7) Integrin αIIbβ3 becomes activated as a result of inside-out signalling, 
enabling fibrinogen to crosslink the activated platelets, culminating in platelet aggregation. 8) Coagulation then occurs, as 
thrombin formation is promoted from the coagulation factors which assemble on PS-rich platelet surface. Thrombin then 
cleaves fibrinogen to form fibrin which associates to form fibrin meshwork. This results in the generation of a stable 
thrombus. 
1.2.2 Primary platelet adhesion to collagen 
Vascular injury results in damage to endothelial cells, which results in exposure of the 
subendothelial extracellular matrix (Stalker et al., 2012). Platelets subsequently recognise and bind to 
exposed sub-endothelial matrix proteins. VWF is an adhesive glycoprotein which is released from 
activated endothelial cells or is exposed upon injury to become immobilised on fibrillar collagen within 
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the matrix via its A3 domain (Reininger, 2008). Shear stress which regulates VWF activity is the result 
of tangential forces in the direction of the blood flow, which occurs due to the occurrence of a pressure 
gradient that occurs when blood flows through vessels (Gogia and Neelamegham, 2015). Shear stress 
induces structural changes of the VWF domains, enabling activation of these domains (O’Brien and 
Salmon, 1987). The binding of VWF to platelet receptors and proteins and endothelial cells is also 
regulated by shear stress (Dayananda et al., 2010; Gogia and Neelamegham, 2015; Kroll et al., 1996). 
 VWF regulates the initial adherence of platelets to the damaged vessel in the initial stages of 
platelet plug formation. VWF crosslinks collagen to platelets via the platelet glycoprotein Ib/V/IX 
(GPIb/V/IX) (Peyvandi et al., 2011) which, unlike other platelet receptors, does not require pre-
activation for binding. Binding of GPIbα to VWF is transient. However, this transient interaction 
enables lower affinity platelet receptors to engage their cognate ligands, resulting in a stronger 
adhesion reaction, and the initiation of intracellular signalling (Hoylaerts, 1997; Wu et al., 2000).  
The adhesion of platelets to collagen is a critical step for inducing the formation of a thrombus. 
There are different types of collagen on the vessel wall. Types I, III and V are crucial in regulating 
platelet adhesion to the damaged vessel wall and have high affinity to VWF (Marjoram et al., 2014). 
Collagen type IV is a sheet-forming collagen and has also been found to regulate adhesion of platelets 
to the damaged vessel wall (Henrita van Zanten et al., 1996). The A3 domain is the major binding 
domain of VWF which binds to collagen. However, Collagen type IV has also been found to bind the 
A1 domain of VWF under high shear stress, indicating the importance of the other domains of VWF 
for collagen binding (Flood et al., 2015; Ferhat-Hamida et al., 2015; Brondijk et al., 2012). The activity 
of collagen type IV is modulated by cations such as Mg2+ in platelets (Henrita van Zanten et al., 1996). 
Although the exact mechanism by which cations influence collagen type IV is yet to be confirmed, this 
provides scope for investigating possible roles of Zn2+ in this process. Collagen binds to collagen 
receptors on the platelet surface, of which two have been characterised: GpVI and integrin α2β1. 
Engagement through these receptors ensures platelet activation and subsequent stable adhesion 
(Gardiner and Andrews, 2014). The interaction between α2β1 and GpVI and their cognate ligands are 
synergistic and dependent on the presence of high-affinity binding motifs in the exposed collagen 
molecule (Pugh et al., 2010). Engagement of GpVI results in the initiation of downstream signals that 
result in a number of cellular effects that constitute platelet activation (Carrim et al., 2014).  
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1.2.3 Platelet activation via Glycoprotein VI signalling 
A member of the immunoglobulin superfamily member, Glycoprotein VI (GpVI) consists of a 
C terminus, a single transmembrane domain and two immunoglobulin domains located on its 
extracellular face (Asselin et al., 1997; Diaz-Ricart et al., 2008). GpVI couples to the Fc receptor γ chain 
(FcγR) via a salt bridge. The FcγR is a receptor for the fragment crystallizable region of 
immunoglobulins (Arman and Krauel, 2015; Hayes et al., 2016; Poole et al., 1997). FcγR contains an 
immunoreceptor tyrosine-based activation motif (ITAM) in the cytoplasmic domain (Gibbins et al., 
1996; Poole et al., 1997; Watson et al., 2005). Collagen motifs consisting of glycine-proline-
hydroxyproline repeats bind to the immunoglobulin domains of GpVI, resulting in receptor 
dimerisation (evoking clustering of the receptor) and the initiation of a downstream signalling cascade 
( Figure 1.3, Bella and Hulmes, 2017; Gibbins et al., 1996, 1997; Nieswandt and Watson, 2003). 
Following adhesion, members of the Src family kinases (SFK, predominantly Fyn and Lyn, which are 
bound to the proline-rich region of the GpVI cytoplasmic tail) are able to interact with Src homology 3 
(SH3) domains and come into proximity with the ITAM motif where phosphorylation of tyrosine 
residues of this motif takes place (Gambaryan et al., 2010; Li et al., 2010). ITAM phosphorylation 
results in the binding and activation of the tyrosine kinase, Syk. Syk activation occurs via 
autophosphorylation following interaction with SH2 domains which enables Syk to be recruited to the 
ITAM motif. The transmembrane adapter linker for activated T-cells (LAT) then associates with the 
developing signalling complex (a signalosome), resulting in the recruitment and activation of other 
signalling proteins, most significantly PLCγ2 which result in the mobilisation of Ca2+ from its store in 
platelets which as stated earlier is e hallmark of platelet activation (Asselin et al., 1997; Li et al., 2010; 
Smith et al., 1992). The cytosolic adaptor proteins Mona/Grap2,GrpL/Grf40 (GADs) and SH2 domain 
containing leukocyte protein of 76kDa (SLP76) have also been found be within the core (alongside 
LAT) of the signalosome induced following Syk activation which mediate activation of PLCγ2 (Judd et 
al., 2002; Pasquet et al., 1999).  
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Figure 1.3. Glycoprotein VI (GpVI) signalling. Engagement of GpVI evokes tyrosine phosphorylation of ITAM motifs of FcγR. 
The Src family kinases, Fyn and Lyn which are bound to the proline-rich tail of GpVI and recruited to the ITAM via interaction 
by SH3 domains, induce the phosphorylation of the ITAM. This is followed by phosphorylation of Syk, which is recruited to 
the ITAM via interactions with SH2 domains. Syk-induced signalling is initiated, resulting in the formation of a signalosome 
which consists of adaptor and effector proteins. Within this signalosome, the transmembrane adapter linker for activated T-
cells (LAT) and cytosolic adapter proteins Mona/Grap2, GrpL/Grf40 (GADs) and SH2 domain containing leukocyte protein of 
76kDa (SLP76) induce the activation of PLCγ2, which enables Ca2+ mobilisations from its store and thereby inducing platelet 
activation. 
Due to its importance in platelet activation, GpVI has been identified as an antithrombotic 
target. Fibrillar collagen strands commonly consist of proline and hydroxyproline repeats, with glycine 
at every third residue to enable folding and a triple helix conformation of the strand (Prockop and 
Kivirikko, 1995). Potent agonists identified as crosslinked collagen-related peptide (CRP-XL) that adopt 
the collagen conformation have been synthesised to activate the GpVI receptors (Smethurst et al., 
2007). Collagen-related peptides (CRP) mimic the triple helix structure of collagen strands. The 
crosslinking of CRP (CRP-XL) enables conformational changes by bestowing a quaternary structure on 
this peptide, which enables this peptide to be a potent GpVI activation agonist (Achison et al., 1996; 
Asselin et al., 1997, 1997). Collagen exists in a tertiary confirmation (triple helical) and can 
spontaneously assemble into the highly organised quaternary (polymeric) conformation (Bella and 
Hulmes, 2017; Smethurst et al., 2007). Quaternary conformations are potent in inducing platelet 
activation and are essential for collagen-induced platelet activation (Kehrel et al., 1998).  
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1.2.4 Platelet activation via G protein-coupled receptors 
In addition to collagen-mediated signalling, platelets also become activated via the action of 
soluble mediators, some of which are generated during the haemostatic response and others released 
from activated platelets (Stalker et al., 2012). Signalling via soluble activators predominantly occurs 
via GPCRs, of which several subtypes are present on platelets. Following receptor engagement, 
conformational changes in GCPRs result in the exposure of an intracellular domain, which is then able 
to couple to cytosolic heterotrimeric G proteins which transmit signals following agonist stimulation 
(Gavi et al., 2006). G proteins act as molecular switches, and can be in their inactive states when they 
are bound to GDP (Guanosine diphosphate) and in their active state when they are bound to GTP 
(Guanosine triphosphate, Figure 1.4 (Rosenbaum et al., 2009).  
 
 
Figure 1.4. Schematic illustrating G protein-coupled receptor activation. Heterotrimeric G proteins consist of α,β and γ 
subunits. The β and γ can form a stable dimeric complex (Gβγ). Conformational changes that occur to the GPCR following 
ligand engagement result in binding of the G protein, and exchange of GDP to GTP within the nucleotide binding pocket. 
Following activation, the α subunit (Gα) of heterotrimeric G proteins dissociates from the βγ dimeric complex and can activate 
downstream signalling cascades. The Gα subunit can eventually re-associate with the Gβγ dimeric complex following 
hydrolysis of GTP to GDP, thus reforming the heterotrimeric G -protein, resetting the signalling cascade cycle)  
A number of Gα isoforms are expressed in platelets where they exert differing signalling 
cascades (Brass et al., 1993b). The activation of platelets via GPCR involves Gα12/13, Gαi or Gαq which 
are coupled to agonist-dependent receptors (Capote et al., 2015; Offermanns, 2006). Receptor 
engagement couples to differential signalling via different G proteins. Gα12/13-mediated signalling 
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induces activation of the small monomeric G-protein, RhoA, which in turn activates Rho Kinases. Rho 
Kinases primarily induce platelet shape change during activation (Kureishi et al., 1997). Gαi-induced 
signalling inhibits the activity of adenylyl cyclase, which in turn inhibits cAMP signalling (cAMP 
signalling induces activation of PKA which inhibits platelet aggregation and granule release) (Beck et 
al., 2014; Pulcinelli et al., 1998). Gαq primarily induces PLCβ-induced Ca2+ mobilisation. The major 
GPCRs found in platelets include the thrombin-activated protease actives receptors (PARs), the TxA2-
activated TP receptors and the ADP-activated P2Y receptors(Brass et al., 1993a). 
Platelet activation via PAR receptors  
Thrombin is one of the most potent agonists of platelet activation. Thrombin induces 
activatory processes such as [Ca2+]i elevation, shape change, degranulation and phosphatidylserine 
(PS) exposure (Lever et al., 2015). Protease-activated receptors (PARs) are activated by thrombin, 
which is generated via the coagulation pathway. PARs operate in a dual system, with PAR1 and PAR4 
expressed in human platelets, and PAR3 and PAR4 in mouse platelets (Jakobsche-Policht et al., 2014). 
PAR1 has a higher sensitivity to thrombin than PAR4, although PAR4 stimulation results in a more 
prolonged response compared to that of PAR1 (Reséndiz et al., 2007). Thrombin is a serine protease 
and can recognise and cleave the extracellular N-terminus of PAR. This results in the exposure of a 
new N-terminus which serves as a ‘tethered ligand’. This newly unveiled N-terminus acts as a receptor 
agonist to induce transmembrane signalling and platelet activation (Jakobsche-Policht et al., 2014; Li 
et al., 2010; Monroe et al., 2002), The PAR receptors in platelets are coupled to Gαq and Gα12/13 which 
induce PLCβ induced Ca2+ mobilisation and platelet shape change (Offermanns, 2006).  
PARs in platelets serve as an antithrombotic target, due to the potency of thrombin on platelet 
activation (Gryka et al., 2017). The drugs, Vorapaxar and Atopaxar, are PAR-1 antagonists that have 
undergone extensive clinical testing (Lam and Tran, 2015; Wurster and May, 2012). Vorapaxar has 
undergone phase 3 of clinical trials whereas Atopaxar has undergone phase 2 (Makris et al., 2013; 
Oestreich et al., 2013). The significant issues with the use of these drugs are the high bleeding risks 
they impose. This warrants the development of safer antithrombotics which are can target PARs 
(O’Donoghue et al., 2011).   
 
Platelet activation via TP receptors  
The thromboxane A2-activated TP receptor (TxA2) is an important platelet GPCR (Offermanns, 
2006). Upon agonist-induced stimulation, phospholipase A2 (PLA2) is activated, which enables the 
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activation of arachidonic acids which are liberated from membrane phospholipids. TxA2 is formed 
from arachidonic acids via enzymatic activation of cyclooxygenase-1 (COX-1) and thromboxane 
synthase (Smith et al., 1980). COX-1 regulates the formation of prostaglandin G2 (PGG2) from 
arachidonic acid, which is then converted to prostaglandin H2 (PGH2) (Moncada and Vane, 1980). PGH2 
is a substrate for many types of prostacyclins including PG12, a potent platelet antagonist via the 
activation of PKA. Thromboxane synthase, a microsomal enzyme which is present in platelets, 
catalyses the conversion of PGH2 to TxA2 (Ornelas et al., 2017; Schrör, 1997).  
TxA2 synthesis is inhibited by aspirin (Gryglewski et al., 1978)., which is a widely used analgesic 
and has been used as an antithrombotic and principal antiplatelet agent (Smith and Willis, 1971). 
Aspirin inhibits TxA2 synthesis by inducing acetylation of the functionally important serine529 in COX-1 
(Gryglewski, 1980). Acetylation inhibits arachidonic acids from interacting with the catalytic site of 
COX-1, resulting in the irreversible inhibition of TxA2 synthesis. Inhibition of COX-1 by aspirin inhibits 
production of prostacyclins such as PG12.  
 Upon synthesis, TxA2 diffuses out of the platelet. TxA2 is unstable with a short half-life of 
approximately 30 seconds (Higuchi et al., 1999). However, during this time period, TxA2 can bind to 
and activate TP receptors, which couple to Gαq and Gα12/13, initiating the signalling cascade induced 
by these G-proteins (Fontana et al., 2014). The unstable nature of TxA2 makes it difficult to investigate 
its signalling mechanism. Therefore the stable TxA2 analogue, U46619, is commonly employed to 
assess TxA2 activity in platelets (Rotondo et al., 1995). U46619 can bind to the TP receptor on platelets 
and induces many platelet activatory processes such as [Ca2+]i elevation, shape change and 
degranulation and aggregation (Kim et al., 2009). These activatory processes are mediated by 
downstream signalling of Gαq and Gα12/13. 
  
Platelet activation via P2Y receptors 
Other GPCRs present on the platelet surface that are important in platelet function include 
the ADP-activated receptors, P2Y1 and P2Y12 (Brass et al., 1993a). ADP (adenosine diphosphate) is 
released from dense granules upon platelet activation. The activation of both P2Y1 and P2Y12 are 
required to enable a full ADP-dependent response (Vaduganathan and Bhatt, 2016). ADP is utilised in 
platelets to activate other pathways and to amplify platelet activation. (Oestreich et al., 2013; Woulfe 
et al., 2001). 
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P2Y1 receptors couple to Gαq, whereas P2Y12 couple to Gαi (Offermanns, 2006). Inhibition of 
P2Y1 impairs [Ca2+]i elevation, shape change and aggregation (Hechler et al., 1998). Platelets from 
mouse P2Y1 knockout models are still sensitive to ADP-induced aggregation (Savi et al., 1998). P2Y1 
couples to Gαq to mediate PLC activation but does not couple to Gαi (Offermanns, 2006). The knockout 
of P2Y12 results in impaired ADP induced aggregation; however, responses such as shape change and 
PLC activation which are responses mediated by the P2Y1 receptor remained unaffected (Andre et al., 
2003; Vaduganathan and Bhatt, 2016). The impaired ADP-induced aggregation coincides with the 
redundancy of cAMP signalling inhibition (Gachet, 2012), indicating that P2Y12 couples to Gαi and not 
Gαq. Thus these studies demonstrate that both P2Y1 and P2Y12 activation enable optimal ADP-induced 
platelet activation (Vaduganathan and Bhatt, 2016). 
The importance of the P2Y receptors in platelet activation makes them an attractive 
antithrombotic target. Current antithrombotics that target P2Y receptors include clopidogrel which is 
a P2Y12 antagonist (Oestreich et al., 2013). Clopidogrel is relatively safe to use, although has associated 
increased bleeding as is the case with many antithrombotics. The restoration of platelet activity after 
discontinuation of clopidogrel usage has raised concerns due to the irreversible effect of clopidogrel 
on P2Y12. However, this effect has not been observed in humans, as full platelet restoration occurs 
approximately seven days after discontinuation of the treatment (Weber et al., 2001). Further clinical 
work is to be carried out to develop further P2Y antagonists which could also target the P2Y1 receptor. 
1.2.5 Platelet activation leads to Integrin activation 
The primary outcome of platelet activation is the upregulation of the activity of integrins on 
the platelet surface (Li et al., 2010). Integrins are a family of heterodimeric receptors consisting of α 
and β subunits which interact with the platelet cytoskeleton (Bennett et al., 1999). Platelets express 
many integrins that play a crucial role in mediating the interaction between platelets to the exposed 
extracellular matrix as well as to another platelet, as integrins are highly important for enabling 
platelet aggregation (Stalker et al., 2012). The most abundant and major integrins found on platelets 
are α2β1 (approximately 2000 to 4000 per platelet) which bind collagen, and αIIbβ3 (approximately 
80,000 per platelet) which bind fibrinogen (Chari-Turaga and Naik, 2011; Reininger, 2008). Other 
integrins such as α5β1 and α6β1 bind other sub-endothelial matrix proteins including laminin and 
fibronectin to enhance the adhesion strength (Huynh et al., 2013; Kunicki et al., 1993). 
Integrin α2β1 contributes to the binding of platelets to collagen as well as aiding in thrombus 
stabilisation (Marjoram et al., 2014). In contrast to GpVI signalling, α2β1 does not induce tyrosine 
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kinase activity (Gibbins, 2004; Gofer-Dadosh et al., 1997). Due to this, previous work has suggested 
that upon collagen-induced activation, α2β1 initially stabilises platelet interaction with collagen, which 
is followed by GpVI signalling (Kirchhofer et al., 1990; Santoro et al., 1991). Inside-out signalling 
enables activation of α2β1 via GpVI signalling (Asselin et al., 1997; Marjoram et al., 2014).  
Integrin αIIbβ3, the most abundantly expressed platelet receptor, acts as a receptor for 
fibrinogen, which is found in plasma and platelet α-granules. αIIbβ3 is maintained at a low-affinity state 
in resting platelets (Chari-Turaga and Naik, 2011; Kunicki et al., 1993). The importance of αIIbβ3 is 
demonstrated by the occurrence of the rare inherited autosomal recessive bleeding disorder known 
as Glanzmann Thrombasthenia (GT) which is caused by a defect of αIIbβ3 (Nurden, 2006). GT results in 
unpredictable and severe bleeding tendencies (Nurden, 2006). Platelet transfusion is the primary 
treatment for GT, although this may evoke the development of platelet antibodies to αIIbβ3 which in 
turn could potentially result in platelet refractoriness (Poon et al., 2016). In the case of platelet 
refractoriness, recombinant activated factor VII (rFVIIa) is employed to induce fibrinogen formation 
which results in platelet aggregation and adhesion to prevent bleeding and induced primary 
haemostasis (Rajpurkar et al., 2014). However, the mechanism of action of rFVIIa is poorly understood 
and requires further investigation and is not safe to employ as of yet as a regular therapeutic agent 
(Poon, 2007; Poon et al., 2006; Rajpurkar et al., 2014).  
 Upon upregulation, αIIbβ3 can bind to the arginine-glycine-aspartate (RGD) tripeptide 
sequence, enabling platelet crosslinking and leading to aggregation (Bernardi et al., 2006; Brass et al., 
1997). The α and β subunits of αIIbβ3 contain cation binding sites (Zhang and Chen, 2012). Cations are 
essential for integrin functions such as ligand binding, as well as inducing stabilisation of the integrin 
structure upon ligand binding. Two cation-specific binding sites are present in αIIbβ3 and must be 
occupied by cations to enable ligand binding. One of these sites binds Ca2+ (being saturated at 10-6 M) 
whereas the other site is less specific and binds to Mg2+ or Ca2+ (with an affinity of 10-3 M) (Zhang and 
Chen, 2012). Direct activation of αIIbβ3 occurs in response to exogenous treatment with Mg2+ (Gailit 
and Ruoslahti, 1988; Phillips and Baughan, 1983; Taylor and Pugh, 2016; Zhang and Chen, 2012). 
Excessive cation concentrations may saturate the cation binding sites and induce inappropriate αIIbβ3 
activation; thus high cation concentrations may be problematic as they may interfere with platelet 
aggregation and induce agglutination instead (Gowland et al., 1969; Phillips and Baughan, 1983; Zhang 
and Chen, 2012).  
 As αIIbβ3 is crucial for platelet activity and thrombus formation, it is a candidate for anti-
thrombotic therapy. Current anti-thrombotic drugs that target αIIbβ3 such as the αIIbβ3 antagonist 
Abciximab, and are commonly used during surgical interventions but is a high-risk strategy due to 
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associated high bleeding risks. (Makris et al., 2013). Studies have found that thrombocytopenia 
(platelet deficiency) occur as a side effect of Abciximab treatment in patients who have undergone 
CVD-related surgery such as coronary stenting and coronary angioplasty, outlining the risks involved 
with Abciximab (Gammie et al., 1998; Merlini et al., 2004). Severe thrombocytopenia requires platelet 
transfusion (Madan and Berkowitz, 1999). Repeated treatment with Abciximab induces severe 
thrombocytopenia and induces high bleeding risks which could be fatal (Tcheng et al., 2001, 1994). 
Thus further the development of safer anti-thrombotic which does not impose bleeding risks is 
required (Orford and Holmes, 2002). 
 
Signalling via αIIbβ3  
Upon agonist-dependent stimulation, the affinity of αIIbβ3 for fibrinogen is amplified via 
‘inside-out’ signalling (Li et al., 2010). Signalling via multiple pathways (including GpVI and Gα proteins, 
GPCRs) upon agonist evoked stimulation induces inside-out activation of the integrin, as a result of 
activation of the small GTPase, Rap1b (Figure 1.5. Nieswandt and Watson, 2003). Activation of Ras-
related protein 1B (Rap1b) is induced by P13K. However, Ca2+ and diacylglycerol (DAG) regulated 
guanine nucleotide exchange factor 1 (CalDAG-GEF1) is also vital for Rap1b activation as it mediates 
the conversion of Rap1b from its inactive state (GDP-bound) to its activated state (GTP-bound) 
(Bernardi et al., 2006). Active Rap1b interacts with talin, an integrin-associated cytoskeletal protein . 
(Nieswandt et al., 2011). These interactions upregulate the affinity of αIIbβ3 to its ligand by allowing 
interactions of the β3 subunit with its cytoplasmic domain, thus enabling integrin activation to a high-
affinity state (Peyvandi et al., 2011).  
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Figure 1.5. Inside-out activation of integrin αIIbβ3. Agonist induced stimulation results in the activation of phospholipase C 
(PLC) which induces the formation of the secondary messenger diacylglycerol (DAG) as well as mobilisation of Ca2+ from its 
store. DAG and Ca2+ evoke activation of protein kinase C (PKC) and CalDAG-GEF1, which mediate GDP/GTP exchange and the 
activation of Rap1b. Rap-1b and talin interact resulting in the exposure of integrin binding. Talin binds to and disrupts the 
salt bridge between the cytoplasmic tails of the αIIb and β3 subunits. This results in conformation changes of these subunits 
which change the integrin from its low-affinity state to its high-affinity state  
 
‘Outside-in’ signalling occurs following ligand binding to αIIbβ3 resulting in the clustering of this 
integrin (Stalker et al., 2012). Ligand binding (which in physiological cases would be fibrinogen and 
VWF)-dependent outside-in signalling initiates intracellular signalling (Bennett et al., 1988), and 
activation of many major processes, including cytoskeletal rearrangement, PKC activation and Ca2+ 
mobilisation (Hammond et al., 2015; Lever et al., 2015; Murugappan et al., 2005; Wee and Jackson, 
2006). Outside-in signalling results in SFK-dependent tyrosine phosphorylation of the β3 cytoplasmic 
domain (Senis et al., 2014). Following phosphorylation, Syk is recruited and activated during outside-
in signalling, mediating activation of PLCγ2(Ozaki et al., 2000). The resulting downstream signalling 
cascade is similar to that mediated by GpVI signalling (Figure 1.6. Chari-Turaga and Naik, 2011; Rivera 
et al., 2009; Soulet et al., 2005).  
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Figure 1.6. Outside-in signalling upon ligand binding to αIIbβ3. Ligand (fibrinogen/ VWF) binding to αIIbβ3, results in the 
phosphorylation by Src Family Kinases (SFK) and numerous enzymes and adaptor proteins. PLCγ2 mediates activatory 
processes in platelets by mobilising Ca2+ from stores and activating protein kinase C (PKC). Syk phosphorylates other proteins 
such as SLP76, which also mediates activation of PLCγ2. There is also the interplay of the phosphorylation of targets induced 
by Src and Syk, which further promotes the outside in signalling activation. Syk can also operate the position of Src on the 
cytoplasmic tail of the β3 subunit.  
1.2.6 Platelet shape change 
Platelet activation induces cytoskeletal rearrangements that regulate shape change, which is 
an essential feature of platelet aggregation (Paul et al., 1999). Upon activation, platelets change from 
their non-active disc shape to their activated state which is spherical with protruding filopodia (Wraith 
et al., 2013). While this morphological state is thought to enable aggregation at a faster rate (Wraith 
et al., 2013), shape change is independent of, and may not be required for aggregation (Maurer-Spurej 
and Devine, 2001). However, shape change is an acknowledged indicator of activated platelets 
(Maurer-Spurej and Devine, 2001). Previous studies have observed activation-dependent 
morphological changes in platelets, by enabling platelets to adhere to and spread on flat surfaces such 
as glass, or fibrinogen-coated coverslips. Upon contact, platelets lose their discoid shape and undergo 
cytoskeletal contraction (Aslan et al., 2012; Li et al., 2010). This is followed by structural extensions 
from the platelets known as pseudopodia, which extend and contract. Following filopodia formation, 
structures known as lamellipodia are formed from the sides of the pseudopodia (Bearer et al., 2002). 
These extend utilising lipid membrane from stores within platelets (the open canalicular system), to 
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cover a large surface area to inhibit blood loss, and providing a substrate for coagulation (Podoplelova 
et al., 2016; Seifert et al., 2017; Tomaiuolo et al., 2017). 
Actin is highly abundant in platelets and plays a significant role in cytoskeletal rearrangements 
(Bearer et al., 2002). Fully spread platelets contain stress-like fibres, lamellipodia, filopodia, and a 
contractile ring which are all actin structures (Maioli et al., 1985). During the morphological change of 
a platelet from the resting discoid state to a fully spread platelet, the contractile ring is initially formed. 
This process is followed by filopodia extensions, which enables lamellipodia to form, and full spread 
to occur (Hartwig, 1992). There are many proteins which interact with actin to regulate polymerisation 
and depolymerisation which occur during platelet shape change (Bearer, 1995; Bearer et al., 2002). 
Different Ca2+ dependent actin-binding proteins may play different and selective roles during the 
stages of platelet shape change as well as maintenance of the cytoskeleton of resting platelets; 
however this requires further investigation in order to elucidate the regulatory roles Ca2+ may have on 
the platelet cytoskeleton (Bearer et al., 2002; Finkenstaedt-Quinn et al., 2015). An example of a well-
documented Ca2+ -dependent cytoskeletal protein is gelosin which has been found to be a dynamic 
regulator of actin filament lengths in platelets. It can be hypothesised that other cations such as Zn2+ 
may also mediate these Ca2+ binding proteins which regulate the platelet cytoskeleton, as these 
proteins may be susceptible to other cations in addition to Ca2+. Cation-dependent cytoskeletal 
changes is a major theme of this thesis. Additionally, a major Ca2+ binding protein known as calmodulin 
can induce platelet shape change via activation of myosin light chain kinase (MLCK). Calmodulin is 
dependent on Ca2+; however studies that focused on the structure of calmodulin have suggested that 
other cations such as Zn2+ could displace Ca2+ (although yet to be confirmed), thus further suggesting 
the potential role that cations may play in regulating the platelet cytoskeleton (Levy, 1983; Mills and 
Johnson, 1985).  
 
Signalling pathways that regulate platelet shape change 
Platelet shape change involves a number of proteins that regulate cytoskeletal 
rearrangement. Previous studies have shown that the specific signalling pathways leading to platelet 
shape change involve Ca2+/calmodulin, myosin light chain kinase (MLCK) and the RhoA/p160ROCK (Rho-
associated coiled-coil-containing protein kinase), (Paul et al., 1999). RhoA protein is a small GTPase 
which is involved in platelet cytoskeletal rearrangements, while p160ROCK is a protein kinase to which 
RhoA associates during cytoskeletal rearrangements during platelet shape change (Paul et al., 1999). 
Platelet signalling pathways that regulate shape change involve MLCK activity (Daniel et al., 1984; 
Retzer and Essler, 2000). Activated MLCK phosphorylates myosin light chains (MLC), resulting in 
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myosin-driven contraction and changes in actin dynamics which results in platelet shape change 
(Jalagadugula et al., 2010). The signalling pathways derived from these studies are thought to be 
dependent on Ca2+. Upon [Ca2+]i mobilisation (via the agonist-induced activation of the PLC/IP3 
pathway), Ca2+ interacts with the Ca2+-binding protein, calmodulin which is then able to activate MLCK.  
Studies have also shown the presence of a secondary Ca2+-independent signalling pathway 
that regulates shape change. In this pathway, Rho-associated coiled-coil-containing protein kinases 
can phosphorylate MLCs or/and enhance MLC phosphorylation by inhibiting MLC phosphatases (MLC-
P) (Paul et al., 1999; Shin et al., 2017). The exact mechanism of platelet shape change is still to be 
confirmed (Shin et al., 2017; Sun et al., 2007). 
Vasodilator-stimulated phosphoprotein [(VASP) (which is a substrate of cAMP-dependent 
protein kinase A (PKA) and cGMP dependent protein kinase (PKG) in platelets (Walter et al., 1993) is 
involved in the regulation of actin dynamics during platelet shape change (Beck et al., 2014). While 
the function of phosphorylated VASP in platelets is not fully understood, recent studies have indicated 
that VASP may mediate actin rearrangement via nucleation, filament formation and bundling 
(Bachmann et al., 1999; Bearer et al., 2002; Walders-Harbeck et al., 2002). VASP also mediates the 
recruitment of actin-binding proteins such as profilin and therefore plays an important role in actin 
dynamics (Bearer et al., 2002; Hartwig, 1992; Hartwig et al., 1999; Wentworth et al., 2006). (Aburima 
et al., 2013; Beck et al., 2014; Wentworth et al., 2006) 
 
1.2.7 Platelet granules and degranulation 
Platelet activation results in degranulation of α and dense granules, releasing their contents 
into the environment of a growing thrombus. α granules are the most abundant secretory 
compartment in platelets (approximately 50-80 per platelet) (Sander et al., 1983; Wencel-Drake et al., 
1985). α-granules contain adhesion molecules such as VWF, fibrinogen, fibronectin and vitronectin, 
which are vital for mediating platelet adhesion and thrombus formation. α-granules also contain a 
number of cytokines and coagulation factors which function in cellular repair, inflammation, 
angiogenesis and coagulation (Maynard et al., 2007). Furthermore, α-granules contain Zn2+ which may 
be released into the platelet cytosol upon activation. However, the role of Zn2+ in platelet is yet to be 
confirmed (Marx et al., 1993a; Milne et al., 1985; Taylor and Pugh, 2016; Watson et al., 2016). The 
mechanisms that induce α-granule packaging of these molecules have yet to be fully characterised 
and warrant further investigation. Cytoskeletal changes in platelets may regulate granule release. The 
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distribution of granules are dispersed in a random manner in resting platelets; however, upon 
activation, cytoskeletal changes centralise the granules, which results in the secretion of the granules 
through the open canalicular system (OCS) in platelets (Flaumenhaft, 2003). The OCS consists of a 
network of surface-connected channels which mediate platelet activation. The full function of the OCS 
is yet to be confirmed and requires further work to determine its full function and importance in 
platelets (Selvadurai and Hamilton, 2018). The influence of cytoskeletal changes on regulating granule 
secretion is also the subject of investigation due to contradictory findings, as inhibition of cytoskeletal 
changes does not influence granule secretion (Kirkpatrick et al., 1980; White and Rao, 1983, 1982). 
However, the signalling pathways that induce cytoskeletal rearrangement during platelet shape 
change also mediate granule secretion; for example, previous work found that Rho kinases induce 
cytoskeletal rearrangements and that inhibition of Rho kinase reduces granule secretion upon agonist-
induced activation (Suzuki et al., 1999; Watanabe et al., 2001).  
  Dense granules are the second most abundant secretory compartment in platelets 
(approximately 3-8 per platelet) and contain many soluble agonists such as ATP, ADP, serotonin and 
Ca2+. Upon activation-dependent degranulation, these agonists activate and recruit circulating 
platelets to mediate sustained platelet aggregation (Golebiewska and Poole, 2015). ADP mediates α-
granule secretion and integrin activation (Andre et al., 2003). Transgenic mouse models which are 
deficient in dense granule secretion also have defects in other markers of platelet activation such an 
α-granule release and integrin activation, suggesting that ADP released from the dense granules 
primarily mediates activatory processes, rather than plasma-derived ADP (Golebiewska and Poole, 
2015; Hashimoto et al., 1994; Woulfe et al., 2001). This highlights the importance of dense granules 
in platelet activation and synergy with α-granule secretion. 
Granule secretion is highly important for platelet activity and thrombus formation, as 
defective granule secretion has been associated with bleeding tendencies, as found in patients with 
storage pool diseases (SPD), a result of defective granule release (Reed et al., 2000). SPD inhibits 
platelet responses such as aggregation and platelet signalling in response to agonist stimulation 
(Holmsen and Weiss, 1970; Nurden and Nurden, 2014; Smith et al., 1997). 
 
1.2.8 Phosphatidyl-serine (PS) exposure 
Activated platelets play a central role in mediating coagulation, which as described earlier in 
this chapter is a significant step in the haemostatic process which reinforces the stable platelet plug 
allowing a stable, long-lasting clot to form (Podoplelova et al., 2016). Coagulation is initiated on 
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activated platelets which externalise PS on their surface, as thrombin formation is promoted from 
several coagulation factors which assemble on the PS-rich surfaces (Gao et al., 2012; Mackman et al., 
2007). Thrombin cleaves fibrin from fibrinogen, giving rise to a fibrin meshwork to enable a more 
stable thrombus (Knappe et al., 2013; Monroe et al., 2002; Podoplelova et al., 2016).  
Previous work has shown that ATP-dependant proteins know as flippase and floppase (a 
family of lipid transport enzymes mediate the transportation of phospholipid molecules between the 
inner and outer faces of cellular membranes) as well as Ca2+-dependent phospholipid scramblases 
(which has been identified as the lipid scramblase transmembrane protein 16F, TMEM16F in platelets) 
which mediates the translocation of phospholipids) mediate PS exposure (Figure 1.7, Pomorski and 
Menon, 2016; Suzuki et al., 2013; Yang et al., 2012). At resting states, negatively charged 
phospholipids such as PS are maintained at the inner face of the membrane via the floppase and 
flippase proteins, whereas the outer face of the membrane consists of positively charged 
phospholipids (Daleke, 2003; Owens and Mackman, 2011). Flippase plays a significant role in 
translocating phospholipids to the inner face of the membranes (floppase induces the opposing 
action). [Ca2+]i elevation results in the inhibition of flippase and mediates scramblase to translocate 
phospholipids to the outer leaflet membrane, thus resulting in PS exposure (Daleke, 2003; Pomorski 
and Menon, 2016; Suzuki et al., 2013; Zhao et al., 2017). The exposure of increased PS on platelets 
serves as a marker of activated platelets and indicates that the platelets may be procoagulant 
(Mackman et al., 2007; Mooberry and Key, 2016; Morel et al., 2008).  
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Figure 1.7. Mechanisms of Phosphatidylserine (PS) exposure in activated platelets. Negatively charged phospholipids such 
as phosphatidylserine (PS) are maintained at the inner face of the membrane via the floppase (translocates phospholipids to 
outer face of membrane) and flippase proteins (translocate phospholipids to inner face of membrane), whereas the outer 
face of the membrane consists of positively charges phospholipids such as phosphatidylcholine (PC). Ca2+ elevation  inhibits 
flippase activity and activates  the Ca2+ dependant scramblase which translocates the negatively charged phospholipids to 
the outer leaflet membrane, resulting in PS exposure. 
 
1.2.9 Oxidative stress and redox-dependent signalling during platelet 
activation 
Redox reactions occur in platelets during activation (Sonego et al., 2017). Modulation of the 
redox state in platelets and the vascular environment may result in or be the result of oxidative stress 
in platelets (Olas and Wachowicz, 2007). Oxidative stress occurs when there is an imbalance between 
antioxidants and oxidants. Modulation of the redox state may be caused by a number of different 
mechanisms or stimuli, which in turn could induce or inhibit the levels of reactive oxygen species (ROS) 
present (Pietraforte et al., 2014). Furthermore, antioxidants ‘mop up’ ROS and alter the redox state in 
platelets. The balance between redox state and oxidative stress in platelets plays a key role in 
regulating platelet activation (Qiao et al., 2018). Whilst epidemiological studies have given early 
indications that supplementation of antioxidants has a reducing effect on cardiovascular illnesses 
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(Pandya et al., 2013; Sinha and Dabla, 2015), other studies using vitamin antioxidant therapy have not 
shown any significant clinical benefits. Further work has shown a significant role for antioxidants on 
platelet activity, following a strong association of antioxidant supplementation and strokes (Gorog and 
Kovacs, 1995; Olas and Wachowicz, 2007; Sonego et al., 2017). Oxidative stress is a major mediator in 
cardiovascular illnesses as a result of cellular damage (Ferroni et al., 2012). 
Platelet aggregation coincides with increased oxygen utilisation (Watt et al., 2012). ROS such 
as superoxide is produced by platelets and enhance platelet aggregation responses (Freedman, 2008). 
Transition metals such as Zn2+ may contribute to oxidative degradation of lipids (lipid peroxidation) by 
superoxide, resulting in the initiation of lipid radical propagation chain reactions as result of the 
formation of peroxyl radicals and lipid alkoxyl (Krötz et al., 2004; Schneider, 2009). Nitric Oxide (NO) 
can halt this radical chain reaction at the expense of losing its bioactivity, by reaction with either 
superoxide or the peroxyl radicals to result in the formation of peroxynitrite. NO is inactivated readily 
upon oxidative stress (Zhao, 2007). NO negatively regulates platelet activation. Thus inactivation of 
NO upon oxidative stress may evoke abnormal platelet activation and haemostasis.  
The NADPH oxidase (NOX) pathway primarily serves to induce modulation of the redox 
signalling pathway in platelets (Begonja et al., 2006). The NOX pathway produces ROS and can also be 
activated by ROS (Figure 1.8), which is why the inhibition of this pathway is crucial for the maintenance 
of resting platelets (Begonja et al., 2006). The isoforms of the NOX complex on platelets that are 
currently known to be expressed on platelets are NOX-1 and NOX-2. The oxidative subunit, neutrophil 
cytosol factor 1 (p47phox) induces activation of the NOX complex on platelets via phosphorylation. 
Activation of NOX has been found to mediate efficient platelet activation, implying the importance 
that ROS has on platelet activity. Interestingly, differences between NOX-1 and NOX-2 regarding 
signalling were suggested in previous work, as NOX-1 was found to primarily mediate Thromboxane 
A2 (TXA2) production following p38 mitogen-activated protein kinase (MAPK) signalling. The 
PLCγ2/PKC/MAPKp38 signalling cascade is potentiated by ROS (Krötz et al., 2004). This cascade 
activates PLA2 which catalyses TXA2 synthesis, increasing platelet activation (Qiao et al., 2018). NOX-2 
was found to favour signalling downstream of collagen stimulation as NOX-2 knockout studies on 
mouse, results in inhibition of ROS generation following collages induced activation. Thus, these 
findings demonstrated that the isoforms of NOX may induce activation of platelets in differing 
manners, further providing evidence to instigate the importance of ROS in efficient platelet activation. 
Furthermore, ROS scavengers such as superoxide dismutase and catalase inhibit platelet response 
upon stimulation thus indicating that ROS acts as a secondary messenger (Gorog and Kovacs, 1995; 
Sonego et al., 2017). 
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Figure 1.8. The NADPH oxidase (NOX) pathway induces thrombus formation via reactive oxygen species (ROS) formation. 
The NOX complex is constituted with its regulatory subunits which include p22phox, p47phox, p67phox and the G-protein, RAC 
which are required for NOX assembly and activation. The subunit, p47phox plays the most crucial role, as it is involved in the 
direct activation of the NOX complex via phosphorylation. The NOX complex also consists of cytoplasmic flavin adenine 
dinucleotide (FAD) and NADPH binding domains, where electrons are passed down an electrochemical gradient from NADPH 
to FAD then through heme groups within NOX. This is followed by the transfer of electrons to oxygen, resulting in the 
formation of the ROS, superoxide (O2-). ROS elevation can mediate the PLCγ2/PKC/MAPKp38 signalling cascade resulting in 
PLA2 activation. PLA2 is then able to induce the synthesis of thromboxane A2 (TXA2), where F2 isoprostane (F2-IsoP) can also 
form as a result of oxidation by peroxides. TxA2 and F2-IsoP can both bind to the thromboxane receptor (TP), which results 
in the Ca2+ mobilisation, which results in platelet activation and thrombus formation. Superoxide (O2-) may be converted (by 
superoxide dismutase, SOD) to hydrogen peroxide (H2O2) which acts as a secondary messenger, also leading to Ca2+ 
mobilisation. Therefore, elevated ROS may result in inappropriate platelet activation and thrombus formation. H2O2 may also 
be converted to dihydrogen oxide (H2O) via catalase, CAT. Superoxide (O2-) can also react with nitrogen oxide (NO), which 
results in the formation of reactive nitrogen species such as peroxynitrite (ONOO-).  
1.3 Negative regulation of platelet activation  
Under normal circulating conditions, platelet activation and adherence are inhibited via the action of 
several factors including nitric oxide and prostacyclin (PGI2) which are released from vascular 
endothelial cells. Nitric oxide (NO) inhibits platelet activation by stimulating the production of cGMP, 
23 
 
which activates cGMP-dependent protein kinase (G-kinase) (O’Brien and Salmon, 1987). The G-kinase 
inhibits the activation of phospholipase C (PLC) which is crucial for the mobilisation [Ca2+]i from the 
dense tubular system, the Ca2+ store in platelets (Peyvandi et al., 2011). The release of [Ca2+]i is crucial 
for platelet activation and activity and will be discussed in much more depth in later sections. PGI2 
binds to the GPCR prostacyclin receptor (IP). This stimulates adenylyl cyclase (AC) to synthesise cyclic 
adenosine monophosphate (cAMP), which inhibits platelet aggregation by activating protein kinase A 
(PKA) (G. R. Wang et al., 1998). Thus, platelet inhibition is an active process, relying on cAMP and 
cGMP signalling, in contrast with activation of other cell types in which cyclic nucleotide synthesis is 
stimulated upon activation (Figure 1.9). Inhibition of platelets (after haemostatic processes have 
successfully occurred, as well as in healthy conditions) is significant to avoid the occurrence of 
inappropriate haemostasis, which can result in thrombosis leading to adverse cardiovascular events 
(Aburima et al., 2013; Beck et al., 2014; Gibbins, 2004).  
 
  
Figure 1.9. Prostacyclin and Nitric oxide signalling inhibit platelet activation. Prostacyclin (PGI2) which is released from 
endothelial cells binds to the prostacyclin receptor (IP) on platelets. This then results in the activation of the transmembrane 
protein, adenylate cyclase (AC), which then produces cyclic adenosine monophosphate (cAMP) from adenosine triphosphate 
(ATP). cAMP is a secondary messenger and activates protein kinase A, which then inhibit platelet activation. Nitric oxide 
(NO), is also released from endothelial cells and is a gas molecule which diffuses through the platelet membrane. NO 
primarily targets soluble guanylate cyclase (sGC), which synthesises cyclic guanosine monophosphate (cGMP) from 
guanosine triphosphate (GTP). cGMP activates PKG which results in the inhibition of platelet activation.  
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1.4 Calcium signalling in platelets  
A hallmark of platelet activation is [Ca2+]i levels which is mediated by release from [Ca2+]i stores 
and influx through cation-permeable membranes channels following agonist-dependent activation 
(Varga-Szabo et al., 2009). The major calcium stores in platelets are the dense tubular system (DTS). 
The release of Ca2+ from intracellular stores is mediated by phospholipase C (PLC) isoforms, of which 
PLCβ and PLCγ2 are present in platelets (Kamiya et al., 2014, Lever et al., 2015). Receptor-mediated 
platelet activation results in the activation of PLC isoforms which hydrolyse phosphoinositide-4,5-
bisphosphate (PIP2) to inositol-1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG) (Varga-Szabo et 
al., 2009, Lever et al., 2015). IP3 mediates release of Ca2+ from the DTS into the platelet cytosol via 
activation of the IP3R, a dense tubular calcium channel. The DTS, however, provides a limited source 
of Ca2+ upon agonist-induced stimulation and is thus readily depleted. This requires replenishment of 
the store which is carried about by a major process known as store-operated calcium entry (SOCE), in 
which a secondary influx of calcium via membrane ion channels such as Orai1 occurs (Figure 1.10, 
Guéguinou et al., 2016). The stromal interaction molecule 1 (STIM1) acts as a Ca2+ sensor molecule on 
the DTS, which binds to Ca2+ via its EF-hand domain. The release of Ca2+ from the DTS via the IP3R 
results in the disruption and then dissociation of Ca2+ binding to STIM1, which induces the 
redistribution of STIM1 to the plasma membrane where it can interact with Orai1. Orai1 consists of 
four transmembrane domains, and structural studies have indicated that STIM1 interacts with one of 
these four transmembrane domains (Hou et al., 2012). Studies in Orai1- or STIM1-deficient mice have 
illustrated the impairment of SOCE and functional processes in platelets which confirmed the 
importance of STIM1 and Orai1 in the SOCE process and the importance of SOCE and sustained Ca2+ 
responses in platelet function (Hou et al., 2012; Lang et al., 2013; Steinckwich et al., 2011). In addition 
to SOCE, other mechanisms are in place which permits Ca2+ entry into the platelets. For example, 
transient receptor potential channels (TRPCs) are expressed in platelets and provide a further point of 
induced Ca2+ entry. The role and presence of difference TRPCs in platelet are yet to be fully confirmed. 
However, TRPC6 induces Ca2+ entry and is mediated by DAG. DAG and IP3 are generated upon 
hydrolysis of PIP2. Other channels through which Ca2+ can gain entry to platelets include TRPC6 (which 
is gated by DAG) and the ATP-gated P2X1 (Varga-Szabo et al., 2009, Gamberucci et al., 2002). The P2X1 
channel which is gated by ATP mediates the fastest way in which Ca2+ can enter cells upon agonist 
stimulation (Mahaut-Smith, 2012).  
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Alternative mechanisms regulating Ca2+ entry are also present in platelets. As minor elevations 
in [Ca2+]i induce platelet activation, the maintenance of resting constant [Ca2+]i (approximately 100nM) 
is important to enable platelets to remain in resting states and not undergo inappropriate activation 
(Arslan et al., 1985a; Jones et al., 2010). Sarcoplasmic/endoplasmic Ca2+ ATPases (SERCAs) are present 
on the DTS and pump Ca2+ back into the store (Sharov et al., 2006). Plasma membrane Ca2+ ATPases 
(PMCAs) pump Ca2+ out of the platelet (Jones et al., 2010). Furthermore, the Na2+/Ca2+ exchanger (NCX) 
which is expressed in platelet can mediate rapid entry and exit of Ca2+ in platelets (Roberts et al., 2012).  
Ca2+ plays an essential role as a secondary messenger in platelets and other cells (Varga-Szabo 
et al., 2009). [Ca2+]i contributes to many platelet processes including aggregation, shape change, 
granule release, PS (Orem et al., 2017; Smith et al., 1992) Regulatory mechanism such as SOCE, TRPCs, 
SERCAs, PMCAs and NCX could serve to be therapeutic targets to help developing antithrombotics, 
due to the central role Ca2+ plays in platelet activation. Furthermore, these Ca2+ regulatory 
mechanisms may also be involved in the handling of other cations such as Zn2+, which will be discussed 
below. 
 
 
Figure 1.10. Schematic detailing Ca2+ mobilisation pathways in platelets. Agonist-induced stimulation results in hydrolysis 
of phosphatidylinositol-4,5-bisphophosphate (PIP2) to inositol-1,4,5-trisphosphate (IP3) and diacyl-glycerol (DAG) by different 
isoforms of phospholipase C (PLC) such as PLCγ and PLCβ. IP3 mediates [Ca2+]i from the DTS (calcium store) via the IP3R, which 
then results in the depletion of Ca2+ from the DTS. A process known as store-operated calcium entry (SOCE), in which store 
depletion is detected by STIM1, is initiated, which signals the opening of the ORAI1 channels in the platelet plasma 
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membranes. DAG mediates non-SOCE via the transient receptor potential channel 6 (TRPC6). The agonist-operated calcium 
channel P2X1, as well as the NCX (Na2+/Ca2+ exchanger), are also involved in elevating [Ca2+]i. The sarcoplasmic/endoplasmic 
reticulum Ca2+ ATPase (SERCA) pumps Ca2+ back into the DTS, allowing replenishment of the store. Also, the plasma 
membrane Ca2+ ATPases (PMCA) pumps Ca2+ back out the plasma membrane. 
 
1.5 The role of Zn2+ in platelet physiology and activity 
The role of Zn2+ as an intracellular or extracellular mediator of platelet function has received 
little research interest in recent years. The investigation of Zn2+ in platelets is to be explored in this 
thesis and provides a novel approach to further understanding platelet physiology. The role of Zn2+ in 
platelets may potentially be comparable to that seen by the major cation, Ca2+ which is a major 
secondary messenger in platelets. 
1.5.1 The importance of Zn2+ in human biology 
Zn2+ is one of the most abundant transition metals in the human body. It is found in all body tissues; 
85% of total body zinc is found in bone and muscle, 11% in skin and liver, and remaining Zn2+ is within 
other tissues. (Plum et al., 2010; Stefanidou et al., 2006; Tapiero and Tew, 2003). 10-15% of the human 
genome encodes proteins such as enzymes, structural proteins, transcription factors and signalling 
proteins, which employ Zn2+ as a cofactor (Haase and Maret, 2003; Hyun et al., 2004a; Vu et al., 2013). 
In various cell types, intracellular Zn2+ ([Zn2+]i) is thought to serve as a secondary messenger for cellular 
activity. Furthermore, increased [Zn2+]i has been shown to mediate intracellular signalling for cellular 
function (Andreini and Bertini, 2012; Vallee and Falchuk, 1993).  
The contribution of Zn2+ to cellular mechanisms has received limited research interest. The 
role of Zn2+ as a bioactive molecule has been overlooked in favour of Ca2+ (Gordon et al., 1982; Heyns 
et al., 1985; Marx et al., 1991; Trybulec et al., 1993; Vallee and Falchuk, 1993; Varga-Szabo et al., 
2009). This may be due to Ca2+-binding fluorophores and chelators used to investigate Ca2+ signalling 
often having higher affinities for Zn2+ than Ca2+, thus it is difficult to separate the effects of these two 
ions. An example of a commonly used Ca2+ fluorophore is Fura-2 which has a higher Kd value (i.e. lower 
affinity) for Ca2+ (0.23µM) than for Zn2+ (3nM) (Abbate et al., 2016). 1,2-bis(o-aminophenoxy) ethane-
N, N, N′, N′-tetraacetic acid (BAPTA) is a commonly used Ca2+ chelator which also has a higher affinity 
for Zn2+ than Ca2+, with Kd values of 8 nM and 160 nM, respectively (Arslan et al., 1985a; Hyun et al., 
2004a; Matias et al., 2010a). Thus, the use of BAPTA may have resulted in the underestimation of the 
importance of Zn2+ in cell function. An example of this has been demonstrated on work carried out on 
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neuronal damage. Previous studies confirmed Ca2+ as a significant mediator in the induction of 
neuronal damage and toxicity (Grienberger and Konnerth, 2012). However, the conclusions of this 
work were challenged with the observation that much of the work relied on the fluorescent indicator 
(Fura-2) which had a much higher affinity for Zn2+ than Ca2+. It was suggested that the measured Ca2+ 
signal might also be attributable to Zn2+. This was confirmed in other reports that showed increases in 
intracellular Zn2+ in hippocampal slices upon oxygen-glucose deprivation (OGD) (Koh et al., 1996; 
Sloviter, 1985; Stork and Li, 2006). Increases in [Ca2+]i in hippocampal slices following OGD were found 
to be attributable to Zn2+, as opposed to Ca2+, via the employment of the highly specific Zn2+ chelator 
N,N,N′,N′-Tetrakis(2-pyridylmethyl)ethylenediamine, (TPEN), implicating the role of Zn2+ may be more 
significant than Ca2+ in response to OGS in hippocampal slices (Koh et al., 1996; Sloviter, 1985; Stork 
and Li, 2006). This work provided evidence to demonstrate that effects previously attributed to Ca2+ 
may actually be a result of Zn2+. It is therefore important to consider whether other cellular processes, 
previously thought to be mediated by Ca2+ alone, may also have a Zn2+-dependent component.  
The importance of Zn2+ in biology is exemplified by dietary Zn2+ deficiency, which results in 
significant consequential effects due to its multitude of biochemical functions (Hambidge, 2000). 
Various physiological systems, including the circulatory system, are affected by Zn2+ deficiency 
(Hambidge and Walravens, 1982), with prolonged bleeding times resulting from disruption of the 
circulatory integrity that is required for normal bodily function. Indeed, cancer patients who are Zn2+-
deficient have prolonged bleeding times which is rectified with Zn2+ supplementation (Stefanini, 1999), 
highlighting the importance of Zn2+ in maintaining physiological function.  
The plasma concentration of Zn2+ ranges from 10 to 20μM and varies among individuals 
according to dietary intake (Roohani et al., 2013). The majority of plasma Zn2+ is bound to plasma 
proteins such as albumin and α2 microglobulin (Foote and Delves, 1984; Scott and Bradwell, 1983; 
Tubek et al., 2008; Vallee and Falchuk, 1993). Binding of Zn2+ to albumin results in exchangeable Zn2+ 
pools (exchangeable Zn2+ pools are the total sum of combined pools which exchange with Zn2+ in the 
plasma) and non-exchangeable Zn2+ pools when bound to α2 microglobulin, which in turn result in a 
final free plasma Zn2+ concentration of approximately 0.5 μM (Foote and Delves, 1984; Rükgauer et 
al., 1997; Taylor and Pugh, 2016; Scott and Bradwell, 1983; Krebs, 2000). Free Zn2+ is utilised by 
different cells for structural, catalytic and regulatory functions (Haeger, 1973; Halsted, 1971; 
International Zinc Nutrition Consultative Group (IZiNCG) et al., 2004). Cellular homeostasis of Zn2+ is 
vital to avoid the accumulation of excessive Zn2+ which could potentially result in cytotoxicity (Plum et 
al., 2010).  
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The regulation of Zn2+ homeostasis is primarily mediated by Zrt-Irt(Zinc transporter)-like 
proteins (ZIPs) and Zn2+ transporters (ZnTs) (Devergnas et al., 2004). At least 15 ZIPs and 10 ZnTs have 
been found in human cells (as illustrated in Figure 1.11) which enable Zn2+ transportation into and out 
of the cytosol (Sekler et al., 2007). ZIPs and ZnTs regulate [Zn2+]i in the Golgi, endoplasmic reticulum 
and mitochondria in a variety of cell types. Vesicles which sequester high concentrations of [Zn2+]i have 
been termed ‘zincosomes’, which act as Zn2+ stores that release Zn2+ upon stimulation with agonists 
such as growth factors (Haase and Maret, 2003; Taylor et al., 2008). Metallothioneins (MTs) are 
intracellular metal binding proteins play a major role in Zn2+ homeostasis. MTs are low molecular 
weight proteins (6-7 kDa) which have a high cysteine content to sequester Zn2+, and can, therefore, 
act as Zn2+ stores (Romero-Isart and Vasák, 2002). In vitro studies show that MT cysteine residues can 
become oxidised. The sulphur clusters from the cysteines in MTs bind to Zn2+ create an environment 
of a shallow redox potential around Zn2+. This low redox environment is susceptible to oxidation, even 
in mild oxidative conditions, resulting in the release of Zn2+ from the MT (Jiang et al., 1998). Therefore 
oxidative stress can induce Zn2+ release from MTs (Feng et al., 2006). 
In neuronal cells, Zn2+ been reported to act as a neurotransmitter (Frederickson and 
Moncrieff, 1994), demonstrating a role for Zn2+ as a signalling molecule Zn2+-containing neurons 
accumulate, sequester and release Zn2+ from their presynaptic vesicles (Frederickson et al., 2000). 
ZnTs which are expressed in the brain, such as ZnT-3, may facilitate Zn2+ uptake into these vesicles 
(Palmiter et al., 1996). Also, MTs, specifically MT-3, is expressed in the brain which may also contribute 
to Zn2+ trafficking in the brain, although this requires further confirmation (Aschner et al., 1997; 
Masters et al., 1994). The mechanisms that enable release of Zn2+ from the presynaptic vesicles within 
neurons is poorly understood, although it likely occurs via exocytosis (Pérez-Clausell and Danscher, 
1986). Zn2+ is released from these neuron cells upon neuronal excitation as first illustrated in rats 
(which is indicative of a neurotransmitter), although the mechanism is yet to be elucidated. This Zn2+ 
release may contribute to toxic damage resulting in neurological disorders such as epileptic seizures 
(Aniksztejn et al., 1987; Assaf and Chung, 1984; Sloviter, 1985). Zn2+ is released from excitotoxic 
neurons, and upon excitotoxicity, Zn2+ is absent from the presynaptic neurons but is present in 
postsynaptic neurons and has been verified in ischaemic seizures (Frederickson, 1989; Koh et al., 1996; 
Sørensen et al., 1998; Suh et al., 1999; Yokoyama et al., 1986). Further studies have shown that Zn2+ is 
also present in synaptic vesicles of glutaminergic neurons, and upon neuronal activity is released into 
the synaptic cleft where it may go on to modulate post-synaptic receptors, ultimately relaying Zn2+-
mediated signals (Paoletti et al., 2009). These studies have demonstrated the importance of Zn2+ in 
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neuronal activity as a neurotransmitter and provide an exciting avenue to further explore Zn2+ in 
neurobiology (Frederickson, 1989; Frederickson et al., 2000, 1988; Suh et al., 1999).  
 
 
Figure 1.11. Subcellular localisation of ZIPs and ZnTs in nucleated cells. Generalised localisations of ZIPs (black arrows) and 
ZnTs (red arrows) are illustrated in this simple schematic in accordance with current findings. The direction of Zn2+ transport 
is illustrated by the arrows. Cytosolic Zn2+ is transferred in and out of different subcellular compartments such as the Golgi 
apparatus, lysosomes and vesicles via the ZIPs and ZnTs.  
Zn2+ mimics actions induced by hormones, cytokines and growth factors (Beyersmann and 
Haase, 2001), consistent with a signalling molecule. Zn2+ has been found to be co-stored with insulin 
and plays a crucial role in mediating the processing, storage and secretion of insulin in β-cells of the 
pancreas (Li, 2014). Zn2+ can bind to insulin to form a crystalline structure in dense vesicles which are 
released in response to physiological signals arising from increased glucose levels (Chausmer, 1998; 
Jansen et al., 2009; Taylor, 2005). Due to the potential regulatory role that Zn2+ may have on insulin 
release, Zn2+ supplementation may play a role in the management of diabetes. However, recent 
studies have demonstrated that the relationship between Zn2+ and diabetes is complicated, as reduced 
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levels of Zn2+ in the pancreas have been associated with the development of diabetes, whereas high 
levels may mediate damage to pancreatic cells via increased oxidative stress (Chimienti, 2013; Li, 2014; 
Wijesekara et al., 2009). Recent work studied the effect of Zn2+ supplementation in disease progression 
in diabetes, which carried out randomised double-blinded placebo-controlled phase 2 clinical trial with 
pre-diabetic subjects (Ranasinghe et al., 2018). Subjects were supplemented daily with 20mg of Zn2+ 
or placebo over a 12-month period. A significantly higher percentage of the subjects on placebo (no 
Zn2+) were found to develop type 2 diabetes in comparison to the treatment group (25.0% (control 
group) to 11.0% (treatment group), p<0.05). This clinical trial concluded that Zn2+ supplementation 
was able to reduce disease progression to debates by improving the β-cell function of the pancreas, 
as well as increasing insulin sensitivity and blood glucose. This trial, therefore, provides evidence to 
exploit the role that Zn2+ may play in preventing diabetic development, and at the correct dosage may 
have therapeutic potential. 
1.5.2 The role of Zn2+ as a secondary messenger  
A secondary messenger is defined as a molecule that is intracellularly modulated in response 
to extracellular stimuli and can then induce appropriate intracellular signalling events with regards to 
the extracellular stimuli, resulting in physiological changes in the cell (Lodish et al., 2000; Newton et 
al., 2016). Zn2+ regulation in cells is highly important as it contributes to the activity of proteins in 
signalling pathways and has a potential role as a secondary messenger (Andreini and Bertini, 2012; 
Taylor and Pugh, 2016; Vu et al., 2013; Yamasaki et al., 2007). Elevated [Zn2+]i modulates intracellular 
signalling pathways in several cell types, indicative of the mechanism of a secondary messenger. 
Changes in Zn2+ concentration have been found to modulate the activity of cytosolic proteins such as 
protein kinase C (PKC), protein kinase A (PKA), adenylate cyclase (AC), calmodulin-dependent kinase 
II (CaMKII), protein tyrosine phosphatases (PTPs) and caspase 3 (Brautigan et al., 1981; Csermely et 
al., 1988; Daaboul et al., 2012; Hubbard et al., 1991a; Lengyel et al., 2000; Perry et al., 1997).  
Zn2+ has been shown to act as an intracellular secondary messenger in mast cells, (Yamasaki 
et al., 2007). Stimulation of mast cells via the IgE receptor (Fcε receptor 1) induces increases in [Zn2+]i, 
originating from the endoplasmic reticulum (ER). The Zn2+ fluorophore Newport green was used in this 
study to determine Increases in [Zn2+]i. The [Zn2+]i increase is described as a ‘Zn2+ wave’ and is different 
from exogenous signalling. In this study, the concentration of [Zn2+]i was not confirmed, however, was 
observed by measuring increases in Newport green fluorescence which is consistent with increases in 
[Zn2+]i (Karim and Petering, 2016). Furthermore, the [Zn2+]i chelator TPEN was used in this study to 
confirm the increases in Newport green fluorescence was attributable to Zn2+. The authors of this 
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study suggest that the behaviour of Zn2+ is consistent with the action of a secondary messenger, in 
that its concentration varies in response to agonist stimulation, leading to intracellular signalling 
changes (Yamasaki et al., 2007). Further studies on monocytes have shown that stimulation with 
lipopolysaccharide (LPS) induced [Zn2+]i elevation and that chelation of [Zn2+]i inhibits LPS induced 
signalling in these cells (Haase and Maret, 2005). This study employed the Zn2+ fluorophore Fluozin-3 
[which has been said to be currently the most sensitive Zn2+ probe (Krezel and Maret, 2007; Muylle et 
al., 2006; Zhao et al., 2008)] to assess increases in [Zn2+]i. In the same manner, as the study described 
above (Yamasaki et al., 2007) TPEN was again used in this study to confirm the increases in Fluozin-3 
fluorescence were attributable to Zn2+. The finding from this study provide further evidence for a role 
for Zn2+ a secondary messenger (Haase et al., 2008). However further work to investigate the role of 
Zn2+ as a potential secondary messenger in other cell types has yet to be clarified (Nakashima-Kaneda 
et al., 2013), before it can be included with the major secondary messengers known to regulate cellular 
activity, including cAMP, Ca2+ and G-proteins (Hadfield et al., 2013; Huang et al., 2015; Kato et al., 
2017; Orem et al., 2017). Such work would provide further insight into the role of Zn2+ in human 
biology and could inform on the development of therapeutics targeting Zn2+-induced signalling 
1.6 The importance of Zn2+ in haemostasis   
Zn2+ deficiency has been found to impair the haemostatic response which is required for the 
cessation of bleeding. Initial studies on Zn2+-deficient rodents demonstrated the importance of Zn2+ in 
platelet function (Apgar, 1968; Gordon and O’Dell, 1980), as rodents subjected to dietary Zn2+ 
deficiency have an increased bleeding tendency and prolonged tail bleeding times, consistent with 
impaired platelet activation (Apgar, 1968). Further studies demonstrated that removal of dietary Zn2+ 
in rats results in impaired platelet function such as aggregation and secondary activation. Platelets of 
Zn2+-deprived rats result in impaired platelet aggregation which is the primary process in haemostasis, 
as platelet aggregation leads to thrombus formation (Gordon and O’Dell, 1980).  
As stated earlier, as a result of Zn2+ binding proteins in the plasma such as albumin and α2 
microglobulin which result in exchangeable and non-exchangeable Zn2+ pools respectively, the final 
free concentration of Zn2+ is approximately 0.5μM in the plasma (Foote and Delves, 1984; Rükgauer et 
al., 1997; Taylor and Pugh, 2016; Scott and Bradwell, 1983). This level may be elevated by release from 
the surrounding vasculature. Zn2+ is released from both damaged cells and activated platelets, which 
can give rise to elevated levels in labile free Zn2+ in the plasma; this suggests that free Zn2+ may be 
concentrated at sites of vascular injury, implying the biological importance of Zn2+ in wound healing 
(Barceloux, 1999; Hallmans and Lasek, 1985; Lansdown et al., 2007, 2007; Michaëlsson et al., 1980; 
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Savlov et al., 1962; Taylor and Pugh, 2016). Previous work has provided evidence to establish that Zn2+ 
mediates wound healing although the exact mechanisms that induce this are yet to be determined. 
Labile Zn2+ or protein bound Zn2+ has been found to accumulate in skin tissue, upon injury (Lansdown, 
1996; Lansdown et al., 2007; Sharir et al., 2010). Furthermore, the topical application Zn2+ of has been 
widely used to mediate efficient wound healing, thus further indicating the biological importance that 
Zn2+ has for cellular repair upon injury. Haemostasis enables wound healing, where platelets are the 
primary determinant of this process. Since activated platelets have been found to release Zn2+ as 
stated above, platelets may serve as an additional source of Zn2+ that may be released into the 
vasculature and promote the haemostatic process upon vascular injury. In addition, this interaction of 
Zn2+ with platelets may have an essential role in platelet activation (due to the association of Zn2+ 
deprivation and loss of platelet activity, as described earlier) and thrombus growth, which is to be 
explored further in this thesis (Murakami and Hirano, 2008, Kren et al., 2015, Matias et al., 2010).  
Zn2+ is involved in other haemostatic processes such as coagulation , anticoagulation and 
fibrinolysis (Woodier et al., 2015). Zn2+ plays a key role in contact-mediated activation on endothelial 
cells and platelets, as it can bind to a number of coagulation proteins such as FXII (Factor XII) and 
induce conformational changes, enabling the proteins to localise to polyanionic surfaces (Vu et al., 
2013). This results in the propagation of coagulation. Previous work has indicated that Zn2+ is involved 
in other haemostatic processes such as modulating fibrin formation, as well as playing a role in the 
anticoagulation pathways (Vu et al., 2013). However, the exact mechanism of Zn2+ in these processes 
is ill understood. Further work is still required to determine the contribution of Zn2+ in haemostasis 
and thrombosis (Woodier et al., 2015, Andreini et al., 2006).  
 
1.6.1 The influence of Zn2+ on platelet physiology  
Elevation of intracellular Zn2+ in platelets 
 Exogenous Zn2+ has been shown in recent work to gain entry into platelets, resulting in 
increased intracellular Zn2+ ([Zn2+]i) in platelets (Watson et al., 2016). In this study, using fluorometry, 
platelets loaded with the Zn2+ specific probe, Fluozin-3 (FZ-3) showed concentration-dependent 
increases in fluorescence upon application of exogenous ZnSO4 (Watson et al., 2016). In addition to 
this, collagen-adhered human platelets loaded with FZ-3 exhibited increases in fluorescence in a time-
dependent manner. These increases in FZ-3 fluorescence are consistent with increases of [Zn2+]i as a 
result of Zn2+ entry which was confirmed by the use of the specific [Zn2+]i chelator TPEN (Watson et al., 
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2016). However, the mechanisms involved in mediating this entry remain to be confirmed in platelets 
(Watson et al., 2016).  
Several mechanisms including Zn2+ transporters, exchangers and cation channels may mediate 
Zn2+ entry into platelets. As described earlier, the ZIP family of Zn2+ transporters could permit [Zn2+]i 
entry into platelets. This is the case with other cell types, where the application of exogenous Zn2+ has 
found to induce [Zn2+]i elevation via members of ZIP (Eide, 2004). ZIP7 (SLC29A7) and ZIP3 (SLC39A3) 
are present in the platelet proteome; however, the expression and function of these are yet to be 
confirmed in platelets (Burkhart et al., 2012; Taylor and Pugh, 2016). Glutamate receptors, which are 
expressed in platelets, may provide a pathway for Zn2+ entry, as has previously been demonstrated in 
neuronal cells (Kalev-Zylinska et al., 2014) (Sensi et al., 1997; Yin and Weiss, 1995). Glutamate is 
present in platelet dense granules and has been shown to mediate platelet activation, suggesting that 
glutamate mediates a secondary effect on platelet activation (Morrell et al., 2008). The relationship 
between glutamate and Zn2+ entry has not as yet been investigated. 
TRP channels may also provide a way of facilitating Zn2+ entry. TRP channels are non-selective 
cation channels, of which TRPC6 and TRPM7 are expressed in megakaryocytes. TRPC6 and TRPM7 are 
Zn2+ -permeable (Bouron and Oberwinkler, 2014; Carter et al., 2006; Monteilh-Zoller et al., 2003). 
TRPC6 canonically mediates DAG-dependant Ca2+ entry into platelets. However, work carried out on 
HEK293 cells shows that TRPC6 also mediates Zn2+ entry in a DAG-dependent manner (Chevallet et al., 
2014; Gibon et al., 2011). TRMP7 is more permeable to Zn2+ than Ca2+ and regulates Zn2+ cytotoxicity 
in cortical neurones. It is also expressed on megakaryocytes, making it a candidate Zn2+-entry channel 
(Inoue et al., 2010; Leng et al., 2015).  
NCX mediates both Ca2+ exit and entry in platelets, by exchanging three Na2+ for one Ca2+. NCX 
may also mediate Zn2+ exit and entry following work carried out on neuron cells, where employment 
of a Zn2+ specific probe, mag-Fura-5 was used to measure [Zn2+]i in cortical neurons. In this study by 
Sensi et al., (1997) the neurons exposed to extracellular Zn2+ and K+ show increases in mag-Fura-5 
fluorescence consistent with increased [Zn2+]i. This increase in fluorescence is inhibited by the addition 
of verapamil, gadolinium, nimodipine and ш-conotoxin GVIA, all blockers of voltage-gated Ca2+ 
channels. Thus, this inhibition indicates that [Zn2+]i elevation as a result of Zn2+ entry is consistent with 
entry via voltage-gated calcium channels. Furthermore, this study illustrates that increases of [Zn2+]i 
are sensitive to benzamil-amiloride, an NCX blocker, thus demonstrating NCX involvement of Zn2+ 
entry in neuron cells (Sensi et al., 1997). In platelets, three isoforms of NCX have been reported, 
primarily associated with Ca2+, but they may also be associated with Zn2+.  
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Zn2+ modulates platelet behaviour 
Upon entry, exogenous Zn2+ modulates platelet behaviour and influence signalling processes 
leading to platelet activation in a manner that is consistent with a platelet agonist (Heyns et al., 1985; 
Taylor and Pugh, 2016; Trybulec et al., 1993; Watson et al., 2016). Platelet aggregation which is 
fundamental for thrombus formation and a marker of full platelet activation occurs in response to Zn2+ 
in the millimolar ranges, whilst sub-activatory micromolar levels of Zn2+ potentiate platelet 
aggregation in response to sub activatory concentrations of collagen, ADP, U46619, thrombin and 
adrenaline (Heyns et al., 1985; Watson et al., 2016). In support of this observation, chelation of [Zn2+]i 
with the highly specific [Zn2+]i chelator, TPEN, prevents the potentiating effect (Trybulec et al., 1993). 
This work indicates a role for Zn2+ in platelet aggregation (Taylor and Pugh, 2016; Watson et al., 2016).  
Furthermore, application of exogenous Zn2+ to platelet suspensions following pre-treatment 
with antagonists of secondary signalling pathways in platelets reveals the mechanisms by which 
exogenous Zn2+ affects platelets. Antagonism of αIIbβ3 (integrin that enables platelet aggregation) 
abrogates platelet aggregation in response to Zn2+, indicating that Zn2+-induced aggregation is αIIbβ3 
dependant and not as a result of cation-mediated agglutination, and further supporting a role for Zn2+ 
in regulating platelet aggregation (Gowland et al., 1969; Watson et al., 2016; Zhang and Chen, 2012). 
Inhibition of TxA2, P2X1 Pre-treatment with aspirin (inhibits TxA2 production), NF449 and 2-MeSAMP 
(purinergic receptor antagonists) inhibit Zn2+ induced aggregation. This demonstrates that Zn2+-
induced aggregation is mediated by other secondary signalling pathways such as TxA2 and purinergic 
signalling which occur in response to primary platelet activation to further amplify platelet activity. 
Furthermore, cAMP signalling may play a role in Zn2+ induced aggregation due to the inhibitory effect 
induced by PGE1 which elevates cAMP.  
Inhibition of PKC fully abrogated Zn2+-induced aggregation confirming a role for PKC in Zn2+ -
induced platelet activation (Kowalska et al., 1994; Trybulec et al., 1993; Watson et al., 2016). PKC 
enzymes are metal-binding enzymes, which contain cysteine-rich zinc-binding domains necessary for 
structural integrity (Corbalán-García and Gómez-Fernández, 2006; Hubbard et al., 1991a). PKC activity 
is mediated via the application of exogenous Zn2+, but not other cations (Csermely et al., 1988). 
Furthermore, studies on Zn2+-deficient rats demonstrated reduced membrane association of PKC, 
suggesting a role for Zn2+ in PKC mobility during platelet activation (O’Dell et al., 1997). PKC mediated 
δ-granule release occurs in a Ca2+- and DAG-dependent manner, whereas Zn2+ induces α-granule 
release and not δ-granule release (Hashimoto et al., 1994; Varga-Szabo et al., 2009). This work 
suggests that PKC activation may potentiate platelet activation in differing pathways, possibly 
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mediated by Zn2+ (Corbalán-García and Gómez-Fernández, 2006; Harper and Poole, 2010; Hashimoto 
et al., 1994; Taylor and Pugh, 2016; Watson et al., 2016). 
Tyrosine phosphorylation is a critical step that occurs in intracellular signalling in platelets 
following receptor engagement (Buitrago et al., 2013; Murugappan et al., 2005). Recent work has 
shown that tyrosine phosphorylation of a wide variety of proteins occurs upon exogenous Zn2+ 
treatment in a time-dependent manner. The pattern of tyrosine phosphorylation induced by Zn2+ was 
found to differ from that induced by CRP-XL or thrombin, indicating that Zn2+ may be inducing a novel 
signalling pathway (Watson et al., 2016). Furthermore, increased phosphorylation of a high molecular 
weight protein (approximately 95kDa) was observed upon chelation of [Zn2+]i, suggesting that Zn2+ 
may influence tyrosine kinase or tyrosine phosphatase activity (Watson et al., 2016). 
Protein tyrosine phosphatases (PTP) positively and negatively regulate platelet activity, some 
of which are inhibited by Zn2+ (Lu and Zhu, 2014). Small fluctuations of [Zn2+]i inhibit phosphatases, 
which would otherwise enhance tyrosine phosphorylation (Brautigan et al., 1981). The platelet 
phosphatase PTP1B is a positive regulator of outside-in signalling and has an IC50 of 17 nM for Zn2+ 
(Haase and Maret, 2003; Tautz et al., 2015). Other platelet PTPs include SHP-1 which is also a positive 
regulator of platelet activation via αIIbβ3 activation following GpVI stimulation and SHP-2 which is a 
negative regulator of platelet activation. The IC50 of SHP-1 and SHP-2 for Zn2+ are 93 nM and 1-2 μM 
respectively (Haase and Maret, 2005, 2003; Lin et al., 2004; Ma et al., 2012; Mazharian et al., 2013). 
Additionally, the phosphatase PTEN which is a negative regulator of collagen-induced aggregation has 
an IC50 of PTEN for Zn2+ of 0.59 nM (Weng et al., 2010). These phosphatases could be prone to 
inhibition upon [Zn2+]i elevation in platelets, which could play a major role in Zn2+ induced platelet 
activation (Taylor and Pugh, 2016).   
 
The findings demonstrate the importance that Zn2+ may have on regulating platelet behaviour, 
as Zn2+ deficiency impairs platelet activity and high concentrations of Zn2+ induce full platelet 
activation as described above. The high concentrations of Zn2+ that induce full platelet activation as 
shown by Watson et al., 2016 may not be reached physiologically during haemostasis. However, the 
release of Zn2+ from ruptured atherosclerotic plaques or cells of the vasculature such as endothelial 
cells upon vascular injury may be high enough to induce Zn2+ mediated platelet activation (Siegel-Axel 
et al., 2006; Stadler Nadina et al., 2008; Taylor and Pugh, 2016; Watson et al., 2016). Interestingly 
chelation of [Zn2+]i reduces agonist-evoked activity as shown by Watson et al., 2016, thus indicating 
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that [Zn2+]i may be involved in regulating platelet activation. However, fluctuations in [Zn2+]i during 
platelet activation is yet to be studied. 
Elevation of [Zn2+]i may be mediated via intracellular stores in a similar manner to [Ca2+]i 
elevation from the DTS. In this manner, Zn2+ may be acting as an intracellular secondary messenger, 
as it is known to do so in other cell types [for example mast cells, as described in section 1.5.2 
(Yamasaki et al., 2007)]. The role of Zn2+ as a secondary messenger in platelet was the primary focus 
of thesis. As the principal objective, the work described in this thesis was to investigate whether Zn2+ 
concentrations in platelets changed in response to agonist stimulation, and to assess the influence 
[Zn2+]i may have had on platelets.  
    
1.7 Aims and objectives  
The information described above indicates that exogenous Zn2+ can induce platelet activation 
at high concentrations, and potentiating platelets to activation at submaximal concentrations. Thus, 
Zn2+ can act as a platelet agonist. However, numerous questions about the role of Zn2+ in platelet 
function remain. For example, the behaviour of Zn2+ as a secondary messenger in nucleated cells may 
indicate alternative activatory methods. Whether Zn2+ concentrations in platelets change as a result 
of conventional agonist stimulation has yet to be investigated. Furthermore, the effects of increases 
in [Zn2+]i on specific aspects of platelet activation have yet to be examined in detail. On the basis of 
known Zn2+-binding enzyme activities, minimal alterations of Zn2+ concentrations (picomolar to 
nanomolar concentrations) could be sufficient enough to alter platelet activity significantly. However, 
the nature of the targets of increased [Zn2+]i remain unclear. A better understanding of the role of Zn2+ 
in platelet function would provide insight into activatory processes and may provide potential targets 
for therapeutic application. 
The experimental program described in this thesis was designed to provide a better 
understand the mechanisms and roles of changes in [Zn2+]i on platelet function. During the course of 
the project, the aims changed and developed resulting in the hypothesis that Zn2+ is an intracellular 
secondary messenger in platelets. Initially, the primary aim was to investigate the influence of 
increased [Zn2+]i on platelet activation using Zn2+-specific ionophores. First findings of this project 
showed that application of Zn2+ ionophores evoked an activatory response which was shape change 
and sub-maximal aggregation. These early findings demonstrated that [Zn2+]i elevation could be 
evoked in platelets and may have a role in modulating platelet behaviour in a manner consistent with 
a secondary messenger. Thus, the elevation and role of [Zn2+]i was assessed during platelet activation 
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upon stimulation with platelet agonists to investigate the hypothesis that Zn2+ is an intracellular 
secondary messenger in platelets.  
The work carried out in this project demonstrated the first findings that [Zn2+]i is elevated 
upon agonist stimulation, and regulates platelet processes such as aggregation, shape change, granule 
release and phosphatidylserine exposure. Thus, this work provides novel evidence to illustrate that 
[Zn2+]i plays a significant role in platelets as a secondary messenger. 
 
The major questions addressed in this thesis are: 
1) Are platelet agonists able to elevate [Zn2+]i in platelets?  
2) Can [Zn2+]i release be modelled in a similar manner to Ca2+?  
3) What is the functional role of [Zn2+]i in platelet activity?  
4) What physiological mechanisms are employed in platelets to increase [Zn2+]i and is there 
interplay between Ca2+ and Zn2+ in platelet activation? 
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Chapter 2 
2.0 Materials and Methods 
2.1 Reagents and Materials  
Fluozin-3-AM (FZ-3, Zn2+ indicator) and Fluo-4-AM (FL-4, Ca2+ indicator) were purchased from 
Invitrogen (Paisley, UK). Z-VAD (Pan-caspase inhibitor) was obtained from RnD Systems (Abingdon, 
UK). Phospho-Vasodilator-Stimulated Phosphoprotein (VASP, Ser157) and Phospho-Myosin Light 
Chain 2 (Ser19) antibodies were from Cell Signalling Technology (Boston, USA) and fluorescently-
conjugated PAC-1, CD62P and CD63 antibodies were from BD Biosciences (Oxford, UK). Cross-linked 
collagen-related peptide (CRP-XL; GpVI agonist) was from Richard Farndale, Cambridge, UK. U46619 
(TPα receptor agonist) was from Tocris (Bristol, UK), thrombin (PAR agonist) was from Sigma Aldrich 
(Poole, UK). Cytochalasin-D (Cyt-D, actin polymerisation inhibitor) was from AbCam (Cambridge, UK). 
Clioquinol, (Cq, Zn2+ ionophore, C9H5ClINO, KdZn: 10-7M, KdCa: 10-4.9M), Pyrithione (Py, Zn2+ ionophore, 
C10H8N2O2S2, KdZn: 10-7M, KdCa: 10-4.9M), A23187 (Ca2+ ionophore, C29H37N3O6), N,N,N′,N′-Tetrakis(2-
pyridylmethyl)ethylenediamine (TPEN, Zn2+ chelator, KdZn: 2.6x10-16M, KdCa: 4.4x10-5M, (Arslan et al., 
1985b; Hyun et al., 2004b; Matias et al., 2010b; Qian and Colvin, 2016a), DM-BAPTA-AM (C34H40N2O18, 
KdZn: 7.9×10−9M, KdCa: 110×10−9M, (Arslan et al., 1985b; Hyun et al., 2004b; Matias et al., 2010b; Qian 
and Colvin, 2016a), and membrane permeant anti-oxidising proteins, PEG-super oxidise dismutase 
(SOD) and PEG-catalase (CAT) were from Sigma Aldrich. Unless stated, all other reagents were from 
Sigma Aldrich. 
 
2.2 Washed platelet suspension preparation from human blood 
Blood was obtained from consenting healthy donors and was extracted via venepuncture into 
sodium citrate anticoagulant (11 mM tri-sodium citrate) in accordance with the Declaration of Helsinki 
and institutional ethics requirements. The whole blood was centrifuged for 15 mins at 240g. Platelet 
rich plasma (PRP) was extracted and mixed with prostaglandin E1 (PGE1, 2 µM) before being 
centrifuged at 640 x g for 15 min. The platelet-poor plasma (PPP) was discarded and the platelet pellet 
re-suspended in Calcium-Free Tyrodes (CFT) solution (10 mM N-2-hydroxyethylpiperazine-N0-2-
ethanesulfonic acid (HEPES), 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 5 mM glucose, 0.42 mM NaH2PO4, 
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12 mM NaHCO3, pH 7.4). Platelets were counted using a coulter counter and re-suspended to 2x108 
/ml before being allowed to rest for at least 30 min at 37oC. 
 
2.3 Intracellular Zn2+ assessment 
The role of intracellular Zn2+ ([Zn2+]i) in platelets and general cellular mechanisms, as described 
in Chapter 1 has always been overlooked in favour of Ca2+. Many (cell permanent, via the constituted 
acetoxymethyl (AM) ester group) modulators that have been employed to assess intracellular Ca2+ 
([Ca2+]i) in platelets and various cell types include fluorescent probes (fluorophores that asses 
fluctuations in [Ca2+]i) and chelators, often have higher affinities for Zn2+ than Ca2+ as illustrated by 
Table 2.1. As shown by this table (Table 2.1), all the Ca2+ fluorophores have higher affinities for Zn2+ 
than Ca2+. However, the affinity (Kd value) for the Ca2+ fluorophore has not been confirmed ( indicated 
by the * in Table 2.1). However Fluo-4 has been screened to evoke a much higher fluorescent intensity 
compared to other cations including Zn2+ (“Fluo-4, AM, cell-permeant",Thermo Fisher Scientific, 2018; 
Li et al., 2003; Paredes et al., 2008; Smith and Parker, 2009) thus demonstrating that Fluo-4 may serve 
as specific Ca2+ probe unlike the other Ca2+ fluorophores ( Table 2.1). Thus Fluo-4 was employed as a 
Ca2+ probe in this thesis to assess fluctuations in [Ca2+]i as a comparative measure to changes in [Zn2+]i. 
The specificity and validity of FL-4 to Ca is shown in figure 2.1, in section 2.3 below. Although 
contradictory evidence in previous work (Sensi et al., 2009) has shown that Fluo-4 has been able to 
bind to Zn2+ which is an underlying problem with Ca2+ probes and is a limitation that can not be 
currently overcome.  
In contrast to Ca2+ fluorophores, commonly used Zn2+ fluorophores have higher affinities for 
Zn2+ than Ca2+ (Table 2.1). Similarly to Fluo-4, the affinity (Kd) of the Zn2+ fluorophore Fluozin-3 (FZ-3) 
to Zn2+ is known (indicated by the * in Table 2.1) but the affinity to Ca2+ is not yet confirmed. However, 
FZ-3 is responsive to Zn2+ in the nanomolar range and is not significantly affected by Ca2+ (Zhao et al., 
2008). Furthermore FZ-3 has been shown to have higher affinity to Zn2+ than other Zn2+ fluorophores, 
and has a higher sensitivity to Zn2+ (Assaf and Chung, 1984; Bailey, 2000; Gee et al., 2002), thus making 
this probe useful for detecting small fluctuations in [Zn2+]i which is desirable due to small fluctuations 
in [Zn2+]i expected to occur in cells and platelet ( as discussed in Chapter 1). Therefore, in this thesis, 
FZ-3 was employed as the Zn2+ probe to measure fluctuations in [Zn2+]i 
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Table 2.1 Commonly used Ca2+ and Zn2+ fluorophores and chelators 
 
 
Chelators are a tool which provides an assessment to see if the signalling being seen is 
attributable to the cation in question. The widely used Ca2+ chelator, as described in Chapter 1 BAPTA 
has a higher affinity for Zn2+ than Ca2+. Therefore the use of BAPTA to assess Ca2+ signalling may not 
provide an accurate assessment, as the signalling evoked by Ca2+ may also be attributable to Zn2+. 
In contrast to BAPTA, the affinity of the Zn2+ chelator, TPEN for Zn2+ is much higher than for 
Ca2+. The Kd for TPEN and Zn2+ is 2.6x10-7 nM whereas with Ca2+ is 4.4x10-5 M(Matias et al., 2010b; Qian 
and Colvin, 2016a). Furthermore, TPEN has a much higher affinity for Zn2+ than other cations such as 
Fe2+, Mn2+, and Mg2+ where the Kds of TPEN and these cations are 2.4x10-6 nM, 5.4x10-2 nM, and 2x107 
nM, respectively (Matias et al., 2010a; Qian and Colvin, 2016b). Thus, the employment of TPEN has 
become a chelator of choice for exploring Zn2+ signalling and was used in this thesis. 
 
2.4 Cation mobilisation studies 
Fluozin-3-AM (FZ-3) and Fluo-4-AM (FL-4) are fluorophores (section 2.3) that can be used to 
detect changes in intracellular Zn2+ concentrations [Zn2+]i or calcium concentrations, [Ca2+]i 
respectively.. These dyes were reconstituted to 5 mM in DMSO, before being loaded into PRP to a final 
concentration of 2 µM for 30 min at 37oC. PRP was centrifuged for 15 minutes at 640 x g, and the 
platelet pellet was then re-suspended to the original PRP volume using CFT and rested at 37°C for 30 
min prior to use. Fluorescence was monitored using a Fluoroskan Ascent fluorometer 
(ThermoScientific, UK) using 485/535 nm excitation and emission filters respectively. Results are 
expressed as an increase of background-corrected fluorescence at each time point relative to baseline: 
(F1-Fbackground)/(F0-Fbackground).  
Reagent  Description/application ~Kd for Ca2+ (in 
vitro) 
~Kd for Zn2+ (in 
vitro) 
Fura-2-AM Ca2+ -fluorophore  2.3x10-7 M 3x10-9 M 
Fluo-4-AM Ca2+ -fluorophore 3.35x10-7 M * 
BAPTA-AM Ca2+ -chelator 110x10-9 M 7.9 x 10 -9 M, 
Newport green Zn2+ -fluorophore 1x10-4 M 1x10-6 Μ 
Fluozin-3-AM Zn2+ -fluorophore * 15Nm 
TPEN-AM Zn2+ -chelator 4.4 x10-5 M 2.6 x10-16 M 
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Specificity and validation of Fluozin-3 and Fluo-4 
Figure 2.1 illustrates calibration curves showing the fluorescence induced by the cations at 
different concentrations and the specificity of FZ-3 and FL-4 to Zn2+ and Ca2+ respectively. This 
calibration curve exhibits the minimal (Fmin) and maximal (Fmax) fluorescent values exhibited by FZ-3 
and FL-4. Washed platelets suspensions were loaded with either FZ-3 or FL-4, before being treated 
with different concentrations of exogenous Zn2+ (ZnSO4) or Ca2+ (CaCl2).  
 
 
Figure 2.1 Calibration curves exhibiting the fluorescence range and specificity of FZ-3 and FL-4 to Zn2+ and Ca2+. Washed 
Fluozin-3 (FZ-3) (A) and (B), or Fluo-4 (FL-4) (C) and (D) loaded platelet suspensions were treated for 15 mins with Zn2+ or 
Ca2+ ionophores in the presence of doses of exogenous 2 mM CaCl2 or ZnSO4, to determine Fmax values. Fz-3 Fmin was obtained 
from platelets pre-treated for 15 mins with 50 µM TPEN in (A), where the dose of ZnSO4 is 0μM)., Fmax was obtained following 
co-incubation with 5 µM Py with 2 mM ZnSO4 for 15 mins as illustrated on (A). Fluo-4 Fmin was obtained from platelets pre-
treated for 15 mins with 2mM EGTA in the absence of extracellular Ca2+ (D). Fmax was obtained following pre-incubation with 
1 µM A23187 in the presence of 2 mM CaCl2 (D). (A)and (C); ● 0μM ZnSO4, ■ 1μM ZnSO4, ▲3μM ZnSO4, ▼ 10μM ZnSO4, ♦ 
30μM ZnSO4,○ 100μM ZnSO4, □ 2mM ZnSO4. (B)and (D); ● 0μM CaCl2, ■ 1μM CaCl2, ▲3μM CaCl2 , ▼ 10μM CaCl2, ♦ 30μM 
CaCl2 ,○ 100μM CaCl2 , □ 2mM CaCl2. 
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To measure the Fmin value of FZ-3 platelets were pre-treated with 50 μM of TPEN and 5 μM 
pyrithione (Py) which enabled platelet Zn2+ to be equilibrated enabling more efficient chelation of Zn2+ 
by TPEN. Similarly, for measuring the Fmin value of FL-4 to Ca2+, 2 mM EGTA and 10μM BAPTA was used 
in conjunction with 1 μM of A23187.  
To measure Fmax values of FZ-3 and FL-4 to Zn2+ and Ca2+ respectively, 2 mM of ZnSO4 or CaCl2 
along with 5 μM of Pyrithione for the FZ-3 loaded platelets, and 1 μM of A23187 for the FL-4 loaded 
platelets. For these Fmax values, the low doses of the ionophores (Py and A23187) that were applied to 
equilibrate the cation (as described above) also acted as cation transporters ( facilitating entry of the 
exogenous cation, into the platelets). This ensured that the respective cation was getting into the 
platelets and providing a correct fluorescent value. These values were used as a reference mark to 
provide indications of the levels of concentrations of the cations present (Bootman et al., 2013).  
Application of ZnSO4, resulted in a dose-dependent increase in FZ-3 fluorescence (Figure 
2.1A), whereas application of CaCl2, resulted in a dose-dependent increase in FL-4 fluorescence (Figure 
2.1D). The maximum and minimum FZ-3 fluorescence (Fmax and Fmin) evoked by ZnSO4 was 32.8 ± 3.4 
and 1.0 ± 0.1, respectively (Figure 2.1A). The maximum and minimum FL-4 fluorescence (Fmax and Fmin) 
evoked by CaCl2 was 24.1 ± 2.8 and 1.0 ± 0.1, respectively (Figure 2.1D). 
 Furthermore, the specificity of the FZ-3 and FL-4 to Zn2+ and Ca2+ respectively was also 
illustrated in Figure 2.5.1. There were no significant changes in FZ-3 fluctuations upon exogenous CaCl2 
treatment and no changes in FL-4 fluctuations upon exogenous ZnSO4 treatment. Thus, providing 
strong evidence that FZ-3 is highly specific to Zn2+ and not to Ca2+ and that FL-4 is highly specific to Ca2+ 
and not to Zn2+. Figure 2.5.1 serves a positive control for quantification of FZ-3 and FL-4 fluorescence 
and provide validity of these probes as indicators of fluctuations of [Zn2+]i and [Ca2+]i, respectively.  
 
2.5 Measurement of reactive oxygen species 
Washed platelets were loaded with the reactive oxygen species (ROS) probe 2’, 7’-
Dichlorofluorescein diacetate (DCFH) in the same manner as FZ-3 and FL-4 in section 2.5 above. DCFH 
(10μM) is a widely used cell permeable ROS-specific probe (Baranwal et al., 2014; Kitajima et al., 2016; 
Liu et al., 2017). This probe is de-esterified intracellularly resulting in the highly fluorescent 2’,7’- 
Dichlorofluorescein to fluoresce upon oxidation (Kitajima et al., 2016; Lopes Pires et al., 2017), 
enabling rapid and sensitive detection of ROS (Kitajima et al., 2016).  
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2.6 Light transmission platelet aggregometry 
Platelet aggregation is the most widely investigated functional response that is induced by 
platelets (Born and Cross, 1963). This is primarily because the formation of blood clots ( as a result of 
platelet aggregation) is of most interest to medical scientists that are studying platelet function, as 
aggregation served as the primary response to platelet activation and thrombus (blood clot) 
formation(Born, 1962). This is further reflected by antithrombotics and anti-platelet drugs being 
characterised as anti-aggregatory agents (Koo et al., 2010; Makris et al., 2013)  
Light transmission aggregometry is a widely used technique that measures the aggregatory 
response of platelets(Born et al., 1978; Born and Cross, 1963). The basic principle of this technique 
(illustrated by Figure 2.2) is that light is passed through stirred suspensions of washed platelets 
(section 2.2) in cuvettes, where the light transmission at this stage represents the baseline and 0% 
aggregation (Born et al., 1978; Born and Hume, 1967; Michal and Born, 1971). Upon the addition of a 
stimulus, platelets activate and undergo shape change which results in a reduced proportion of light 
passing through the suspensions, thus illustrating a reduction in the percentage of light transmission 
upon the initial activatory stages of platelets (Michal and Born, 1971). This is followed by an increase 
in light transmission as the platelets aggregate and take up less volume in the cuvette (Latimer, 1983). 
 
 
Figure 2.2. Light transmission aggregometry. Addition of a stimulus (in stirring conditions) induces a drop in the light 
transmission % from the baseline (0% aggregation), as a result of platelet shape change. As the platelets change shape, less 
light is able to pass through the cuvette. Aggregation proceeds following shape change which results in an increase in light 
transmission %. As the platelets aggregate, more light is able to pass through the cuvettes, eventually resulting in full platelet 
aggregation and maximal light transmission %.   
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 Aggregation of washed platelet suspensions was quantified using an AggRam aggregometer 
(Helena Biosciences, Gateshead, UK) under stirring conditions at 37°C. Background light transmission 
was established using cuvettes containing CFT. Stir bars and 250 µL of rested washed platelet 
suspensions were added to cuvettes which were then placed in the aggregometer. 2.5 µL (a 1:100 
dilution) of agonist was added to the platelets. Aggregation traces were acquired using proprietary 
software (Helena Biosciences) and analysed with Microsoft Excel and GraphPad Prism (Version 7.01). 
 
2.7 Western Blotting of platelet proteins  
Western blotting was used to examine the expression or changes in the phosphorylation state 
of specific platelet proteins in response to specific treatments. Platelets were prepared as before and 
stimulated with the given agonists for the given time in aggregometry cuvettes. Reducing sample 
buffer (0.125 M Tris HCL pH 6.8, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol 
blue) was added (5%) to the platelets, which were then heated to 95oC for 10 minutes before being 
centrifuged at 13000 x g for 10 min to pellet insoluble materials. Samples were electrophoresed on 
SDS-PAGE gels at 100V for 2 hours. Electrophoresed proteins were transferred to a polyvinylidene 
difluoride (PVDF) membrane and preincubated with methanol for 5 mins followed by transfer buffer 
(1 x NuPAGE transfer buffer, ThermoFisher) for 5 mins. Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) gels were assembled with PVDF membrane and filter paper on a semi-dry 
protein transfer apparatus (Bio-Rad, Trans-Blot Turbo transfer system, UK). Proteins were transferred 
from the gel to the membrane at 15V for 30 mins. Membranes were blocked with 1 x Tris-buffered 
saline, TBS (20mM Tris, 150mM NaCl, pH 7.6) with 5% bovine serum albumin buffer) for 1 hour. The 
membranes were then incubated with primary antibody in blocking buffer (TBS; 5% bovine serum 
albumin; 0.05% Tween-20) and were incubated overnight at 4oC under constant agitation. Membranes 
were washed with TBS/0.05% Tween-20 three times for 5 minutes to remove excess antibody. The 
membranes were then incubated for 1 hour at room temperature with horseradish peroxidase (HRP)-
conjugated or the fluorescently tagged secondary antibodies. The membrane was rewashed three 
times as before. Antigen-antibody interactions were visualised on the membrane following incubation 
with Enhanced Chemiluminescent reagent (ECL). Table 2.4.1 outlines the antibodies that were used 
for Western blotting. 
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 0.2Table 2.7.1 Primary antibodies used for Western blotting  
Primary Antibody Species 
derived from 
Dilution  Supplier  References of application 
on human samples 
Anti-
Phosphotyrosine 
Antibody, clone 4G10 
Mouse 1:5000 Merck 
Millipore 
(Aman et al., 2011; Bochtler 
et al., 2012; Lin et al., 2009; 
Petersen and Hagan, 2005; 
Roll and Reuther, 2012; 
Rollet-Labelle et al., 2013) 
β-Actin  Mouse 1:1000 AbCam (Du et al., 2018; Fiaturi et al., 
2018; Joshi et al., 2018; Lee 
et al., 2018; Minashima and 
Kirsch, 2018) 
Phospho-Myosin 
Light Chain 2 (Ser19) 
Rabbit 1:1000 Cell 
Signalling 
Technology  
(Cao et al., 2017; Miskolczi et 
al., 2018; Mogami et al., 
2018; Ye and Sun, 2017) 
Phospho- Phospho-
Vasodilator-
Stimulated 
Phosphoprotein 
(VASP, Ser157) 
Rabbit 1:1000 Cell 
Signalling 
Technology 
(Bernusso et al., 2015; 
Canton et al., 2016) 
Anti-phospho-ZIP7 
(Ser275/276) 
Mouse 1:1000 Merck 
Millipore 
(Olgar et al., 2018; Taylor et 
al., 2012, 2008) 
 
 
3Table 2.7.2 Secondary antibodies used for Western Blotting  
Secondary 
Antibody  
Species 
derived from 
Dilution  Supplier  References of application 
on human samples 
α – Mouse 
horseradish 
peroxidase (HRP)  
Goat 1:5000 Thermo-
Fisher 
(Kim et al., 2016) 
α – Rabbit HRP Donkey 1:5000 Thermo-
Fisher 
(Zhao et al., 2015) 
α – Goat HRP Rabbit 1:5000 Thermo-
Fisher 
(Alsted et al., 2009; 
Wingelhofer et al., 2016) 
 
2.7.1 Western blot quantification 
ImageJ (v1.45, NIH, Bethesda, MD, USA) was used as a tool to quantify the expression of western blots 
( refer to section 30.13, Image J user guide, (Ferreira and Rasband, 2012). Levels of protein expression 
were quantified as a ratio of each protein band relative to the loading control of that protein bands 
lane. Values were expressed as arbitrary units. Quantification of western blots via Image J has been 
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widely used as a consistent measurement to assess levels of expression of proteins (Gassmann et al., 
2009; Kumar et al., 2014; Lopes Pires et al., 2017).  
 
2.8 Quantification of Phosphatidyl-serine (PS) exposure in platelets  
Fluorescein isothiocyanate (FITC)-Annexin V binds to exposed Phosphatidyl-serine (PS) in a 
Ca2+ dependent manner (Meers and Mealy, 1993). Thus, this protein enabled assessment of PS 
exposure that occurs on activated platelets that may also be procoagulant (Sims et al., 1989; 
Thiagarajan and Tait, 1990; Zwaal et al., 1992).  
Washed platelets were prepared to 2x108/mL as described in section 2.2. FITC_-Annexin V 
antibody was diluted in Tyrode’s solution (CFT buffer containing 2mM CaCl2, at pH 7.4) to a 1:100 
dilution (Annexin V solution). 50 µl of washed platelets were diluted into 445 µl of Tyrodes solution 
containing the treatment of interest at its final working concentration and allowed to incubate at the 
designed time. Following incubation for the designed time, 25 µl of sample (washed platelets in 
Tyrodes with treatment of interest) was added to 25 µl of the Annexin V solution and analysed using 
the BD Accuri C6 flow cytometer (Beckton Dickinson, UK) via the FL1-A laser of this instrument to 
detect the FITC-tagged Annexin V antibody (representation of this is shown in Figure 2.3).   
 
 
Figure 2.3. Representation of Annexin V binding via flow cytometry. Increased binding of Fluorescein isothiocyanate (FITC)-
Annexin V antibody binds to exposed Phosphatidyl-serine (PS). This results in a shift of the FL1-A laser reading, which 
increases (shifts to the right), illustrating a population of platelet that is annexin-V bound (Annexin V +), that is distinguishable 
from platelets that are not bound to annexin V (Annexin V -).  
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2.9 Detection of platelet activation  
The PAC-1 antibody is widely used to detect activation of αIIbβ3. PAC-1 recognises an epitope 
on activated αIIbβ3 which is very close to the binding site of fibrinogen. PAC-1 binds to of αIIbβ3 when it 
is converted into a high-affinity binding state following platelet activation (Bennett et al., 1988; Shattil 
et al., 1986, 1985). Activated αIIbβ3 binds to the arginine-glycine-aspartate (RGD) sequence found on 
proteins such as fibrinogen. Binding of PAC-1 to αIIbβ3 is inhibited by peptides which contain the 
arginine-glycine-aspartate sequence, thus providing further evidence to confirm the ability of PAC-1 
to bind to the upregulated state (high-affinity state) of αIIbβ3(Gartner and Bennett, 1985; Plow et al., 
1985; Taub et al., 1989). 
The  CD62P (a membrane glycoprotein also known as P-selectin) antibody is used to assess α-
granule release in platelets which occurs upon platelet activation (Matowicka-Karna, 2016). α-
granules contain  CD62P which is transported rapidly and expressed on the platelet surface upon 
platelet activation (Fägerstam et al., 2000). The  CD62P antibody specifically binds to  CD62P and 
provides an assessment of the level of  CD62P externalisation, which thus quantifies α-granule release 
(Frenette et al., 2000). 
The CD63 antibody is widely used to assess dense granule release upon platelet activation 
(Vinholt et al., 2017; Wauters et al., 2015). CD63 (a membrane glycoprotein) is present in dense 
granules and upon platelet activation, is rapidly translocated to the surface of platelets (Heijnen and 
van der Sluijs, 2015; Joseph et al., 1998). Binding of the anti-CD63 antibody to CD63 quantifies dense 
granule release (Choudhury et al., 2007).  
Washed platelet suspensions were prepared as previously described (section 2.2) and 
incubated with fluorescently-conjugated antibodies targeting markers of platelet activation: FITC-
PAC-1 (Integrin αIIbβ3 activation), Phycoerythrin (PE)-CD62P (α granule release) and Alexa Fluor 647-
CD63 (dense granule release). Antibody binding, following agonist or ionophore stimulation, was 
assessed using an Accuri C6 flow cytometer over the designed time. The total volume per sample that 
was analysed by the flow cytometer was 120 µL plus the volume of the antibody (1.2μL). 3 µL of 
washed platelets were added to 105 µl of CFT, with 1.2 µL of the fluorescently-conjugated antibodies 
(1:100 dilution), and 12 µl of the agonist or ionophore was added at the appropriate concentration.  
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2.10 Real-time analysis using flow cytometry 
Washed platelets were prepared in the same manner as describes in section 2.4. The samples were 
analysed using the Accuri C6 flow cytometer in the same manner as described in section 2.9; however 
the agonist was added after 30 seconds, and changes in fluorescence of the probe were measured in 
real time, to assess live changes in signalling upon treatment. Real-time analysis using flow cytometry 
has been widely used in biological application and has been used to asses real-time mobilisation of 
Ca2+ in human platelets and depletion of Ca2+ stores (Park et al., 2002; Vines et al., 2010). Thus, this 
type of analysis was employed in this thesis to assess real-time mobilisation of cations and to assess 
store-operated cation entry and mobilisation. Gates were applied every 5 seconds on the plot, which 
gave a reading every 5 seconds for analysis.   
 
2.11 Platelet spreading  
Real-time imaging of platelet spreading was carried out using the protocol employed by Aslan 
et al., 2012. Glass coverslips (25mM diameter, 1.5 thickness, Fisher Scientific) were coated with 
100μM of fibrinogen and were left to incubate at 4oC for 24 hours. Following incubation, the coverslip 
was washed with PBS three times ( phosphate buffered saline) and blocked with 1 % BSA (bovine 
serum albumin, blocking buffer), before being washed again with PBS three times, making sure the 
coverslips did not dry out.  
 Washed platelet suspensions were prepared in the same manner described in section 2.2. 
However, a higher concentration of 2x107 was used to enable easier visualisation of platelets under 
the microscope. Washed platelets were stained (incubated for 1 hour at 37oC, following preparation 
of the washes platelets) with 1μM of DIOC6 (Dihexyloxacarbocyanine Iodide) which is a green 
fluorescent membrane stain and was employed to enable quantification of the surface coverage of 
spread platelets. 10μL of platelets with their appropriate treatment was pipetted directly onto the 
fibrinogen-coated coverslip, and after each specified time point in the experiment, platelets were fixed 
with 10μL of formaldehyde (0.85% NaCl and 0.2% formaldehyde), before being washed with CFT to 
wash away the fixative and any unbound platelets. 
 Images of platelets adhering to coated fibrinogen (100µM) coverslips were acquired using an 
LSM510/Axiovert laser scanning confocal microscope with 60x oil NA1.45 objective (Zeiss, UK). Surface 
coverage of DIOC6-stained platelets was quantified using ImageJ (v1.45, NIH, Bethesda, MD, USA) and 
the LSM reader plugin in the software. The fluorescence of the DIOC6 stain on the spread platelets 
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was measured to assess the surface area coverage of the platelets. The laser excitation/ emission of 
the confocal microscope that was used to assess DIOC6 fluorescence was 488/543nM.   
 
2.12 Tissue culture 
2.12.1  Culture of mouse embryonic fibroblast (MEF) cell lines 
In addition to platelets, mouse embryonic fibroblasts (MEF) were employed to assess the 
influence of intracellular Zn2+ on cytoskeletal changes that may occur in cells that were found to be 
significantly influenced by Zn2+ in platelets in this thesis.  
MEF are widely used as models to study cell spreading for a variety of reasons including; they 
are the primary source of extracellular matrix (ECM) proteins, which, in addition to providing a scaffold 
for cells, play key roles in determining cell phenotype and function (Ltd, 2011).Thus MEF are ideal cell 
lines to efficiently study cytoskeletal rearrangement in nucleated cells (Cai et al., 2006; Chen et al., 
2016; Ltd, 2011; J. Wang et al., 2014) 
 
MEF cells were cultured in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 
10% foetal bovine serum (FBS), 2 mM glutamine, 10μL/mL of the Penicillin-Streptomycin solution in 
an incubator at humidified conditions (37oC and 5% CO2). Cells were passaged once they had reached 
approximately 80% confluence. Media was removed, and the cells were washed with Dulbecco’s 
Phosphate Buffered Saline (DPBS) before being treated with trypsin-EDTA (5 mM for 2-3 mins in a 
humidified incubator) to detach the cells from the flask. Cells were then re-suspended in fresh DMEM, 
centrifuged 200 x g for 5 minutes, and the pellet was resuspended in fresh DMEM. The cells were 
diluted down to their appropriate concentrations for the designated experiment or were sub-cultured 
for continuous culturing.     
  
2.12.2 Mouse embryonic fibroblast (MEF) spreading assays 
MEF cells were seeded into 6 well plates prior to experimentation for the designated time periods. 
Following incubation, cells were rinsed with DPBS and fixed with 4% paraformaldehyde (PFA) for 
approximately 10 minutes at room temperature. Cells were then washed with DPBS and 
permeabilised with 0.2% Triton-X100 in 5% goat serum-DPBS (goat serum was added here as a 
blocking agent) for 15 minutes at room temperature. The cells were then washed with DPBS and actin 
was stained for 1 hour at room temperature with Phalloidin- iFluor 594 Conjugate (Cayman Chemical, 
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USA), at a 1:1000 dilution. Cells were washed with DPBS and then co-stained 4’,6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI). Following staining, the cells were then imaged using the ZOE 
fluorescent cell imager (Bio-Rad). DAPI was visualised using excitation/emission of 358/461nm, while 
Phalloidin-iFluor594 was visualised using excitation/emission of 590/618nm 
 
2.13 Data Analysis  
Maximum and minimum aggregation, F/F0 values, activation marker percentages and Annexin 
V binding were calculated using Microsoft Excel. Western blots and platelet spreading were analysed 
calculated ImageJ (NIH Image) and Microsoft Excel. Data were analysed in GraphPad Prism 7.01 by 
either student t-test or two-way ANOVA followed by Tukey’s post hoc test with Dunnett’s, Tukey’s or 
Sidak’s multiple comparison tests as appropriate. Data are presented as the means±SEM and 
significance is denoted as **** (P<0.0001), *** (P<0.001), ** (P<0.01) and * (P<0.05). 
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Chapter 3  
3.0 Intracellular platelet Zn2+ increases in response to physiological 
agonists and acts as a secondary messenger.  
3.1 Background 
The role and importance of Zn2+ in haemostasis and platelets has not been fully elucidated. 
Zn2+ is concentrated in atherosclerotic plaques, and also in epithelial cells, from where it is released 
upon damage (Sharir et al., 2010; Stadler Nadina et al., 2008). Thus Zn2+ present in the vasculature is 
likely to be present at areas of haemostasis and may be elevated in the microenvironment of a growing 
thrombus. Zn2+ has an acknowledged role in haemostasis, in particular in coagulation, where it acts as 
a cofactor of Factor XII (Vu et al., 2013). Exogenous Zn2+ enters platelets and induces platelet activation 
that is dependant on protein tyrosine phosphorylation, although the specific proteins that undergo 
tyrosine phosphorylation have not been confirmed (Watson et al., 2016). The route of Zn2+ entry into 
platelets is yet to be determined, although candidate mechanisms potential involve Zn2+ transporters 
(ZIPs), TRP channels, glutamate receptors, and the Na2+/Ca2+ exchanger (NCX, Bouron and 
Oberwinkler, 2014; Carter et al., 2006; Kalev-Zylinska et al., 2014; Morel et al., 2008; Sensi et al., 1997; 
Yin and Weiss, 1995). Exogenous Zn2+ at sub activatory concentrations (30μM ZnSO4) potentiates 
platelet aggregation in response to agonists including thrombin and CRP-Xl at low concentrations, 
ranging from 0.03-1U/mL for thrombin and 0.01-0.3 μg/mL for CRP-XL (Watson et al., 2016). This work 
provides evidence that Zn2+ serves as an agonist, and may play an integral part in platelet activation 
and signalling. 
The importance of elevation of intracellular Ca2+ ([Ca2+]i) in response to agonist stimulation of 
platelets is well documented. Agonists such as CRP-XL, thrombin, and U46619 (a thromboxane A2 
receptor agonist) induce [Ca2+]i release from the DTS (dense tubular system) via the the activity of PLC 
isoforms (PLCβ and PLCγ, Figure 1.4.1) (Varga-Szabo et al., 2009). Increases in [Ca2+]i couple to 
physiological responses, consistent with a role as a secondary messenger. Conversely, the 
physiological role of intracellular Zn2+ ([Zn2+]i) has yet to be investigated in platelets. Whilst platelets 
are known to release Zn2+ via their α-granules (Marx et al., 1993a), whether [Zn2+]i increases upon 
activation, as well as the nature of storage sites are yet to be determined. Labile or ‘free’ Zn2+, as well 
as membrane-bound and protein-bound Zn2+ which act as intracellular storages sites for Zn2+, are 
found in various cell types such as neurons and immune cells. The mobilisation of Zn2+ from these 
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intracellular stores increases Zn2+ bioavailability which is then able to regulate downstream processes 
(Marger et al., 2014; Nakashima-Kaneda et al., 2013; Takeda et al., 2014).  
Proteins such as metallothioneins (MT’s) can sequester Zn2+ and act as a Zn2+ store. The release 
of Zn2+ from metallothionines is redox-dependent (Andrews, 2001; Hardyman et al., 2016; Marreiro 
et al., 2017). These proteins contain cysteines which have thiol groups that undergo redox changes 
(Bell and Vallee, 2009). Under reducing conditions,thiols are able to bind Zn2+. However, upon 
oxidation (for example by reactive oxygen species, ROS), crosslinking the thiols results in liberation of 
Zn2+ (Hardyman et al., 2016; Kimura and Kambe, 2016). Thus elevation of [Zn2+]i in nucleated cells is 
dependant on ROS concentration and signaling (Faller et al., 2014; Tang et al., 2014). ROS levels and 
antioxidant levels are tightly maintained to avoid oxidative stress which is evoked upon an imbalance 
between levels of ROS and antioxidants (such as superoxide dismutase (SOD) and catalase (CAT). The 
role of Zn2+ in the regulation of oxidative stress nucleated cells has been widely investigated (Marreiro 
et al., 2017). SOD utilises metal ions such as copper (Cu2+) and Zn2+ as co-factors to convert ROS species 
such as O2- (superoxide radicals) to less harmful ROS species such as H2O2 (hydrogen peroxide) (Noleto 
Magalhães et al., 2011; Paz Matias et al., 2014; Tainer et al., 1983). Therefore Zn2+ is important for 
preventing oxidative stress, and may have evolved as a defense mechanism against oxidative stress 
(Foster and Samman, 2010). Tight regulation of [Zn2+]i is therefore critical for the regulation of 
oxidative stress, as excessive Zn2+ can induce oxidative stress and pro-inflammation and cytotoxicity 
as illustrated in studies on neurons (described in Chapter 1) (Bush and Tanzi, 2008; Frederickson, 1989; 
Inoue et al., 2010). In support of this observation, it has been shown that Zn2+ deficiency evoke 
oxidative stress, for example in endothelial cells, where Zn2+ deficiency results in increased activity of 
inflammatory molecules as a result of oxidative stress (Abdelhalim et al., 2010; Bao et al., 2010; 
Biagiotti et al., 2016) 
Increases in [Zn2+]i induces expression of MTs in various nucleated cell types such as neurons 
(McCord and Aizenman, 2014). This was initially observed in rodents, where dietary Zn2+ 
supplementation resulted in increased expression of the transcription factor known as Metal 
Transcription Factor-1 (MTF-1) (Andrews, 2001; Hardyman et al., 2016). This Zn2+_dependant 
transcription factor is responsible for the expression of MTs and ZnTs. MTF-1 plays a key role in the 
regulation of Zn2+ concentrations in cells, by regulating expression of both MTs (which sequester 
Zn2+),and ZnTs (which enable the efflux of Zn2+ from the cytoplasm of cells, illustrated in Figure 1.11) 
when Zn2+ levels are excessive within cells (Marreiro et al., 2017). Other transcription factors such as 
nuclear factor (erythroid-derived 2)-like 2 (Nrf2) are also able to mediate the expression of MTs as 
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well as genes which encode antioxidants and contribute to the regulation of Zn2+ and oxidative stress 
in cells (Ha et al., 2006; Li et al., 2014).  
The implications of elevations of [Zn2+]i and the subsequent effect on the regulation of 
oxidative stress via ROS scavenging is yet to be studied thoroughly in platelets. The mechanism of 
[Zn2+]i elevation in response to oxidative stress (which results in ROS level increases) may also be 
applicable in platelets, where it could serve as a major mechanism for [Zn2+]i elevation in platelets. To 
summarise, nucleated cells can store Zn2+ via MT sequestration, which under oxidative stress releases 
Zn2+ into the cytosol (Andrews, 2001, 2001; Hardyman et al., 2016). Zn2+ then mediates antioxidant 
activity to prevent oxidative stress-induced damage (Noleto Magalhães et al., 2011; Paz Matias et al., 
2014, 2014). Zn2+ released from the MTs may also act on other signalling proteins in cells, as Zn2+ 
interacts with various cytosolic signalling proteins. 
 In nucleated cells, agonist-evoked increases in [Zn2+]i result in the modulation of signalling 
proteins such as PKC and CamKII in a similar manner to that induced by elevated [Ca2+]i as described 
in Chapter 1 (Csermely et al., 1988; Hubbard et al., 1991a; Perry et al., 1997; Pitt and Stewart, 2015). 
Whilst the role of Zn2+ as a secondary messenger in nucleated cells has been the subject of recent 
research interest, the role of [Zn2+]i modulation upon agonist stimulation in platelets is yet to be 
determined.    
 
3.1.1 Aims and Hypothesis  
The aim of the work described in this chapter was to determine whether platelet agonists are able to 
elevate [Zn2+]i in platelets. The experiments described in this chapter focus on determining whether 
[Zn2+]i concentrations change in response to agonist stimulation in a manner consistent with a 
secondary messenger. The primary hypothesis of this chapter is that [Zn2+]i is elevated upon agonist 
stimulation. Additionally, due to the extensive work that has been previously documented with 
regards to oxidative stress and [Zn2+]i elevation in various cell types, the role of ROS increases on [Zn2+]i 
in platelets was also investigated. The hypothesis was that upon platelet activation, fluctuations in 
[Zn2+]i are redox-sensitive as a result of changes in levels of ROS.   
 
3.1.2 Methods  
A review of the literature has confirmed that platelet activation occurs upon stimulation of 
the major collagen receptor, glycoprotein VI (GpVI), and G-protein coupled receptors (GPCR’s) such as 
Protease-Activated Receptors (PAR) and the Thromboxane receptor (TP) (Cimmino and Golino, 2013; 
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Corinaldesi, 2011; Stalker et al., 2012). GpVI is activated by the collagen mimetic; cross-linked 
collagen-related peptide (CRP-XL), PAR is activated by thrombin, and TP is activated by the 
thromboxane A2 (TxA2) analogue, U46619 which is a more stable for experimental use than TxA2 (Brass 
et al., 1993a; Dunster et al., 2015; Reséndiz et al., 2007; Smith et al., 1980; Watson et al., 2005). CRP-
XL, thrombin, and U46619 mediate [Ca2+]i fluctuations via the activation of either PLCβ and PLCγ, which 
enables mobilisation of Ca2+ from the DTS (dense tubular system) (Authi et al., 1993; Brüne and Ullrich, 
1991; Smith et al., 1992). In a similar manner to the assessment of [Ca2+]i fluctuations in previous 
publications, [Zn2+]i fluctuations in response to the agonists stated above were measured. Agonist-
dependent [Zn2+]i fluctuations was recorded using fluorometry following stimulation of washed, FZ-3-
loaded platelet suspension. Fluorescence fluctuations were measured over a 6min period (section 2.4, 
Chapter 2). [Ca2+]i fluctuations (as measured by FL-4 fluorescence fluctuations) were also assessed, as 
a comparison to Zn2+. Fluorescence responses are expressed as corrected fluorescence (F/F0) (section 
2.4, Chapter 2). Validation of the use of FZ-3 and FL-4 as probes to measure [Zn2+]i and [Ca2+]i 
respectively, is provided in Chapter 2. 
Reagents used to manipulate platelet cation levels included [Zn2+]i and [Ca2+]i chelators, 
N,N,N′,N′-Tetrakis (2-pyridylmethyl)ethylenediamine) (TPEN) and 2-bis(o-aminophenoxy) ethane-N, 
N, N′, N′-tetraacetic acid (BAPTA), respectively. Previous work found that 50μM of TPEN was the most 
effective concentration in chelating [Zn2+]i in washed human platelets, even when a high concentration 
of exogenous Zn2+ (1 mM ZnSO4) was applied to the platelets (Watson et al., 2016). Thus 50μM of 
TPEN was used as the working concentration in this work. Several studies which investigated Ca2+ 
signalling in platelets confirmed that 10μM of BAPTA-AM is the most effective concentration to 
chelate [Ca2+]i (Davies et al., 1989; Sargeant et al., 1994; Vostal et al., 1991). Thus 10μM of the [Ca2+]i 
chelator was employed in this work to assess Ca2+ signalling.  
In order to assess redox sensitivity, hydrogen peroxide (H2O2) was used as a ROS agonist. The 
antioxidants Polyethylene glycol-superoxide dismutase (PEG-SOD) and Polyethylene Glycol-catalase 
(PEG-CAT) were also employed at concentrations previously shown to be effective in platelets 
(30U/mL and 300U/mL, respectively, Lopes Pires et al., 2017). Changes in ROS concentration were 
measured using the ROS probe, 2’, 7’-Dichlorofluorescein diacetate (DCFH) at a concentration of 10μM 
(Lopes Pires et al., 2017). 
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3.2 Results 
3.2.1 Intracellular Zn2+ is released during platelet activation by 
physiological agonists 
In the experiments described in this chapter, conventional platelet agonists, CRP-XL, U46619, and 
thrombin were employed to investigate whether [Zn2+]i levels fluctuate in response to platelet 
activation, in a similar manner to Ca2+. The hypothesis of this section was that [Zn2+]i elevation occurs 
in response to agonist stimulation. 
Treatment of FZ-3-loaded platelet suspensions with different concentrations of CRP-XL or 
U46619 resulted in increased FZ-3 fluorescence, consistent with increases in [Zn2+]i. Stimulation with 
thrombin did not induce a response (Figure 3.1). 
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Figure 3.1. Agonist stimulation of platelets results in increases in FZ-3 fluorescence that are were abrogated by TPEN and 
BAPTA. Fluozin-3 (FZ-3)-labelled washed human platelets were stimulated by increasing concentrations of CRP-XL (A), 
U46619 (B) or thrombin (C), and FZ-3 fluctuations were recorded over 6 mins using fluorometry. FZ-3-labelled washed human 
platelets were also pre-treated with the Zn2+ chelator, N,N,N′,N′-Tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) (50µM), 
before being stimulated by increasing concentrations of CRP-XL (D), U46619 (E) or thrombin (F) over a 6 min time period 
using fluorometry. Similarly, FZ-3-labelled washed human platelets were pre-treated with the Ca2+ chelator, 2-bis(o-
aminophenoxy) ethane-N, N, N′, N′-tetraacetic acid (BAPTA) (10µM), before being stimulated by increasing concentrations 
of CRP-XL (G), U46619 (H) or thrombin (I) and FZ-3 fluorescence fluctuations were recorded over 6 mins using fluorometry. 
CRP-XL (1µg/mL) and U46619 (1U/mL) induced significant increases in FZ-3 fluorescence which were abrogated following 
TPEN (50μM) or BAPTA (10μM) pre-treatment. Thrombin did not cause any increases in FZ-3 fluorescence. A, D and G:) ○ 1 
μg/mL CRP-XL, ■ 0.3 μg/mL CRP-XL, ▲ 0.1 μg/mL CRP-XL, ▼ 0.03 μg/mL and ● vehicle (dimethyl sulfoxide, DMSO). B, E, and 
H: ○ 10 μM U46619, ■ 3 μM U46619, ▲1 μM U46619, ▼ 0.3 μM U46619, and ● vehicle. C, F and I: ○ 1 U/mL Thrombin, ■ 
0.3 U/mL Thrombin, ▲ 0.1 U/mL Thrombin, ▼ 0.03 U/mL Thrombin and ● vehicle. Data are mean±standard error of mean 
(SEM) from 6 independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05).  
 
Increases in FZ-3 fluorescence following stimulation with 1 µg/mL CRP-XL were evident after 
30s with F/F0 of 1.9±0.3, compared to 1.00±0.01, for the vehicle control, DMSO (p<0.0001, Figure 
3.1A). After 30s, increases in fluorescence continued at a slower rate up until 6 mins with F/F0 of 
2.2±0.3 (Figure 3.1A). This result is consistent with a sustained increase in [Zn2+]i levels following CRP-
XL stimulation, suggestive of a role for [Zn2+]i in mediating platelet activatory processes. 
 U46619 (10 µM) also induced significant increases of FZ-3 fluorescence; however, this was 
only significant after 3 mins of stimulation (F/F0 increased to 1.2±0.1, compared to 1.01±0.01 for the 
vehicle control, p<0.05, Figure 3.1B). The fluorescence signal reached a plateau after 6 mins at 1.3±0.1 
(Figure 3.1B). This provides further evidence in for sustained, agonist-evoked [Zn2+]i elevations during 
platelet activation. Stimulation with lower concentrations of CRP-XL and U46619 did not induce a 
significant increase in fluorescence during stimulation.  
Thrombin did not induce any significant Zn2+ fluorescence fluctuations relative to the vehicle 
control (p>0.05,ns, Figure 3.1C). This was an unexpected finding as thrombin is a potent agonist. 
Furthermore, thrombin mediates activation via GPCRs in a similar manner to U46619 (TxA2 analogue), 
which did induce increases in FZ-3 fluorescence. This suggests that a novel signalling pathway is 
involved in mediating [Zn2+]i elevation in platelets, that is activated and engaged upon GpVI and TP 
signalling, but is independent of PAR signalling.  
To investigate whether the FZ-3 signal induced by CRP-XL and U46619 (Figure 3.1A-B) was 
specific to Zn2+, platelets were pre-treated with the [Zn2+]i chelator, TPEN (50μM), prior to agonist 
stimulation (Figure 3.1.D-F). The increase in FZ-3 F/F0 following CRP-XL (1 μg/mL) stimulation was 
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abrogated in TPEN (50 μM) pre-treated platelets from 2.2±0.3 (for the vehicle) to 1.04±0.03 (p<0.0001, 
Figure 3.1.A and D). Thus these data indicate that the FZ-3 fluorescence is Zn2+-specific, and not due 
to other cations such as Ca2+. Furthermore, this data further validates the working concentration of 
TPEN that was selected for this work, as 50μM of TPEN effectively reduces the FZ-3 response induced 
by CRP-XL (Figure 3.1A, D).  
A similar effect was seen with U46619 stimulation. The FZ-3 F/F0 induced by U46619 (10 μΜ) 
was reduced from 1.3±0.1 (vehicle) to 0.8±0.1 (after 6mins) upon TPEN pre-treatment, reaching the 
level achieved by the vehicle control (p<0.05, Figure 3.1B and E).Thus confirming that agonist (CRP-XL 
and U46619)-evoked fluorescence fluctuations are attributable to Zn2+. These findings support the 
hypothesis that [Zn2+]i elevation is induced upon agonist stimulation in platelets. Thrombin did not 
induce any fluctuations in FZ-3 fluorescence and remained unaffected with TPEN treatment (Figure 
3.1F).  
In order to investigate the influence of Ca2+ signaling on changes in FZ-3 fluorescence, washed 
platelet suspensions were pretreated with the Ca2+ chelator, BAPTA, prior to agonist stimulation 
(Figure 3.1G-I). BAPTA pre-treatment (10µM) abolished agonist-dependent FZ-3 increases. The F/F0 
induced by CRP-XL (1 μg/mL) and U46619 (10 μΜ) after 6 mins was reduced from 2.2±0.3 and 1.3±0.1 
(vehicle control) to 0.9±0.2 and 0.94±0.03, respectively, upon BAPTA pre-treatment (p<0.05, Figure 
3.1A, B, G, and H). Thrombin did not induce any fluctuations in FZ-3 fluorescence and remained 
uninfluenced with BAPTA treatment (Figure 3.1I). These data show that chelation of [Ca2+]i abrogates 
agonist-evoked increases in FZ-3 fluorescence. As discussed in Chapter 1, BAPTA has a higher affinity 
for Zn2+ than for Ca2+ and is a non-specific cation chelator. Thus the abrogation of FZ-3 fluorescence by 
BAPTA may be attributable to chelation of [Zn2+]i. Therefore, the use of BAPTA to assess in Ca2+ 
signalling in situations where Zn2+ fluctuations may be occurring may not be an appropriate strategy. 
However, due to the ability of BAPTA to chelate Zn2+, application of this chelator did provide further 
validation of the FZ-3 probe as this chelator also abrogated the FZ-3 fluorescence induced by the 
agonists, indicating further that FZ-3 is a valid tool to assess [Zn2+]i.  
 
The work described in this section provides evidence to address the major research question 
of this chapter; whether agonist stimulation evokes increases in [Zn2+]i in platelets. CRP-XL and 
U46619, but not thrombin, induced increases in FZ-3 fluorescence, consistent with elevations of [Zn2+], 
(Figure 3.1). This implicates activation via GpVI and TP (Thromboxane receptor) but not via PARs 
(Protease-Activated Receptor) in mechanisms that modulate [Zn2+]i elevation. Given that activation via 
the GPCR TP results in elevation of [Zn2+]I, the absence of PAR-dependent [Zn2+]i elevation is an 
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interesting an unexpected observation that warrants further investigation. TP and PAR initiated similar 
signalling pathways involving [Ca2+]i signalling and PLCβ activity, as illustrated in Figure 1.10. Thus TP 
may have mediated [Zn2+]i elevation via a novel mechanism with GpVI.  
 
3.2.2 Intracellular Ca2+ release differs from intracellular Zn2+ release 
during platelet activation by physiological agonists.  
Agonist-mediated elevation of [Ca2+]i in platelets is well documented (Authi et al., 1993; Brüne 
and Ullrich, 1991; Orem et al., 2017; Pozzan et al., 1988; Smith et al., 1992). Experiments discussed in 
section 3.2.1 determined that stimulation of platelets with CRP-XL or U46619 increased [Zn2+]i. 
However, the influence of Ca2+ signalling on this process was not addressed, BAPTA has a higher 
affinity for Zn2+ than Ca2+. Therefore distinguishing between Zn2+ and Ca2+ signalling using this chelator 
is impossible. Whilst it is known that Ca2+ is released from intracellular stores, the existence of Zn2+ 
stores in platelets has yet to be confirmed. Experiments were carried out to assess the differences in 
agonist-induced [Ca2+]i and [Zn2+]i elevation. The hypothesis was that [Ca2+]i is elevated independently 
to [Zn2+]i upon agonist stimulation.  
  
[Ca2+]i release was assessed in platelets loaded with the Ca2+ fluorophore, FL-4. As previously 
reported, stimulation with CRP-XL, U46619 or thrombin all resulted in significant, concentration-
dependent increases in FL-4 fluorescence, with 1U/mL thrombin inducing the highest response (Figure 
3.2) which is consistent with previous studies (Gamberucci et al., 2002; Jones et al., 2010; Smith et al., 
1992; Varga-Szabo et al., 2009).  
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Figure 3.2. Agonist-evoked stimulation results in increases in FL-4 fluorescence that are sensitive to Ca2+ chelation- but not 
Zn2+-chelation. Fluo-4 (FL-4)-labelled washed human platelets were stimulated by increasing concentrations of CRP-XL (A), 
U46619 (B) or thrombin (C) and FL-4 fluctuations were recorded over 6mins using fluorometry. FL-4-labelled washed human 
platelets were also pre-treated with TPEN (50µM), before being stimulated by increasing concentrations of CRP-XL (D), 
U46619 (E) or thrombin (F) over a 6 mins time period using fluorometry. FL-4-labelled washed human platelets were also 
pre-treated with BAPTA (10µM), before being stimulated by increasing concentrations of CRP-XL (G), U46619 (H) or thrombin 
(I) and again FL-4 fluctuations were recorded over 6mins using fluorometry. CRP-XL, U46619, and thrombin-induced a 
significant increase in FL-4 fluorescence relative to the vehicle control. TPEN treatment did not influence agonist-mediated 
increases in FL-4 fluorescence, whereas BAPTA treatment inhibited in agonist-evoked FL-4 fluorescence increases. A, D and 
G: ○ 1μg/mL CRP-XL, ■ 0.3μg/mL CRP-XL, ▲ 0.1μg/mL CRP-XL, ▼ 0.03μg/mL and ● vehicle (dimethyl sulfoxide, DMSO). B, E, 
and H: ○ 10μM U46619, ■ 3μM U46619, ▲1μM U46619, ▼ 0.3μM U46619, and ● vehicle. C, F and I: ○ 1U/mL Thrombin, ■ 
0.3U/mL Thrombin, ▲ 0.1U/mL Thrombin, ▼ 0.03U/mL Thrombin and ● vehicle. Data are mean±standard error of mean 
(SEM) from 6 independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05) 
 
60 
 
After 30 s of stimulation with 1 μg/mL of CRP-XL, the F/F0 was significantly higher than the 
vehicle control (2.1±0.2 and 1.0±0.1 respectively, p<0.0001, Figure 3.2A). The FL-fluorescence signal 
fell during the course of the experiment, perhaps as a result of Ca2+ recycling through SERCA (Figure 
1.10, Chapter 1) with F/F0 falling to 1.6±0.2 after 6 mins (Figure 3.2A),  
Similarly, the highest concentration of U46619 (10 µM) induced a significant increase in FL-4 
fluorescence, followed by a slight reduction before reaching a plateau. The F/F0 in response to 10 μM 
U46619 was 1.5±0.1 after 30 s, and 1.4±0.1 after 6 mins which were significantly higher compared to 
the vehicle control (where F/F0 after 30 s and 6 mins were 1.0±0.1 and 1.0±0.1 respectively, p<0.0001, 
Figure 3.2B.).  
Thrombin-induced a significant increase in FL-4 fluorescence. After 30 s of stimulation the F/F0 
in response to the highest concentrations of thrombin (1U/mL and 0.3U/mL) increased to 3.7±0.2 and 
2.0±0.2 respectively (compared to the vehicle control (1.0±0.1) p<0.0001, Figure 3.2C). Interestingly, 
unlike CRP-XL and U46619, FL-4 fluorescence in response to thrombin  was sustained throughout the 
experiment. This suggests that stronger stimulation of the PARs via higher concentrations of thrombin 
mediate enhances [Ca2+]i mobilisation from the DTS. This data also illustrates the greater potential for 
thrombin to induce Ca2+ responses compared to CRP-XL or U46619. This was interesting given the 
inability of thrombin to evoke Zn2+ responses. There are a number of possibilities for this observation. 
For example, Ca2+ and Zn2+ release pathways could be distinct and unrelated. Alternatively, high levels 
of [Ca2+]i may negatively regulate [Zn2+]i, suggesting an interplay between these cations in platelets. 
The difference in cation handling observed here warrants further investigation in understanding this 
potential relationship between Zn2+ and Ca2+ and it’s implications on platelet activity.  
TPEN was employed to examine the influence of [Zn2+]i on [Ca2+]i responses, and to validate 
the specificity of the reagents used (for example, the specificity of FL-4 in detecting Ca2+ and whether 
any of the fluorescence being detected is attributable to changes in [Zn2+]i). Figure 3.2.D-F shows the 
FL-4 fluorescence responses in TPEN -treated platelets following stimulation with CRP-XL (D), U46619 
(E) or thrombin (F). 
Agonist-evoked FL-4 signals were not significantly affected in TPEN-treated platelets (Figure 
3.2D-F). F/F0 values after 30s or 6 mins following CRP-XL stimulation (1μg/mL) on TPEN pre-treated 
platelets were 2.0±0.2 and 1.5±0.2, respectively, compared to the F/F0 induced by CRP-XL on untreated 
platelets which were 2.1±0.2 and 1.6±0.2, respectively (p>0.05, ns, Figure 3.2A, D). These data indicate 
that the FL-4 signal induced by CRP-XL was not attributable to changes in [Zn2+]i as chelation of Zn2+ 
did not influence the FL-4 fluorescence signal. 
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Similar responses in FL-4 fluorescence were observed following treatment with U46619, 
where TPEN also had no significant influence on increases in FL-4 fluorescence. The F/F0 induced by 
U46619 (10 μM) after 30s and 6mins were 1.5±0.1 and 1.4±0.1 respectively, compared to the F/F0 
induced by U46619 on TPEN pre-treated platelets of 1.4±0.1 and 1.3±0.1 respectively(p>0.05, ns, 
Figure 3.2B, E).  
FL-4 fluorescence increases following stimulation with thrombin were also not significantly 
influenced by TPEN pretreatment. TPEN pre-treatment did not inhibit thrombin-induced FL-4 
fluorescence. F/F0 in response to 1U/mL thrombin was 3.7±0.3 (vehicle control) compared to TPEN-
pretreated (3.0±0.3, p>0.05, ns, Figure 3.2C, and F). Lower concentrations of thrombin (0.3U/mL) were 
also not affected by TPEN pre-treatment. FL-4 F/F0 at 6mins in response to thrombin 0.3U/mL on TPEN 
pre-treated platelets was 1.7± 0.2 whereas on vehicle platelets the F/F0 was 1.5±0.1 (ns, Figure 3.2C, 
and F). The data here indicate that agonist-mediated elevation of [Ca2+]i is independent of [Zn2+]i. 
Further validating the FL-4 as a Ca2+ specific probe which is not influenced by changes in [Zn2+]i.    
BAPTA was used to assess the validity of the FL-4 signal detected. As shown in Figure 3.2.G-I, 
pre-treatment with BAPTA (10μM) abolished increases of FL-4 fluorescence induced by all agonists 
used, providing evidence that the signal detected in these experiments is attributable to Ca2+. The final 
FL-4 F/F0 induced by CRP-XL (1μg/mL), U46619 (10μΜ) and thrombin (1U/mL) was abrogated from 
1.6±0.2, 1.4±0.1 and 3.7±0.3, respectively to 1.0±0.1 (p<0.05, Figure 3.2A-C and G-I). 
  
The experiments described in this section provide evidence to support the hypothesis that 
agonist-mediated [Ca2+]i elevations are independent of [Zn2+]i. Initial work illustrated that all three 
agonists, CRP-XL, U46619 and thrombin mediate [Ca2+]i increases (Figures 3.2A-C), as previously shown 
in the literature. Thrombin-induced the largest FL-4 response compared to the CRP-XL and U46619, 
leading to speculation as to whether the [Ca2+]i levels attained in response to thrombin may negatively 
regulate [Zn2+]i elevation. The interplay between these two cations in platelets could regulate platelet 
activity and requires further analysis. 
Initial data from this section required validation to establish whether the FL-4 response being 
evoked by the agonist in these experiments was attributable to Ca2+ and to investigate whether the 
elevation of [Ca2+]i was influenced by [Zn2+]i elevation evident upon CRP-XL and U46619 stimulation. 
Application of TPEN (a [Zn2+]i chelator) had no influence on CRP-XL or U46619-evoked FL-4 responses 
(Figure 3.2.D-F), indicating that FL-4 response was not attributable to changes in Zn2+. Thus agonist-
induced FL-4 increases were not influenced upon chelation of [Zn2+]I, supporting the hypothesis of this 
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section that agonist-induced [Ca2+]i elevation is independent of [Zn2+]i. These data also further validate 
the specificity of FL-4 probe to Ca2+, as chelation of [Zn2+]i had no significant influence on the FL-4 
fluorescence confirming that the FL-4 probe was more specific to Ca2+ than Zn2+, thus a valid probe to 
measure [Ca2+]i. 
BAPTA was employed to determine whether agonist-evoked FL-4 response were attributable 
to [Ca2+]i elevation. Pre-treatment with BAPTA abolished all agonist-evoked FL-4 fluorescence 
increases (Figure 3.2G-I). This result, in conjunction with the TPEN data, indicates that the observed 
fluorescence was specific to Ca2+ and provides further evidence to validate the use of FL-4 as an 
appropriate [Ca2+]i probe.  
 
3.2.3 Intracellular Zn2+ increases in response to platelet stimulation 
with exogenous reaction oxygen species   
Experiments described in sections 3.2.1 and 3.2.2 indicate that [Zn2+]i and [Ca2+]i are elevated 
in response to stimulation by conventional agonists. These results supported the major hypothesis of 
this chapter; that [Zn2+]i is elevated upon agonist stimulation. The mechanism by which [Ca2+]i is 
elevated is well documented. However, the mechanism by which these agonists induce [Zn2+]i is yet to 
be investigated. Reactive Oxygen Species (ROS) regulate platelet activity and have been linked to the 
liberation of labile Zn2+ from Zn2+-binding proteins such as metallothioneins in nucleated cells (Kimura 
and Kambe, 2016; Marreiro et al., 2017; Xiong et al., 1992). In order to investigate an association 
between cation signalling in platelets and ROS, the influence of ROS on changes in [Ca2+]i and [Zn2+]i 
were investigated in this section. Elevation of ROS induces changes in redox states in many cell types 
including platelets (Pietraforte et al., 2014; Zorov et al., 2014). Experiments were carried out to test 
the second hypothesis of this chapter; that agonist-evoked [Zn2+]i fluctuations in platelets are redox 
sensitive, and occur as a result of changes in levels of ROS.  
 
The commonly employed ROS, hydrogen peroxide (H2O2), acts as a secondary messenger at 
micromolar levels in various cell-signalling pathways and mediates release of intracellular [Ca2+]i from 
stores (Freedman, 2008; Görlach et al., 2015; Krötz et al., 2004a; Sies, 2014). H2O2 was employed as a 
ROS agonist to assess fluctuations in [Zn2+]i  and [Ca2+]i responses following agonist stimulation in the 
experiments described here. ROS effects on [Zn2+]i were assessed by treating FZ-3-loaded platelets 
with different concentrations of H2O2 (from 0.3μM to 10μM) and changes in fluorescence were 
monitored using fluorometry (Figure 3.3).  
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Figure 3.3. Treatment of platelets with H2O2 results in increases in [Zn2+]i. Fluozin-3 (FZ-3)-labelled washed human platelets 
were stimulated with increasing concentrations of hydrogen peroxide (H2O2) (A), following pre-treatment with 10µM BAPTA 
(B) or following pre-treatment with 50µM TPEN (C) and FZ-3 fluctuations were recorded over 6mins using fluorometry. H2O2 
induced a significant increase in FZ-3 fluorescence, which was a loss with BAPTA and TPEN treatment. ○ H2O2 10μM, ■ H2O2 
3μM, ▲ H2O2 1μM,▼ H2O2 0.3μM and ● vehicle (dimethyl sulfoxide, DMSO). Data are mean±standard error of mean (SEM) 
from 6 independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
Stimulation with the highest concentration (10 μM) of H2O2 resulted in a significant increase 
in FZ-3 fluorescence relative to the vehicle control. The FZ-3 F/F0 increased for 1 min (to 1.7±0.2) 
before reaching a sustained plateau (the FZ-3 F/F0 after 6 mins was 1.8±0.2), which were much higher 
than the vehicle control, DMSO (1.0±0.1, p<0.0001, Figure 3.3A). These data demonstrate that 
elevation of ROS within platelets evokes [Zn2+]i elevations. Furthermore, the FZ-3 fluorescence 
response to H2O2 was sustained between 1-6 mins. This was similar to that seen following stimulation 
with CRP-XL and U46619 (Figure 3.1.A, B). Therefore, these data suggested that the elevated and 
sustained FZ-3 increases evoked by CRP-XL and U46619 may be dependent on ROS elevation. 
 
The validity of the elevation of FZ-3 fluorescence increases induced by H2O2 was assessed using BAPTA 
and TPEN. The effect of BAPTA as mentioned earlier does not provide a valid assessment of Ca2+ 
signalling in Zn2+ signalling, due to its higher affinity for Zn2+ than Ca2+. However, this does serve as an 
extra measure of validation alongside TPEN to assess whether the FZ-3 increases being induced by 
H2O2 were truly attributable to Zn2 
 Pre-treatment of platelet suspensions with BAPTA (Figure 3.3B) or TPEN (Figure 3.3C) 
abolished any increases in FZ-3 fluorescence induced by H2O2, confirming a role for Zn2+ in this process. 
The final FZ-3 F/F0 induced by H2O2 (10μM) was abrogated from 1.8±0.2 to 0.9±0.2 and 1.0±0.1 upon 
pre-treatment with BAPTA (10μΜ) and TPEN (50μM). (p<0.0001, Figure 3.3A-C). This data 
demonstrated that FZ-3 signal increases induced by H2O2 were in accordance with Zn2+.  
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The effect of ROS on [Ca2+]i fluctuations was also assessed by treating FL-4 loaded platelets 
with H2O2 (Figure 3.4). These experiments were carried out to assess differences between [Ca2+]i and 
[Zn2+]i evoked elevation upon ROS increases. This potential difference was assessed to help establish 
if the hypothesis that upon platelet activation fluctuations in [Zn2+]i are redox sensitive as a result of 
changes in levels of ROS was also attributable to [Ca2+]i. In a similar manner to FZ-3 fluorescence, only 
the highest concentration of H2O2 (10μM) induced a significant increase in FL-4 fluorescence relative 
to the vehicle control. Increases in FL-4 fluorescence were observed in the first 30s of the experiment, 
following which the signal plateaued. The FL-4 F/F0 values following stimulation with 10μM, H2O2 for 
30s and 6mins respectively were 1.4±0.1 and 1.4±0.2 respectively compared to vehicle control 
(DMSO), 1.0±0.1 (p<0.0001, Figure 3.4A). Thus, ROS elevation evokes [Ca2+]i elevation.  
 
Figure 3.4. Platelet stimulation with H202 results in increases in FL-4 fluorescence that are sensitive to cation chelation 
with BAPTA or TPEN. Fluo-4 (FL-4)-labelled washed human platelets were stimulated different concentrations of H2O2 (A), 
following 10µM BAPTA pre-treatment (B) or 50µM TPEN pre-treatment (C) and FL-4 fluctuations were recorded over 6mins 
using fluorometry. H2O2 induced a significant increase in Ca2+ fluorescence, which was abrogated following BAPTA or TPEN 
pre-treatment. ○ H2O2 10μM, ■ H2O2 3μM, ▲ H2O2 1μM,▼ H2O2 0.3μM and ● vehicle (DMSO). Data are mean±standard 
error of mean (SEM) from 6 independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** 
(p<0.01) or * (p<0.05). 
 
Pre-treatment with BAPTA or TPEN abolished any significant increases in FL-4 fluorescence 
induced by H2O2. The final FL-4 F/F0 induced by H2O2 (10μM) was abrogated from 1.4±0.1 to 1.0±0.1 
and 1.0±0.1 upon pre-treatment with BAPTA (10μM) or TPEN (50μM), respectively (p<0.0001, Figure 
3.4A-C). These final FL-4 F/F0 values evoked by H2O2 (10μM) on BAPTA and TPEN treated platelets did 
not significantly differ to the vehicle control as the final F/F0 induced by the vehicle control on BAPTA 
and TPEN pre-treated platelets which were 0.9±0.1 and 1.0±0.1 respectively (p>0.05, ns, Figure 3.4A-
C). These data show that ROS elevation also evokes [Ca2+]i elevation. However, since the application 
65 
 
of the highly specific [Zn2+]i chelator TPEN abrogated the FL-4 fluorescence evoked by H2O2, it can be 
surmised that the elevation of FL-4 fluorescence is attributable to Zn2+ and not Ca2+.    
The experiments described above provide evidence to confirm the hypothesis that ROS 
elevation mediates elevated [Zn2+]i. Stimulation with H2O2 resulted in significant increases in FZ-3 
fluorescence which were inhibited by the chelators, TPEN or BAPTA (Figure 3.3A-C). As both BAPTA 
and TPEN were shown to act as [Zn2+]i chelators (due to the higher affinity to Zn2+ that BAPTA has, as 
previously stated), these data suggested that elevation of [Zn2+]i is mediated by ROS elevation.  
Stimulation with H2O2 also resulted in significant increases in FL-4 fluorescence (Figure 3.4A) 
which was inhibited by BAPTA, outlining that elevation of [Ca2+]i is mediated by ROS elevation (Figure 
3.4B). However, this increase in FL-4 fluorescence was also inhibited by TPEN (Figure 3.4C), suggesting 
that the elevation in fluorescence induced by H2O2 was attributable to Zn2+ as opposed to Ca2+. This 
suggests a potential mechanism activatory involving redox changes upon ROS stimulation. This 
mechanism may be independent of Ca2+ and may mediate elevation of [Zn2+]i. Changes in redox in 
platelets upon ROS elevation may result in the release of Zn2+ from redox proteins such as 
metallothioneins. Released Zn2+ may contribute to activatory responses. This proposed mechanism 
coincides well with the work exhibited in this section and supports the hypothesis that fluctuations in 
[Zn2+]i are redox sensitive as a result of changes in levels of ROS in platelets.  
 
 
3.2.4 Agonist-induced intracellular Zn2+ release is redox-sensitive in 
platelets 
Experimental data discussed in section 3.2.3 indicates that ROS elevation mediates the 
elevation of [Zn2+]i. This section aims to investigate the validity and physiological relevance of this 
proposed mechanism. ROS-dependent Zn2+ release has been investigated in other cell types. In 
neurons, free Zn2+ is tightly coordinated by metal binding proteins such as metallothionines (MT’s) 
and upon oxidative stress, ROS is elevated, liberating Zn2+ (Stork and Li, 2016). Interestingly elevated 
Zn2+ further enhanced ROS generation in neurons, producing a positive feedback effect. Whether this 
scheme operates in platelets is not known and may be the reason as to why the FZ-3 fluorescence in 
response to CRP-XL, U46619, and H2O2 was sustained throughout the duration of the experiments. It 
is possible that the positive feedback effect maintains the elevated levels of [Zn2+]i (Krötz et al., 2004; 
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Pietraforte et al., 2014; Stork and Li, 2016). The hypothesis of this section is that elevation of [Zn2+]i 
upon agonist stimulation is redox sensitive in platelets.  
The antioxidant superoxide dismutase (SOD) was employed to assess the potential redox-
mediated mechanism that may regulate agonist-dependent [Zn2+]i release in platelets. SOD is a 
cytosolic antioxidant, which catalyzes the formation of the less reactive ROS, H2O2 and O2 upon 
dismutation of the very reactive ROS, O2- (Machtay et al., 2006), as illustrated by the equation below.  
 
SOD has been used in various cell types to protect cells against oxidative stress by inhibiting 
the elevation of ROS (Pandya et al., 2013; Pietraforte et al., 2014; Sinha and Dabla, 2015). SOD has 
been found in platelets as a ROS scavenger (Figure 1.8, Chapter 1) and serves as an appropriate 
enzyme to reduce ROS levels and modulate the redox state in the platelet.  
 Covalent conjugation of SOD with Polyethylene Glycol (PEG) enhance the level of enzyme 
activity in a variety of cells (Beckman et al., 1988). PEG is widely used due to its ability to increase the 
solubility of the conjugate and keep toxic effects to a minimal in comparison to when there is no 
conjugation with PEG (Beckman et al., 1988; Kim et al., 2015). Thus PEG-SOD which is a mimetic of 
SOD was chosen to enable optimal SOD activity (Kim et al., 2015).  
Another antioxidant, Catalase (CAT) was also employed to further investigate the potential 
redox-mediated mechanism that may regulate agonist-dependent [Zn2+]i release in platelet. The major 
differences between SOD and CAT are that they target different ROS. SOD primarily inhibits superoxide 
anion (O2-) which is an unstable intermediate of H2O2, whilst CAT inhibits H2O2 as illustrated in the 
equation below.  
 
CAT catalyses the formation of H2O and O2 upon dismutation of H2O2 (Machtay et al., 2006). 
Thus, CAT is expected to reduce ROS elevation being induced upon exogenous H2O2 whereas SOD is 
not. However, exogenous ROS treatment induces oxidative stress in various cell types which then 
result in the elevation of other ROS such as O2- (Freedman, 2008). This suggests that SOD reduces ROS 
elevation of other species, which may elevate upon exogenous H2O2 treatment. This was evident from 
the work described in this section. In physiological conditions in both nucleated cells and platelets 
both SOD and CAT work in synergy to scavenge ROS, as SOD initially targets the more reactive ROS 
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species such as O2- which then results in the formation of H2O2. H2O2 is then catalyzed to H2O and 
oxygen (Pandya et al., 2013; Sinha and Dabla, 2015). Thus, eradicating the ROS species. In this work, 
CAT was employed as a further antioxidant along with SOD to provide further validation of the 
proposed ROS-mediated [Zn2+]i elevation mechanism. The mimetic of CAT, PEG- CAT was employed in 
a similar manner to PEG-SOD 
As previously shown, stimulation of FZ-3 loaded platelets with CRP-XL, U46619 or H2O2 
resulted in elevated FZ-3 fluorescence (Figures 3.1 and 3.3), indicating that elevation of [Zn2+]i may be 
modulated by ROS. Platelets were pre-treated with 30U/mL of PEG-SOD (Lopes Pires et al., 2017), 
prior to being treated with increasing concentrations of CRP-XL (Figure 3.5D), U46619 (Figure 3.9E), 
or thrombin (Figure 3.5F), and changes in FZ-3 fluorescence were recorded using fluorometry as 
before. Pre-treatment with PEG-SOD significantly reduced CRP-XL (1µg/mL)-stimulated increases in 
FZ-3 fluorescence (Figure 3.5 A-F).  
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Figure 3.5. Agonist-evoked increases in intracellular Zn2+i are abrogated in PEG-SOD and PEG-CAT –treated platelets. 
Fluozin-3 (FZ-3)-labelled washed human platelets were stimulated by increasing concentrations of CRP-XL (A), U46619 (B) or 
thrombin (C), and FZ-3 fluctuations were recorded over 6mins using fluorometry. FZ-3-labelled washed human platelets were 
also pre-treated with the antioxidant PEG-SOD (30U/mL), before being stimulated by increasing concentrations of CRP-XL 
(D), U46619 (E) or thrombin (F) and FZ-3 fluctuations were recorded over six minutes using fluorometry. FZ-3 labelled washed 
platelets were also pre-treated with PEG-CAT (300U/mL), before being stimulated by increasing concentrations of CRP-XL 
(G), U46619 (H) or thrombin (I). PEG-SOD and PEG-CAT treatment inhibited the increase in FZ-3 fluorescence induced by the 
agonists. (A, D and G) ○ 1μg/mL CRP-XL, ■ 0.3μg/mL CRP-XL, ▲ 0.1μg/mL CRP-XL, ▼ 0.03μg/mL and ● vehicle (dimethyl 
sulfoxide, DMSO). (B, E, and H) ○ 10μM U46619, ■ 3μM U46619, ▲1μM U46619, ▼ 0.3μM U46619, and ● vehicle. (C, F and 
I) ○ 1U/mL Thrombin, ■ 0.3U/mL Thrombin, ▲ 0.1U/mL Thrombin, ▼ 0.03U/mL Thrombin and ● vehicle. Data are 
mean±standard error of mean (SEM) from 6 independent experiments. Significance is denoted as **** (p<0.0001), *** 
(p<0.001), ** (p<0.01) or * (p<0.05). 
After 6mins of stimulation with CRP-XL (1μg/mL), FZ-3 F/F0 was abrogated from 2.6±0.3 to 
1.2±0.1 upon PEG-SOD pre-treatment (p<0.0001, Figure 3.5A and D). Furthermore, the FZ-3 signal in 
response to CRP-XL on PEG-SOD pre-treated platelets did not significantly differ to that induced by the 
vehicle control treatment (1.1±0.1, p>0.05, ns, Figure 3.5D). This data demonstrated that CRP-XL 
induced [Zn2+]i elevation is dependent on ROS.  
PEG-SOD treatment also reduced the FZ-3 fluorescence induced by U46619 (Figure 3.9B). F/F0 
induced by U46619 (10μM) after 6mins was abolished from 1.30 ±0.04 to 0.98±0.02 (p<0.0001, Figure 
3.5B and E). Thus, this work further strengthened the hypothesis that agonist-induced [Zn2+]i elevation 
is dependent on ROS, and thus sensitive to changes in redox (as fluctuations in ROS modulate redox 
states). No apparent fluctuations in FZ-3 signal were observed with thrombin upon PEG-SOD 
treatment. This was expected as thrombin stimulation did not result in increases [Zn2+]i.  
These data support the concept that elevation of [Zn2+]i upon agonist stimulation is redox 
sensitive in platelets, as PEG-SOD inhibited the increases in FZ-3 fluorescence induced by CRP-XL and 
U46619. This may be due to PEG-SOD preventing the changes in redox which would otherwise liberate 
Zn2+ from thiols on redox-sensitive metal ion-binding proteins such as metallothioneins. 
Platelets were pre-treated with 300U/mL of PEG-CAT (Lopes Pires et al., 2017), prior to being 
treated with different concentrations of CRP-XL (Figure 3.5G), U46619 (Figure 3.5H), or thrombin 
(Figure 3.5I), and changes in FZ-3 fluorescence were recorded. Agonist-evoked increases in FZ-3 
fluorescence was also inhibited by PEG-CAT. 
In a similar manner to PEG-SOD treatment, F/F0 induced by CRP-XL (1μg/mL after 6mins was 
reduced from 2.6±0.3 to 1.2±0.1 upon PEG-CAT (300U/mL) pre-treatment (p<0.0001, Figure 3.5A and 
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G). PEG-CAT treatment also reduced the FZ-3 signal by U46619, as the final F/F0 induced by U46619 
(10μM) was abrogated from 1.30±0.04 to 0.97±0.02 (p<0.0001, Figure 3.5B and H). Thrombin did not 
induce FZ-3 fluctuations thus had no effect with PEG-CAT pre-treatment as described above. Thus, 
PEG-CAT treatment resulted in similar effects to PEG-SOD treatment. Thus, targeting ROS via different 
mechanisms (i.e. SOD and CAT target different ROS) resulted in the same effect in terms of inhibition 
of agonist-evoked [Zn2+]i elevation. The work with PEG-CAT provides further evidence in conjunction 
with the work carried out with PEG-SOD in this section to support the hypothesis that elevation of 
[Zn2+]i upon agonist stimulation is redox sensitive in platelets.  
Data from this section support the hypothesis that elevation of [Zn2+]i upon agonist 
stimulation is redox-sensitive in platelets. The increases in FZ-3 fluorescence in response to CRP-XL or 
U46619 (Figures 3.5A-B) were significantly inhibited upon treatment with the antioxidants PEG-SOD 
(Figure 3.5D-E) and PEG-CAT (Figure 3.5G-H), which were employed to scavenge any ROS elevation 
upon stimulation. These data demonstrate that the scavenging of ROS via application of PEG-SOD and 
PEG-CAT may be preventing the changes in redox which enable changes in redox in platelets upon 
ROS elevation which result in the release of Zn2+ from redox-sensitive proteins such as 
metallothioneins. Furthermore, these data are consistent with results from section 3.2.3 which show 
that changes in redox in platelets upon ROS elevation results in elevation of [Zn2+]i. Therefore, [Zn2+]i 
elevation is sensitive to redox changes. This may be an important mechanism by which [Zn2+]i is 
elevated upon platelet activation. 
  
3.2.5 Agonist-induced intracellular Ca2+ release is not sensitive to redox 
changes in platelets 
Experiments described in sections 3.2.3 and 3.2.4 demonstrated that agonist-mediated [Zn2+]i 
elevation is redox sensitive. However, the data from section 3.2.4 showed that ROS elevation that has 
previously been thought to be caused by increases in [Ca2+]i was attributable to [Zn2+]i. This implies 
that [Ca2+]i elevation is not sensitive to redox changes upon ROS elevation, indicating that [Ca2+]i and 
[Zn2+]i elevation are mediated by different mechanisms in platelets.  
Whilst the mechanism through which [Ca2+]i is elevated is well documented, the elevation of 
[Ca2+]i during changes in platelet redox state upon agonist stimulation was assessed. This was carried 
out to investigate whether redox-sensitive [Zn2+]i elevation was also independent to Ca2+. The 
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hypothesis of this section is that agonist-evoked [Ca2+]i increases are not sensitive to changes in the 
platelet redox state. 
PEG-SOD and PEG-CAT were employed to assess the role of ROS on [Ca2+]i release. Pre-
treatment of washed, FL-4-loaded platelet suspensions with PEG-SOD (30U/mL) and PEG-CAT 
(300U/mL) had no significant influence on increases in agonist-evoked FL-4 increases in all of the 
experiments shown below (Figure 3.6).  
The FL-4 F/F0 following stimulation for 6 mins with CRP-XL (1.9±0.3) did not significantly differ to the 
F/F0 induced by CRP-XL (1μg/mL) of PEG-SOD pre-treated platelets (2.0±0.2, p>0.05, ns, Figure 3.6A 
and D). Thus, PEG-SOD had no influence on CRP-XL evoked [Ca2+]i increases. U46619 (10μΜ) evoked 
FL-4 increases were also not influenced by PEG-SOD treatment, as F/F0 following 6 mins of stimulation 
with U46619 (10μM) was 1.5±0.1 compared to 1.4±0.1 in PEG-SOD pre-treated platelets(p>0.05, ns, 
Figure 3.6B and E). These data confirm that PEG-SOD had no influence on CRP-XL evoked FL-4 
increases.  
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Figure 3.6. PEG-SOD and PEG-CAT treatment do not effect agonist-evoked increases in [Ca2+]i. Fluo-4 (FL-4) labelled washed 
human platelets were stimulated by increasing concentrations of (CRP-XL) (A), U46619 (B) or thrombin (C) and FL-4 
fluctuations were recorded over 6mins using fluorometry. FL-4-labelled washed human platelets were also pre-treated with 
PEG-SOD (30U/mL), before being stimulated by increasing concentrations of CRP-XL(D), U46619 (E) or thrombin (F) and FL-4 
fluctuations were recorded over six minutes using fluorometry. FL-4 labelled washed platelets were also pre-treated PEG-
CAT (300U/mL), before being stimulated by increasing concentrations of CRP-XL(G), U46619 (H) or thrombin (I). PEG-SOD 
and PEG-CAT treatment had no significant influence on agonist-evoked [Ca2+]i elevation. (A, D and G) ○ 1μg/mL CRP-XL, ■ 
0.3μg/mL CRP-XL, ▲ 0.1μg/mL CRP-XL, ▼ 0.03μg/mL and ● vehicle (dimethyl sulfoxide, DMSO). (B, E and H) ○ 10μM U46619, 
■ 3μM U46619, ▲1μM U46619, ▼ 0.3μM U46619, and ● vehicle. (C, F and I) ○ 1U/mL Thrombin, ■ 0.3U/mL Thrombin, ▲ 
0.1U/mL Thrombin, ▼ 0.03U/mL Thrombin and ● vehicle. Data are mean±standard error of the mean (SEM) from 6 
independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05).  
 Thrombin treatment, which evoked significant increases in FL-4 fluorescence also was not 
influenced by PEG-SOD pre-treatment (Figure 3.6C, F). The final F/F0 induced by thrombin (1U/mL and 
0.3U/mL) were 3.8±0.1 and 2.0±0.4, respectively whereas on PEG-SOD pre-treated platelets were 
3.0±0.1 and 2.1±0.3, respectively (p>0.05, ns, Figure 3.6C, and F). These data confirm that agonist-
evoked [Ca2+]I in not sensitive to changes in the platelet redox state 
In a similar manner to PEG-SOD treatment, pre-treatment with PEG-CAT also had no effect on 
agonist-evoked [Ca2+]i increases (Figure 3.6). The F/F0 induced by CRP-XL (1μg/mL) after 6 mins was 
1.9±0.3, compared to 2.0±0.2 with PEG-CAT pre-treated platelets (p>0.05, ns, Figure 3.6A and D). 
U46619 (10μΜ) evoked FL-4 increases were also not affected by PEG-CAT treatment. The F/F0 induced 
by U46619 (10μM) after 6mins were 1.5±0.1 and on PEG-CAT pre-treated platelets and 1.3±0.1 on 
untreated platelets (ns, Figure 3.6B, and H). F/F0 values following stimulation with 1U/ml or 0.3U/mL 
thrombin after 6mins on untreated platelets were 3.8±0.1 and 2.0±0.4 respectively, compared to 
3.0±0.2 and 2.0±0.1, respectively for PEG-CAT pre-treated platelets (p>0.05, ns, Figure 3.6C and I). 
Thus agonist-induced [Ca2+]i elevation is not sensitive to the reduction of ROS via PEG-SOD and PEG-
CAT treatment. 
The data from this section support the hypothesis that [Ca2+]i elevation is not sensitive to 
redox changes upon agonist stimulation. ROS reduction (resulting in changes in redox states) via the 
use of PEG-SOD and PEG-CAT had no significant influence on agonist-mediated [Ca2+]i (Figure 3.6). 
Although previous work (Görlach et al., 2015) has suggested that ROS impacts [Ca2+]i, Zn2+ was not 
taken into account in these studies, perhaps due to Zn2+ being overlooked due to the assumption that 
its intracellular concentration is insignificant compared to Ca2+. However, the data described here 
demonstrate that redox-sensitive cation elevation is only applicable to Zn2+ and not Ca2+, providing 
evidence [Zn2+]i and [Ca2+]i elevation rely on differing mechanisms. 
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3.2.6 Agonist-induced ROS elevation is influenced by intracellular Zn2+  
In nucleated cell types such as neuron cells, elevation of [Zn2+]i results in increases in 
intracellular ROS levels, in what has suggested being a positive feedback mechanism (Stork and Li, 
2016). It is possible that the same mechanism applies in platelets, whereby elevated ROS results in 
elevated [Zn2+]i which in turn results in further ROS elevation. Whilst, activation via PAR and GpVI 
induce intraplatelet ROS production (Arthur et al., 2008; Qiao et al., 2018; Walsh et al., 2014), the 
mechanism by which ROS is elevated in platelets is yet to be fully determined. Experiments were 
carried out to further investigate the relationship between ROS and cation fluctuations during agonist 
stimulation. The hypothesis of this section is that ROS elevation is dependent on [Zn2+]i elevation upon 
agonist stimulation.  
To assess the role of ROS in platelet activity, the agonist-dependent fluctuations of ROS were 
measured in washed platelet suspensions following stimulation with the conventional agonists, CRP-
XL, U46619, and Thrombin. The widely used cell permeable ROS-specific probe, 2’, 7’-
Dichlorofluorescein diacetate (DCFH), was used to detect increases in ROS (section 2.5, Chapter 2). 
DCFH (10μM) -loaded platelets were stimulated with increasing concentrations of CRP-XL (A), 
U46619 (B) or thrombin (Figure 3.7). Stimulation with 1μg/mL CRP-XL resulted in steady increases of 
DCFH fluorescence throughout the 6min experiment. The final DCFH F/F0 induced by CRP-XL (1μg/mL) 
was 1.8±0.1, compared to 0.9±0.3 for the vehicle control (p<0.0001, Figure 3.7A). Thus, GpVI 
stimulation results in a substantial increase in ROS elevation. 
 Stimulation with U46619 (10μM) or thrombin (1U/mL) also increased DCFH fluorescence, 
although to a lower level than that seen with CRP-XL. The final DCFH F/F0 induced by U46619 (10μM) 
increased to 1.21± 0.03 compared to 1.01±0.02 for the vehicle control (p<0.001, Figure 3.13A). 
Thrombin (1U/mL) also induced a significant increase in DCFH fluorescence relative to the vehicle, as 
the final DCFH F/F0 was 1.4±0.1 compared to 1.0±0.1 for the vehicle control (p<0.0001, Figure 3.7C). 
These data correlate with previous observations in the literature that agonist stimulation results in 
increases in platelet ROS (Arthur et al., 2008; Krötz et al., 2004; Qiao et al., 2018).  
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Figure 3.7. Agonist-evoked increases in DCFH fluorescence are inhibited by TPEN and BAPTA and abrogated by PEG-SOD 
and PEG-CAT. DCFH-labelled washed human platelets were stimulated by increasing concentrations of CRP-XL (A), U46619(B) 
and thrombin (C). DCFH-labelled washed human platelets were also pre-treated with 10μΜ BAPTA before being stimulated 
by increasing concentrations of CRP-XL(D), U46619(E) and thrombin (F). DCFH-labelled washed human platelets were also 
pre-treated with 50μM TPEN before being stimulated by increasing concentrations of CRP-XL(G), U46619(H) and thrombin 
(I). DCFH-labelled washed human platelets were also pre-treated with 30U/mL PEG-SOD before being stimulated by 
increasing concentrations of CRP-XL (J), U46619 (K) or thrombin (L). Finally, DCFH-labelled washed human platelets were pre-
treated with 300μΜ PEG-CAT before being stimulated by increasing concentrations of CRP-XL (M), U46619 (N) and thrombin 
(O). ROS fluctuations were recorded over six minutes using fluorometry. BAPTA and TPEN treatment significantly inhibited 
evoked CRP-XL increases and abolished U46619 and thrombin evoked increases in DCFH fluorescence. Agonist-evoked 
increases in DCFH fluorescence were also abolished upon PEG-SOD and PEG-CAT treatment. (A, D, G, J and M) ○ 1μg/mL CRP-
XL, ■ 0.3μg/mL CRP-XL, ▲ 0.1μg/mL CRP-XL, ▼ 0.03μg/mL and ● vehicle. (B, E, H, K, and N) ○ 10μM U46619, ■ 3μM U46619, 
▲1μM U46619, ▼ 0.3μM U46619, and ● vehicle. (C, F, I, L and O) ○ 1U/mL Thrombin, ■ 0.3U/mL Thrombin, ▲ 0.1U/mL 
Thrombin, ▼ 0.03U/mL Thrombin and ● vehicle (dimethyl sulfoxide, DMSO). Data are mean±standard error of mean (SEM) 
from 6 independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). 
Further experiments were carried out to investigate the relationship between agonist-evoked 
[Ca2+]i signalling and ROS generation during platelet activation. DCFH-loaded platelets were pre-
treated with BAPTA (10μM) prior to agonist stimulation, and changes in DHCF fluorescence were 
quantified using fluorometry. CRP-XL-evoked increases in DCFH fluorescence were significantly 
reduced in BAPTA pre-treated platelets, as the F/F0 after 6 mins were reduced from 1.8±0.1 down to 
1.3±0.1 upon BAPTA pre-treatment (p<0.01, Figure 3.7A, D). Interestingly, BAPTA pre-treatment did 
not entirely abrogate CRP-XL-induced increases in DCFH fluorescence, as the F/F0 after 6 mins (1.3±0.1) 
was higher than the vehicle control (0.9±0.02, p<0.01, Figure 3.7D). These data suggest that [Ca2+]i 
may mediate ROS elevation upon CRP-XL stimulation, although another mechanism may be in place 
as the DCFH fluorescence was not entirely abrogated upon application of BAPTA. 
In contrast, BAPTA treatment abolished any significant increases induced by U46619 and 
thrombin. The final DCFH F/F0 induced by U46619 (10μM) was abrogated from 1.21±0.03 to 1.01±0.01 
(p<0.05, Figure 3.7B and E). The final DCFH F/F0 induced by thrombin (1U/mL) was also abolished from 
1.4±0.1 to 1.01±0.01 in BAPTA pre-treated platelets (p<0.01, Figure 3.7C and F). Thus [Ca2+]i mediates 
ROS elevation upon thrombin and U46619 stimulation, but not following CRP-XL stimulation. This may 
be due to CRP-XL inducing a greater elevation in DCFH fluorescence in comparison to that induced by 
thrombin and U46619, which could cause further oxidative stress and thus further increase in ROS. 
Such an increase may not be apparent with thrombin and U46619 stimulation, where ROS generation 
is reduced. 
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In order to investigate the role of [Zn2+]i fluctuations during ROS production during platelet 
activation, DCFH-loaded platelets were pre-treated with the Zn2+ chelator TPEN (50μM) prior to being 
stimulated with different concentrations CRP-XL (Figure 3.7G), U46619 (Figure 3.7H) or thrombin 
(Figure 3.7I).  
TPEN pre-treatment inhibited increases in CRP-XL-evoked DHCF fluorescence in a similar 
manner to BAPTA pre-treatment (Figure 3.7D-F) indicating that the reduction in DCFH seen upon 
BAPTA application was attributable to Zn2+ and not Ca2+. After 6 mins, the DCFH F/F0 was reduced from 
1.8±0.1 to 1.3±0.1 in TPEN-treated platelets (p<0.01, Figure 3.7A, G). In a similar manner to BAPTA 
pre-treatment, TPEN did not fully abrogate CRP-XL-mediated (1μg/mL) increases of DHCF 
fluorescence. After 6 mins, the F/F0 (1.3±0.1, in TPEN pre-treated platelets) in response to CRP-XL 
(1μg/mL) was still significantly higher compared to the vehicle control ( 0.93±0.02, p<0.01, Figure 
3.14A). This suggests that the elevation of ROS is mediated by [Zn2+]i and not [Ca2+]i and that other 
mechanisms may be in place that enables CRP-XL induced ROS generation that is independent of 
cations.  
Increases in DCFH fluorescence in response to U46619 or thrombin were abolished with TPEN 
(50μM) pre-treatment. After 6 mins, DCFH F/F0 induced by U46619 (10μM) was abrogated from 
1.2±0.03 to 1.08±0.02 in TPEN pre-treated platelets (p<0.05, Figure 3.7B, H). The DCFH F/F0 induced 
by thrombin (1U/mL) was also abrogated from 1.4±0.1 to 1.08±0.03 upon TPEN application (p<0.05, 
Figure 3.7C, I). These data support a role for [Zn2+]i and not [Ca2+]i in ROS generation. As BAPTA has a 
higher affinity for Zn2+ than Ca2+, the inhibition effect induced by BAPTA pre-treatment may be 
primarily due to the chelation of Zn2+ as opposed to Ca2+. This is consistent with the effects seen with 
TPEN pre-treatment, which is highly specific to Zn2+.    
Further experiments were performed using PEG-SOD (30U/mL) and PEG-CAT (300U/mL) to 
assess the validity of the ROS being detected by the ROS probe. PEG-SOD and PEG-CAT scavenge ROS, 
and should, therefore, inhibit elevation of ROS mediated by the agonist (Pietraforte et al., 2014; Sinha 
and Dabla, 2015). 
 PEG-SOD and PEG-CAT pre-treatment abolished agonist-dependent increases in DCFH 
fluorescence (Figure 3.7J-O). The final DCFH F/F0 induced by CRP-XL (1μg/mL) after 6mins was 
abrogated from 1.8±0.1 to 1.0±0.2 and 1.02±0.01 upon PEG-SOD and PEG-CAT pre-treatment, 
respectively (p<0.001, Figure 3.7A, J and M). Similarly, with U46619 (10μM) treatment, DCFH F/F0 was 
also abolished from 1.2±0.03 to 0.93±0.01 and 0.95±0.01 upon PEG-SOD and PEG-CAT pre-treatment, 
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respectively (p<0.05, Figure 3.7B, K and N). Furthermore, DCFH F/F0 induced by thrombin (1U/mL) was 
also abolished from 1.4±0.1 to 1.04±0.04 and 0.99±0.01 upon PEG-SOD and PEG-CAT pre-treatment, 
respectively (p<0.05, Figure 3.7C, L and O). These data confirm that the fluorescence signal generated 
upon agonist stimulation is attributable to ROS, thus validating the use of DCFH. The sensitivity to 
antioxidants described here confirm that agonist-mediated changes in fluorescence are a result of ROS 
elevation. 
As a positive control of ROS production, platelets were treated with H2O2 (Figure 3.8). 
Treatment with the highest two concentrations of H2O2 (10μM and 3μM) resulted in significant 
increases in DCFH fluorescence relative to the vehicle control (DMSO). After 6 mins, DCFH F/F0 induced 
by 10μM and 3μM H2O2 treatment were 4.6±0.2 and 1.9±0.2 respectively, which was significantly 
higher the vehicle control (0.91±0.02, p<0.0001, Figure 3.8A,). This data are consistent with the 
detection of ROS by DCFH. 
Pre-treatment of platelet suspensions with BAPTA or TPEN reduced the H2O2-induced DCFH 
fluorescence signal. The final DCFH F/F0 in response to the highest concentration (10μM) of H2O2 was 
reduced from 4.6±0.2 (vehicle) to 3.0±0.4 and 3.6±0.5 upon BAPTA and TPEN pre-treatment 
respectively (p<0.0001, Figure 3.8A-C). The reduced DCFH F/F0 in response to H2O2 on BAPTA and TPEN 
pre-treated platelets did not significantly differ (final DCFH value on TPEN and BAPTA pre-treated 
platelets were 3.0±0.4 and 3.6±0.5 respectively, p>0.05, ns, Figure 3.8B-C). These data illustrate that 
TPEN or BAPTA pre-treatment had similar effects in terms of inhibition of DCFH fluorescence, 
suggesting that  Zn2+, as opposed to Ca2+, can influence ROS signalling. This correlates with data from 
the previous sections (Figures 3.5-7), which demonstrate a role for ROS in Zn2+, but not Ca2+ signalling. 
Furthermore, DCFH fluorescence following treatment with high concentrations (10μM and 3μM) of 
H2O2 in BAPTA and TPEN pre-treated platelets were still significantly higher than that observed with 
vehicle control. The final DCFH F/F0 in BAPTA pre-treated platelets following stimulation with 10μM 
or 3μM H2O2 was 3.0±0.4 and 1.8±0.2, respectively, after 6mins, compared to 1.0±0.1 for vehicle 
control, p<0.01, Figure 3.18B). For TPEN pre-treated platelets, the final DCFH F/F0 was 3.6±0.5 and 
2.2±0.1, respectively for 10µM and 3µM H2O2, compared to 0.90±0.02 for the vehicle control 
(p<0.0001, Figure 3.8C). This finding indicates that ROS signalling is also evoked by other mechanisms 
(yet to be studied) that does not involve Zn2+ or Ca2+ since increases in DCFH fluorescence was still 
significant even with chelation of [Zn2+]i and [Ca2+]i.  
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Figure 3.8. ROS-evoked increases in DCFH fluorescence are inhibited by TPEN and BAPTA and abrogated by PEG-SOD and 
PEG-CAT. DCFH-labelled washed human platelets were stimulated by different concentrations of H2O2 (A), following 
pretreatment with BAPTA (B), TPEN (C), PEG-SOD (D) or PEG-CAT pre (E). ROS fluctuations were recorded over six minutes 
using fluorometry. H2O2 induced a significant increase in Zn2+ fluorescence. This was reduced upon treatment with BAPTA, 
TPEN, PEG-SOD or PEG-CAT. ○ H2O2 10μM, ■ H2O2 3μM, ▲ H2O2 1μM,▼ H2O2 10μM and ● vehicle ( DMSO). Data are 
mean±standard error of mean (SEM) from 6 independent experiments. Significance is denoted as **** (p<0.0001), *** 
(p<0.001), ** (p<0.01) or * (p<0.05). 
PEG-SOD and PEG-CAT were again employed to assess the validity of the ROS elevation upon 
H2O2 treatment. PEG-SOD (30U/mL) and PEG-CAT (300U/mL) pre-treatment abolished any significant 
increases in DCFH fluorescence in response to H2O2. The final DCFH F/F0 in response to H2O2 (10μΜ, 
the highest concentration that resulted in the greatest elevation of DCFH fluorescence) was abrogated 
from 4.6±0.2 (vehicle) to 1.01±0.01 and 1.01±0.02 respectively upon PEG-SOD and PEG-CAT pre-
treatment (p<0.0001, Figure 3.18A, D-E). These data verify that changes in DCFH are attributable to 
changes in ROS production. 
The work described above supports the hypothesis ROS elevation occurs following the 
elevation of [Zn2+]i upon agonist stimulation. CRP-XL stimulation resulted in a greater increase in ROS 
compared with thrombin or U46619 (Figure 3.7A-C). As CRP-XL treatment also resulted in the largest 
elevation of [Zn2+]i (Figure 3.1), this indicates a causal relationship between elevation [Zn2+]i and ROS 
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elevation. This relationship between ROS and Zn2+ may be independent of Ca2+, as [Zn2+]i chelation but 
not [Ca2+]i chelation influenced ROS elevation upon agonist and H2O2 treatment (Figure 3.7D-I). These 
data correlate well with data from other cell types such as neuron cells, where elevated Zn2+ further 
elevates ROS levels in a positive feedback mechanism (Stork and Li, 2016). Data described here, 
suggests that a positive feedback mechanism may be in place in platelets, and may be independent of 
Ca2+, and primarily dependant on Zn2+. Application of the antioxidants confirmed that increases in 
fluorescence observed upon treatment with the agonists was in accordance with ROS elevation as 
PEG-SOD and PEG-CAT pre-treatment abrogated the agonist-evoked DCFH fluorescence response 
(Figure 3.7) 
Application of PEG-SOD and PEG-CAT provided additional data to validate the ROS probe, 
DCFH, as the increases in DCFH fluorescence induced by H2O2 was abrogated upon pre-treatment with 
PEG-SOD and PEG-CAT (Figure 3.8D-E). Furthermore, this fluorescence was inhibited upon pre-
treatment with the [Ca2+] chelator BAPTA (Figure 3.8B) and the [Zn2+]I chelator TPEN (Figure 3.8C), 
further outlining the role that Zn2+ may have on regulating ROS fluctuations. This relationship between 
ROS and Zn2+ may serve to be the major mechanism which enables [Zn2+]i elevation upon activation, 
as illustrated in previous sections of this Chapter.  
 
3.3 Discussion 
The experiments described in this chapter were designed to investigate whether platelet 
[Zn2+]i fluctuates in response to agonist stimulation, and to investigate potential mechanisms for 
changes in [Zn2+]i. The data generated provides the first evidence that [Zn2+]i increases upon activation 
with physiological agonists, in a manner that is consistent with a secondary messenger. Furthermore, 
the mechanisms by which [Zn2+]i was elevated were found to be redox sensitive.  
 
Stimulation of platelets with agonists that target GpVI or TP (CRP-XL or U46619) resulted in 
increases in FZ-3 fluorescence, consistent with a liberation of labile Zn2+ from stores (as yet 
unidentified) into the cytosol of the platelet. CRP-XL stimulation produced a much greater increase in 
FZ-3 fluorescence than U46619, and PAR stimulation did not result in FZ-3 fluctuations. Differential 
responses to agonists indicate that that fluctuations of [Zn2+]i occur as a result of different signalling 
pathways. Signalling via GpVI differs from the signalling via TP or PAR. GpVI signalling involves tyrosine 
phosphorylation of platelet proteins such as Syk and LAT, resulting in the activation of PLCγ2 (Figure 
A A 
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1.3). Conversely, TP and PAR are G-protein coupled receptors that propagate signalling via G-proteins, 
resulting in activation of PLCβ2 (Li et al., 2010). It is difficult to reconcile the different responses in Zn2+ 
signalling following TP or PAR receptor stimulation, as these two receptors both couple to similar 
signalling pathways which involve Gα12/13 and Gαq (Capote et al., 2015). These findings in this chapter 
suggest that [Zn2+]i increases are regulated by proteins that are not shared by GpVI- and thrombin-
dependent signalling pathways. This coincides well with the work carried out by Watson et al., (2016), 
which found that exogenous Zn2+ treatment resulted in differing patterns of tyrosine phosphorylation 
than from that induced by GpVI and PAR (Watson et al., 2016). Tyrosine phosphorylation is a major 
platelet activatory signalling event. The work carried out by Watson et al., (2016) indicates that Zn2+ 
induces activatory signalling via a novel pathway in comparison to CRP-XL and thrombin. The 
differential responses of [Zn2+]i fluctuations to the agonists suggest that [Zn2+]i elevation is mediated 
by a novel GpVI or TP dependent signalling pathway, although this would require further investigation. 
The major finding of this work is that stimulation with conventional platelet agonists results in 
significant increases in [Zn2+]i indicating that Zn2+ may play a major role in platelet activity in 
physiological conditions.      
Differences in fluorescence values for FZ-3 and FL-4, measuring Zn2+ and Ca2+ respectively, 
were observed following agonist stimulation. Pre-treatment of platelets with BAPTA abolished any 
increases in FZ-3 or FL-4 fluorescence, indicating that FZ-3 does not respond to changes in [Ca2+]i. This 
was expected, due to the strong chelating effect by BAPTA of Zn2+ and Ca2+ (discussed in Chapter 1). 
Although BAPTA is a strong [Ca2+]i chelator, BAPTA has a higher affinity for Zn2+, thus it is likely to 
chelate [Zn2+]i in addition to [Ca2+]i (Radford and Lippard, 2013) (Matias et al., 2010a). As seen in Figure 
3.1, the significant increases in [Zn2+]i that occurred in response to stimulation by CRP-XL or U46619 
were abolished in TPEN or BAPTA treated platelets. These data provide evidence that [Zn2+]i is elevated 
upon CRP-XL and U46619 stimulation in a similar manner to [Ca2+]i. Differences in agonist-dependent 
fluctuations in FZ-3 and FL-4 fluorescence were observed (Figure 3.1-2). As expected, pre-treatment 
with BAPTA abolished any significant increases in FL-4 fluorescence (Figure 3.2), as BAPTA is able to 
chelate Ca2+. Interestingly, pre-treatment with TPEN did not significantly influence the agonist-evoked 
FL-4 increases (Figure 3.2), indicating that changes in [Zn2+]i do not play a significant role of [Ca2+]i 
handling. These data also provide strong evidence for the specificity of the fluorophores, FZ-3 and FL-
4 for Zn2+ and Ca2+ respectively since the fluorescence being detected by FL-4 was independent of Zn2+ 
as the application of TPEN did not significantly affect the fluorescence that was exhibited using FL-4. 
These data validate our approach to these experiments.  
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The initial findings of this chapter provide the first indications that [Zn2+]i may be a secondary 
messenger in platelets and may mediate platelet activation in conjunction with [Ca2+]i. Agonist-
dependent elevation of [Ca2+]i is well documented (Smith et al., 1992, 1992; Varga-Szabo et al., 2009). 
[Ca2+]i elevation is a hallmark of platelet activation and is a secondary messenger in platelets (Authi et 
al., 1993; Li et al., 2010; Orem et al., 2017; Smith et al., 1992; Varga-Szabo et al., 2009). [Zn2+]i may act 
in a similar manner to Ca2+ in platelets , due to the elevation of [Zn2+]i also occurring upon platelet 
activation as demonstrated in this chapter. Thus [Zn2+]i elevation may also occur in conjunction with 
[Ca2+]i elevation where Zn2+ may also mediate platelet activatory processes similarly to Ca2+ therefore 
acting as a secondary messenger in platelets (Authi et al., 1993; Smith et al., 1992). 
The mechanisms that regulate agonist-evoked [Zn2+]i increases was investigated using 
pharmacological inhibitors. Previous work in nucleated cells has shown that alterations to the in redox 
state results in the release of Zn2+ from thiol groups on intracellular cation storage proteins such as 
metallothionines into the labile pool (Krężel and Maret, 2017a). Furthermore, collagen treatment of 
platelets stimulates ROS-dependent platelet activation (Carrim et al., 2014; Krötz et al., 2004; Sinha 
and Dabla, 2015). Studies have found that an adaptor receptor known as TNF (tumour necrosis factor) 
adaptor receptor 4 (TRAF4) mediates downstream signalling from the ligated GpVI/FcRγ complex, 
which in turn results in amplified ROS production via the NOX pathway (illustrated in Figure 1.8, 
(Cangemi et al., 2014; Violi et al., 2015)). The p47phox subunit of NOX is a major contributor to 
mediating the downstream signalling from upon GpVI stimulation. TRAF4 interacts with other proteins 
that are involved in the GpVI downstream signalling pathway, including Lyn and Syk (Arthur et al., 
2011). Other work has indicated that there may be specific phases in which ROS is elevated during the 
platelet activation pathways. These studies illustrate the importance of ROS in GpVI signaling 
(Cangemi et al., 2014; Carrim et al., 2014; Krężel and Maret, 2017a). Due to the strong link between 
Zn2+ and redox changes and ROS in many cell types, it was hypothesized that GpVI-induced [Zn2+]i 
elevation may be redox dependant, and thus regulated by ROS concentrations in platelets. To explore 
this hypothesis, the effect of ROS on elevating [Zn2+]i was explored via the modeling of ROS elevation. 
In previous work, ROS elevation was modeled via direct administration of H2O2, which is a stable ROS 
that readily diffuses across membranes (Krötz et al., 2004). Due to its stability compared with other 
ROS , H2O2 has become the primary ROS used in the study of ROS biology in cells. Early research found 
that high concentrations of H2O2 mediate ROS-induced activities such as cellular damage, which 
confirmed its activity as an active ROS species in cells. Such work also indicated that application of 
exogenous H2O2 can mediate intracellular signaling (via the NOX pathways) leading onto further 
elevated intracellular ROS (Gough and Cotter, 2011). H2O2 was also employed to model ROS elevation 
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in platelets and was found to induce apoptotic events (Beckman et al., 1988; Gough and Cotter, 2011, 
; Lopez et al., 2007). This study indicated that the application of H2O2 resulted in further ROS relocation 
endogenously (Beckman et al., 1988; Lopez et al., 2007; Wee and Jackson, 2006). Application of H2O2 
can also induce oxidative stress which can mediate further ROS production via mechanisms such as 
the NOX pathway (Figure 1.8) (Cangemi et al., 2014; Krötz et al., 2004; Pietraforte et al., 2014; Violi et 
al., 2015). 
 In the work described in this chapter, H2O2 treatment resulted in significant increases in 
[Zn2+]i, which was sensitive to BAPTA or TPEN pretreatment (Figure 3.3), providing evidence that ROS 
acts to elevate [Zn2+]i in platelets. Sensitivity to ROS implicates redox-sensitive Zn2+-storage proteins, 
such as metallothioneins, as a mechanism by which Zn2+ is increased. Metallothioneins are cysteine-
rich proteins which transiently bind heavy metals such as Zn2+, and are present at a concentration of 
30 μg/1010 in platelets (Krężel and Maret, 2017a). Metallothionein has been found to have a higher 
affinity for Zn2+ than most other Zn2+ binding proteins (Bell and Vallee, 2009; Krężel and Maret, 2017a). 
Zn2+ binds to cysteines, producing a sulphur and Zn2+ network (Sugiura and Nakamura, 1994) (Rahman 
and De Ley, 2008). The proposed mechanism of Zn2+ binding and release from and to the 
metallothionines is redox dependent. Sulphur and Zn2+ complex can undergo oxidation and reduction 
to release and bind Zn2+ (Bell and Vallee, 2009), (Maret, 2000). This mechanism enables Zn2+ to be 
released, elevating the [Zn2+]i concentration. Although the role of metallothioneins in Zn2+-handling in 
platelets is yet to be determined, previous work has suggested that metallothioneins may play 
inhibitory roles in platelet aggregation and thrombus formation (Sheu et al., 2003). These conclusions 
were reached by incubating platelets with metallothioneins, which inhibited agonist-induced 
aggregation. The authors of this study suggested that metallothioneins play an inhibitory role in [Ca2+]i 
mobilization (Sheu et al., 2003). Whilst further work is required to fully elucidate the role of 
metallothioneins in platelets, the possibility remains that metallathionines may play a significant role 
in regulating the concentration of labile [Zn2+]i in platelets. Since H2O2 provided evidence that elevation 
of ROS induces elevated [Zn2+]i (Figure 3.7) possibly in a redox-dependent manner involving 
metallothionines, the specificity of this potential mechanism was explored by measuring Ca2+ 
fluorescence in response to H2O2 stimulation. Although Ca2+ mobilization upon ROS elevation has been 
previously documented (Görlach et al., 2015; Krötz et al., 2004) these experiments act as a positive 
control to measure ROS elevation on inducing intracellular cation elevation. Data show in Figure 3.4 
demonstrates that increases in ROS induce intracellular Ca2+ mobilization, although was chelated by 
TPEN, indicating that this ROS elevation is attributable to Zn2+ and not Ca2+.   
82 
 
The mechanism by which agonist stimulation results in [Zn2+]i elevation (Figure 3.1) was 
investigated using the antioxidants PEG-SOD and PEG-CAT. PEG-SOD and PEG-CAT, are enzymes, that 
under physiological conditions, act as a defense mechanism against ROS and free radical accumulation 
by breaking these down into less harmful oxygen and water. Accumulation of ROS can cause extreme 
damage to the cells (Pandya et al., 2013; Sinha and Dabla, 2015). PEG-SOD and PEG-CAT, have been 
widely used to regulate ROS in various cells. In recent work, PEG-SOD and PEG-CAT were found to 
offer a greater level of resistance upon high levels of oxidative stress in endothelial cells, thus 
regulated ROS elevation (Beckman et al., 1988). Another example of the use of PEG-SOD and PEG-CAT 
was in research that was investigating the implications of oxidative injury upon radiation-induced 
tissue damage to lungs, in particular, pulmonary fibrosis in mice (Machtay et al., 2006). This work 
indicated that application of PEG-SOD and PEG-CAT inhibited radiation-induced pulmonary fibrosis in 
mice, by protecting the cells from oxidative stress. PEG-SOD and PEG-provided regulation of ROS levels 
in the cells, by scavenging high levels of ROS (Machtay et al., 2006). PEG-SOD and PEG-CAT were also 
employed in work that investigated LPS (Lipopolysaccharide) induced platelet aggregation, which has 
been suggested to be mediated by ROS elevation (Lopes Pires et al., 2017). In this study, the 
antioxidants were found to inhibit LPS induced aggregation, demonstrating the potential of these 
reagents to regulate ROS levels in platelets (Lopes Pires et al., 2017).  
As shown in Figure 3.5 pre-treatment with PEG-SOD and PEG-CAT, inhibited agonist-dependent 
increases in FZ-3 fluorescence, providing evidence that the agonist-induced Zn2+ increases in platelets 
are ROS dependent. Interestingly, PEG-SOD and PEG-CAT did not inhibit agonist-evoked Ca2+ 
fluorescence increases (Figure 3.6). Thus [Ca2+]i elevation is not ROS dependent. Whilst the mechanism 
of agonist-dependent [Ca2+]i elevation are well documented and are not reliant on ROS, previous work 
has found that there is the interplay between Ca2+ signalling and ROS signalling. Studies have indicated 
that ROS may play a role in the regulation of Ca2+ signalling and that Ca2+ signalling is crucial for ROS 
production (Görlach et al., 2015). In this work, the authors stated that elevated Ca2+ is able to induce 
the formation of free radicals by activating ROS producing enzymes (Görlach et al., 2015; Zorov et al., 
2014). ROS production in platelets occurs via mechanisms such as the NOX pathway (Figure 1.8, 
Chapter 1). The NOX pathway is regulated by cytosolic subunits such as p47phox, which are activated 
by Ca2+ mediated PKC induced phosphorylation, thus Ca2+ plays a key role in ROS formation. 
Furthermore, in addition to ROS formation being mediated by Ca2+, ROS elevation and redox 
modulation have been suggested to regulate Ca2+ channels, pumps, and exchangers. TRP channels 
such as TRPM2 and TRPC6 are redox sensitive (Gamberucci et al., 2002; Görlach et al., 2015; Kitajima 
et al., 2016; Zorov et al., 2014). Exposure to ROS induces conformational changes to these channels, 
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thereby regulating activation (Görlach et al., 2015; Kitajima et al., 2016). These studies indicate that 
ROS may play a major role in Ca2+ homeostasis in platelets. STIM1 and Orai1 (which are involved in 
SOCE, Figure 1.10) have also been suggested to be redox sensitive (Görlach et al., 2015). STIM1 and 
Orai1 assist in ROS formation as well as being activated by ROS (Gandhirajan et al., 2013; Steinckwich 
et al., 2011). IP3R has also been suggested to be redox sensitive. Work carried out on various cell types 
such as endothelial cells, targeted the multiple thiol groups found in IP3R. Application of exogenous 
ROS has been suggested to induce the sensitivity of IP3R to IP3 via modulation of thiol groups. The 
exact mechanism of this ROS mediated IP3R activation is yet to be elucidated, however, may be an 
interesting target due to the importance of IP3R in calcium signalling (Bánsághi et al., 2014; Lock et al., 
2012). Further studies have suggested that ROS may play an inhibitory role in the Ca2+ pumping activity 
induced by SERCA , by inducing uncoupling of ATP hydrolysis from the Ca2+ pumping activity 
(Gamberucci et al., 2002; Sharov et al., 2006; Smith et al., 1992). Whilst these studies provide further 
support for a role for ROS and redox in Ca2+ signalling, the data presented in this chapter indicate that 
ROS is not a key determinant in agonist-dependent elevated [Ca2+]i whereas it is for [Zn2+]i elevation. 
Whilst previous studies indicate that there is the potential interplay between ROS and Ca2+, all 
previous work has not taken Zn2+ into account (Görlach et al., 2015). The work carried out in this 
chapter, Is suggestive to a relationship between Zn2+ and ROS in platelets. This is a novel finding that 
warrants further investigation. The data described here indicates that [Zn2+]i elevation in platelet is 
dependant on ROS and that redox changes induced by the agonists may be the major mechanism 
elucidating [Zn2+]i elevation, which may be independent of Ca2+.  
Further experiments were carried out to measure ROS upon agonist stimulation. As 
demonstrated in Figure 3.7, agonist stimulation resulted in significant increases in ROS. CRP-XL 
induced the highest increase in ROS fluorescence in comparison to U46619, or thrombin. This 
correlates with previous work which showed that CRP-XL stimulation resulted in higher levels of ROS 
release than other agonists (Arthur et al., 2008; Begonja et al., 2006; Freedman, 2008; Krötz et al., 
2004; Qiao et al., 2018; Walsh et al., 2014). Pre-treatment of platelets with BAPTA significantly 
reduced the CRP-XL-induced ROS and abolished increases that were induced by U46619 and thrombin. 
This was also the case when the platelets were pre-treated with TPEN, providing further evidence for 
interaction between ROS and Zn2+. As chelation of Ca2+ and Zn2+ (using BAPTA) did not produce a ROS 
response that was significantly different to [Zn2+]i chelation (following TPEN treatment), these data 
indicate that [Zn2+]i elevation is redox-sensitive and independent of Ca2+, providing further evidence 
to suggest a novel mechanism by which [Zn2+]i is elevated in platelets may be in place.  
84 
 
 Further experiments were performed to determine the biological validity of the ROS 
fluorescence that is being induced by the agonists. The antioxidants PEG-SOD and PEG-CAT which 
scavenge ROS were employed to determine whether the fluorescence increases were attributable to 
ROS production. As shown in Figure 3.7, the ROS fluorescence induced by the agonists was completely 
abolished by antioxidant treatment, confirming that changes in fluorescence are due to ROS. H2O2 was 
used again to test the biological validity of the DCFH in detecting ROS in platelets. As illustrated in 
Figure 3.8, H2O2 induced a significant increase in ROS fluorescence, which was slightly reduced with 
BAPTA or TPEN treatment, outlining further evidence of the relationship between cations and ROS in 
platelets. As expected the antioxidants, PEG-SOD and PEG-CAT, inhibited any ROS fluorescence 
increases induced by H2O2. Thereby confirming the biological validity of the ROS probe DCFH in 
platelets.  
 
3.3.1. Conclusion 
The data described here is the first to show fluctuations of [Zn2+]i in response to agonist stimulation of 
platelets. This finding suggests a novel mechanism of [Zn2+]i elevation upon agonist stimulation with 
agonists in a redox-sensitive manner in platelets. CRP-XL and U46619, but not thrombin, induced 
significant elevations in [Zn2+]i. Although thrombin treatment did not result in fluctuations in FZ-3 
fluorescence, thrombin-induced the greatest increase in [Ca2+]i, which in contrast to CRP-XL or 
U46619, was sustained throughout the experiment. The reason why thrombin-induced activation does 
not result in Zn2+ fluctuations is not clear. It is possible that differential receptor engagement results 
in heterogeneous Zn2+ responses, with PAR receptors (unlike GpVI or TP), not coupling to [Zn2+]i 
release. Conversely, since thrombin results in the largest and most sustained [Ca2+]i elevation, 
thrombin-induced [Ca2+]i elevation could be negatively regulating [Zn2+]i elevation, possibly as a result 
of competition between the cations. Further investigation is required to determine as to why thrombin 
does not induce [Zn2+]i elevation, however differences in ROS increases evoked by these agonists 
(Figure 3.7) may also provide an explanation as to why PAR stimulation by thrombin did not evoke 
[Zn2+]i  fluctuations. Collagen, thromboxane A2 and thrombin stimulation all result in increases in ROS 
levels, with GpVI signalling inducing the greatest rise in ROS levels as shown in previous studies (Arthur 
et al., 2008; Krötz et al., 2004; Qiao et al., 2018; Walsh et al., 2014). These findings correlate well with 
the data presented in this chapter. Stimulation via GpVI induced the greatest increase in ROS 
fluorescence in comparison to U46619 and thrombin. The greater increase in ROS in response to GpVI 
stimulation relative to thrombin indicates that perhaps the differences in [Zn2+]i fluctuations are 
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attributable to differences in ROS signalling evoked upon GpVI and PAR stimulation. Interestingly 
thrombin evoked increases in ROS was found to be mediated by [Zn2+]i (Figure 3.7), which is difficult 
to reconcile as thrombin does not mediate [Zn2+]i fluctuations. Thus Zn2+ may serve as a mechanism 
for mediating ROS signalling which is most apparent upon GpVI stimulation, however, serves as a 
complex mechanism that requires further investigation. Overall this work provides the first reports 
demonstrating that agonist-dependent changes in platelet redox state result in a rapid and sustained 
[Zn2+]i elevation. Although this is not the case with thrombin which suggests alternative mechanisms 
that are yet to be confirmed may be in place.  
This work also shows that changes to the redox state of platelets result in an increase in FZ-3 
fluorescence, consistent with the liberation of Zn2+ from stores. Whilst the nature of Zn2+ stores is not 
known, redox sensitivity is compatible with storage by metal ion binding proteins such as 
metallothioneins. [Ca2+]i mobilization was not influenced by changes in redox state and was 
independent of such mechanisms that affected [Zn2+]i mobilisation; thus cation release is differentially 
regulated. As Ca2+ is predominantly mobilized from the dense tubular system, these data correlate 
with a different release mechanism for Zn2+. Release from Zn2+ binding proteins is consistent with this 
idea. 
This work has addressed the aims of this chapter, as the data generated provides the first 
finding of agonist-induced [Zn2+]i mobilization which is redox sensitive. [Zn2+]i is elevated upon platelet 
stimulation and may be regulated in a redox-sensitive manner.This is consistent with a role for Zn2+ as 
a secondary messenger. However, for such a conclusion to be drawn, it is necessary for increased 
[Zn2+]i to have a causal relationship with aspects of platelet activation. In order to test this, further 
experiments were designed to investigate how increases in platelet [Zn2+]i affected functional 
responses. These experiments are described in the following chapters. 
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Chapter 4  
4.0 Modelling intracellular Zn2+ release in platelets using ionophores  
4.1 Background 
The data described in Chapter 3 demonstrated that [Zn2+]i was elevated in platelets stimulated by 
conventional agonists, including CRP-XL and U46619. Zn2+ fluctuations were redox-sensitive, 
suggesting that Zn2+-binding proteins which are sensitive to redox changes (such as metallothioneins) 
may release Zn2+ upon changes in redox state. Whilst Zn2+ release is redox-dependent, the nature of 
the Zn2+ store has yet to be confirmed.  
 Agonist-evoked changes in [Zn2+]i are consistent with a role for Zn2+ as a secondary messenger. 
However, to conclude a secondary messenging role, changes in Zn2+ need to be linked to functional 
responses. Whilst this has been done in several nucleated cell types, functional responses to increased 
[Zn2+]i in platelets has yet to be demonstrated.  
 In this chapter, a number of experiments are described in which the cytosolic concentration 
of Zn2+ is artificially increased via pharmacological means, and resulting effects on platelet function 
are assessed. The pharmacological modulators used here are ionophores, of which a number have 
been described in the literature as being specific for Zn2+, and not affected by other physiological 
cations such as Ca2+.  
 
4.1.1. Modelling cation release using ionophores 
Ionophores are lipid-soluble reagents that facilitate metal ion transport across cell 
membranes and have been widely used to study the effects of ions in cellular activity (Ding and Lind, 
2009). Ionophores tend to have moderate to low affinity to their selective metal ion. When utilised in 
cell research, ionophores bind to the ions in a highly concentrated area (for example in an ion store in 
a cell) and then diffuse to areas where the ion concentration is low (for example the cytosol of a cell). 
Thus ionophores can be used to equilibrate ions in a given cellular environment (Ding and Lind, 2009; 
Fasolato and Pozzan, 1989; Pressman, 1976). Ionophores are sensitive to protonation, due to the 
mechanism of cation transport which have been modelled by previous studies, where cations are 
exchanged for protons (H+) in an electron neutral process (Fasolato and Pozzan, 1989; Pfeiffer et al., 
1978; Shastri et al., 1987). Thus, the binding of ions to ionophores may be pH-dependent. If the pH of 
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the milieu surrounding the ionophore is higher than the pKa of the ionophore, then the metal ion will 
bind to the ionophore. However, if the pH of the surrounding space is lower than the pKa of the 
ionophore, then the metal ion will be released (Ding and Lind, 2009, Andreini et al., 2006). Ionophores 
therefore essentially transport ions from one region to another across the membrane. However, an 
alternate mechanism has been proposed, whereby the ionophore can form a hydrophilic pore on the 
cell membrane, allowing the ions to pass through the pore, in essence forming a channel for the ions 
(Ding and Lind, 2009; Pressman, 1976). Ionophores have been used to equilibrate ion concentrations 
as well to incorporate ions into cellular environments. However, most notably, ionophores have been 
widely used to enable increases in intracellular ion concentration in order to study the effects of ions 
on the specific cellular activity (Shastri et al., 1987; Verma et al., 2011; Xue et al., 2014). 
On account of the magnitude of importance of Ca2+ in many cell processes, a widely used 
ionophore in cell research is the calcium ionophore, A23187(Pfeiffer et al., 1978; Shastri et al., 1987, 
p. 23187; Verma et al., 2011). The increase of cytosolic Ca2+ levels by A23187 mimics the effects of 
signal pathway engagement and [Ca2+]i release (Pfeiffer et al., 1978). A23187 is widely accepted to 
have specificity for Ca2+ over other cations (E. Wang et al., 1998), and it is often used to increase 
cytosolic Ca2+ concentrations by liberating Ca2+ from intracellular stores, thus aiding in the 
understanding of the roles calcium plays in many cellular processes such as apoptosis and proliferation 
(Fasolato and Pozzan, 1989). However, A23187 may also coordinate other cations such as Zn2+. A23187 
has been suggested to potentially have different transport mechanisms for different cations, although 
this is yet to be studied. The transport of Ca2+ via A23187 occurs in a 2 (ionophore): 1 (cation) state, 
whereas if the complex were in a 1:1 state then Ca2+ transport does not occur (Erdahl et al., 1995, 
1994; E. Wang et al., 1998). The destabilisation of the 2:1 complex state can result in the loss of an 
ionophore and form the 1:1 state complex, although this change in stoichiometry (2:1- 1:1) requires 
further investigation to confirm the validity of this proposed mechanism. These studies provide 
evidence to suggest that A23187 may not be as Ca2+ specific and could also enable Zn2+ transport 
(Erdahl et al., 1996, 1995, 1994). Work carried out in rat thymocytes found that increases in Ca2+ 
fluorescence induced by A23187 were not influenced by TPEN application; however, increases in Zn2+ 
fluorescence that was induced by A23187 was abrogated upon TPEN application (Sakanashi et al., 
2009). Thus showing that A23187 was also able to evoke [Zn2+]i increases in addition to [Ca2+]i 
increases. In human platelet research, application of A23187 results in a full aggregation response, as 
a result of Ca2+ mobilisation from the Ca2+ store (Verma et al., 2011). A23187 has been widely used in 
platelet research to investigate Ca2+ signalling, however, due to the ability of A23817 being able to 
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coordinate Zn2+, the behaviours in platelets induced by A23187 may also be attributable to Zn2+. 
Therefore, further demonstrating how Zn2+ may have been overlooked in favour of Ca2+.  
Zn2+ ionophores have been used as a tool to model and extensively study the role of 
intracellular Zn2+, in a similar manner to Ca2+ (Woodier et al., 2015), (Smith et al., 1992). Two widely 
used Zn2+ specific-ionophores are pyrithione (Py, Zn2+ ionophore, C10H8N2O2S2 , Kds: 10-7M, KdCa: 10-
4.9M) and clioquinol (Cq, Zn2+ ionophore, C9H5ClINO, KdZn: 10-7M, KdCa: 10-4.9M) (Arslan et al., 1985a; 
Hyun et al., 2004a; Matias et al., 2010a; Qian and Colvin, 2016b). Py is an antimicrobial agent and is 
used as an antidandruff compound in shampoos. Similarly, Cq is used as an antifungal and is also 
applied as a bacteriostatic drug. However, the full mechanism of action of both of these Zn2+ 
ionophores is yet to be determined (Krenn et al., 2009). 
Py has been widely used as a means of increasing [Zn2+]i in various cell types to study cellular 
effects (Kim et al., 1999). Py induces apoptosis of cancer cells in vitro and is being investigated as a 
potential anti-cancer agent (Truong-Tran et al., 2000). Py activates a member of the transient receptor 
potential channel family (TRP channels) known as TRPA1, which are ion channels expressed on the 
membranes of various cell types. TRPA1 is expressed in dorsal root ganglia in mice. Treatment with Py 
induces activation of TRPA1 by elevating [Zn2+]i. This study provides a characterisation of the 
properties of Py as a Zn2+ ionophore (Ding and Lind, 2009; Krenn et al., 2009). 
Cq is another Zn2+ specific ionophore which elevates [Zn2+]i in various cell types (Park et al., 
2011; Schimmer et al., 2012; Seo et al., 2015). Cq belongs to a class of compounds known as 
hydroxyquinolines and consists of two electron donor sites, one at its phenol oxygen atom and the 
other at its quinolone ring nitrogen atom which enables Cq to bind Zn2+. Cq also contains the halogens, 
iodine and chlorine (Ding and Lind, 2009). Halogen groups increase lipophilicity, which may enable 
increased absorption at its intracellular target sites (Ding and Lind, 2009). The properties of Cq to 
characterise its role as an ionophore has been confirmed in studies showing Cq-induced increases in 
[Zn2+]i in cancer cells(Yu et al., 2009). Other studies have found that Cq induces apoptosis and may 
potentially be used as an anti-cancer therapy via Zn2+ modulation (Ding et al., 2005; Ding and Lind, 
2009; Rodríguez-Santiago et al., 2015; Yu et al., 2009). 
 
4.1.2. Aims and Hypothesis 
The aim of the work described in this chapter was to investigate whether ionophore-mediated 
increases in [Zn2+]i couple to functional responses. Previous work in the literature has modelled [Ca2+]i 
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elevation using ionophores, which enabled the role of Ca2+ in platelets to be extensively studied 
(Davies et al., 1989; Erdahl et al., 1994; Sargeant et al., 1994; Verma et al., 2011). Ionophores enable 
a higher intracellular elevation of the cation (due to reasons discussed above) in comparison to that 
when stimulated with agonists. Thus the full role of the cation in platelet activity can be studied upon 
modelling release via ionophores, which may not be possible with agonist stimulation. The specific 
signalling pathways induced by the agonists result in varied responses and mobilisation of cations as 
illustrated in the previous chapter and the literature. The hypothesis of this chapter is that increases 
in [Zn2+]i regulate platelet functional responses. 
 
4.1.3. Methods 
The release of [Zn2+]i and [Ca2+]i was measured in washed platelet suspensions in the same 
manner as Chapter 3, using fluorometry following staining with the [Zn2+]i and [Ca2+]i probes, Fluozin-
3 (Fz-3) and FL-4 (FL-4), respectively (section 2.5). 
The Zn2+ ionophores, Cq and Py, were investigated for use in platelets.The Ca2+ ionophore, 
A23187, was employed as a comparative measure to Zn2+ signalling as well as acting as a positive 
control to assess the action of ionophores in terms of modelling cation release. 
In the same manner as Chapter 3, BAPTA and TPEN were employed to assess [Zn2+]i and [Ca2+]I 
fluctuations. Furthermore, the antioxidants PEG-SOD and PEG-CAT were employed in this chapter, to 
asses redox sensitivity in the context of cation release modelling, and changes in ROS were monitored 
with (DCFH) as before. 
 
4.2 Results  
4.2.1. Modelling intracellular Zn2+ release in platelets 
Zn2+ specific ionophores were employed to mobilise Zn2+ from potential Zn2+ stores in 
platelets. This work was carried out to model [Zn2+]i release using a similar scheme used to investigate 
[Ca2+]i increases (Varga-Szabo et al., 2009).  
Stimulation of FZ-3 loaded platelets with Zn2+ ionophores Cq or Py resulted in rapid, 
concentration-dependent increases in FZ-3 fluorescence, consistent with an elevation of [Zn2+]i (Figure 
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4.1A-B). Treatment with the highest concentrations of the Cq or Py resulted in the largest increase in 
FZ-3 fluorescence relative to that induced by the vehicle. F/F0 values following Cq (300µM) treatment 
increased throughout the stimulation time, reaching 6.2±1.1 after 6 mins. This was significantly higher 
than that generated by the vehicle control (0.98±0.02 after 6 mins, P<0.0001, Figure 4.1A). These 
results demonstrate that treatment of platelets with Zn2+ ionophores results in increases in [Zn2+]i. 
Treatment with the highest concentration of Py also resulted in a significant increase in FZ-3 
fluorescence relative to that induced by the vehicle control, although this was lower than that in 
response to Cq. After 6 mins, the F/F0 in response to 300 μM Py was 3.3±0.3, compared to 0.97±0.01 
for the vehicle control (P<0.0001, Figure 4.1B). The reason why the two ionophores result in 
differences in Fz-3 fluorescence is unclear, as they both would be expected to elicit a similar response. 
It is possible that differences in ion binding affinity or differences in membrane permeability 
contribute to differences in ion handling. 
A23187 was employed to determine whether changes in Ca2+ would affect FZ-3 fluorescence, 
and also to investigate the specificity of FZ-3 for Zn2+.  
Treatment with 300 μM of A23817 (the highest concentration used) resulted in a modest 
increase in FZ-3 fluorescence that only differed significantly from the vehicle control after 4 mins of 
treatment. F/F0 values after 4 mins and 6 mins of stimulation with 300 μM A23187 were 1.6±0.3 and 
1.8±0.3, respectively compared to 0.97±0.01 for the vehicle control, P<0.05, Figure 4.1C. There are 
different explanations for this observation. FZ-3 may be potentially detecting Ca2+ at high 
concentrations (evoked by A23817). Alternatively, A23187-dependent Ca2+ release may stimulate 
[Zn2+]i release as a secondary response. However, the increase in FZ-3 fluorescence induced by A23187 
(300μM) was low in comparison to that induced by the Zn2+ ionophores, indicating that FZ-3 is Zn2+ 
specific. 
 
91 
 
 
Figure 4.1. Ionophore treatment results in increases in FZ-3 fluorescence in platelets, which is abrogated by BAPTA and 
TPEN pre-treatment. Fluozin-3 (FZ-3)-loaded washed human platelets were stimulated by increasing concentrations of 
clioquinol, Cq (A), pyrithione, Py (B), or A23187 (C). FZ-3-labelled washed human platelets were pre-treated with BAPTA 
(10μΜ) before being stimulated by increasing concentrations of Cq (D), Py (E) or A23187 (F). FZ-3-labelled washed human 
platelets were pre-treated with TPEN (50μM) before being stimulated by increasing concentrations of Cq (G), Py (H), or 
A23187 (I). FZ-3 fluctuations were recorded over six minutes using fluorometry. Treatment with Zn2+ ionophores resulted in 
rapid, significant increases in FZ-3 fluorescence which was abolished upon BAPTA and TPEN pre-treatment. Treatment with 
the Ca2+ ionophore A23187 resulted in a reduced response which was also abolished upon BAPTA and TPEN pre-treatment. 
○ 300μM, ■ 100μM, ▲ 30μM, ▼ 10μM and ● vehicle. Data are mean±standard error of mean (SEM) from 6 independent 
experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
BAPTA is a potent chelator of both Ca2+ and Zn2+ and was employed to investigate the nature 
of the ionophore-induced fluorescent signal. BAPTA (10 μM) pre-treatment abolished any FZ-3 
92 
 
fluorescence increases that were induced by the ionophores (Figure 3.1D-F). After 6 mins, F/F0 induced 
by Cq (300 μM) was abrogated from 6.2±1.1 (vehicle) to 0.90±0.03 on BAPTA pre-treated platelets 
(p<0.0001, Figure 3.1A, D). Similarly, F/F0 induced by Py (300 μM) was abolished from 3.3±0.3 (vehicle) 
to 0.90±0.03 on BAPTA pre-treated platelets (p<0.0001, Figure 3.1B, E). Thus, ionophore-induced Fz-
3 fluorescence is attributable to BAPTA-chelatable cations. 
After 6 mins, F/F0 in response to A23187 (300 μM) was also abrogated from 1.8±0.3 to 0.8±0.1 
in BAPTA pre-treated platelets (p<0.05, Figure 3.1C, F). Thus these results provided validity of the FZ-
3 fluorescence increases evoked by this ionophore. However, this data still did not confirm whether 
Zn2+ or Ca2+ were responsible for the increases in FZ-3 fluorescence. Therefore the highly specific [Zn2+]i 
chelator TPEN (as demonstrated in chapter 3) was employed to confirm that FZ-3 fluorescence 
fluctuations induced by the ionophores were attributable to Zn2+.  
Pre-treatment of platelet suspensions with the Zn2+ chelator TPEN also resulted in abrogation 
of ionophore-induced FZ-3 fluorescence (Figure 4.1G-I). The final F/F0 induced by Cq (300µM) was 
reduced from 6.2±1.1 to 1.09±0.01 on TPEN (50μM) pre-treated platelets (p<0.0001, Figure 4.1A, G). 
The final F/F0 induced by Py (300μM) was also reduced from 3.3±0.3 to 0.94±0.02 on TPEN pre-treated 
platelets (p<0.0001, Figure 3.1B, H). As TPEN is specific to Zn2+ with no effect on Ca2+. these data 
confirm that the FZ-3 fluorescence induced by Cq and Py is attributable to [Zn2+]i and not [Ca2+]i,  
Interestingly the FZ-3 fluorescence induced by A213187 was also abolished by TPEN pre-
treatment in the same manner as BAPTA pre-treatment. After 6 mins, F/F0 in response to A23187 
(300μM) was reduced from 1.8±0.3 to 0.96±0.02 in TPEN pre-treated platelets (p<0.05, Figure 3.1C, I). 
This data indicates that the FZ-3 fluorescence increases evoked by A23187 are actually attributable to 
Zn2+. This further validates FZ-3 as a specific Zn2+ probe, as this data confirms that the fluorescence 
being detected was not due to [Ca2+]i elevation. Thus A23187 may not be Ca2+ specific and may also 
act on Zn2+ as has been the case with other commonly used cation chelators and ionophores as 
discussed in Chapter 2. These findings demonstrated that application with the Ca2+ ionophores, 
A23187 resulted in slight increases in FZ-3 fluorescence consistent with modest increases in [Zn2+]i. 
These data demonstrated that A23187 may not be Ca2+-specific as it was able to induce increases in 
[Zn2+]i elevation. This coincided with previous studies which show that A23187 is able to evoke 
increases in Zn2+ fluorescence as shown in rat thymocyte studies (Sakanashi et al., 2009). Thus 
indicating that A23187 induces [Zn2+]i elevation and is not specific to Ca2+ as described earlier. These 
results indicated the increase in fluorescence induced by A23187 was attributable to Zn2+. This 
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warrants further investigation and could further unveil the importance of Zn2+ in supposed Ca2+ specific 
processes. 
The work conducted in this section demonstrates that Zn2+ ionophores increase [Zn2+]i in 
platelets, and can therefore be used to model agonist-dependent increases in [Zn2+]i to investigate 
potential activatory effects.Use of Zn2+-specific ionophores (Cq and Py) and chelators (TPEN), and non-
specific chelators (BAPTA) confirmed that Zn2+ is responsible for the changes in FZ-3 fluorescence. 
Interestingly, these experiments were performed in the absence of extracellular Zn2+. 
Therefore, any Zn2+ that is liberated by the ionophores must be present within stores in the platelets 
that are inaccessible to cytosolic FZ-3 under resting conditions. This would be consistent with a 
membrane-bound store of Zn2+, similar to the DTS Ca2+ store. The nature of such a store is not known, 
although platelet a-granules contain significant quantities of Zn2+. Whether this is accessible for 
increasing cytosolic Zn2+ concentrations upon agonist stimulation is not known.  
 
4.2.2. Intracellular Ca2+ release is independent to intracellular Zn2+ 
release in platelets 
The experiments described above demonstrate that [Zn2+]i release can be modelled using Zn2+-
specific ionophores. However, despite having low affinities for Ca2+, it is possible that the Zn2+ 
ionophores influence Ca2+ dynamics. To address this issue, fluctuations of [Ca2+]i in response to 
ionophore treatment were investigated. This was primarily done as a comparison with [Zn2+]i 
fluctuations, but also to verify the nature of the specificity of the fluorophores FZ-3 and FL-4 to Zn2+ 
and Ca2+ respectively.  
Treatment with Cq or Py resulted in no significant fluctuations in FL-4 fluorescence. After 6 
mins, the FL-4 F/F0 following Cq (300μM) or Py (300μM) stimulation were 1.02±0.02 and 1.06±0.02, 
respectively compared to the vehicle control (1.01 ±0.01, p>0.05, ns, Figure 4.2A, B). Thus, FL-4 is 
specific for Ca2+, and [Zn2+]i has a negligible effect on FL-4 fluorescence.  
Treatment with the highest four concentrations of A23187 (300μM, 100μM, 30μM and 10μM) 
resulted in significant increases in FL-4 fluorescence relative to the vehicle treatment. After 6 mins, FL-
4 F/F0 values were 5.8±0.9, 4.1±0.7, 2.6±0.5 and 1.9±0.2 respectively for 300µM, 100µM, 30µM and 
10μM compared to 0.96±0.01 for the vehicle control (p<0.05, Figure 4.2C). This data illustrates the 
validity of A23187 as an ionophore for Ca2+, as well as the validity of FL-4 as a specific [Ca2+]i probe.  
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Figure 4.2. Ionophore treatment results in increases in FL-4 fluorescence, which is abrogated by BAPTA but not by TPEN 
pre-treatment. Fluo-4 (FL-4)-loaded washed human platelets were stimulated by increasing concentrations of Cq (A), Py (B), 
or A23187 (C). FL-4-labelled washed human platelets were also pre-treated with BAPTA (10μΜ) before being stimulated by 
increasing concentrations of Cq (D), Py (E) or A23187 (F). FL-4-labelled washed human platelets were also pre-treated with 
TPEN (50μM) before being stimulated by increasing concentrations of Cq (G), Py (H), or A23187 (I). FL-4 fluctuations were 
recorded over six minutes using fluorometry. Treatment with Ca2+ ionophore A23187, but not the Zn2+ ionophores resulted 
in rapid, significant increases in FL-4 fluorescence. BAPTA abolished increases in FL-4 fluorescence resulting from ionophore 
treatment. TPEN pre-treatment had no significant effect on ionophore-induced increases FL-4 fluorescence.  ○ 300μM, ■ 
100μM, ▲ 30μM, ▼ 10μM and ● vehicle. Data are mean±standard error of mean (SEM) from 6 independent experiments. 
Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
BAPTA (10μM) pre-treatment inhibited FL-4 fluctuations in response to ionophore treatment, 
consistent with chelation of cytosolic cations. Cq and Py treatment produced no significant increase 
in FL-4 fluorescence; thus the effect of BAPTA pre-treatment was negligible. However, the increases 
in FL-4 fluorescence induced by A23187 were abolished upon BAPTA pre-treatment. The final F/F0 
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induced by the highest concentration (300μM) of A23187 was reduced from 5.8±0.9 to 1.0±0.1 in 
BAPTA pre-treated platelets (p<0.0001, Figure 4.2C, F).  
 TPEN (50μM) pre-treatment did not significantly affect A23187 induced FL-4 fluorescence 
fluctuations (Figure 4.2I), confirming that ionophore-induced [Ca2+]i increases were not sensitive to 
Zn2+. Slight reductions in FL-4 fluorescence were observed following TPEN pre-treatment although this 
was not found to be significant. The F/F0 induced by 300μM, 100μM and 30μM A23187 after 6 mins 
were slightly reduced from 5.8±0.9, 4.1±0.7 and 2.6±0.5 to 4.2±0.6, 2.6±0.3 and 2.1±0.4, respectively 
in TPEN pre-treated platelets (p>0.05, ns, Figure 4.2C, I). Again, the application of this chelator had a 
negligible effect on Cq or Py treatment, as no fluctuations in FL-4 fluorescence were observed with 
these Zn2+ ionophores. This data further demonstrates the specificity of FL-4 as Ca2+ probe, as chelation 
of [Zn2+]i had no significant influence on the FL-4 fluctuations induced by the Ca2+ ionophore, A23187.  
The data described above indicate that increases in [Ca2+]i are not influenced by [Zn2+]i. Initial 
experiments demonstrate the specificity of FL-4 for Ca2+. As [Zn2+]i elevation in response to Zn2+ 
ionophores did not evoke any fluctuations in FL-4 fluorescence, and thus were also not influenced by 
TPEN or BAPTA (Figure 4.2A-B, D-E, G-H). Thus FL-4 does not respond to Zn2+. 
Application of the Ca2+ chelator BAPTA further demonstrated that the FL-4 fluctuations 
induced by A23187 were attributable to [Ca2+]i elevation (Figure 4.2F). Pre-treatment with TPEN had 
no significant influence on the FL-4 response induced by A23187 (Figure 4.2I). Thus [Ca2+]i elevation is 
not influenced by [Zn2+]. 
To conclude, this work justified the use of the ionophores (Cq, Py and A23187) and the 
fluorophores (FZ-3 and FL-4) as valid tools to model and assess Zn2+ and Ca2+ fluctuations. 
 
4.2.3. Ionophore-induced intracellular Zn2+ and Ca2+ release is not 
sensitive to modulators of the redox state platelets 
Experiments carried out using the ionophores demonstrated that there is [Zn2+]I within 
platelets , possibly representing an accessible Zn2+ store. At present, the site from which labile Zn2+ is 
released within platelets is not known, although [Zn2+]i is present in platelet granules (Marx et al., 
1993a; Maynard et al., 2007; Taylor and Pugh, 2016). Experiments discussed in Chapter 3 indicate that 
redox-dependent metal binding proteins such as metallothioneins can store Zn2+ and that [Zn2+]i 
elevation is regulated by changes to the platelet redox state. In order to further investigate the nature 
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of the Zn2+ store in platelets, experiments were performed to assess the if changes in platelet redox 
state influence ionophore-induced [Zn2+]i fluctuations. This would help elucidate whether redox-
operated mechanisms enable [Zn2+]i storage and release, or if other storage mechanisms are present 
in platelets. To investigate whether redox changes affected ionophore-induced [Zn2+]i fluctuations, 
platelets were pre-treated with the anti-oxidants PEG-SOD (30U/mL) and PEG-CAT (300U/mL)which 
have been widely employed to regulate redox changes and to investigate ROS biology in a wide variety 
of cells (Beckman et al., 1988; Görlach et al., 2015; Machtay et al., 2006). 
Pre-treatment of washed platelet suspensions with PEG-SOD (30U/mL) or PEG-CAT (300U/mL) 
did not significantly influence FZ-3 fluctuations induced by Cq, Py or A23187 (Figure 4.3). FZ-3 F/F0 
values in PEG-SOD or PEG-CAT pre-treated platelets were 5.2±0.7 and 4.9±0.6, respectively following 
stimulation with Cq (300µM) after 6mins (Figure 4.3D, G). Whereas FZ-3 F/F0 in response to by Cq 
(300μM) on untreated (vehicle) platelets was 6.5±0.4 after 6mins (p>0.05, ns, Figure 4.3A, D, G). This 
was also the case with Py treatment, as the FZ-3 F/F0 induced by Py on PEG-SOD and PEG-CAT pre-
treated platelets were 3.0±0.3 and 3.0±0.2, respectively which did not differ to the final FZ-3 F/F0 
induced by Py (300μΜ) on untreated (vehicle) platelets which were 3.0±0.4 after 6mins (p>0.05, ns, 
Figure 4.3B, E, H). Furthermore, the FZ-3 F/F0 following A23187 stimulation (300µM) after 6mins, of 
PEG-SOD and PEG-CAT pre-treated platelets which were 1.6±0.6 and 1.7±0.2 respectively, also did not 
differ significantly to that induced by the vehicle-treated platelets( 1.8±0.1, p>0.05, ns, Figure 4.3C, F, 
I). 
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Figure 4.3. PEG-SOD and PEG-CAT do not effect ionophore-evoked increases in FZ-3 fluorescence. Fluozin-3 (FZ-3)-labelled 
washed human platelets were stimulated by increasing concentrations of Cq (A), Py (B) and A23187 (C) FZ-3-labelled washed 
human platelets were pre-treated with PEG-SOD (30U/mL) before being stimulated by increasing concentrations of Cq (D), 
Py (E) and A23187 (F). Finally, FZ-3-labelled washed human platelets were pre-treated with PEG-CAT (300U/mL) before being 
stimulated by increasing concentrations of Cq (G), Py (H) and A23187 (I). FZ-3 fluctuations were recorded over 6 minutes 
using fluorometry. PEG-SOD and PEG-CAT pre-treatment had no significant effect on ionophore-induced increases in FZ-3 
fluorescence. ○ 300μM, ■ 100μM, ▲ 30μM, ▼ 10μM and ● vehicle. Data are mean±standard error of mean (SEM) from 6 
independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
Modulation of redox states with PEG-SOD and PEG-CAT did not significantly influence the 
ionophore-induced FZ-3 fluctuations, indicating that ionophore-induced [Zn2+]i increases are not 
sensitive to the platelet redox state. These findings suggest that ionophore-induced [Zn2+]i elevation 
do not operate through a redox-dependent mechanism, which may indicate a non- redox-sensitive 
store of Zn2+ in platelets. 
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Further experiments were performed to investigate whether the redox state affected 
ionophore-induced Ca2+ release. Pre-treatment of platelets with PEG-SOD or PEG-CAT did not 
significantly influence ionophore-induced increases in FL-4 fluorescence, (Figure 4.4). 
 
Figure 4.4. PEG-SOD or PEG-CAT do not effect ionophore-evoked increases in FL-4 fluorescence. Fluo-4 (FL-4)-labelled 
washed human platelets were stimulated by increasing concentrations of Cq (A), Py (B) and A23187 (C). FL-4-labelled washed 
human platelets were pre-treated with PEG-SOD (30U/mL) before being stimulated by increasing concentrations of Cq (D), 
Py (E) and A23187 (F). Finally, FL-4-labelled washed human platelets were pre-treated with PEG-CAT (300U/mL) before being 
stimulated by increasing concentrations of Cq (G), Py (H) and A23187 (I). FL-4 fluctuations were recorded over 6 minutes 
using fluorometry. PEG-SOD and PEG-CAT pre-treatment had no significant effect on ionophore-induced increases in FL-4 
fluorescence. ○ 300μM, ■ 100μM, ▲ 30μM, ▼ 10μM and ● vehicle. Data are mean±standard error of the mean (SEM) from 
6 independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). 
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As Zn2+ ionophores had no effect on FL-4 fluorescence, further effects of PEG-SOD and PEG-
CAT were negligible (Figure 4.2A, B and 4.4A, B); nevertheless, PEG-SOD and PEG-CAT were still applied 
with the Zn2+ ionophores as a measure of control and consistency. The FL-4 F/F0 induced by Cq (300μM) 
on PEG-SOD and PEG-CAT pre-treated platelets after 6mins were 1.04±0.02 and 0.99±0.03, 
respectively compared to 1.04±0.01 for the vehicle control (p>0.05, ns, Figure 4.4A, D). Stimulation 
with Py produced comparable results. As the FL-4 F/F0 induced by Py (300μM) on PEG-SOD and PEG-
CAT pre-treated platelet after 6mins were 0.99±0.08 and 0.94±0.03 compared to 1.03±0.03 for vehicle 
control (p>0.05, ns, Figure 4.4B, E). Although showing a negligible effect due to Cq and Py not evoking 
an FL-4 response, this data did provide further evidence to validate that the FL-4 probe does not detect 
[Zn2+]i fluctuations and is Ca2+ specific.  
A23187-induced fluctuations of [Ca2+]i were not significantly affected by PEG-SOD or PEG-CAT 
pre-treatment. FL-4 F/F0 in response to A23187 (300μM, 100μM, 30μM or 10μM) on PEG-SOD pre-
treated platelets were 5.1±0.7, 3.6±0.4, 2.6±0.2 and 1.9±0.1 respectively, whilst on PEG-CAT pre-
treated platelets these were 4.7±0.7, 4.1±0.5, 3.4±0.4 and 2.2±0.2 respectively (Figure 4.4F, I). These 
did not differ significantly from vehicle-treated platelets where the final FL-4 F/F0 values were 5.4±0.8, 
3.0±0.4, 2.6±0.4 and 1.9±0.1 respectively (p>0.05, ns, Figure 4.4C, F, I). These data provided evidence 
to confirm that, in a similar manner to A23187-mediated [Zn2+]i elevation, [Ca2+]i elevation via A23187 
was not influenced by changes in redox. Thus, ionophores are able to mobilise Ca2+ and Zn2+ from 
stores within platelets in a redox-independent manner. However, this may be due to the artificial 
nature of the ionophores ( releasing cations from proteins and stores which may not be physiologically 
accessible) overcoming any redox dependent mechanism that may be sequestering the cations. 
Therefore modulation of redox may have a null effect when ionophores are applied.  
Initial experiments from this section illustrated that ionophore-induced FZ-3 increases were 
not influenced by modulation of redox upon treatment with PEG-SOD and PEG-CAT (Figure 4.3). This 
contrasts with data seen in Chapter 3, where PEG-SOD and PEG-CAT abolished agonist-evoked FZ-3 
fluorescence increases, which provided evidence to show that redox-sensitive mechanisms evoke 
[Zn2+]i elevation in platelets. The data from this chapter suggest the ionophores are mobilizing the Zn2+ 
from potential stores that are not sensitive to changes in redox, due to no exogenous Zn2+ being 
present in these experiments thus the increases in Zn2+ is evoked intracellularly in platelets from 
potential stores.  
Further experiments were carried out to assess if [Ca2+]i elevation via A23187 was also 
modulated by changes in redox. Modulation of the redox state upon application of PEG-SOD and PEG-
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CAT had no significant influence on the FL-4 response in response to A23187. This data correlates well 
with the work from Chapter 3, which demonstrated that agonist induces FL-4 fluorescence increases 
were also not influenced by changes in redox upon PEG-SOD and PEG-CAT treatment. Therefore, 
mobilisation of Ca2+ from its store (DTS, dense tubular system) in platelets which is well documented 
(see Chapter 1) is not sensitive to changes in redox.  
Modulation of redox (via PEG-SOD and PEG-CAT treatment) may not effect ionophore-evoked 
response, due to the ionophores mobilising the cations from stores that are not influenced by changes 
in redox or from proteins regardless of their sensitivity to changes in redox. Thus, although these 
experiments with ionophores illustrate that cation release can be modelled, the location from where 
the cations are mobilised from has not been determined. This may be the reasoning as to why changes 
in redox had no influence on the cation release induced by the ionophores.  
To conclude the presence and mechanism of Ca2+ store release is well documented (Smith et 
al., 1992; Varga-Szabo et al., 2009; Verma et al., 2011). However, the storage capabilities of Zn2+ in 
platelets is yet to be determined. Data from chapter 3 suggest that a redox-sensitive mechanism 
(possibly involving metal binding proteins such as metallothionein’s) act as a storage mechanism for 
Zn2+ in platelets. This work indicates the presence of another potential Zn2+ storage site that is 
accessible to ionophores in a redox-independent manner. It is not known whether this store 
represents a physiologically relevant, store that is accessible upon agonist stimulation. 
 
4.2.4. ROS elevation is potentiated by increases in intracellular Zn2+ 
The data described above show that the modulation of redox states has no significant effect 
on ionophore-induced [Zn2+]i and [Ca2+]i fluctuations. ROS has been suggested to influence [Ca2+]i 
signalling and vice versa, although as previous work did not take Zn2+ into account (Görlach et al., 
2015), this effect has yet to be fully studied in platelets. The data presented in this thesis thus far 
indicates that [Ca2+]i mobilisation is not influenced by redox modulation, suggesting that ROS does not 
play a major role in [Ca2+]i mobilisation. 
 [Zn2+]i mobilisation via ionophores was also not influenced by changes in redox states, 
however this may have been due to artificial nature ( as discussed above) of the ionophores potentially 
releasing Zn2+ from proteins such as redox sensitive proteins that may be sequestering Zn2+. 
Experiments described in Chapter 3 showed that agonist-induced [Zn2+]i fluctuations (but not [Ca2+]i 
fluctuations) are redox-sensitive, indicating a key role for ROS in regulating [Zn2+]i in platelets. Previous 
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work has shown that elevated [Zn2+]i may mediate further ROS generation which in turn would elevate 
Zn2+ further (Stork and Li, 2016). This relationship between ROS and Zn2+ may also occur in platelets 
and could be a mechanism which regulates [Zn2+]i concentrations in platelets. Experiments were 
performed to investigate this relationship further.  
The effect of elevated [Zn2+]i and [Ca2+]i on ROS elevation in platelets was assessed. The ROS 
probe, DCFH was employed to assess changes in ROS upon stimulation with the Zn2+ and Ca2+ 
ionophores (in the same manner as the previous chapter). All ionophores induced significant 
concentration-dependent increases in ROS fluorescence (Figure 4.5). 
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Figure 4.5. Ionophore treatment results in increases in ROS fluorescence which is abrogated by cation chelation or anti-
oxidant treatment. DCFH-labelled washed human platelets were stimulated by increasing concentrations of clioquinol, Cq 
(A), pyrithione, Py (B) or A23187 (C). DCFH-labelled washed human platelets were also pre-treated with 10μΜ BAPTA before 
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being stimulated by increasing concentrations of Cq (D), Py (E) or A23187 (F). DCFH-labelled washed human platelets were 
pre-treated with 50μΜ TPEN before being stimulated by increasing concentrations of Cq (G), Py (H) or A23187 (I). DCFH-
labelled washed human platelets were also pre-treated with 30U/mL SOD before being stimulated by increasing 
concentrations of Clioquinol (J), Pyrithione (K) or A23187 (L). DCFH-labelled washed human platelets were also pre-treated 
with 300U/mL CAT before being stimulated by increasing concentrations of Cq (M), Py (N) or A23187 (O). DCFH fluorescence 
fluctuations were recorded over six minutes using fluorometry. Treatment with all ionophores induced increases in ROS 
which was abolished upon BAPTA, TPEN, PEG-SOD and PEG-CAT pre-treatment. ○ 300μM, ■ 100μM, ▲ 30μM, ▼ 10μM and 
● vehicle. Data are mean±standard error of mean (SEM) from 6 independent experiments. Significance is denoted as **** 
(p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
Stimulation with the highest two concentrations of Cq (300μM and 100μM) resulted in 
significant increases in ROS fluorescence relative to the vehicle control. DCFH F/F0 values following 
stimulation by 300μM or 100μM of Cq after 6mins were 3.7±0.3 and 2.4±0.4 respectively, compared 
to the vehicle control of 1.04±0.03 (P<0.05, Figure 4.5A). A similar effect was observed with Py (Figure 
4.11B). However, Py stimulation resulted in lower increases in ROS fluorescence compared to Cq which 
was consistent with the differences in FZ-3 increases induced by these ionophores. DCFH F/F0 values 
following stimulation with 300μM or 100μM of Py after 6mins were 2.37±0.34 and 1.92±0.30 
respectively, compared to 0.10±0.01 for the vehicle control (P<0.05, Figure 4.5B). Therefore, elevation 
of [Zn2+]i results in increased ROS in platelets.  
Ca2+ release, in response to A23187 also resulted in significant increases in ROS fluorescence 
(Figure 4.5C). Stimulation with the highest three concentrations (300μM, 100μM or 30μM) of A23187 
resulted in significant increases in DCFH fluorescence relative to the vehicle control. DCFH F/F0 values 
following stimulation with 300μM, 100μM or 30μM of A23187 after 6 mins were 3.9±0.2, 2.8±0.3 and 
1.8±0.2 respectively, compared to the 1.05±0.07 for the vehicle control (P<0.05, Figure 4.5C). These 
data demonstrate that elevation of [Zn2+]i and [Ca2+]i induces ROS elevation in platelets. The [Ca2+]i and 
[Zn2+]i chelators, BAPTA(10μM) and TPEN(50μΜ) were employed to confirm that elevations in ROS 
observed were attributable to increases in [Ca2+]i and [Zn2+]i.  
Pre-treatment with BAPTA (Figure 4.5D-F) or TPEN (Figure 4.5G-I) abrogated ionophore-
stimulated ROS fluctuations. DCFH F/F0 values induced by the highest concentration (300μM) of Cq or 
Py after 6mins were reduced from 3.7±0.3 and 2.37±0.34, respectively to 1.05±0.07 and 0.93±0.01 on 
BAPTA pre-treated platelets (p<0.05, Figure 4.5 D-E). These F/F0 values were comparable to that 
induced by Cq and Py on TPEN (50μM) pre-treated platelets, where final DCFH F/F0 induced by Cq 
(300μM) and Py (300μM) was reduced from 3.7±0.3 and 2.37±0.34, respectively to 1.01±0.01 and 
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0.93±0.03 (p<0.05, Figure 4.5, G-H). These data confirm that increases in [Zn2+]i mediate ROS elevation 
in platelets. 
 BAPTA pre-treatment also abolished any ROS fluctuations that were induced by A23187, 
indicating that ROS elevation is also mediated by [Ca2+]i in platelets. However, A23187-induced ROS 
elevations were also abrogated by TPEN. DCFH F/F0 values induced by the highest concentration 
(300μM) of A23187 after 6mins were abrogated from 3.9±0.2 to 0.92±0.01 and 0.93±0.01 on BAPTA 
and TPEN pre-treated platelets, respectively (p<0.05, Figure 4.5C, F, I). Indicating that the response 
being mediated by A23187 is attributable to [Zn2+]i as opposed to [Ca2+]i. A23187 induced a slight 
elevation in [Zn2+]i, (Figure 4.1C and 4.5C), which may responsible for the ROS elevation. 
This data suggests that there is a relationship between ROS and Zn2+ in platelets which further 
demonstrates that the ROS and Zn2+ interplay may evoke the major mechanism for inducing [Zn2+]i 
elevation. This coincides well with the work carried out in chapter 3 which provided evidence showing 
that ROS elevation evoked [Zn2+]i elevation and that agonist-induced [Zn2+]i elevation coincides with 
agonist-induced ROS increases. Therefore, the work from this chapter and the previous chapter 
provide the first evidence to exhibit that [Zn2+]i elevation is mediated by ROS increases, and thus 
sensitive to changes in redox ( as ROS fluctuations modulate changes in redox, as described in Chapter 
1 and 3).  
Further experiments were performed to confirm the validity of ROS being detected upon 
ionophore stimulation. PEG-SOD and PEG-CAT scavenge ROS and should, therefore, inhibit elevation 
of ROS mediated by the agonist, and in turn, reduce in DCFH fluorescence. PEG-SOD (Figure 4.5J-L) 
and PEG-CAT (Figure 4.15M-O) pre-treatment abolished ionophore-induced increases in DCFH 
fluorescence. After 6mins, DCFH F/F0 induced by Cq (300μM), Py (300μM) or A23187 (300μM) after 
was abrogated from 3.7±0.3, 2.37±0.34 and 3.9±0.2, to 1.02±0.04, 0.92±0.01 and 0.90±0.02, 
respectively on PEG-SOD pre-treated platelets (p<0.05, Figure 4.5A-C, J-L). These values were 
comparable to those obtained with PEG-CAT (300U/mL) pre-treatment. After 6mins, DCFH F/F0 
induced by Cq (300μM), Py (300μM) or A23187 (300μM) were also abolished from 3.7±0.3, 2.37±0.34 
and 3.9±0.2, respectively to 0.98±0.03, 0.92±0.01 and 0.89±0.03, respectively on PEG-CAT pre-treated 
platelets (p<0.05, Figure 4.5A-C, M-O). These data confirm that the elevation in DCFH fluorescence 
induced by the ionophores was in accordance with increased ROS levels. 
The data described above demonstrate that elevated [Zn2+]i mediates ROS elevation. Use of 
Zn2+ and Ca2+ ionophores-mediated increases in DCFH fluorescence were abrogated by the BAPTA or 
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TPEN (Figure 4.5A-I), indicating that ROS elevation is primarily attributable to Zn2+ as opposed to Ca2+. 
Pre-treatment with the antioxidants, PEG-SOD and PEG-CAT also abolished the ionophore-induced 
DCFH fluorescence induced by the ionophores thus validating that this increase in DCFH fluorescence 
is due to increased ROS levels ( Figure 4.5J-O)  
These data contrast with previous studies, that suggests that Ca2+ regulates ROS formation 
and that elevation of [Ca2+]i may be redox sensitive (Görlach et al., 2015). This may be due to the 
reason that the previous work did not take Zn2+ account; thus the regulatory role of Ca2+ on ROS 
formation may perhaps be attributable to Zn2+. This data provides further evidence to strengthen the 
mechanism hypothesised in chapter 3, that there may be a ROS/Zn2+ interplay in platelets which 
enables regulation of [Zn2+]i 
 
4.3 Discussion  
The work conducted here was designed to investigate whether increases in [Zn2+]i could be 
modelled in platelets in a manner similar to Ca2+. The Ca2+ ionophore, A23187, and Zn2+ ionophores, 
Cq and Py, have been widely used in nucleated cells to model changes in intracellular cation 
concentrations (Krenn et al., 2009; Pressman, 1976). Here, Cq and Py were employed to model [Zn2+]i 
increases in platelets. A23187 was principally used as a positive control; however, A23187 treatment 
increased in [Zn2+]i, which may reflect a lack of cation specificity of A23187, or alternatively a functional 
interaction between the two cations.  
Data described above support the existence of a redox-insensitive Zn2+ store in platelets which 
is accessible to Zn2+ ionophores. Evidence for a Zn2+ store in platelets is provided by experiments which 
show that Zn2+ ionophores induce significant increases in FZ-3 fluorescence (consistent with increases 
in [Zn2+]i), which is abrogated with Ca2+ and Zn2+ chelation. These experiments were carried out in a 
Zn2+ free environment, thus any elevations of FZ-3 fluorescence were from Zn2+ present within 
platelets. Interestingly, modest TPEN-sensitive increases of FZ-3 fluorescence were observed in 
response to A23187 treatment. This correlates with previous work on rat thymocytes which found 
that A23187 induced increases in Zn2+ fluorescence were abolished with TPEN treatment (Sakanashi 
et al., 2009; E. Wang et al., 1998), indicating that A23187 is able to mediate Zn2+ transport. This is 
consistent with work that has shown that A23187 also induces Zn2+ permeability (Pfeiffer et al., 1978). 
The affinity of A23187 for Ca2+ has been claimed to be very specific relative to other ions. The kd value 
of A23187 with Ca2+ has been approximately found to be 10-6M (E. Wang et al., 1998). However the 
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exact binding affinity of A23187 and Zn2+ is yet to be confirmed (Fujikawa et al., 2015; Xiong et al., 
1992). Although as stated above A23187 was able to act on Zn2+ indicating A23187 may not be Ca2+ 
specific and may bind to Zn2+ in a similar manner to other Ca2+ reagents such as BAPTA and Fura-2 (see 
chapter 1). In contrast to this, the Zn2 ionophores have a high specificity to Zn2+ relative to Ca2+, as the 
kd values of Cq and Py with Zn2+ and Ca2+ are approximately 10-7M, K 10-4.9M, respectively (Arslan et 
al., 1985a; Hyun et al., 2004a; Matias et al., 2010a; Qian and Colvin, 2016b).  
To conclude, the initial data from this chapter demonstrates the [Zn2+]i release could be 
modelled in platelets which indicated that Zn2+ stores were present in platelets.  
 The work described above also provides an assessment of the specificity of the Zn2+ and Ca2+ 
probes, Fz-3 and FL-4 respectively. The data illustrates opposing effect induced by the ionophores on 
increases in FL-4 fluorescence (consistent with increases in [Ca2+]i) in comparison to the increases in 
FZ-3 fluorescence (consistent with increases in [Zn2+]i). The Zn2+ ionophores had no effect in FL-4 
fluorescence, whereas the Ca2+ ionophore-induced a much greater increase in FL-4 fluorescence. Also 
pre-treatment with the Zn2+ specific chelator, TPEN did not significantly influence the fluctuations in 
FL-4 fluorescence induced by the ionophores, indicating that the increases in FL-4 fluorescence were 
attributable to Ca2+ rather than Zn2+. Experiments performed provided evidence to confirm that 
increases in FL-4 fluorescence were attributable to Ca2+, and thus verify the specificity of the FL-4 to 
Ca2+. To summarise, this work demonstrates the specificity of FZ-3 and FL-4 for Zn2+ and Ca2+ 
respectively. Also, these sections provided further evidence to indicate that Zn2+ is present in platelets, 
as extracellular Zn2+ were not present in these experiments, thus the increases in FZ-3 fluorescence 
(consistent with [Zn2+]i increases) were from within the platelets.  
Zn2+ ionophores induce a much greater increase in FZ-3 fluorescence than CRP-XL and U46619 
(shown in chapter 3), indicating that ionophore-induced Zn2+ release may not be the principal way in 
which Zn2+ is mobilised as the location from which Zn2+ is mobilised via the ionophores is not known. 
It is likely that Zn2+ is mobilised from granules or another storage mechanism with the platelets by the 
ionophores. A good candidate here would be alpha granules, which have been shown to contain Zn2+. 
Agonist-induced [Zn2+]i elevations was redox-sensitive, implicating metal binding proteins 
such as metallothioneins in [Zn2+]i storage and release. In order to investigate if changes in redox were 
the primary mediator of evoking increases in [Zn2+]i , experiments were performed to determine 
whether ionophore-induced [Zn2+]i fluctuations were redox-sensitive. Ionophore-induced FZ-3 
fluorescence increases were not influenced by changes to the redox state. This is suggestive of the 
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presence of Zn2+ stores in platelets that are not mobilised by redox modulation, however ionophores 
may be releasing Zn2+ from redox-sensitive proteins thus bypassing any changes in redox.  
To conclude the experiments described here show that ionophores are able to increase [Zn2+]i 
in a manner that does not depend on the platelet redox state. This suggests that there is a Zn2+ store 
in platelets which is distinct from the cytosol. Whether this Zn2+ store is accessible physiologically is 
not known. It is possible that the Zn2+ stores are platelet alpha granules, which are known to contain 
Zn2+. Whether the Zn2+ is accessible from the granules to the cytosol during activation, but prior to 
granule release is not yet known. 
Further experiments were conducted to investigate if changes in redox influenced [Ca2+]i 
fluctuations induced by the ionophores. Experiments described in chapter 3 show that agonist-
induced [Ca2+]i elevation are not redox-sensitive; thus ionophores induced [Ca2+]i elevation was also 
expected not to be influenced by redox modulation, which was the case in this chapter. However, this 
may be due to the ionophore as stated above being able to bypass any changes in redox.  
Further work was carried out to investigate the effect of ionophore treatment on ROS 
elevation in platelets. This was carried out to investigate further the mechanisms that relate ROS 
generation to Zn2+, that may mediate secondary responses during platelet activation. Ionophore 
treatment resulted in increases in ROS that were abrogated by cation chelation. Inhibition of ROS 
generation by TPEN indicates that Zn2+ is important in ROS elevation. This correlates well with the data 
from Chapter 3, which showed agonist-induced ROS elevation was shown to be inhibited by chelating 
[Zn2+]i. Thus, this work provides further evidence to demonstrate that [Zn2+]i and ROS interplay may 
mediate platelet responses. Furthermore, these findings correlate with previous work showing that 
elevated Zn2+ mediates further ROS generation, which in turn would elevate Zn2+ further (Stork and Li, 
2016). This feedforward loop may be a major mechanism in platelets for mediating [Zn2+]i as illustrated 
by the schematic (Figure 4.6) below. 
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4.3.1. Conclusion  
The data presented in this chapter provides evidence that Zn2+ stores are present in platelets 
and can be mobilised upon ionophore treatment. Whether Zn2+ release occurs from these stores 
during agonist-dependent activation is not known. However, unlike agonist-dependent Zn2+ release, 
the ionophore-induced Zn2+ release was not sensitive to modulation of the platelet redox state, 
suggesting that conventional store release (as per Ca2+ release) is not the principal mechanism by 
which ionophore-induced [Zn2+]i increases in the cytosol. 
These experiments (in conjunction with experiments described in chapter 3) indicate that ROS and 
[Zn2+]i levels in platelets are mechanistically linked. As agonist stimulation may induce ROS elevation, 
resulting in changes in redox states leading on to Zn2+ bound to (for example) metallothioneins to be 
released and elevating [Zn2+]i. Platelet stimulation may also induce the release of Zn2+ from other 
intracellular stores (yet to be confirmed), which may contribute to elevating ROS, and thus enabling 
further sustained Zn2+ elevation. Thus, redox-sensitive proteins may synchronise with Zn2+ stores in 
platelets to induce elevated and sustained [Zn2+]i release. Chapter 3 and 4 have provided evidence 
that [Zn2+]i elevation occurs in platelets. The effect of Zn2+ on platelets and its potential role as a 
secondary messenger in platelets was assessed, and the results are discussed in Chapter 5. 
 
 
Figure 4.6. Schematic illustrating the feedforward 
loop mechanism evoking ROS and [Zn2+]i elevation. 
Elevation of ROS results in the oxidation of redox 
sensitive (Zn2+ sequestering) proteins such 
metallothionines (MTs) which then liberate Zn2+ 
from its thiols. Therefore, resulting in increased 
intracellular Zn2+ ([Zn2+]) concentrations. In a 
reducing environment, Zn2+ is sequestered by the 
MTs via reduction, thus reducing the [Zn2+]i 
concentration. Elevation of ROS further evoked ROS 
elevation which in turn results in elevation of [Zn2+]i. 
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Chapter 5   
 
                  5.0 Investigation of the role of intracellular Zn2+ as a secondary 
messenger during platelet activation  
5.1 Background 
The role of Zn2+ in modulating platelet behaviour is not yet fully understood. Recent work by 
Watson et al., (2016) demonstrated that exogenous Zn2+ gains access to the platelet cytosol and acts 
as an agonist, inducing platelet activation. Furthermore, at sub-activatory concentrations, exogenous 
Zn2+ potentiates platelet activation by conventional agonists (Watson et al., 2016). This outlines the 
importance of Zn2+ in platelet activity and indicates its potential as a mediator of thrombus formation 
(Taylor and Pugh, 2016; Watson et al., 2016). The role of [Zn2+]i as an intracellular signalling molecule 
has yet to be studied in platelets. In many other cell types [Zn2+]i acts as a signalling molecule, for 
example, in mast cells where it acts as a secondary messenger (Beyersmann and Haase, 2001; 
Brautigan et al., 1981; Csermely et al., 1988; Daaboul et al., 2012; Hubbard et al., 1991a; Lengyel et 
al., 2000; Perry et al., 1997; Yamasaki et al., 2007). Whether Zn2+ has similar signalling roles as an 
intracellular secondary messenger in platelets has yet to be examined experimentally and is the 
primary focus of this chapter.  
The work carried out in Chapters 3, and 4 demonstrated that elevation of [Zn2+]i occurs upon 
agonist stimulation. In Chapter 3 it was shown that CRP-XL and U46619 induced significant increases 
in [Zn2+]i in a redox-dependent manner. In Chapter 4 elevation of [Zn2+]i was modelled using 
ionophores. The ionophores induced greater levels of [Zn2+]i elevation in comparison to that induced 
by CRP-XL and U46619, which indicated that Zn2+ stores may not be fully mobilised upon agonist 
stimulation. Furthermore, the ionophore-induced rise of [Zn2+]i was not redox-sensitive, which 
suggests different mechanisms may be in place in platelets which enable [Zn2+]i elevation. Data 
provided in these Chapters show that [Zn2+]i is elevated upon platelet stimulation, suggestive of a role 
as a secondary messenger. Although as defined in Chapter 1, a secondary messenger upon stimulation 
must not only be elevated in concentration but also modulate the cell activity.  
Zn2+ may modulate platelet activity in a similar manner to Ca2+, which plays a central role as a 
secondary messenger in platelets by mediating many platelet processes, including aggregation, shape 
change, degranulation and phosphatidyl-Serine (PS) exposure (Chapter 1). 
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5.1.2. Aims 
This chapter addresses the functional effects of elevated [Zn2+]i in platelets. These studies 
characterised the influence of increases in [Zn2+]i on various aspects of platelet behaviour such as 
aggregation, shape change, degranulation and PS exposure providing information on the potential 
role of Zn2+ as a platelet secondary messenger.  
5.1.3. Methods 
A range of methodologies were employed to assess platelet functionality in response to 
fluctuations in [Zn2+]i. The major functional responses that were measured in this chapter were 
platelet aggregation, tyrosine phosphorylation, shape change, degranulation and PS exposure. 
Light transmission aggregometry (section 2.6, Chapter 2) was carried out to assess platelet 
aggregation and shape change. Western blotting was carried out to assess changes in tyrosine 
phosphorylation of platelet proteins, via the Anti-Phosphotyrosine Antibody, clone 4G10 antibody 
(section 2.7, Chapter 2).Western blotting was also employed to assess shape change signalling 
pathways of platelets by assessing the expression of the major cytoskeletal regulator's myosin light 
chains via phospho-myosin light chain 2 (Ser19) antibody, and Vasodilator-stimulated 
phosphoprotein (VASP) via the phospho-VASP (Ser157) antibody (section 2.7, Chapter 2).  
Confocal microscopy was used to assess platelet shape change, by quantifying the level of 
platelet spreading on fibrinogen-coated coverslips (section 2.11, Chapter 2). The role of Zn2+ was 
determined in mouse embryonic fibroblasts (MEF) to assess the wider implications of Zn2+ signalling 
on cytoskeletal rearrangements in nucleated cells in a comparable manner to that seen in platelets. 
The changes in morphology were observed via the fluorescence microscopy using a ZOE fluorescent 
cell imager (section 2.12, Chapter 2). 
Flow cytometry was used to assess degranulation by detecting the expression of the 
conventional activation markers,  CD62P and CD63 which are expressed upon α-granule release and 
dense granule release, respectively (section 2.9, Chapter 2). The expression of another conventional 
activation marker, PAC-1 was also assesed to measure the activity of the major integrin αIIbβ3 which 
mediates platelet aggregation, (Chapter 2). PS exposure was assessed via Annexin V bindings using flow 
cytometer (section 2.8, Chapter 2). 
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A wide range of reagents including ionophores, inhibitors, agonist, antagonists were 
employed in this work to assess the functional response of [Zn2+]i in platelets. The specific reagants 
that were employed are discussed in each of the specific sections below.  
 
5.2 Results 
5.2.1 Increasing intra- platelet Zn2+ using Zn2+-specific ionophores 
results in increases in platelet activity 
The ability of platelets to aggregate, leading to thrombus formation is of fundamental 
importance to thrombus formation. Experiments described in this section were performed to 
investigate the effect that elevated [Zn2+]i would have on platelet aggregation. The Zn2+-specific 
ionophores clioquinol (Cq) and pyrithione (Py) were employed to model the release of [Zn2+]i from 
platelet stores and to enable [Zn2+]i elevation. The validity of these Zn2+ ionophores was demonstrated 
in the previous chapter, where the application of these ionophores resulted in substantial increases 
in FZ-3 (which is consistent with elevated [Zn2+]i.  
Washed platelet suspensions were treated with ionophore concentrations ranging from 
300µM to 0.3µM and platelet aggregation was assessed. Aggregation profiles, shown below produced 
by ionophore treatment (Figure 5.1A-C) were analysed to yield values of maximum aggregation 
(highest positive peak on the trace, Figure 5.1D) and the minimum aggregation (highest negative peak 
on the trace, Figure 5.1E). 
A23187 was employed as a positive control to assess the validity of ionophore treatment, as 
this ionophore induces full platelet aggregation following the elevation of [Ca2+]i (Gamberucci et al., 
2002; Smith et al., 1992; Varga-Szabo et al., 2009; Verma et al., 2011). A23187 treatment resulted in 
a concentration-dependent effect on platelet aggregation (Figure 5.1C-E). Treatment resulted in an 
initial downward deflection in light transmission (consistent with a platelet shape change and 
quantified as minimum aggregation), followed by an increase in light transmission consistent with 
rapid and complete platelet aggregation (Born, 1962; Born and Cross, 1963; Gibbins and Mahaut-
Smith, 2004). A23187 concentrations of 10µM or higher induced full aggregation, as platelet 
aggregates were observed following visual inspection of tests cuvettes at the end of each experiment 
(not shown). The maximum aggregation induced by 300µM, 100μM, 30μM or 10μM of A23187 were 
70.19±8.64% 58.0±2.1%, 58.1±15.1% and 59.1±16.6%, respectively, which did not significantly differ 
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against each other (p>0.05, ns, Figure 5.1C-E). Maximal aggregation were also found to be significantly 
higher than that induced by the vehicle control (DMSO) which was 2.1±1.5% (not shown, p<0.05). 
These data confirm the validity of A23187 in these experiment as a positive control to assess platelet 
activity, as this ionophore evoked near maximal platelet aggregation. 
 The minimum aggregation in response to A23187-dependent increases of [Ca2+]i was a rapid 
process , as illustrated in Figure 5.1C and E. The minimum aggregation induced by the highest 
concentration (300μM) of A23187 was -12.0±1.9%, which was significantly higher than the vehicle 
control (-1.2±1.1, not shown, p<0.05). The minimum aggregation induced by lower concentrations 
(100-10μM) did not significantly differ to that induced by 300μM A23187 (p>0.05, ns, Figure 5.1C, E). 
However, as illustrated in Chapter 4, the top four concentrations of A23187 all induced significant 
increases in [Ca2+]i which may be the reason why these concentrations of A23187 displayed a similar 
response in terms of shape change and aggregation. Therefore, use of A23187 demonstrates that the 
platelet suspensions undergo shape change and aggregate in response to the elevation of platelet 
[Ca2+]i. 
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Figure 5.1. Ca2+ and Zn2+ ionophores induce platelet shape change. Representative aggregation traces were obtained 
following treatment of washed platelet suspensions with Zn2+ ionophores Clioquinol, Cq (A), Pyrithione, Py (B) or the Ca2+ 
ionophore A23187 (C). Aggregation traces were analysed to yield the maximum aggregation (D) and minimum aggregation 
(E), which quantifies the degree of shape change. Treatment with A23187 resulted in full aggregation, whereas Cq treatment 
resulted in sub-maximal aggregation at high concentrations. Py treatment did not induce aggregation. The minimum 
aggregation induced by ionophores did not significantly differ, with the exception of 30μM of Py inducing a significantly 
higher level of minimum aggregation than Cq or A23187. ▲ A23187, ● Clioquinol, ■ Pyrithione. Data are mean±standard 
error of mean (SEM) from 5 independent experiments. Significance is denoted as * (p<0.05).  
 
Responses of platelets to the Zn2+ ionophores were heterogeneous. Platelet aggregation only 
occurred following stimulation with the highest concentration (300μM) of Cq (maximum aggregation 
was 27.8±5.1%. Figure 5.1D). Platelet aggregation in response to 300µM Py (5.0±2.9%) did not 
significantly differ from the vehicle control (2.1±1.5%,p>0.05, ns), and was significantly lower than that 
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induced by 300μΜ Cq (27.8±5.1%, p<0.05, Figure 5.1 D). This difference in aggregation responses may 
reflect different affinities of the ionophores for Zn2+ (although is approximately the same, Chapter 2), 
or differences in the mechanism by which the reagents penetrate the platelet cytosol. Experiments 
described in Chapter 4 showed a much greater increase in [Zn2+]i following Cq treatment than Py, 
which suggest that Py is not able to induce aggregation due to its inability to induce a great enough 
elevation of [Zn2+]i.   
In contrast to platelet aggregation, both Cq and Py induced initial downward deflections in 
light transmission, quantified by minimum aggregation levels. These downward deflections are 
consistent with changes in platelet morphology indicative of platelet shape change (Born et al., 1978; 
Caen and Michel, 1972; Frontroth, 2013; Hvas and Favaloro, 2017). The greatest minimum aggregation 
was observed following treatment with 300µM Cq (-17.3±1.5%). Interestingly the greatest minimum 
aggregation was apparent following treatment with a lower concentration of Py (30µM) which was -
27.5±2.2. This was significantly greater than that induced by Cq, A23187, or every other concentration 
of the ionophore used (p<0.05, Figure 5.1E). These data reflect a biphasic response to Py, as an 
intermediate concentration (30μM) induced the most significant levels of shape change.  
These data demonstrate that treatment of platelet suspensions with Zn2+ ionophores results 
in changes in light transmission that are consistent with shape change. At high concentrations, Cq 
treatment elicits a partial aggregatory response. The extent to which platelet aggregation is altered 
by Zn2+ ionophores is lower than that for the Ca2+ ionophore A23187. This suggests that Ca2 + plays a 
more significant role in mediating platelet activity. A23187 can mediate both [Ca2+] and [Zn2+]i 
elevations (Chapter 3), whereas the Zn2+ ionophores are specific to Zn2+. Given the effects of Zn2+ 
ionophores, it is possible that platelet aggregation and shape change (as demonstrated by A23187) is 
not fully attributable to Ca2+ but could also be influenced or mediated by Zn2+. The interplay of Ca2+ 
and Zn2+ in platelet activity requires further investigation and would help further elucidate the 
mechanisms of platelet activation. 
 
Data shown in Figure 5.1 suggests that [Zn2+]i elevation induces platelet shape change and 
aggregation. Further experiments were performed with TPEN pre-treatment to confirm the role of 
Zn2+ in these processes. The top four concentrations (300μM-10μM) of the ionophores evoked a 
significant (relative to the vehicle control, DMSO) effect in terms of shape change and aggregation; 
thus these concentrations were selected for further studies. Washed platelet suspensions were pre-
treated with 50µM TPEN prior to stimulation by Cq, Py or A23187 (Figure 5.2). 
 
115 
 
 
Figure 5.2. Chelation of intracellular Zn2+ with TPEN inhibits Zn2+-ionophore-induced aggregation and shape change. In 
order to confirm a role for [Zn2+]i in Zn2+-ionophore-induced effects, platelets were pre-treated with the Zn2+ chelator, TPEN 
(50µM) prior to treatment with the given ionophores. Representative traces of the most effective concentration of 
Clioquinol, Cq (A, 300µM), Pyrithione, Py (B, 30µM) or A23187, (C, 300µM). Aggregation traces were quantified to yield values 
for maximum aggregation in response to Cq (D) Py E) or A23187 (F). Further quantification yielded values for minimum 
aggregation in response to Cq (G), Py (H), or A23187, (I). TPEN pre-treatment inhibited Zn2+ ionophore-induced aggregation 
and shape change but had no influence on A23187 induced shape change and aggregation. ● Vehicle control,  50µM TPEN. 
Data are mean±standard error of mean (SEM) from 5 independent experiments. Significance is denoted as *** (p<0.001), ** 
(p<0.01) or * (p<0.05). 
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 Maximum aggregation in response to 300µM of Cq was reduced in TPEN pre-treated platelets 
(50µM) from 26.4±6.8% to 5.9±2.2% (p<0.001, Figure 5.2A, D). Cq-mediated shape change (minimum 
aggregation) was also significantly reduced. Minimum aggregation in response to 300μM, 100μM, 
30μM or 10μM of Cq were reduced from -29.6±4.4%, -20.5±4.9%, -21.7±2.8% and -18.1±3.6% 
respectively to -10.2±2.2%, -8.5±0.9%, 5.4±1.7% and 6.4±1.6% respectively (p<0.05, Figure 5.2G). 
These data confirm that the Cq induced aggregation and shape change was attributable to [Zn2+]i. 
Interestingly the lower concentrations of Cq (100μM-10μM), which did not induce an aggregation 
response, did induce shape change , which was inhibited upon chelation of [Zn2+]i upon TPEN 
application. This indicates that lower concentrations of [Zn2+]i evoke shape change without proceeding 
to aggregation. However, these lower concentrations of Cq were not shown to result in significant 
increases in [Zn2+]i (Chapter 4). This may indicate that very low levels of [Zn2+]i are enough to evoke an 
shape change response.  
 As Py treatment did not result in aggregation, no changes in Py-induced aggregation were 
apparent in TPEN pre-treated platelets (Figure 5.2E). However, the degree of shape change in 
response to Py was significantly inhibited by TPEN pre-treatment. Minimum aggregation in response 
to 300μM, 10μM, 30μM or 10μM Py was reduced from -18.1±3.6% to -6.8±1.3%, -25.9±4.1% to -
8.6±1.7%, -33.3±4.0% to -14.3±2.8 and -29.5±2.6 to -10.8±2.0 respectively with TPEN pre-treatment, 
(p<0.05, Figure 5.2H). These data confirm that the Py induced shape change occurs in response to 
[Zn2+]i elevation. However, as with Cq, lower concentrations of Py which induced the greatest level of 
shape change also induced insignificant increases in [Zn2+]i (Chapter 4). This provides further evidence 
to suggest that small-scale rises in [Zn2+]i may mediate shape change, warranting further investigation 
into the underlying mechanism.  
 A23187-induced maximum aggregation and shape change was not significantly influenced by 
TPEN pre-treatment (Figure 5.3C, F, I). The maximum aggregation in response to 300μM A23187 (the 
highest concentration used) was 77.8±9.5, whereas with TPEN pre-treatment this was 74.3±5.7 
(p>0.05, ns, Figure 5.3C and F). No significant changes were observed in response to lower 
concentrations of A23187 (100μM-10μM) upon TPEN pre-treatment. The maximum aggregation 
induced by 100μΜ, 30μM or 10μM was 57.7±5.7%, 48.3±6.4% and 43.6±5.1%, respectively, whereas 
with TPEN pre-treatment these were 52.8±3.5%, 55.6±10.3% and 41.3±8.3%, respectively (p>0.05, ns, 
Figure 5.3F). This was also the case for the level of shape change induced by A23187, as the minimum 
shape change induced by A23187 was not significantly affected by TPEN pre-treatment. The highest 
level of minimum aggregation induced by 300μM, 100μΜ, 30μM or 10μM of A23187 was -24.5±1.4%, 
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-22.0±2.3%, -17.2±3.4% and -20.6±2.2%, respectively. These did not significantly differ from TPEN pre-
treatment platelets (minimum aggregation levels were -22.7±1.9%, -20.7±1.6%, -22.6±1.4% and -
18.2±4.2%, respectively (p>0.05, ns, Figure 5.3I).  
The data shown in Figure 5.2 provide evidence that the effect induced by the Zn2+ specific 
ionophores on platelet shape change and aggregation is biologically valid, as the specific Zn2+ chelator 
TPEN reduced the effects that occurred upon Zn2+ mobilisation by the Zn2+ ionophores. This supports 
the hypothesis that chelation of [Zn2+]i inhibit ionophore-dependant processes. Data presented in this 
section also provided further evidence of the specificity of TPEN to Zn2+, as the application of TPEN did 
not significantly affect the aggregatory and shape changing effect induced by Ca2+ mobilisation (via 
A23187). This also indicates that Zn2+ plays a role in platelet shape change and aggregation 
independently of Ca2+ signalling, as the chelation of [Zn2+]i had no significant effect on A23187 induced 
platelet aggregation and shape change.   
Tyrosine phosphorylation is a major platelet signalling event that is induced by numerous 
agonists, including thrombin, CRP-XL and exogenous Zn2+ (Watson et al., 2016). In order to examine 
the mechanism of action of Zn2+ ionophores, immunoblotting using phosphotyrosine sensitive 
antibodies was carried out using suspensions of ionophore-treated washed platelets (section 2.7, 
chapter 2). Py (30µM) or Cq (300µM) treatment for 15 mins resulted in tyrosine phosphorylation of 
platelet proteins, with both high and low molecular weight protein phosphorylation observed (Figure 
5.3). 
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Figure 5.3. Elevation of platelet intracellular Zn2+ using ionophores results in increases in tyrosine phosphorylation of 
platelet proteins. Platelets were treated with the vehicle control (DMSO), 30μΜ Pyrithione (Py) 300μΜ Clioquinol (Cq) or 
300μΜ A23187 for 15 minutes before being subjected to SDS-PAGE and Western blotting using the phosphotyrosine-specific 
antibody, 4G10. Platelets were also pre-treated with TPEN (50μM), prior to stimulation with pre-treatment. Similar patterns 
of tyrosine phosphorylation were observed following ionophore treatment. TPEN treatment reduced Cq or Py—induced 
phosphorylation, whilst not fully abrogating A23187-mediated phosphorylation. TPEN pre-treatment resulted in the 
phosphorylation of a different panel of proteins. (A) illustrates a representative blot of 4 independent experiments, (B) 
illustrates the total level of phosphorylation (average) evoked by each treatment. Data are mean±standard error of mean 
(SEM) from 4 independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). 
  
 The pattern of phosphorylated proteins induced by Py and Cq were similar, although Cq 
induced greater phosphorylation of higher molecular weight proteins, suggesting involvement by 
kinases or phosphatases may be influenced by elevated [Zn2+]i. This was further illustrated by the total 
(average of each band) level of tyrosine phosphorylation (section 2.7.1, Chapter 2) as the level of 
phosphorylation evoked by Cq (0.7±0.2) was significantly higher than induced by Py (0.4±0.2, p<0.001, 
Figure 5.3B), furthermore these levels of phosphorylation were induced by Cq and Py were both higher 
than the vehicle control (0.2±0.1, p<0.0001, Figure 5.3B).  
 A23187 also evoked phosphorylation of proteins of similar molecular weight as observed with  
the Zn2+ ionophores. The similarity of a pattern of phosphorylated proteins induced by the Zn2+ and 
Ca2+ ionophores suggests that the cations are inducing similar signalling processes. The nature of the 
cation responsible for A23187-mediated phosphorylation could be either Zn2+ or Ca2+, as A23817 
results in the release of both cations, although the increase in FZ-3 fluorescence (consistent with 
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increased [Zn2+]i) was moderate (Figure 4.1). However, the phosphorylation of additional proteins 
upon A23187 treatment suggest differences between [Ca2+]i and [Zn2+]i signalling, this was also evident 
with the increased level of total tyrosine phosphorylation evoked by A23187 (1.1±0.2) compared to 
that evoked by Cq (0.7±0.2, p<0.0001, Figure 5.3B). These data are the first to demonstrate a 
correlation between elevated [Zn2+]i and phosphotyrosine signalling responses in platelets. 
Chelation of [Zn2+]i by TPEN resulted in decreased protein phosphorylation following Cq or Py 
treatment. The total level of phosphorylation evoked by Cq and Py decreased from 0.7±0.2 and 0.4±0.2 
to 0.4±0.2 and 0.3±0.1, p<0.001, Figure 5.3B). This was most evident in high molecular weight proteins 
(ranging from approximately 100-150 kDa). Interestingly, ionophore stimulation of TPEN-treated 
platelets resulted in the increased phosphorylation of an unidentified protein of a molecular weight 
of 80-90 kDa. These data indicate that modulation of [Zn2+]i may mediate the behaviour of kinases or 
phosphatases which regulate platelet activity. These are novel findings and provide a further area of 
research that warrants further investigation.  
Pre-treatment with TPEN produced a pattern of phosphorylated proteins that differed from 
A23187 treatment. Although the total level of phosphorylation was not influenced upon TPEN 
treatment ( as the total level of phosphorylation evoked by A2317 was 1.1±0.2 and with TPEN 
treatment was 0.9±0.3, p>0.05, ns, Figure 5.3B). However, A23187-mediated phosphorylation of low 
molecular weight proteins was reduced upon TPEN treatment, and the phosphorylation of the high 
molecular weight proteins also differed. This was interesting due to TPEN having no effect on 
aggregatory and shape change response induced by A23187, as illustrated above (Figure 5.2C, F, I). 
This suggests that A23187-induced aggregation and shape change is independent of Zn2+. 
Furthermore, this finding indicates the potential influence of [Zn2+]i on kinase and phosphatase activity 
that has hitherto been associated with [Ca2+]i elevation. If this were the case, then A23187-induced 
signalling may in part be attributable to Zn2+. It is possible that there is the interplay between the two 
cations during platelet activation. This work above demonstrates that changes in [Zn2+]i assessed by 
Zn2+ ionophore and TPEN treatment results in a biologically relevant signalling event in platelets. 
In conclusion, combined with the observation that [Zn2+]i causes platelet shape change and 
platelet aggregation (Figure 5.1-2), changes in tyrosine phosphorylation of platelet proteins (Figure 
5.3) implicates Zn2+ in a biologically important platelet processes. Whilst previous work demonstrated 
agonist-dependent elevations of [Zn2+]i, the data presented here demonstrate that increased [Zn2+]i is 
biologically active. This supports the hypothesis that Zn2+ is acting as a secondary messenger in 
platelets.  
120 
 
5.2.2 Zn2+ ionophore-induced platelet aggregation is αIIbβ3 dependent  
The data described above shows that aggregatory responses are induced upon [Zn2+]i mobilization 
using Cq, but not Py. This may be attributable to the higher levels of [Zn2+]i elevation induced by Cq than Py 
(section 4.2.1, Chapter 4). The validity of this observation was assessed by inhibition of integrin αIIbβ3 using 
the antagonist GR144053 (GR). GR144053 is effective as a αIIbβ3 antagonist at concentrations of 2μM which 
abolishes platelet aggregation (Watson et al., 2016). Here GR144053 was employed to assess whether 
ionophore-induced aggregation is mediated by αIIbβ3 (Figure 5.4). 
Pre-treatment of platelets with GR144053 abolished Cq induced aggregation (Figure 5.4. A, D), 
demonstrating that aggregation induced by Cq is dependent on αIIbβ3. The maximum aggregation induced 
by the highest concentration (300μM) of Cq was significantly reduced from 31.5±2.8% to 6.9±2.8% upon 
GR144053 (2µM) treatment (p<0.0001, Figure 5.4D). As expected, GR144053 treatment had no effect on 
Py as this ionophore did not induce aggregation. The validity of these experiments was tested using A23187, 
as Ca2+ mobilization is known to induce platelet aggregation via αIIbβ3 (discussed in Chapter 1). A23187-
induced aggregation was significantly reduced upon GR144053 treatment. The maximum aggregation in 
response to 300μM, 100μΜ, 30μM or 10μΜ of A23187 was reduced from 88.4± 5.8% to 22.3 ± 2.1%, 82.9 
± 2.3% to 17.6±2.3%, 74.0±3.9% to 16.7±4.6% and 60.8±2.6% to 5.6±1.0% respectively upon GR144053 
treatment, (p<0.0001, Figure 5.4F). Thus, these data with A23187 treatment confirmed that GR144053 
was a valid inhibitor of platelet aggregation in these experiments. 
Pre-treatment with GR144053 had no significant effect on minimum aggregation, indicating that 
inhibition of platelet aggregation did not significantly influence ionophore-mediated shape change. The 
minimum aggregation induced by 300μΜ of Cq was -20.3±0.6% and with GR144053 pre-treatment was -
13.1±2.9%, (p>0.05, ns, Figure 5.4G). This was also the case with Py, the minimum aggregation induced by 
30μM (the concentration of Py which resulted in the greatest level of minimum aggregation) was -30.4±1.9% 
compared to 21.3±3.1% following GR144053 treatment (p>0.05, ns, Figure 5.4F). GR144053 pre-treatment 
also did not affect A23187-induced shape change. The minimum aggregation induced by 300μM A23187 
was -14.6±1.4% and with GR144053 pre-treatment was -20.3±5.0% (p>0.05, ns, Figure 5.4I). These data 
provided evidence to show that ionophore-induced aggregation is independent of platelet shape change. 
Indicating that the inhibition of αIIbβ3 has no influence on the shape change process. 
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Figure 5.4. Antagonism of αIIbβ3 abrogates ionophore-induced platelet aggregation. In order to test the biological validity 
of ionophore-induced platelet aggregation, platelets were pre-treated with the αIIbβ3 antagonist GR144053 (2µM) prior to 
treatment with the given ionophores. Representative traces following treatment with the most significant concentration of 
Clioquinol, Cq, (A, 300µM), Pyrithione. Py (B, 30µM) or A23187, (C, 300µM) are shown. Aggregation traces were quantified 
to yield maximum aggregation values in response to different concentrations of Cq (D), Py (E) or A23187 (F). Minimum 
aggregations which were calculated following treatment with different concentrations of Cq (G), Py (H) or A23187 (I). 
Ionophore induced aggregation, but not shape change were inhibited with GR144053 pre-treatment. ■ Vehicle control, ● 
2µM GR144053. Data are mean±standard error of mean (SEM) from 5 independent experiments. Significance is denoted as 
**** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05).  
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5.2.3 Increases in intracellular Zn2+ mediate platelet shape change 
Figures 5.1-2 and 5.4 showed that Zn2+ ionophores influence light transmission of platelet 
suspensions in a manner that is consistent with activation-dependent shape change. 300µM Cq 
induced significant aggregation and the greatest degree of shape change. Treatment with lower 
concentrations of Cq resulted in shape change with no progression to aggregation. A similar effect was 
seen following treatment with all concentrations of Py. Lower concentrations (30μM or 10μM) of Py 
induced the highest level of shape change, consistent with a biphasic concentration response. The 
conclusions from these experiments were that Zn2+ ionophore-induced activatory-dependant shape 
change in a manner independent of aggregation. Thus, the role of Zn2+ in platelet shape change was 
further investigated. 
 
5.2.3.1 Cytochalasin D inhibits Zn2+ ionophore mediated platelet shape 
change 
In order to confirm a role Zn2+ on is effect on the platelet cytoskeleton, platelets were pre-treated with 
the actin cytoskeleton polymerisation inhibitor, Cytochalasin D (Cyt D), which has been widely used in 
studies which investigated the platelet cytoskeletal changes (Casella et al., 1981; Torti et al., 2000). As 
10µM of Cyt D has previously been shown to be effective at inhibiting actin polymerisation in washed 
platelet suspension (Cerecedo et al., 2002; Finkenstaedt-Quinn et al., 2015; Ge et al., 2012), this 
concentration was used in the experiments described here.  
Pre-treatment of washed platelet suspensions with Cyt D (10µM) significantly reduced the 
level of shape change induced by the ionophores employed (Figure 5.5). The minimum aggregation 
induced by 300μM, 100μΜ, 30μM or 10μM Cq treatment was significantly reduced from -29.3±2.6% to 
4.0±1.6%, -24.2±5.1 to -8.6±1.6, -24.2±6.7% to 7.1±4.6% and -18.2±2.2% to 3.0±1.1%, respectively 
upon Cyt D treatment (p<0.05, Figure 5.5G). The minimum aggregation induced by 300μM, 100μΜ, 
30μM or 10μM of Py was significantly reduced from -13.7±0.8% to -3.7±0.9%, -18.8±2.7% to -8.6±1.3%, 
-30.4±1.9% to -11.3±2.7 and -16.7±4.3% to -4.6±1.9%, respectively upon Cyt D treatment (p<0.05, 
Figure 5.5H). The minimum aggregation induced by 300μM, 100μΜ,30μM or 10μM of A23187 was 
significantly reduced from -24.8±2.0% to -14.0±1.2%, -16.8±1.3% to -6.7±1.6%, -13.3±1.3% to -4.4±1.7 
and -8.9±1.6% to -1.9±0.6%, respectively upon Cyt D treatment (p<0.05, Figure 5.5I). This work 
demonstrates that ionophore-mediated shape change is sensitive to Cyt D treatment as the data 
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described above confirms that downward deflections in light transmission induced by Zn2+ ionophores 
are a biological response, rather than a chemical phenomenon.  
 
 
Figure 5.5. Cytochalasin D (Cyt-D) abrogates ionophore-induced platelet shape change. Washed platelet suspensions were 
pre-treated with 10µM Cyt-D
 
before being stimulated with ionophores. Representative aggregation traces are shown for 
treatment with Clioquinol, Cq (A), Pyrithione, Py (B) or A23187 (C). Maximum aggregation in Cyt D treated and untreated 
platelets was quantified following stimulation with Cq (D) Py (E), or A23187 (F).) Similarly, minimum aggregation in Cyt D 
treated and untreated platelets was quantified following stimulation with Cq (G), Py (H) or A23817 (I). Cyt D pre-treatment 
significantly inhibited the ionophore-induced shape change and aggregation. ■ Vehicle control, ● 10µM Cyt D. Data are 
mean±standard error of mean (SEM) from 5 independent experiments. Significance is denoted as **** (p<0.0001), *** 
(p<0.001), ** (p<0.01) or * (p<0.05).  
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Cyt D treatment also significantly reduced the maximum aggregation level induced by the 
ionophores, indicating that cation induced aggregation may be dependent on the activatory shape 
change process for optimal aggregation. The maximum aggregation response to 300μM Cq was 
reduced significantly from 29.50±3.60% to 8.79±2.15% upon Cyt D treatment (p<0.0001, Figure 5.5D). Py 
treatment did not result in significant levels of aggregation; thus Cyt D had no effect on the maximum 
aggregation in response to this ionophore. The maximum aggregation induced by 300μM, 100μΜ, 
30μM or 10μM of A23187 was significantly reduced from 81.40±7.05% to 56.84±4.21%, 68.17±6.22% 
to 43.10±2.63%, 56.69±8.20% to 35.53±1.90% and 41.55±7.02% to 20.35±1.69%, respectively upon 
Cyt D treatment (p<0.05, Figure 5.5F).  
 The observation that Zn2+ ionophore treatment resulted in significant shape change without 
progression to aggregation indicates that shape change may be independent of aggregation. Published 
work has provided conflicting evidence for the requirement of shape change for full aggregation, with 
some studies suggesting that aggregation is independent of shape change, (Maurer-Spurej and 
Devine, 2001; Ohlmann et al., 2000), whilst others indicate that shape change is a prerequisite for 
platelet aggregation (Shin et al., 2017) as evident from the reduced aggregatory response evoked by 
A23187 (and 300μM Cq) in the presence of Cyt D.  
 
5.2.3.2 Zn2+ mediated signalling induces platelet shape change  
Data described in Figure 5.5 supports the conclusion that ionophore treatment results in 
shape change that is dependent on cytoskeletal rearrangements and is thus biologically valid and not 
an artefact of ionophore treatment. Prior to the experiments described here, the role of Zn²+ in 
signalling pathways that regulate platelet shape change was unstudied. The data described above are 
therefore the first to indicate the potential importance of Zn2+ in platelet shape change. This suggests 
that increased [Zn2+]i could act upon specific proteins in signalling cascades leading to shape change 
in a manner that is consistent with a secondary messenger. Further experiments were performed to 
investigate the role of [Zn2+]i in signalling pathways that are known to mediate platelet shape change. 
As calmodulin, ROCK (Rho-associated coiled-coil-containing protein kinase) and MLCK are involved in 
mediating platelet shape change, their contributions to Zn2+ -dependent shape change were assessed. 
The selective MLCK inhibitor, ML7 hydrochloride (ML7), the Calmodulin antagonist, W-7 
hydrochloride (W-7) and the selective p160 ROCK inhibitor, Y-27632 dihydrochloride (Y-27632) were 
employed to assess the potential involvement of [Zn2+]i in the shape changing signalling pathways. 
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ML7 is a widely used potent inhibitor of MLCK with working concentrations commonly being 1-10μM 
(Feghhi et al., 2016; Qiu et al., 2014). Similarly, Y-27632 (10μM) has been used to investigate the 
importance of p160 ROCK in platelet shape change (Paul et al., 1999; Wee and Jackson, 2006). W-7 is 
a potent calmodulin antagonist, with working concentrations for washed platelet suspensions 
reported in the 40-60µM range (Gardiner et al., 2004; Levy, 1983). Similar concentrations of 
antagonist were employed in the experiments described here. 
 
Cq induced shape change in response to ML7, W-7 and Y-27632 application 
Pre-treatment of washed platelet suspensions with ML7 (10µM) significantly reduced the level 
of shape change induced by Cq (Figure 5.6 A, E). The minimum aggregation induced by 300μM, 100μΜ, 
30μM or 10μM of Cq was significantly reduced from -15.5±2.4% to -5.3±1.3%, -14.3±1.6% to -6.2±1.6, 
-15.7±2.2% to -3.4±1.7% and 11.1±2.6% to 3.0±0.7%, respectively upon ML7 treatment (p<0.05, Figure 
5.6E).  
Treatment with W-7 (60μM) did not affect Cq-mediated shape change, as the minimum 
aggregation of W-7-pretreated platelets in response to 300μM Cq was -19.5±3.1% compared to -
23.6±1.2% for untreated platelets (p>0.05, ns, Figure 5.6F). These data are the first to show that Cq 
induced shape change is independent of calmodulin. This is in contrast to previous studies which have 
shown that Ca2+-dependent calmodulin activity induces MLCK activation, and thus shape change in a 
Ca2+ dependent manner (Paul et al., 1999). 
In contrast to W-7 treatment, pre-treatment with Y-27632 (10μM) significantly inhibited the 
level of shape change induced by Cq. The minimum aggregation induced by 300μM, 100μΜ, 30μM or 
10μM of Cq was significantly reduced from -21.3±1.9% to -7.3±0.8%, -12.1±2.60% to -3.9±1.4, -
12.7±3.7% to -3.7±1.1% and -11.9±1.9%, respectively, upon Y-27632 treatment (p<0.05, Figure 5.6G). 
This demonstrates that Cq induced shape change is mediated by p160 ROCK. These data along with 
data shown in Figure 5.6F confirms that p160 ROCK-mediated shape change is a Ca2+-independent 
process (Paul et al., 1999), and may be a Zn2+ dependent process.  
The maximum aggregation in response to Cq (300μM) was reduced upon pre-treatment of 
these inhibitors and antagonists (Figure 5.6B-D). Maximum aggregation was reduced from 34.4±3.4% 
to 22.1±2.4% upon ML7 (10μM) pre-treatment (p<0.001, Figure 5.6B), from 29.8±2.7% to 11.2±3.2% 
upon W-7 (60μΜ) pre-treatment (p<0.0001, Figure 6.6C), and from 31.4±5.6% to 12.2±4.2% upon Y-
27632 (10μM) pre-treatment (p<0.001, Figure 6.6D). These data indicate that Cq induced aggregation 
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is mediated by signalling pathways that evoke platelet shape change, coinciding with earlier findings 
which found that Cyt D application also inhibited Cq induced aggregation. Thus, Cq-induced 
aggregation is dependant on shape change. Furthermore, inhibition of calmodulin did not inhibit 
shape change, but still significantly reduced the maximum aggregation induced by 300μM Cq. This 
suggests that calmodulin may not be involved in Cq induced shape change but may influence the 
aggregatory response of Cq; thus aggregation induced upon [Zn2+]i may occur in a Ca2+ dependent 
manner.  
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Figure 5.6. Clioquinol-induced aggregation and shape change are sensitive to inhibition of signalling proteins involved in 
cytoskeletal rearrangements. Washed platelets were pre-treated with 10µM ML7, 60μM W-7 or 10μM Y-27632 before being 
stimulated with clioquinol, Cq (300µM, A). Aggregation traces were analysed to yield values for maximum aggregation 
induced by the different concentrations of Cq in the absence and presence of ML7 (B), W-7 (C), or Y-27632 (D). Similarly, 
minimum aggregation were quantified following treatment with different concentrations of Cq in the absence and presence 
of ML7 (E), W-7 (F), or Y-27632 (G). ML7 and Y-27632 but not W-7 treatment inhibited Cq induced shape change. ■ Vehicle 
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control, ● 10µM ML7 (B and E), ● 60µM W-7 (C and F) and ● 10µM Y-27632 (D and G). Data are mean±standard error of 
mean (SEM) from 5 independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * 
(p<0.05). 
Py induced shape change in response to ML7, W-7 and Y-27632 application  
Pre-treatment of platelet suspensions with 10μΜ of ML7 significantly reduced the level of 
shape change induced by Py (Figure 5.7 A and E). The minimum aggregation in response to 300μM, 
100μΜ,30μM or 10μM of Py went down from -15.8±1.0% to -4.1±1.3%, -15.1±2.7% to -3.0±1.0%, -
25.9±3.6% to -4.50±1.8 and -21.6±3.5% to -5.9±2.5%, respectively upon ML7 treatment (p<0.05, 
Figure 5.7E). Pre-treatment with 60μM of W-7 did not result in significant changes in the level of shape 
change induced by Py (Figure 5.7 A, F). The minimum aggregation induced by 30μM of Py following 
W-7 pre-treatment was -25.16±1.94% compared to -24.65±2.23% for untreated platelets (p>0.05, ns, 
Figure 5.7F). Pre-treatment with Y-27632 however significantly inhibited the level of shape change 
induced by Py. The minimum aggregation induced by 300μM, 100μΜ, 30μM or 10μM of Py was 
significantly reduced from -12.8±1.3% to -6.3±1.1%, -13.7±1.2% to -5.9±0.5%, -21.8±2.3% to -
10.1±2.4% and -14.6±1.73% to -7.1±1.04%, respectively, upon Y-27632 pre-treatment (p<0.05, Figure 
5.7G). Thus, Py resulted in a similar effect to these inhibitors as Cq (Figure 5.6), further demonstrating 
that Zn2+ mediated shape change occurs in a Ca2+ independent manner.  
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Figure 5.7. Pyrithione-induced aggregation and shape change are sensitive to inhibition of signalling proteins involved in 
cytoskeletal rearrangements. Washed platelets were either pre-treated with 10µM ML7, W-7 or Y-27632 before being 
challenged with pyrithione, Py (A) Representative aggregation traces showing the most effective concentration of Py in the 
platelets pre-treated with the inhibitors, ML7, W-7 and Y-27632. Aggregation traces were analysed to yield maximum 
aggregation values following pre-treatment with ML7 (B), W-7 (C), or Y-27632 (D). The minimum aggregation induced by the 
different concentrations of Py were also yielded in the absence and presence of ML7 (E), W-7 (F), or Y-27632 (G). ML7 and 
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Y-27632 but not W-7 treatment inhibited Py induced shape change. ■ Vehicle control, ● 10µM ML7 (B and E), ● 60µM W-7 
(C and F) and ● 10µM Y-27632 (D and G). Data are mean±standard error of mean (SEM) from 5 independent experiments. 
Significance is denoted as *** (p<0.001), ** (p<0.01) or * (p<0.05). 
   
A23187 induced shape change in response to ML7, W-7 and Y-27632 application 
Further experiments were carried out using A23187 and the shape changes inhibitors (ML7, 
W-7 and Y-27632, Figure 5.8) as a positive control and to enable comparisons to be made with the 
shape induced mechanisms mediated by [Zn2+]i. 
Pre-treatment with ML7 (10μM) significantly reduced the level of shape change induced by 
A23187 (Figure 5.8 A, E). The minimum aggregation induced by 300μM, 100μΜ, 30μM or 10μM of 
A23187 was significantly reduced from -14.5±2.3% to -6.8±1.0%, -11.3±0.9% to -3.9±0.8%, -13.2±2.3% 
to -6.3±0.8% and -12.9±0.2% to -5.8±2.0%, respectively upon ML7 treatment (p<0.05, Figure 5.8E). 
Application of W-7 (60μM) also significantly reduced the level of shape change induced by A23187 
(Figure 5.8 A, F). The minimum aggregation induced by 300μM, 100μΜ, 30μM or 10μM of A23187 was 
significantly reduced from -16.0±0.8% to -7.3±0.9%, -16.2±1.35% to -7.0±1.3%, -16.6±1.8% to -
7.5±1.5% and -15.5±3.2% to -5.4±2.0%, respectively upon W-7 treatment (p<0.05, Figure 5.8 F). 
However, pre-treatment with Y-27632 (10μM) did not influence the level of shape change induced by 
A23187 (Figure 5.8 A, G). The minimum aggregation induced by the highest concentration (300μΜ) of 
A23187 was -17.9±1.4% and with Y-27632 (10μM) pre-treatment was -18.1±1.9% (p>0.05, ns, Figure 
5.8G). These data confirm previous studies that indicate Ca2+ mediated shape change is independent 
of p160 ROCK (Kureishi et al., 1997; Paul et al., 1999).  
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Figure 5.8. A23187-induced aggregation and shape change are sensitive to inhibition of signalling proteins involved in 
cytoskeletal rearrangements. Washed platelets were either pre-treated with ML7, W-7 or Y-27632 before being challenged 
with A23187. A) Representative aggregation traces showing the effect of A23187 treatment (300µM) on platelets pre-treated 
with ML7, W-7 Y-27632. Traces were analysed to yield maximum aggregation values in platelets pre-treated with ML7 (B), 
W-7 (C), or Y-27632 (D). As well as minimum aggregation induced by the different concentrations of A23187 in the absence 
and presence of ML7 (E), W-7 (F), or Y-27632 (G). ML7 and W-7 but not Y-27632 treatment inhibited A23187 induced shape 
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change and aggregation. ■ Vehicle control, ● 10µM ML7 (B and E), ● 60µM W-7 (C and F) and ● 10µM Y-27632 (D and G). 
Data are mean±standard error of mean (SEM) from 5 independent experiments. Significance is denoted as *** (p<0.001), ** 
(p<0.01) or * (p<0.05). 
Maximum aggregation in response to A23187 was significantly reduced upon pre-treatment 
with ML7 or W-7, but not Y-267632 (Figure 5.8A, B). Maximum aggregation induced by 300μM, 100μΜ, 
30μM or 10μM of A23187 was reduced from 77.6±7.6% to 44.7±1.7%, 62.5±3.0% to 41.1±5.3%, 
54.8±6.3% to 35.8±2.8% and 57.7±0.50% to 36.1±2.8%, respectively upon ML7 treatment (p<0.05, 
Figure 5.8B). Maximum aggregation induced by 300μM, 100μΜ, 30μΜ or 10μΜ was significantly 
reduced from 84.7±2.30% to 58.7±7.6%, 74.5±2.3% to 49.4±7.0%, 66.9±3.3% to 39.0±5.2% and 
64.9±5.2% to 36.6±9.4%, respectively upon W-7 (60μM) treatment (p<0.05, Figure 5.8C). The 
maximum aggregation induced by 300μM of A23187 was 84.8±3.0% and with Y-27632 (10μM) pre-
treatment was 90.0±1.9% (p>0.05, ns, Figure 5.8D). This confirms that A23187 induced aggregation is 
mediated by cytoskeletal signalling involving MLCK and calmodulin but not Rho kinases. This is yet to 
be fully explored and correlates well with the data showing that Cq mediated aggregation is also 
inhibited by these inhibitors and antagonists. This suggests that full platelet aggregation is mediated 
by pathways that evoke shape change.   
 
Ionophore induced myosin light chain (MLC) phosphorylation  
The influence of Zn2+ on signalling pathways that are involved with shape change was further 
assessed by examination of ionophore-mediated changes in the phosphorylation state of MLC (at 
position ser157) in platelets pre-treated with shape change inhibitors (employed above). 
Phosphorylation of MLC is an important step in the shape changing signalling pathway, as phospho-
MLCs mediate actin rearrangement. Ser157 of MLC is phosphorylated by both MLCKs and RhoA ROCK. 
Therefore measurement of the level of phosphorylation of this MLC provides a means to assess the 
influence of Zn2+ signalling on platelet shape change. 
Thrombin was employed as a positive control, to see the levels of MLC phosphorylation 
induced by a physiological agonist. Thrombin is known to induce platelet shape change in a calcium-
dependant manner by inducing elevated intracellular Ca2+ elevation which in turn activates the 
Ca2+/Calmodulin-dependent MLCK, which increases in phosphorylation of MLC (Bodie et al., 2001; 
Hathaway and Adelstein, 1979; Shin et al., 2017b). Thrombin treatment induces shape change in a 
Ca2+ independent manner, by activating ROCK (Rho-associated coiled-coil-containing protein kinase) 
A 
B C D 
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which inhibits MLC-P, enabling enhanced MLC phosphorylation which in turns leads to cytoskeletal 
rearrangement for platelet shape change.  
Significant increases in MLC phosphorylation were evident upon stimulation with 1U/ml of 
thrombin, 300μM of A23187, 300μM of Cq and 30μM of Py in comparison to that induced by the 
vehicle (DMSO, Figure 5.9A). The levels of phosphorylation induced by 1U/ml of thrombin, 300μM of 
A23187, 300μM of Cq and 30μM of Py were 0.52±0.13 AU, 0.74±0.06 AU, 0.54±0.06 AU and 0.55±0.03, 
respectively which were all significantly higher than that induced by the vehicle, which was 0.158±0.04 
AU (p<0.05, Figure 5.9A). These findings provide further evidence to show that Zn2+ ionophores induce 
shape change via increased MLC activity. In order to confirm the role of Zn2+ in ionophore-induced 
MLC phosphorylation, platelets were pre-treated with 50μM of TPEN prior to stimulation. TPEN did 
not influence changes in phosphorylation in response to thrombin or A23187, but significantly reduced 
the level of phosphorylation induced by Cq or Py (Figure 5.9B). The levels of MLC phosphorylation in 
the presence of TPEN in response to 1U/ml of thrombin, 300μM of A23187, 300μM of Cq, or 30μM of 
Py were 0.5±0.1 AU, 0.6±0.1 AU, 0.14±0.03 AU and 0.14±0.03 AU. There were no significant 
differences in MLC phosphorylation in the presence of TPEN, induced by Cq, Py stimulation and the 
vehicle control (0.10±0.04 AU, p>0.05, Figure 5.9B). Thrombin and A23187 treatment resulted in 
significantly higher levels of phosphorylation than the vehicle, Cq or Py in the presence of 50μM TPEN 
(p<0.05, Figure 5.9B). These data confirm that Zn2+ ionophore-induced MLC phosphorylation is 
attributable to Zn2+. 
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Figure 5.9. Ionophore-mediated increases in intracellular Zn2+regulate platelet shape change and phosphorylation of 
cytoskeletal regulators. A) Representative Western blots showing changes in MLC phosphorylation following stimulation of 
washed platelet suspensions for 15 mins with vehicle (DMSO), thrombin (1U/mL), A23187 (300µM),clioquinol, Cq (300µM), 
or pyrithione, Py (30µM). Western blots of platelets pre-treated with (B), TPEN (50μM), (C) ML7 (10μM), (D) W-7 (60μM), (E) 
Y-27632 (10μM). Representative Western blot showing changes in VASP phosphorylation following pre-treatment of 
platelets for 15 mins with vehicle (DMSO), PGE1 (1U/mL), A23187 (300µM), Cq (300µM), Py (30µM), (F) or 50μM TPEN (G). 
Blots and quantification (means±SEM) are representative of 4 experiments. Significance is denoted as *** (p<0.001), ** 
(p<0.01) or * (p<0.05). 
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Phosphorylation of MLC in response to thrombin or the ionophores was significantly reduced 
upon ML7 treatment. The levels of MLC phosphorylation in the presence of ML7 in response to 1U/ml 
of thrombin, 300μM of A23187, 300μM of Cq or 30μM of Py were 0.06±0.01 AU, 0.06±0.01 AU, 
0.05±0.01 and 0.05±0.02, respectively (Figure 5.9C). MLC phosphorylation in ML7 pre-treated 
platelets in response to the vehicle was 0.06±0.02. Therefore, there were no significant differences in 
MLC phosphorylation between the vehicle, thrombin and ionophore treatments (p>0.05, ns, Figure 
5.9C). These data correlate with the data described in Figure 5.6-8 (A, E), which showed that shape 
change induced by the inhibitors was significantly reduced with ML7 statement. This further supports 
the biological validity of the ionophore-induced shape change, as this data indicates that ionophore-
dependent shape is dependent on MLC phosphorylation.  
Data described in Figures 5.6 to 5.8 (A, F) showed that the shape change induced by A23187, 
but not the Zn2+ ionophores, was inhibited by W-7, indicating that Zn2+-mediated shape change is 
independent of calmodulin. W-7 pre-treatment inhibited MLC phosphorylation induced by thrombin 
or A23187 but did not inhibit phosphorylation induced by Cq and Py relative to the vehicle (p<0.05, 
Figure 5.9D). MLC phosphorylation in W-7 pre-treated platelets in response to 1U/ml of thrombin, 
300μM of A23187, 300μM of Cq, or 30μM of Py were 0.06±0.02 AU, 0.08±0.01 AU, 0.40±0.08 and 
0.37±0.08, respectively, whereas the level of phosphorylation induced by the vehicle was 0.07±0.02 
(Figure 5.9D). No significant differences were found between the level of phosphorylation between 
the vehicle and thrombin and A23187 in the presence of W-7, but Cq and Py induced significantly 
higher levels of MLC phosphorylation than the vehicle (p<0.05, Figure 5.9D). These findings correlate 
with the aggregation data (Figures 5.6-5.8) and provide further evidence to suggest that Zn2+ mediated 
signalling can induce platelet shape change in a manner independent of Ca2+/Calmodulin.  
Y-27632 pre-treatment reduced MLC phosphorylation in response to the ionophores. MLC 
phosphorylation in Y-27632 pre-treated platelets, in response to 1U/ml of thrombin, A23187 (300μM), 
Cq (300μM), or of Py (30μM) were 0.21±0.03 AU, 0.22±0.02 AU, 0.10±0.01 and 0.10±0.01, respectively, 
whereas the level of phosphorylation induced by the vehicle was 0.10±0.03 (Figure 5.9E). Thrombin 
and A23187 (p<0.01) but not Cq or Py–mediated phosphorylation differed from the vehicle (p<0.05, 
ns, Figure 5.9E). Thrombin or A23187 treatment also resulted in lower levels of MLC phosphorylation 
in Y-27632-treated platelets compared to untreated platelets (MLC phosphorylation induced by 
thrombin or A23187 on untreated platelets was 0.52±0.13 AU and 0.74±0.06 AU, respectively, p<0.05, 
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Figure 5.9A, E). This suggests that p160 ROCK enables higher levels of Ca2+ induced MLC 
phosphorylation, possibly indicating synergy between Ca2+ dependent and independent pathways.  
Phosphorylation of VASP in response to ionophores was investigated to determine whether 
elevated [Zn2+]i has a role in PKA or PKG signalling, as VASP is a substrate of these kinases. Furthermore, 
VASP plays a key role in cytoskeletal rearrangement in platelets, although its role yet to be fully 
elucidated (section 1.2.6, Chapter 1). This was of considerable interest as recent work has 
demonstrated an inhibitory role for cAMP signalling in ROCK activity, which in turn would lead to 
continued MLC-P (myosin light chain phosphatase) activity and inhibition of MLC phosphorylation 
(Aburima et al., 2017, 2013). This would inhibit platelet shape change.  
        Stimulation with the ionophores had no effect on phosphorylation levels of VASP compared to 
the vehicle control (Figure 5.9F). PGE1 was employed as a positive mediator of VASP phosphorylation. 
PGE1 activates the cAMP signalling pathway, which enables PKA to phosphorylate VASP (Beck et al., 
2014). PGE1 induced a significant increase in VASP phosphorylation relative to the ionophores and the 
vehicle (Figure 5.9F). The level of VASP phosphorylation induced by PGE1 (1U/mL), A23187 (300µM), 
Cq (300µM) or Py (30µM) was 1.6±0.1 AU, 0.4±0.1 AU, 0.5±0.4 AU and 0.5±0.1 AU, whereas the level 
of VASP phosphorylation induced by the vehicle was 0.5±0.1 AU (Figure 5.9F). Only PGE1 induced a 
significantly higher level of VASP phosphorylation compared to the vehicle treatment (p<0.05, Figure 
5.9F). TPEN was used to correlate phosphorylation events with Zn2+ increases further. TPEN pre-
treatment did not affect the levels of phosphorylation induced by PGE1 or the ionophores (relative to 
the vehicle treatment,), as the level of VASP phosphorylation in TPEN-treated platelets in response to 
PGE1 (1U/mL), A23187 (300µM), Cq (300µM), Py (30µM) or the vehicle control were 1.3±0.1, 
0.26±0.04, 0.22±0.03, 0.32±0.04 and 0.25±0.03, respectively (p>0.05, ns, Figure 5.9. F-G) These data 
indicate that [Zn2+]i plays no significant role in mediating cAMP signalling (Aburima et al., 2013).  
 
5.2.3.3 Chelation of intracellular Zn2+ abrogates platelet shape change 
and spreading 
The data described above demonstrate that increases in [Zn2+]i result in platelet shape change 
independently of Ca2+/Calmodulin suggesting a potential mechanism by which Ca2+ -independent 
signalling can result in MLC phosphorylation. Further experiments were performed to explore the 
importance of [Zn2+]i on platelet shape change. Previous work has demonstrated that morphological 
changes in platelets can be observed microscopically during adhesion to onto fibrinogen-coated 
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coverslips (Aslan et al., 2012; Li et al., 2010). A similar approach (Section 2.11, Chapter 2) was used 
here to investigate the influence of Zn2+ on platelet shape change. 
Platelets rapidly adhered and spread on fibrinogen-coated coverslips (100µM, Figure 5.10) 
which evoke outside-in signalling (Figure 1.2.5, Chapter 1). The influence of [Zn2+]i on cytoskeletal 
changes was investigated by pre-treating platelets with TPEN (50μM). TPEN -treated platelets were 
able to adhere to fibrinogen, but did not spread, as evidenced by an absence of visible lamellipodia or 
filopodia (Figure 5.10A). Mean platelet surface coverage for TPEN treated platelets after 2, 5 and 
10mins were significantly lower than for untreated platelets. After 2, 5 and 10mins the mean surface 
area coverage for untreated platelets was reduced from 13.4±0.9μm2 to 9.8±0.6μm2, 18.9±1.9μm2 to 
10.1±0.6μm2 and 22.7±1.6µm2 to 12.8±1.5µm2 upon TPEN (50μΜ) pre-treatment respectively 
(p<0.001, Figure 5.10B). This further demonstrates that [Zn2+]i is required for cytoskeletal 
rearrangements in platelets. 
 
 
 
Figure 5.10. Intracellular Zn2+ is required for platelet spreading on fibrinogen. Washed platelet suspensions were incubated 
on fibrinogen-coated coverslips following pre-treatment with 50µM TPEN or vehicle control (DMSO). A) Representative 
images of platelet spreading. B) Quantification of the surface coverage by adherent platelets. Pre-treatment with 50μM of 
TPEN significantly inhibited platelet spreading.  Vehicle,  50µM TPEN. Data are mean±standard error of mean (SEM) from 
4 independent experiments. Significance is denoted as *** (p<0.001), ** (p<0.01) or * (p<0.05).  
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5.2.3.4 Intracellular Zn2+ is required for cytoskeletal changes in 
nucleated cells  
The data discussed above outlines the importance of [Zn2+]i in platelet shape change. The data 
in this section explores the wider application of [Zn2+]i by investigating whether its role in cytoskeletal 
rearrangement is platelet-specific or is also viable in other cells types. Experiments were conducted 
using a model cell line, Mouse Embryonic Fibroblasts (MEF) (Chen et al., 2016; J. Wang et al., 2014). 
These were selected because they readily undergo spreading, making them a suitable candidate for 
investigating the role of intracellular Zn2+ on cytoskeletal rearrangement (section 2.12, Chapter 2).  
Attachment and spreading of MEF cells on glass coverslips following pre-treatment with TPEN 
was imaged using a fluorescent cell imager (section 2.12, Chapter 2). After 2 hours attachment of 
untreated MEFs to the glass substrate, subsequent cytoskeletal changes were apparent (subjective 
observations, Figure 5.11). Cells appeared firmly adhered and were beginning to increase in surface 
area. After 6 hours of incubation, the cells had spread more extensively. Upon treatment with the 
vehicle (DMSO) after 2 hours cellular attachment and spreading was apparent. Slight increases in cell 
spreading were observed after 6 hours of DMSO treatment. TPEN pre-treatment resulted in minimal 
cell attachment after 2 hours, with no indication of cell spreading. No further changes were seen after 
6 hours.  
The data described here correlates a role for Zn2+ in both platelets spreading, and in nucleated 
cell spreading. This may be indicative of a wider role for Zn2+ in cytoskeletal behaviour. 
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Figure 5.11. Intracellular Zn2+ mediates adhesion and cytoskeletal changes in mouse embryonic fibroblast (MEF) cells. MEF 
cells were pre-treated with 50µM TPEN, vehicle control (DMSO), or no pre-treatment prior to incubation on glass coverslips 
for 6 hours. Cells were stained with Phalloidin-iFluor 594 and DAPI and were imaged by Zoe imager. Representative images 
(n=3) of Phalloidin- iFlour 594 Conjugate and DAPI stained MEF cells undergoing adhesion and spreading are shown.  
   
5.2.4 Intracellular Zn2+ mediates platelet activation   
The data presented thus far in this chapter demonstrates that elevating [Zn2+]i induces platelet 
activatory processes such as aggregation and shape change in a manner which may be independent 
of Ca2+-signalling mechanisms. To better understand the extent to which changes in [Zn2+]i regulate 
platelet activation, the influence of ionophore treatment on conventional markers of platelet 
activation (including granule release and integrin activation) was investigated. 
In order to correlate Zn2+ increases with platelet activation, and also to verify data obtained 
from light transmission aggregometry, experiments were performed to assess the influence of 
increasing [Zn2+]i on PAC-1 binding to platelets using flow cytometry. Thrombin was employed as a 
comparison to see the levels of PAC-1 binding upon physiological stimulation. Zn2+ ionophore-induced 
elevation of [Zn2+]i increased PAC-1 binding (Figure 5.12A), supportive of a role for Zn2+ in mediating 
αIIbβ3 activity. The level of PAC-1 binding after 60mins of stimulation with Cq (300µM), Py (300µM,), 
A23187 (300µM) or thrombin (1U/mL) were 47.4±4.2%, 28.6±5.4%, 64.5±5.8%, 69.4±5.8%, 
respectively. These were significantly higher than that induced by the vehicle control (3.9±1.5%, 
p<0.0001, 5.12A). Interestingly, Py evoked increased levels of PAC-1 binding but not full aggregation 
(Figure 5.1-5.2 and 5.4). This is difficult to reconcile as increased PAC-1 bindings is associated with 
aggregation. It is possible that the level of Py mediated-αIIbβ3 activation is not sufficient to fully activate 
αIIbβ3 mediated aggregation as a result of low increases in [Zn2+]i This would be consistent with data 
showing lower increases in [Zn2+]i compared to Cq (Chapter 4). Furthermore, PAC-1 binding 
experiments were quantified after 60mins of stimulation as A233187 and thrombin (positive controls 
in these experiments) evoked optimal PAC-1 binding after 60mins. Thus this was the chosen time for 
analysis in this work. This was also the case with the other activation makers  CD62P and CD63 as 
discussed below. 
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Figure 5.12. Elevated intra-platelet Zn2+ increases platelet activation markers. (A) Washed platelet suspensions were 
stimulated by thrombin (Thr, 1U/mL), Clioquinol (Cq, 300µM), Pyrithione (Py, 300µM) or A23187 (300µM) and changes of 
PAC-1 (white),  CD62P (grey), and CD63 (black) binding were recorded after 60 mins. (B) Washed platelet suspensions were 
pre-treated with TPEN (50μM) prior to stimulation with thrombin (Thr, 1U/mL), Clioquinol (Cq, 300µM), Pyrithione (Py, 
300µM) or A23187 (300µM) and changes of PAC-1 (),  CD62P (), and CD63 () binding were obtained after 60 mins. Data 
are means±SEM, of at least 5 independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** 
(p<0.01) or * (p<0.05). 
The [Zn2+]i chelator TPEN was employed to assess the validity of the Zn2+ induced PAC-1 
binding. Pre-treatment of platelet suspensions with TPEN reduced the levels of ionophore- or 
thrombin-induced PAC-1 binding (Figure 5.12B). The percentage of PAC-1 binding of platelets 
following stimulation with Cq (300µM), Py (300µM,), A23187 (300µM) and thrombin (1U/mL) were 
significantly reduced from 47.4±4.2% to 8.9±1.3%, 28.6±5.4% to 5.6±1.50%, , 64.5±5.8% to 33.3±4.5% 
and 69.4±5.8% to 33.0 ±3.10%, respectively in TPEN pre-treated platelets (50µM, p<0.05, Figure 
5.12A-B). Cq- or Py- induced PAC-1 binding in TPEN pre-treated platelets (8.9±1.3% and 5.6 ±1.5%, 
respectively) was not significantly different to the vehicle control (3.80±0.90%, p>0.05, Figure 5.13B). 
These data further support a role for [Zn2+]i in the regulation of the activation of αIIbβ3. 
 Conversely, A23187 or thrombin-induced PAC-1 binding in TPEN pre-treated platelets 
(33.3±4.5% and 33.0±3.1, respectively) were still significantly higher the vehicle control (3.80±0.90%) 
after 60 mins (p<0.001, Figure 5.12B). This indicates that A23187 or thrombin-induced PAC-1 binding 
is only partially influenced by [Zn2+]i. This was interesting, as TPEN did not influence A23187 induced 
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aggregation, as shown earlier (Figure 5.2C, F). However, A23187 has shown to be non-specific and is 
also able to coordinate Zn2+ (Chapter 4). Therefore A23187-mediated activity may also be attributable 
to Zn2+. This finding correlates with Py induced PAC-1 binding, which did not display aggregation but 
did evoke significant increases in PAC-1 binding. Thus Zn2+ may play a potentiating role in inducing 
aggregation by mediating the upregulation of αIIbβ3 at low concentrations.     
 
Investigation of the influence of increased intracellular Zn2+ on granule release 
Experiments were performed to assess the role of [Zn2+]i in other activatory processes. 
Granule secretion releases bioactive molecules into the vicinity of a growing thrombus, mediating 
activation in a para-and autocrine manner (Corinaldesi, 2011; Joseph et al., 1998; Stalker et al., 2012; 
Wauters et al., 2015; Yacoub et al., 2006). Assessment of the level of  CD62P and CD63 on the platelet 
surfaces quantifies the degree to which α and dense granule release respectively are released.  
Treatment of washed platelet suspensions with Cq or Py did not evoke  CD62P externalisation 
as measured using flow cytometry (Figure 5.12A). The percentage of  CD62P positive platelets after 
60 minutes of stimulation with Cq (300µM) or Py(300µM) was 5.5 ±2.8% and 7.1±2.3%, respectively, 
compared to that induced by the vehicle control (2.9±1.3%, p>0.05, ns, Figure 5.12A)  
Treatment with A23187 or thrombin both resulted in significant increases in  CD62P and CD63 
externalisation. The percentage of  CD62P positive platelets after 60 minutes following A23187 
(300µM) or thrombin (1U/mL) treatment was 31.20±5.72%, 85.11±4.20%, respectively, (both 
significantly higher than the vehicle control, 2.90±1.03%, p<0.0001, Figure 5.12A).  
TPEN was used to further assess the influence of Zn2+ on granule secretion. Pre-treatment with 
TPEN had no significant influence on the  CD62P externalisation in response to the ionophores or 
thrombin (Figure 5.12B). The percentage of  CD62P positive TPEN-pre-treated platelets followed by 
60 minutes of stimulation with Cq (300µM), Py (300µM), A23187 (300µM), thrombin (1U/mL) or 
vehicle were 4.7±1.8%, 3.7±0.8%, 31.9 ±7.0%, 81.9±6.1% and 2.8±0.5%, respectively(p>0.05, ns, Figure 
5.12). This data indicate that increases in [Zn2+]i have no influence on α granule release. 
Conversely, elevation of [Zn2+]i significantly increased CD63 externalisation. All ionophores and 
thrombin-induced significant increases in CD63 externalisation in comparison to that induced by the 
vehicle (Figure 5.12A). The percentage of CD63 positive platelets after 60 minutes of stimulation with 
Cq (300µM), Py (300µM,), A23187 (300µM) or thrombin (1U/mL) were 56.0±7.8%, 50.2±2.7%, 
55.0±5.0% and 48.9±3.1%, respectively. These were significantly higher than that induced by the 
vehicle control 21.0±2.9%, p<0.001, Figure 5.12A).  
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TPEN was then employed to confirm the role of Zn2+ in this process. Pre-treatment with TPEN 
reduced the percentage of CD63 externalisation induced by the ionophores and thrombin. The 
background (vehicle) CD63 expression was also reduced in following vehicle treatment although this 
was not found to be significant (p>0.05, Figure 5.12B). The percentage of CD63 positive platelets after 
60 mins of stimulation with Cq (300µM), Py (300µM), A23187 (300µM) or thrombin (1U/mL) were 
significantly reduced from 56.0±7.8% to 10.1±1.4%, 50.2±2.7% to 8.2±1.7%, 55.0±5.0% to 36.9±7.0% 
and 48.90±3.1% to, 28.2±6.1%, respectively upon 50μΜ TPEN pre-treatment (p<0.05, Figure 5.12A-
B). However, A23187 and thrombin-induced CD63 externalisation in TPEN pre-treated platelets 
(33.3±4.5% and 33.0±3.1, respectively) were still significantly higher than CD63 externalisation 
induced by the vehicle control after 60 mins which were 12.1±1.8% (p<0.01, Figure 5.12B). This 
indicates that whilst A23187 and thrombin-induced CD63 externalisation is not fully dependent on 
[Zn2+]i , Zn2+ is a requirement for optimal dense granule secretion. Whereas Cq or Py induced CD63 
externalisation in TPEN pre-treated platelets, (10.12±1.42% and 8.20±1.74%, respectively) was not 
significantly different from the vehicle control (12.1±1.8%, p>0.05, Figure 5.12B). This data suggest 
that [Zn2+]i regulates the activity of dense granule release and supports a role for [Zn2+]i in activation-
dependent platelet behaviour.  
 
5.2.5 Agonist-induced platelet activation is mediated by intracellular 
Zn2+  
The data discussed in the previous section demonstrate that increased [Zn2+]i results in dense 
granule release, supporting the role of Zn2+ as a secondary messenger. Additionally, thrombin-induced 
PAC-1 binding and dense granule release are inhibited upon chelation of [Zn2+]i via further indicating 
the importance Zn2+ in agonist-induced platelet activation. As thrombin-mediated platelet activation 
is shown to be influenced by Zn2+, further experiments were designed to test whether activation by 
other conventional agonists was also sensitive to Zn2+ levels. Agonists targeting GpVI or TP (CRP-XL, 
U46619) were selected to further assess a physiological role for Zn2+ in platelet activation (Figure 5.13), 
as these agonists were found to evoke [Zn2+]i elevation (Chapter 3). 
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Figure 5.13. Agonist-induced platelet activation is mediated by intracellular Zn2+. Washed platelet suspensions were 
stimulated by CRP-XL (1μg/ml), Thrombin (1U/mL) or U46619 (10μM) with or without TPEN (50μM) pre-treatment. Changes 
of PAC-1 (A),  CD62P (B), and CD63 (C) binding were obtained after 60 mins. Data are mean±standard error of mean (SEM) 
from 5 independent experiments. Significance is denoted as *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
Pre-treatment with TPEN (50μM) significantly reduced the percentage of PAC-1 binding 
induced by all agonists tested. Upon TPEN treatment, the percentage of PAC-1 binding platelets 
induced by CRP-XL (1μg/ml), thrombin (1U/ml) or U46619 (10μM) was reduced from 55.4±5.0% to 
29.0±1.5%, 64.6±5.2% to 32.1±3.4% and 36.3±2.8% to 16.5±1.20%, respectively (p<0.001, Figure 5.13). 
This indicates that [Zn2+]I levels are important during activation initiated by heterogeneous signalling 
pathways. These data correlate with the previous experiments (Figure 5.12), which illustrated that 
[Zn2+]i evokes PAC-1 binding. 
Pre-treatment with TPEN did not significantly affect agonist-evoked  CD62P externalisation 
(Figure 5.13). In TPEN pre-treated platelets, the percentage of  CD62P externalising platelets following 
CRP-XL (1μg/ml), thrombin (1U/ml) or U46619 (10μM) treatment did not differ significantly from 
untreated platelets. Untreated and treated platelets had  CD62P levels respectively of 38.0±5.1% and 
32.54±2.80% for CRP-XL, 40.70±2.73% and 30.40±1.02% for U46619, and 20.43±1.84% and 
14.43±1.52%, for thrombin (p>0.05, ns, Figure 5.13). These data support previous results showing that 
alpha granule release was not mediated by Zn2+ (Figure 5.12) 
Pre-treatment with TPEN significantly reduced CD63 externalisation induced by CRP-XL or 
thrombin (Figure 5.13). Upon TPEN treatment, CD63 externalisation induced by CRP-XL (1μg/ml) or 
thrombin (1U/ml) was reduced from 46.6±4.0% to 24.2±2.6%, 40.8±3.8% to 17.6±2.3%, respectively, 
(p<0.001, Figure 5.13), further supporting a role for [Zn2+]i as a mediator of dense granule release.  
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 A significant reduction in CD63 binding was not observed following U46619 stimulation of 
TPEN-pre-treated platelets, suggesting TxA2-mediated dense granule release may not be influenced 
by [Zn2+]i. This requires further investigation to determine as to why [Zn2+]i had no significant influence 
on TxA2 induced platelet dense granule release. U46119 induces [Zn2+]i elevation (chapter 3) 
suggesting that [Zn2+]i may play a role in TxA2 signalling. However, the increase in [Zn2+]i evoked by 
U46619 was much lower to that induced by CRP-XL. Thus, the greater elevation of [Zn2+]i induced by 
CRP-XL may be responsible for mediating the higher level of CD63 externalisation. Therefore, it can be 
suggested that U46619 does not evoke a high enough increase in [Zn2+]i to mediate a CD63 
externalisation response that is influenced by [Zn2+]i. This may explain why the chelation of [Zn2+]i had 
no influence on U46619-induced CD63 externalisation. 
The data from this section is supportive of a role for [Zn2+]i in agonist-induced activation. 
Upregulation of αIIbβ3 activity and dense granule release upon agonist stimulation were reduced upon 
chelation of [Zn2+]I, indicating a role for [Zn2+]i in these processes (Figure 5.13) This data provides novel 
findings outlining the importance of [Zn2+]i in physiological platelet activation, which further provides 
evidence to confirm Zn2+ as a secondary messenger in platelets.  
 
5.2.6 Intracellular Zn2+ mediates phosphatidylserine exposure in 
platelets 
Further experiments were performed to investigate the influence of [Zn2+]i on 
phosphatidylserine (PS) externalisation in platelets. Both extracellular Zn2+ and agonist-induced 
changes in [Zn2+]i have been linked to apoptosis and related responses in nucleated cells (Eron et al., 
2018; Hamatake et al., 2000; Iitaka et al., 2001; Treves et al., 1994). PS exposure serves as an activation 
marker in platelets, being induced upon [Ca2+]i elevation (Suzuki et al., 2013; Zhao et al., 2017). 
However, the role of Zn2+ in PS exposure during platelet activation has yet to be studied. To investigate 
the influence of [Zn2+]i on PS exposure, platelets were treated with ionophores, and annexin-V binding 
was quantified in real time using flow cytometry (section 2.8, Chapter 2). 
Elevation of [Zn2+]i via Cq (300μM) or Py (300μM) stimulation, or elevation of [Ca2+]i using 
A23187 resulted in significant increases in annexin-V binding. After 30mins of stimulation, Annexin-V 
binding was modestly (although significantly) increased upon Zn2+ ionophore treatment, whilst 
A23187 treatment resulted in a large increase in Annexin-V binding. The percentage of Annexin-V 
binding after 30 minutes of stimulation with Cq (300μM), Py (300μM) or A23187 (300μM) were 
13.6±0.9%, 24.1±2.9%, 77.6±3.40% respectively. Binding was significantly higher than that induced by 
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the vehicle (3.7±0.7%, p<0.05, Figure 5.14). After more extended time periods of stimulation annexin-
V binding following treatment with Zn2+ and Ca2+ ionophores reached similar plateau levels. The 
percentage of Annexin-V binding after 3 hours of stimulation with Cq (300μM), Py (300μM) or A23187 
(300μΜ) and the vehicle were 90.9±0.9%, 88.7±2.4% and 88.6±2.7%, respectively. These were 
significantly higher than the vehicle control (7.3±2.0%, p<0.05, Figure 5.14). 
 
 
 
Figure 5.14. Elevation of intracellular Zn2+ in platelets using Zn2+ ionophores increases PS externalisation. Washed platelet 
suspensions were treated with Ca2+ or Zn2+ ionophores prior to analysis of annexin-V binding by flow cytometry. Changes in 
the percentage of platelets binding to annexin-V were recorded over a 3-hour time period. Platelets were stimulated by 
Clioquinol (A, 300µM), Pyrithione (B, 300µM), A23187 (C, 300µM), Vehicle (D, DMSO), either without pre-treatment (●), 
following pre-treatment with the caspase inhibitor Z-VAD (20μM) ( ), or following pre-treatment with the Zn2+ chelator, 
TPEN (50 µM) (▲). Data are means±SEM, of at 5 independent experiments. Significance is denoted as **** (p<0.0001), *** 
(p<0.001), ** (p<0.01) or * (p<0.05). 
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Pre-treatment of platelet suspensions with TPEN was carried out to confirm the role of Zn2+ 
ionophore-induced PS exposure. TPEN significantly reduced annexin-V binding following Zn2+ 
ionophore treatment throughout the experiment. Annexin-V binding following by Cq (300μM) or Py 
(300μM) treatment was reduced from 90.93±0.86% and 88.72±2.40% to 16.61±6.35% and 
17.94±3.94%, respectively upon TPEN (50μM) pre-treatment after 3 hours (p<0.0001, Figure 5.14A-
B). These data confirm a role for Zn2+ in regulating PS exposure. TPEN treatment also significantly 
reduced annexin-V binding induced by A23187 throughout the whole experiment. After 30 mins, 1 
hour, 2 hours and 3 hours of stimulation A23187 treatment was reduced from 77.6±3.4% to 
25.4±4.0%, 84.4±1.7% to 35.3±7.2%, 83.8±2.6% to 48.4±6.4% and 88.6±2.6% to 75.2±5.5%, 
respectively following TPEN pre-treatment (p<0.05, Figure 5.14C). These data confirm that Zn2+ is 
important in cellular processes leading to PS exposure in platelets. 
 
Caspases are involved in mediating PS exposure, usually upon apoptosis. Previous work has 
shown that caspases are present in platelets, and inhibition of caspases with the caspase inhibitor Z-
VAD inhibits ADP and A23187 induced PS exposure (Cohen, 1999; Cohen et al., 2004a). Here Z-VAD 
was employed to examine the mechanisms by which ionophore treatment results in PS exposure, and 
also to assess the biological validity of the observed responses (Cohen et al., 2004b) (Cohen et al., 
2004), Previous studies showed that 20μM of ZVAD is sufficient to inhibit caspase activity in washed 
platelet suspensions(Cohen, 1999; Cohen et al., 2004a). 
Pre-treatment of washed platelet suspensions with Z-VAD resulted in a significant reduction 
in annexin-V binding after 1 to 2 hours of stimulation with Cq (300μΜ). The percentage of platelets 
binding to annexin-V was reduced from 85.2±3.8% to 53.6±4.7% and 86.4±1.8% to 72.9±4.8% 
respectively upon Z-VAD (20μM) pre-treatment (p<0.01, Figure 5.14A). Pre-treatment with 20μM of 
Z-VAD also resulted in significant reduction in annexin-V binding after 1 to 2hours of stimulation with 
Py (300μΜ). Here, Annexin-V positive platelets were reduced from 75.9±2.3% to 55.1±2.7% and 
84.6±1.9% to 73.3±3.8% respectively upon Z-VAD (20μM) pre-treatment (p<0.05, Figure 5.14B). Thus, 
indicating that caspase inhibition does not fully inhibit but may partially inhibit Zn2+ ionophore-
induced PS exposure. Similarly, A23187 induced annexin-V binding was reduced following Z-VAD pre-
treatment, but only during the first hour. As the percentage of annexin-V–positive platelets was 
reduced from 77.6±3.4% to 51.0±3.9% after 30 mins and 84.4±1.7% to 62.70±3.10% after 1 hour upon 
Z-VAD pre-treatment (p<0.01, Figure 5.13C). Z-VAD did not inhibit the annexin-V binding after 1 hour,  
The experiments described in this section demonstrate that [Zn2+] induces PS exposure in 
platelets in a manner that may be partially mediated by caspases (Figure 5.14A-B). The data also 
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suggest that Ca2+-mediated PS exposure is dependent on the presence of [Zn2+]I (Figure 5.14C). These 
experiments represent the first example of work to investigate the signalling pathways that operate 
during Zn2+-induced PS exposure in platelets. The data provided here are consistent with a role for 
Zn2+ as a secondary messenger in platelets 
 
5.2.7 Agonist-induced phosphatidylserine exposure is mediated by 
intracellular Zn2+ 
Further experiments were performed to examine the influence of [Zn2+]I on agonist-evoked 
PS exposure. In these experiments, changes were observed in annexin-V binding to TPEN pre-treated 
platelets following stimulation with conventional platelet agonists (CRP-XL, U46619 and thrombin, 
Figure 5.15). 
 
Figure 5.15. Platelet PS exposure occurs following agonist-evoked activation is sensitive to Zn2+ chelation. Washed platelet 
suspensions were treated with conventional agonists prior to analysis of annexin-V binding by flow cytometry. Changes in 
the percentage of platelets binding to annexin-V were recorded. Platelets were stimulated by (A) CRP-XL (1µg/ml), (B) 
thrombin (1U/ml), (C) U46619 (10µM), (D) vehicle (DMSO) following pre-treatment with vehicle (●), with the caspase 
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inhibitor Z-VAD (20μM) present (□), or with the Zn2+ chelator, TPEN (50 µM) (▲). Data are mean±standard error of mean 
(SEM) from 6 independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
Pre-treatment of washed platelet suspensions with TPEN reduced the level of PS exposure 
induced by CRP-XL, and U46619, but did not influence thrombin-evoked PS exposure (Figure 5.15), 
Upon TPEN (50μM) pre-treatment, the percentage of annexin-V positive platelets following CRP-XL 
(1μg/ml) or U46619 (10μM) treatment was reduced at every time point measured. Annexin-V positive 
TPEN-treated platelets following treatment with CRP-XL (1μg/mL) after 30 minutes, 1 hour, 2 hours 
and 3 hours was reduced from 25.4±4.8% to 13.6±1.5%, 32.2±2.50% to 20.1±2.4%, 34.8±1.5% to 
21.9±2.0% and 34.4±2.90% to 26.3±1.0%, respectively (p<0.05, Figure 5.15A). TPEN pre-treatment 
reduced U46619-mediated annexin-V binding after 1, 2 and 3 hours from 18.2±0.9% to 10.9±1.7%, 
27.2±1.6% to 14.1±3.5%, 30.9±2.5% to 19.2±3.32% and 34.40±2.53% to 21.43±2.70%, respectively 
(p<0.05, Figure 5.15C).  
The percentage of annexin-V positive platelets did not significantly differ following thrombin 
treatment. After 30 minutes, 1 hour, 2 hours and 3 hours in the absence and presence of TPEN (50μM) 
annexin-V binding was 13.60±1.53% and 11.0±1.2%, 24.9±3.7% and 23.3±3.4%, 28.7±3.3% and 
25.8±3.6% and 32.5±4.8% and 28.3±4.6% respectively for untreated and TPEN-treated platelets 
(p>0.05, Figure 5.15B). These data indicate that [Zn2+]i may play a significant role in mediating PS 
exposure in response to CRP-XL or U46619, but not thrombin, providing further support for a role Zn2+ 
following GpVI and TP signalling, but not via PARs. 
 
Z-VAD was again employed to assess the biological validity of the observed response as 
previously demonstrated, (Cohen et al., 2004b) (Cohen et al., 2004). Z-VAD significantly reduced the 
Annexin-V binding in response to CRP-XL, U46619 and thrombin. Significant reductions in CRP-XL-
mediated annexin-V binding with Z-VAD pre-treatment were evident at every time point tested. 
Annexin-V binding percentages were reduced from 25.4±4.8% to 3.0±1.7%, 32.2±2.5% to 12.4±2.5%, 
34.8±1.5% to 17.7±2.1% and 34.4±2.9% to 23.1±2.0% after 30 minutes, 1 hour, 2 hours and 3 hours 
stimulation, respectively upon Z-VAD (20μΜ) pre-treatment (p<0.05, Figure 5.15A). A similar effect 
was seen with U46619 as where annexin-V binding in the presence of Z-VAD was reduced from 
18.2±0.9% to 5.4±1.2%, 27.2±1.6% to 8.70±1.62%, 30.9±2.6% to 13.9±2.0% and 34.4±2.5% to 
15.2±2.0% after 30 mins, 1 hour, 2 hours and 3 hours stimulation, respectively (p<0.05, Figure 5.15C). 
Thrombin-induced annexin-V–binding was reduced from 13.6±1.5% to 3.3±1.1%, 24.9±3.4% to 
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13.9±2.3%, 28.7±3.3% to 17.5±1.1% and 32.56±4.8% to 21.2±2.4%, respectively upon Z-VAD 
treatment after 30 mins, 1 hour 2 hours and 3 hours of stimulation (p<0.05, Figure 5.15B).  
These results correlate well with the data showing that [Zn2+]i elevation mediates PS exposure 
(Figure 5.14). The experiments described in this section provide further evidence indicating the 
importance of [Zn2+]i in mediating agonist-induced PS exposure which is a major activatory process in 
platelets (discussed in chapter 1). As agonist-evoked PS exposure was inhibited upon chelation of 
[Zn2+]i. Thus, the elevation of [Zn2+]i may have mediatory roles in PS exposure which further 
strengthens the hypothesis that Zn2+ is a secondary messenger in platelets. 
 
 
5.3 Discussion  
The work described in this chapter was designed to investigate the effect of elevated [Zn2+]i 
on platelet activity, and the importance of [Zn2+]i in agonist-dependent activation. The hypothesis 
being tested here is that Zn2+ acts as a secondary messenger in platelets. A secondary messenger is 
defined as a molecule that is intracellularly modulated in response to extracellular stimuli and can 
then induce appropriate intracellular signalling events with regards to the extracellular stimuli, 
resulting in physiological changes in the cell. In Chapters 3 and 4 experiments demonstrated that 
[Zn2+]i elevation occurs in platelets in response to agonist stimulation. Here, experiments were 
performed to investigate whether increases in [Zn2+]i influenced platelet behaviour. The data 
described in this chapter confirms that upon elevation, [Zn2+]i mediates a variety of platelet processes. 
These experiments are consistent with a role for Zn2+ as a secondary messenger in platelets.  
Increases in [Zn2+]i elevation were modelled using Zn2+ ionophores. Initial experiments were 
performed to investigate the effect of ionophore treatment on platelet behaviour using light 
transmission aggregometry. In these experiments, Zn2+ ionophore treatment resulted in aggregometry 
traces that were consistent with platelet shape change (Figure 5.1). Platelet responses to Cq and Py 
were heterogeneous. Cq induced sub-maximal aggregation whereas Py did not evoke an aggregatory 
response. The differences in responses to the two Zn2+ ionophores suggests differing mechanisms. Cq 
induced a much greater increase in [Zn2+]i than Py (Chapter 4). This could explain the differences in 
ionophore responses, as an increased level of [Zn2+]i in response to Cq correlates with an increased 
aggregation response. Thus, the differing responses induced by Cq and Py could be due to the different 
levels of [Zn2+]i elevation induced by these ionophores. However, as both ionophores have 
approximately the same affinity for Zn2+, other factors may have an effect. These ionophores may 
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interact with platelets in a different manner, for example as their ability to enter platelets may differ, 
the way in which the ionophores enter stores in platelet may also differ. However, the nature of these 
differences requires further investigation.  
 
Increases in [Zn2+]i mediate platelet aggregation  
Cq induced aggregation may have occurred as a result of substantial increases in [Zn2+]i. This 
correlates with recent studies which demonstrated that treatment with Zn2+ at a millimolar range was 
able to gain access to the platelet cytosol to induce full platelet aggregation and activation (Watson 
et al., 2016). Further work from this indicated that sub-activatory micromolar concentrations of Zn2+ 
potentiate agonist-induced activation. Here, increases in [Zn2+]i in response to agonist stimulation 
occur independently of extracellular Zn2+ and therefore rely on the liberation of stores. It is likely that 
the release of intracellular Zn2+ is having a similar effect to Zn2+ entry observed by Watson et al., (2016). 
In this scheme, substantial increases in [Zn2+]i in response to agonist stimulation would initiate platelet 
aggregation, whilst low levels of Zn2+ release would potentiate activatory changes in platelets.  
Experiments were carried out to assess the biological validity of the ionophore-induced 
aggregation, to address concerns that changes in light transmission were not attributable to platelet 
aggregometry but could be an artefact of drug treatment. These experiments utilised the [Zn2+]i 
chelator, TPEN and the αIIbβ3 antagonist, GR144053 (Figure 5.2, 5.4). 
 TPEN abrogated Cq induced aggregatory response (Figure 5.2A), confirming that aggregation 
was a result of elevated [Zn2+]i. Furthermore, TPEN application did not influence the aggregatory 
response induced by the Ca2+ ionophore, A23187, indicating that A23187-induced aggregatory 
responses are not attributable to Zn2+. This is an interesting observation because A23187 has been 
reported to act as both Ca2+ and Zn2+ ionophore (Chapter 4), so a Zn2+-dependent response might have 
been expected. One explanation is that there is a higher concentration of Ca2+ in platelets, compared 
to Zn2+ (resting concentration of Ca2+ in platelets is approximately 100nM, whereas Zn2+ is much lower, 
although is yet to be confirmed (Oliver et al., 1999; Taylor and Pugh, 2016; Watson et al., 2016)), so 
A23187 might be saturated with Ca2+ on application. As Py and Cq are specific to Zn2+, a reciprocal 
saturation with Ca2+ is not possible. 
Pre-treatment of platelets with GR144053 inhibited Cq-induced aggregation. This indicates 
aggregation induced upon elevation of [Zn2+]i is mediated by αIIbβ3. These findings confirm that the 
aggregation trace profile is attributable to aggregation, and not non-specific agglutination. Agglutination has 
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been reported to occur as a result of direct binding of cations to platelet integrins activating the integrin 
directly as opposed to upregulation of the integrin via platelet signalling (Gowland et al., 1969; Watson et 
al., 2016). A23187-induced aggregation was also inhibited by GR144053 which validated the use of the 
antagonist. The data presented here confirm that elevated [Zn2+]i (via Cq) is able to mediate platelet 
aggregation via αIIbβ3, this was also the case with exogenous Zn2+ treatment which induced platelet 
aggregation in recent work (Watson et al., 2016). Furthermore, the use of TPEN abrogated the aggregatory 
response evoked by Cq, thus demonstrating that the Cq induced aggregation via αIIbβ3 is a result of elevated 
[Zn2+]i and not the ionophore itself having a direct effect on the αIIbβ3. Thus, these data (Figure 5.2, 5.4) 
provide evidence showing that the Cq induced aggregation is mediated by αIIbβ3 as a result of [Zn2+]i 
elevation. The mechanisms by which Zn2+ upregulates αIIbβ3 requires further investigation. Such work could 
assist in the development of safer antithrombotics which have lower bleeding risks, which has been an issue 
with current antithrombotics as Abciximab impose high bleeding risks (Makris et al., 2013; Tcheng et al., 
2001).  
The role of [Zn2+]i in platelet aggregation was further examined using flow cytometry. PAC-1 
binding is a measurement of αIIbβ3 activation. Elevation of [Zn2+]i via Cq or Py induced increases in PAC-1 
binding, confirming that [Zn2+]i mediates aggregation via αIIbβ3. Whilst treatment with either ionophore 
resulted in increases in PAC-1 binding; only Cq produced an increase in aggregation (Figure 5.1-5.4). 
PAC-1 binding in response to Cq was higher than that for Py, indicating that αIIbβ3 upregulation did not 
reach a minimal threshold required for aggregation. The level of PAC-1 binding following Cq treatment 
were consistent with the sub-maximal aggregation observed during aggregometry).  
 As expected, A23187 induced a significant increase in PAC-1 binding This is consistent with 
aggregation data (Figures 5.1-2, 5.4), and consistent with previous work (Authi et al., 1993; Brüne and 
Ullrich, 1991; Smith et al., 1992; Varga-Szabo et al., 2009; Verma et al., 2011). Interestingly TPEN 
reduced the level of PAC-1 binding evoked by A23187 although did not influence the level of 
aggregation. it is possible that the level of PAC-1 binding induced by A23187 following TPEN pre-
treatment is enough to evoke the levels of platelet aggregation induced by A23187. Data presented 
in Chapter 4 demonstrated that A23187 treatment resulted in modest increases in [Zn2+]i , thus the 
greater level of PAC-1 binding that was induced by A23187 in the absence of TPEN may be attributable 
to Zn2+. This suggests that although Zn2+ may not significantly influence A23187-induced aggregation, 
it may potentiate A23187 induced αIIbβ3 activation, implying a potential role for Zn2+ in Ca2+-evoked 
activity. This interplay between these cations in platelets warrants further investigation.  
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Chelation of [Zn2+]i via TPEN also significantly reduced the level of PAC-1 binding in response to 
conventional agonists (CRP-XL, U46619 or thrombin), supporting a role for Zn2+ in agonist-evoked platelet 
activation. 
 In summary, these findings demonstrate that elevated [Zn2+]i regulates platelet aggregation, 
supporting a role for Zn2+ as a secondary messenger in platelets. The mechanisms by which Zn2+ 
upregulates αIIbβ3 and induced aggregation is yet to be investigated and provides a platform for future 
work.  
 
Increases in [Zn2+]i induce phosphorylation of platelet proteins  
Elevation of [Zn2+]i using ionophores resulted in increases in tyrosine phosphorylation of 
platelet proteins, which is an acknowledged signalling event that is induced by numerous agonists, 
including thrombin, CRP and exogenous Zn2+ (Watson et al., 2016). This observation further implicates 
elevations of [Zn2+]i results in platelet signalling leading to functional responses. Cq and Py elicited 
similar patterns of tyrosine phosphorylation, although Cq induced greater levels of phosphorylation 
than Py. This may explain differences in the aggregation profiles of these ionophores and is consistent 
with the heterogeneous effects of these reagents on platelet function. A23187 treatment resulted in 
a similar pattern of tyrosine phosphorylation to the Zn2+ ionophores. This may be due to the reason 
that A23187 has been reported to act as both Ca2+ and Zn2+ ionophore (Chapter 4). Thus A3187 may 
be mediating Zn2+-induced as well as Ca2+-induced phosphorylation. Whilst A23187 did not induce 
phosphorylation of proteins which were not apparent with the Zn2+ ionophore treatment, chelation of 
[Zn2+]i resulted in a different pattern of phosphorylation to A23187 stimulation. This further suggests 
that the A23187-induced tyrosine phosphorylation is influenced by [Zn2+]i. However, the difference in 
tyrosine phosphorylation induced by A23187 with TPEN treatment did not correlate with data (Figure 
5.2C, F) showing that TPEN had no influence on A23187 induced aggregation. Thus, these findings 
suggest that A23187 induced aggregation is not attributable to Zn2+. However, since the Zn2+ 
ionophore Cq was able to mediate aggregation, and evoked phosphorylation in a similar manner to 
A23187 , a similar signalling event which occurs by these ionophores, may be the reason as to why Cq 
is able to evoke aggregation.  
 Chelation of [Zn2+]i reduced the level of Cq and Py dependent tyrosine phosphorylation, 
confirming that ionophore-dependent phosphorylation is attributable to Zn2+. Interestingly, chelation 
of [Zn2+]i increased phosphorylation of another high molecular weight protein (approximately 80-90 
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kDa) , possibly reflecting the activity of a phosphatase or kinase that is activated or inhibited 
respectively by Zn2+. The identity of such a kinase or phosphatase is currently unknown. 
These data correlate well with the recent work carried out by Watson et al., (2016), which 
demonstrated that exogenous Zn2+ treatment induced tyrosine phosphorylation. As the pattern of 
phosphorylated protein differed from that induced by conventional agonists, it was concluded that 
tyrosine phosphorylation occurred in a novel manner. In this work pre-treatment with TPEN resulted 
in increased phosphorylation of a high molecular weight protein (approximately 95kDa). As chelation 
of Zn2+ resulted in increases of phosphorylation here, it can be inferred that phosphorylation of this 
protein is under the control of Zn2+-dependent kinases or phosphatases. Published work has shown 
that elevation of [Zn2+]i inhibits specific phosphatases, including SHP-2 and PTEN. In platelets these 
proteins are negative regulator of platelet activation upon GpVI stimulation, with and have IC50s of 1-
2μM and 0.59nM respectively (Haase and Maret, 2005, 2003; Lin et al., 2004; Ma et al., 2012; 
Mazharian et al., 2013; Weng et al., 2010). Thus, elevation of [Zn2+]i to these levels could inhibit these 
phosphatases. This could explain the increase in phosphorylation of proteins following TPEN 
treatment. In this scheme, chelation of Zn2+ would inactivate phosphatases which would then be 
unable to dephosphorylate given proteins. Whether the concentration of [Zn2+]i is able to reach the 
required level to modulate these phosphatases is not yet known. Interestingly, GpVI stimulation 
mediates [Zn2+]i elevation (Chapter 3), suggesting that [Zn2+] may enhance GpVI induced activation by 
inhibiting these phosphates. These findings warrant further investigation and could be carried out in 
more depth in future projects as the primary focus of the investigation. This work from this thesis has 
demonstrated that [Zn2+]i can regulate platelet behaviour and has opened many avenues of research 
to solely investigate each of these behaviours regulated by [Zn2+]i.  
 
Increases in [Zn2+]i mediate platelet shape change  
A significant finding of the experiments performed in this chapter was that platelet shape 
change occurred following [Zn2+]i elevation with the ionophores. This was first observed as a 
downward deflection in aggregation traces and was subsequently investigated using platelet adhesion 
to fibrinogen, and by pharmacological inhibition of cytoskeletal reorganisation. Whilst shape change 
occurred following treatment with both the Zn2+ ionophores; it was more evident following Py 
treatment. Here, shape change did not progress to a full aggregation response. However, it did result 
in the upregulation of αIIbβ3. Previous studies have shown that a large proportion of the αIIbβ3 complex 
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resides in the plasma membrane of resting platelets in association with an intracellular cytoskeletal lattice 
(Fox et al., 1993; Hartwig, 1992). Platelet activation disrupts this cytoskeletal lattice as a result of platelet 
shape change, leading to the disruption of the association between αIIbβ3 and cytoskeletal, which alters the 
state of αIIbβ3 (Bennett et al., 1999). This suggests a mechanism by which Py-induced shape change 
mediates αIIbβ3 upregulation. Cq stimulation resulted in shape change at a lower concentration, with no 
progression to aggregation. Py-induced shape change was biphasic with lower concentrations (30μM 
and 10μM) of Py inducing a greater level of shape change in than high concentration. The reasons for 
different responses to the ionophores is not clear. Both ionophores are specific for Zn2+, and in neither 
case is Zn2+ included with the reagent. Possible suggestions relate the relative penetration of the 
ionophores into the platelet cytosols, as mentioned earlier. Further work will be required to determine 
the reasons for this.  
Validation and investigation of the mechanism of ionophore-induced shape change in 
platelets were further explored. An important role for Zn2+ in regulating cytoskeletal changes has also 
been shown in nucleated cells (Rudolf et al., 2008a). In HeLa and prostate cancer (PC)-3 cells, Zn2+ 
regulates the actin cytoskeleton, cellular migration and focal adhesion dynamics (Li et al., 2016a). The 
chelation of Zn2+ in these cells results in the loss of filopodia formation whereas application of the Zn2+ 
ionophore enabled increases in filopodia formation (Li et al., 2016a). Studies on neuronal cells show 
that Zn2+ also regulates the polymerisation for tubulin which is required the transport of transcription 
factors in these cells (Mackenzie and Oteiza, 2007; Perrin et al., 2017a). 
 In addition to these studies illustrating the role of Zn2+ in regulating cytoskeleton 
rearrangement in nucleated cells, further work carried out in this chapter showed that the chelation 
of [Zn2+]i resulted in a loss of attachment, and cellular spread of mouse embryonic fibroblast (MEF) 
cells (Figure 5.11). Quantification of MEF spreading (Figure 5.11) was problematic, due to varied 
structures and numbers of cells that were observed. Furthermore, the staining of actin, via the stain, 
Phalloidin-iFluor 594 , was also not an appropriate method to accurately quantify these images, as the 
purpose of these experiments was to assess cellular spread (i.e. cytoskeletal changes in cells that 
results in this spread), as the cells spread, the brightness of the stain dispersed and was brighter on 
cells which had not fully spread, as illustrated by Figure 5.11). Therefore, the subjective analysis was 
sufficient for these experiments, as clear differences were observed upon TPEN treatment (Figure 
5.12). TPEN treatment inhibited cellular attachment as the number of cells that adhered to the 
coverslips were very minimal relative to that seen when TPEN was absent, and cellular spread was 
also not apparent with TPEN treatment. This may have been due to the prevention of cells adhering 
thus not undergoing spreading on the coverslips. The mechanisms for this are yet to be confirmed. 
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However, this finding demonstrates the role that Zn2+ may have on regulating MEF cell surface 
adhesion and spreading. Integrins which are cell surface adhesion receptors mediate adhesion upon 
activation which results in the integrin to switch to their high-affinity state (Harburger and 
Calderwood, 2009). Inside out signalling in MEF cells upregulates the integrins from their low to high 
affinity (Calderwood, 2004)results as a result of stimulation occurring once in contact with the 
coverslips or adjacent cells in these experiments , which as shown in the absence of TPEN resulted in 
adhesion and spread (Figure 5.11). Since chelation of [Zn2+]i in MEF prevented adhesion, it can be 
suggested that Zn2+ may be regulating the affinity state of integrins in these cells by influencing inside 
out signalling. These findings outline the importance of Zn2+ on regulating cytoskeletal changes in 
other cells types, thus indicating the likelihood of Zn2+ also mediating cytoskeletal changes in platelets. 
Therefore, warranting the further exploration of Zn2+ in platelet shape change.   
Zn2+ ionophore-induced shape change was abrogated following Cyt D treatment. This validates 
the downward deflection on the aggregation traces induced by the Zn2+ ionophores as an indication 
of biologically relevant shape change, as opposed to a non-specific chemical response. Further 
experiments were carried out to assess the influence of [Zn2+]i on the signalling pathways that induce 
platelet shape change. Previous studies have shown that the specific signalling pathways leading to 
platelet shape change are primarily Ca2+ dependent and involve Ca2+/calmodulin, myosin light chain 
kinase (MLCK) and RhoA-p160 ROCK. Platelet shape change is also known to occur in a Ca2+ 
independent manner, where ROCK either phosphorylates MLC and/or enhances MLC phosphorylation 
by inhibiting MLC phosphatases (MLC-P) (Paul et al., 1999; Shin et al., 2017). In order to investigate 
the role of increased [Zn2+]i in shape change, the influence of these proteins on ionophore-induced 
events was investigated. Inhibition of MLCK and p160 ROCK via the inhibitors ML7 and Y-27632 
respectively resulted in similar levels of inhibition of shape change in response to both Zn2+ ionophores 
tested. Conversely, inhibition of calmodulin via W-7 did not significantly influence Zn2+ ionophore-
induced shape change. In contrast, shape change in response to A23817 was sensitive to Y-27632, W-
7 and ML7 treatment. This is consistent with a role for Zn2+-induced shape change that is independent 
of Ca2+ dependent signalling pathways. Furthermore, these findings indicated that [Zn2+]i induced 
shape change influences the signalling pathways that involve both direct and indirect phosphorylation 
of MLC, which is mediated by p160 ROCK and MLCK, as illustrated by the speculative signalling 
pathway (Figure 5.16) drawn from these findings.  
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This work provides the first reports demonstrating a role for Zn2+ in regulating p160 ROCK induced 
platelet shape change. Previous studies have shown that Rho-binding domain of p160 ROCK (which 
enables association with RhoA and p160 ROCK) consists of a cysteine-rich Zn2+ finger-like motif, 
although the contribution of this motif to p160ROCK activity has not been confirmed. Previous work 
that investigated the role for Zn2+ in regulating hypoxia-induced contractile events in pulmonary 
endothelium showed a role for Zn2+ in regulating hypoxia-induced MLC phosphorylation by inhibiting 
the MLC phosphatase MYPT1 (myosin phosphatase target subunit 1) (Bernal et al., 2011). This was 
shown to be dependant on ROCK such as ROCK1 (Rho-associated binding protein kinase 1), which 
similar to p160 ROCK consists of a cysteine-rich Zn2+ binding motif, however the relationship between 
ROCK induced cytoskeletal rearrangement and Zn2+ has not been investigated in this study (Bernal et 
al., 2011; Leung et al., 1996). These studies implicate the potential mechanism by which Zn2+ may 
evoke p160 induced platelet shape change, as Zn2+ may regulate p160 ROCK activity by binding to the 
Zn2+ binding motif found within this kinase. The relationship between p160 ROCK signalling and Zn2+ 
serves as a novel signalling pathway to investigate in platelets  
  
 This putative Zn2+-dependent shape changing signalling pathway illustrated by Figure 5.16 
was further explored by assessing levels of MLC phosphorylation in response to ionophore treatment 
Figure 5.16. Schematic of signalling pathways 
involved in Zn2+ induced shape change in platelets. 
Elevation of [Zn2+]i may mediate the association of 
RhoA and p160 ROCK, resulting in direct and indirect 
activation of myosin light chain (MLC), by either 
directly inducing phosphorylation of the MLC, or by 
inhibiting MLC-P. [Zn2+]i may also mediate the 
activation of myosin light chain kinase (MLCK) which 
can then phosphorylate MLC to its active form 
phosphorylated-MLC (P-MLC). P-MLC can then evoke 
actin rearrangement and induce platelet shape change. 
The dashed arrow represent an inhibitory effect whilst 
the solid arrows represent a stimulatory effect. 
157 
 
(Figure 5.10). Phosphorylation of ser157 of MLC, mediated by MLCK or RhoA/ROCK, is a major step in 
the shape changing signalling pathway. Initial experiments demonstrated that treatment with Zn2+ 
ionophores resulted in significant increases in P-MLC. This phosphorylation was significantly reduced 
upon [Zn2+]i chelation, which confirms that the increases in P-MLC evoked by the ionophores were 
attributable to Zn2+. Furthermore, application of the inhibitors of MLCK and p160 ROCK also 
significantly reduced Zn2+-ionophore-mediated MLC phosphorylation whereas inhibition of 
calmodulin had no effect. This correlates with data from aggregometry experiments using these 
inhibitors. These data provide further evidence to indicate that [Zn2+]i induced platelet shape change 
is independent of Ca2+/Calmodulin and mediates shape change via the p160 ROCK pathway. This is in 
contrast to A23187 induced phosphorylation of MLC, which was abrogated by ML7 (MLCK inhibitor) 
or W-7 (calmodulin antagonist). Interestingly inhibition of P160 ROCK reduced the levels of P-MLC 
induced by A23187, however, this level of P-MLC was still significantly higher than the vehicle control 
(Figure 5.9E). This suggested that Ca2+ dependent and independent pathways synergise to enable 
efficient platelet shape change. Conversely, published work has shown that Zn2+ can occupy Ca2+ 
binding sites on calmodulin (Hathaway and Adelstein, 1979; Mills and Johnson, 1985). Calmodulin 
consists of 2 globular domains, each with EF-hand motifs. Ca2+ binding to the EF-hand domains of 
calmodulin induces significant conformational changes which result in calmodulin induced signal 
transduction (Warren et al., 2007a). On the basis of these models, it has been proposed that Zn2+ plays 
an intermediate role in calmodulin induces signal transductions (Warren et al., 2007a). These concepts 
have been tested in the experiments described in this chapter. The work carried out in this chapter 
does not correlate with previous work stated above that suggests Zn2+ could mediate calmodulin 
induced signalling. As inhibition of calmodulin (which is a major mediator of Ca2+ dependent shape 
change (Paul et al., 1999)) had no significant influence on the shape change response evoked by [Zn2+]i 
elevation.  
Increases in [Zn2+]i did not result in phosphorylation of VASP. This indicates that [Zn2+]i 
elevation does not influence the activity of cyclic nucleotide-dependent kinases such as PKG or PKA, 
which play inhibitory roles in platelet shape change (Aburima et al., 2013). Thus [Zn2+]i is not a negative 
regulator of cytoskeletal rearrangements but acts in a positive manner to initiate shape change. 
Chelation of [Zn2+] also abrogated platelet spreading on fibrinogen, providing further evidence 
of a link between Zn2+ and regulation of the platelet cytoskeleton. The shape change observed here 
was as a result of outside-in signalling, due to the platelet shape change occurring in response to 
binding to fibrinogen via αIIbβ3 (illustrated in Figure 1.7, Chapter 1). Therefore these findings 
demonstrate that chelation of [Zn2+]I inhibit shape change occurring upon outside-in signalling, 
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although the exact mechanisms of how this is caused require further work. Furthermore, this finding 
also suggested that perhaps Zn2+ may be influencing the binding of αIIbβ3 to fibrinogen by disrupting 
the inside-out signalling that enables αIIbβ3 to switch to its high-affinity state which is essential for 
enabling fibrinogen to bind to αIIbβ3 (Figure 1.6, Chapter 1). This suggests that Zn2+ may play a key role 
in regulating the upregulation of αIIbβ3 via inside-out signalling, further outlining the importance that 
Zn2+ may have on platelet activatory shape change. These findings require further work and open an 
avenue to explore in terms of platelet shape change that occurs via outside-in signalling, which may 
be significantly influenced by Zn2+ as the data from this work suggests.  
 In summary, these data demonstrated that [Zn2+]i may play a major role in mediating platelet 
shape change and provide further evidence to indicate its modulatory role as a secondary messenger 
in platelets.  
 
Increases in [Zn2+]i induce platelet degranulation  
From these data discussed above, it can be concluded that agonist-evoked increases in [Zn2+]i 
are able to regulate or initiate platelet shape change. As shape change is linked to aggregation and 
granule release, further experiments were performed to better understand the effects of increasing 
platelet [Zn2+]i on activatory processes in addition to aggregation, tyrosine phosphorylation and shape 
change. 
Experiments were carried out to assess the effect of [Zn2+]i elevation on dense and alpha-
granule release. Interestingly [Zn2+]i elevation resulted in the externalisation of CD63, but not CD62P, 
supporting a role for Zn2+ in regulating dense, but not α granule release (Figure 5.12). Furthermore, 
chelation of [Zn2+]i using TPEN inhibited agonist-induced dense granule release but not α-granule 
release (Figure 5.13). This provides evidence for differential regulation of release of the two granule 
subtypes. The signalling pathways and mechanism which contribute to the differential release of α 
and dense granules are poorly understood. Previous work has shown that granule secretion is 
regulated by cytoskeletal rearrangement, which occurs as a result of platelet activation. For example, 
inhibition of Rho kinases inhibits granule secretion (Suzuki et al., 1999; Watanabe et al., 2001). Thus 
Zn2+ induced shape change may play a role in regulating dense granule release upon [Zn2+]i elevation. 
This is yet to be investigated and would be interesting to explore further as this potential relationship 
between Zn2+ induced shape change, and granule release provides a novel approach to understanding 
granule release regulation. 
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PS exposure increases in response to [Zn2+]i elevation  
Elevation of [Zn2+]i via ionophore treatment also resulted in increases in PS exposure and the 
development of a pro-coagulant phenotype, which is an important process in platelet activation. 
Interestingly the percentage of platelets that expresses PS increased were much higher following 
treatment with the Zn2+ ionophores, in comparison to that evoked by conventional agonist (CRP-XL, 
thrombin or U46619, Figure 5.14-15). This correlates with previous data that show greater levels of 
[Zn2+]i following ionophore treatment than for conventional agonists (Chapter 3-4). Given that only a 
subset of platelets adopts a pro-coagulant phenotype following agonist stimulation, this observation 
implicates [Zn2+]i elevation as a potential mechanism that initiates the procoagulant pathway. Whilst, 
the mechanisms by which Zn2+ induced PS exposure is not fully understood, A23187 is thought to 
induce significant increases in PS exposure as a result of elevated [Ca2+]i. [Ca2+]i influences PS exposure 
by mediating the translocation of PS from the inner leaflet of the membrane to the outer leaflet of 
the membrane via the activation of the Ca2+ dependent scramblase protein (Figure 1.9, Chapter 1). 
Interestingly [Zn2+]i chelation via TPEN also inhibited A23187-induced PS exposure suggesting that 
[Ca2+]i mediated PS exposure may depend on basal [Zn2+]i., PS exposure in platelets is mediated by 
caspase and caspase-independent mechanisms (Schoenwaelder et al., 2009; van Kruchten et al., 
2013). Inhibition of caspases reduces the level of PS exposure induced by A23187 or conventional 
agonists (Cohen et al., 2004a; Schoenwaelder et al., 2009). In the experiments described here, 
inhibition of caspases with the inhibitor Z-VAD partially reduced PS exposure implicating caspases in 
[Zn2+]i-induced PS exposure. These data further outline the importance [Zn2+]i may play in modulating 
platelet behaviour and provides further evidence to suggest that Zn2+ is a secondary messenger in 
platelets. 
 
5.4 Conclusion 
In conclusion, the work carried out in this chapter provides evidence to support the hypothesis 
of this thesis that Zn2+ is a secondary messenger in platelets. [Zn2+]i elevation was found to evoke a 
functional role in many activatory processes including aggregation, tyrosine phosphorylation, shape 
change, upregulation of αIIbβ3, dense granule release and PS exposure. Thus, [Zn2+]i may have novel 
roles in the signalling pathways in platelets that are consistent with that of the secondary messenger. 
The mechanisms by which [Zn2+]i mediates these activatory processes are not yet known, however, 
this work provides the first report outlining the importance of Zn2+ in platelet activity.  
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The work carried out in the previous chapters demonstrated that [Zn2+]i elevation occurs upon 
agonist stimulation in a redox-sensitive manner (Chapter 3) and could also be modelled via ionophores 
in a non-redox sensitive manner (Chapter 4). Therefore, the work carried out in Chapter 3, 4 and this 
chapter provides the first reports demonstrating that [Zn2+]i elevation can occur upon activation and 
also be modelled, which then results in the modulation of platelet activity. This is consistent with the 
definition of a secondary messenger which is defined as a molecule that is intracellularly modulated 
in response to extracellular stimuli and can then induce appropriate intracellular signalling events with 
regards to the extracellular stimuli, resulting in physiological changes in the cell. 
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Chapter 6  
6.0 Investigation of the signalling pathways which mediate 
intracellular Zn2+ release 
6.1 Background 
The work detailed in Chapters 3 and 4 demonstrates the presence of Zn2+ storage mechanisms 
in platelets, which act to release Zn2+ into the platelet cytosol following stimulation with conventional 
platelet agonists. This results in significant elevations of [Zn2+]i. These elevations are redox sensitive, 
indicating a possible mechanism involving thiol-containing storage proteins. The work described in 
Chapter 4 demonstrated that increases in platelet [Zn2+]i could be modelled using Zn2+ ionophores, in 
a similar manner to the Ca2+ ionophore, A23187 which has been widely used to explore Ca2+ signalling 
in platelets. Data from this chapter demonstrated the presence of Zn2+ stores which were accessible 
using Zn ionophores. Other potential mechanisms that could contribute to [Zn2+]i increases include 
release from the dense tubular system via the inositol-1,4,5-trisphosphate receptor (IP3R), in a similar 
manner to Ca2+ (Figure 1.10). The DTS may also store Zn2+ in addition to Ca2+, although this yet to be 
investigated. 
In nucleated cells, ZIP7 associates with Ca2+ store membranes such as the DTS (Hogstrand et 
al., 2013; Taylor et al., 2008) where it mediates Zn2+ release in response to signalling in a similar 
manner to PLC/IP3R mediated Ca2+ release, and it may be performing a similar role in platelets (Taylor 
and Pugh, 2016). Most notably previous work illustrating ZIP7 mediated Zn2+ release from stores within 
nucleated cells is consistent with Zn2+ acting as a secondary messenger in platelets. Thus investigation 
of ZIP7 [which has been found to be expressed in platelets (Burkhart et al., 2012)] in platelets would 
provide further evidence to strengthen the hypothesis of this thesis that Zn2+ is a secondary messenger 
in platelets.  
The observation of agonist-evoked increases of both [Zn2+]i and [Ca2+]i raises the possibility of 
functional interplay between these cations. Zn2+ and Ca2+ associate with similar proteins via the same 
motif. For example, calmodulin has been shown to bind to Zn2+ at the same EF-hand motifs to which 
Ca2+ binds(Mills and Johnson, 1985; Schumacher et al., 2004; Warren et al., 2007). Interestingly these 
studies indicate that Zn2+ may bind to calmodulin as an intermediate step (inducing structural changes) 
before the binding of Ca2+, suggesting that signalling via calmodulin may require Zn2+ to play an 
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intermediate role (Warren et al., 2007b). Other calcium-binding proteins which contain EF-hand 
motifs include calcineurin B, CIB (Ca2+ and integrin binding protein), and S100 family members which 
are involved in Ca2+-dependent signal transduction pathways, and are also expressed in platelets (Naik 
et al., 1997; Y. Wang et al., 2014). Therefore Zn2+ may be able to bind to the EF-hand motifs to these 
Ca2+ binding proteins, influencing Ca2+ transduction pathways(Lood et al., 2016). Previous studies have 
shown that Zn2+ binds to S100 proteins (Nakayama and Kretsinger, 1994; Schäfer et al., 2000). Similarly 
to calmodulin Zn2+ has also been suggested to play an intermediate role in mediating the S100 function 
by evoking an increase in affinity between S100 and Ca2+ (via structural changes)(Baudier et al., 1986). 
Furthermore in nucleated cells, Zn2+ has been shown to compete with Ca2+ for a range of bindings 
sites, for example in mitochondrial Ca2+ transporters and tubulin (Jemiolo and Grisham, 1982; Jeng et 
al., 1978). These studies provide evidence to suggest that Zn2+ influences Ca2+ signalling. This may also 
apply to platelets and warrants investigation, as the interplay between these two cations may be a 
major feature of platelet activation regulation.  
6.1.1 Aims 
Experiments discussed in previous chapters showed that both [Zn2+]i + and Ca2+ are elevated 
upon platelet activation. As both cations bind to and regulate similar proteins, there is the potential 
for the actions of the two cations to synergise in platelets. The work described in this chapter was 
designed to investigate the interplay of Zn2+ and Ca2+, and to investigate the potential storage 
mechanisms which these cations might share. 
6.1.2 Methods 
A range of methodologies were employed in this chapter, and the specific application of 
reagants are discussed in depth in the results section accordingly. Here a general overview of the 
methods employed in this chapter will be discussed. 
The release of [Zn2+]i and [Ca2+]i was measured in washed platelet suspensions using 
fluorometry following staining with the [Zn2+]i and [Ca2+]i probe, Fluozin-3 (FZ-3) and Fluo-4 (FL-4), 
respectively (section 2.4, Chapter 2). 
The IP3R antagonist, 2-aminoethoxydiphenyl borate (2-APB) was employed to assess cation 
mobilisation from the dense tubular system upon agonist stimulation. The working concentration of 
2-APB that was employed by previous studies to antagonise IP3R was 100μM. Thus similar 
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concentrations were employed in the experiments described in this chapter (Diver et al., 2001; Djillani 
et al., 2014).  
Western blotting was used to assess changes in the phosphorylation status of ZIP7 using the 
anti-phospho-ZIP7 (Ser275/276) antibody (section 2.7, Chapter 2). ZIP7 activity was also assessed 
using CX-4955 which is an inhibitor of the protein kinase CK2, which is responsible for inducing ZIP7 
activation (Taylor et al., 2012). Previous work has determined that 10µM of CX-4955 is sufficient to 
inhibit protein kinase CK2 activity in platelets (Ampofo et al., 2015). A similar concentration was 
used here. 
Store-operated cation entry was measured using real-time flow cytometry (section 2.10, 
Chapter 2). The sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) inhibitor thapsigargin (TG) 
was used to evoke the store-operated cation entry response. 1μM of TG has been widely used in 
previous work thus similar concentrations were also used here (Authi et al., 1993; Tepel et al., 1994; 
Vostal and Shafer, 1996) 
  
6.2 Results 
6.2.1 Agonist-induced [Zn2+]i elevation is mediated by Ca2+ store 
mobilisation  
Experiments using the IP3R antagonist 2-APB were performed to investigate whether agonist-
evoked elevation of [Zn2+]i occur as a result of release via IP3R, in a similar manner to agonist-evoked 
[Ca2+]i release.  
[Zn2+]i release was assessed using fluorometry FZ-3. Data from chapter 3 demonstrated that 
stimulation with CRP-XL and U46619, but not thrombin, resulted in significant increases in FZ-3 
fluorescence, consistent with elevated [Zn2+]i. Pre-treatment of washed platelets with 2-APB (100μM) 
significantly reduced the levels of FZ-3 fluorescence in response to CRP-XL (1μg/mL) or U46619 (10μM) 
throughout the duration of the experiment (Figure 6.1A). The FZ-3 F/F0 in response to CRP-XL (1μg/ml) 
after 6mins was reduced from 2.2±0.2 to 1.5±0.1 upon 2-APB pre-treatment (p<0.05, Figure 6.1A). The 
FZ-3 fluorescence in response to CRP-XL in 2-APB pre-treated platelets was significantly higher than 
the vehicle treatment in the absence and presence of 2-APB where FZ-3 F/F0 values were 1.01±0.5 and 
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1.0±0.1, respectively (p<0.05, Figure 6.1A). This suggests that CRP-XL-evoked increases in [Zn2+]i is 
potentially mediated by IP3R activity.  
 
 
Figure 6.1. 2-APB treatment inhibits agonist-evoked increases in FZ-3 fluorescence. Fluozin-3 (FZ-3)-labelled washed human 
platelets were pre-treated with the IP3R antagonist, 2-APB, before being stimulated by CRP-XL (A), U46619 (B) or Thrombin 
(C) and FZ-3 fluctuations were recorded over six minutes using fluorometry. A) Stimulation with CRP-XL in platelets 
pretreated with vehicle control ( ○ 1μg/ml), 2-APB (■, 100µM), or pretreated with 2-APB (100µM) in the absence of 
stimulation (●). Vehicle control (DMSO, ▲). B) Stimulation with U46619 (10µM) in platelets pretreated with vehicle control 
(○, 1μg/ml), 2-APB (■, 100µM), or pretreated with 2-APB (100µM) in the absence of stimulation (●).Vehicle control (DMSO, 
▲). C) Stimulation with thrombin (1U/mL) in platelets pretreated with vehicle control (○, 1μg/ml), 2-APB (■, 100µM), or 
pretreated with 2-APB (100µM) in the absence of stimulation (●).Vehicle control (DMSO, ▲). Data are mean±standard error 
of mean (SEM) from 6 independent experiments Significance is denoted as *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
Similarly, upon U46619 (10µM) stimulation, FZ-3 F/F0 after 6mins was reduced from 1.49±0.03 
to 1.19±0.01 in 2-APB pre-treated platelets (p<0.05, Figure 6.1B). This was significantly higher than 
the vehicle treatment in the presence and absence of 2-APB (0.94±0.06 and 1.01±0.04, respectively, 
p<0.05, Figure 6.1B). Therefore, TP receptor engagement leading to increases in [Zn2+]i is mediated by 
IP3R activity. As expected, Thrombin stimulation did not result in fluctuations of Fz-3 fluorescence.  
These findings (Figure 6.1A) indicate that agonist-evoked [Zn2+]i increase is mediated by a 2-
APB-sensitive route, most likely involving the activation of IP3R. This implies that Zn2+ is also present 
alongside Ca2+ within the DTS and may perhaps be co-released upon activation. Alternatively, Ca2+ 
release may be required to act a prerequisite for Zn2+ release from alternative stores. Further work 
would need to be carried out to explore this potential mechanism of [Zn2+] elevation  
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Fluctuations in FL-4 fluorescence following 2-APB treatment were also assessed primarily to 
validate the use of 2-APB as an inhibitor of IP3R. Pre-treatment with 2-APB (100μΜ) abolished 
increases in Fluo-4 fluorescence induced by the agonists (Figure 6.2). 
 
Figure 6.2. 2-APB treatment inhibits agonist-evoked increases in FL-4 fluorescence. Fluo-4 (FL-4)-labelled washed human 
platelets were pre-treated with the IP3R antagonist, 2-APB, before being stimulated by CRP-XL (A), U46619 (B) or Thrombin 
(C) and FZ-3 fluctuations were recorded over six minutes using fluorometry. A) Stimulation with CRP-XL in platelets 
pretreated with vehicle control ( ○ 1μg/ml), 2-APB (■, 100µM), or pretreated with 2-APB (100µM) in the absence of 
stimulation (●).Vehicle control (DMSO, ▲). B) Stimulation with U46619 (10µM) in platelets pretreated with vehicle control 
(○, 1μg/ml), 2-APB (■, 100µM), or pretreated with 2-APB (100µM) in the absence of stimulation (●).Vehicle control (DMSO, 
▲). C) Stimulation with thrombin (1U/mL) in platelets pretreated with vehicle control (○, 1μg/ml), 2-APB (■, 100µM), or 
pretreated with 2-APB (100µM) in the absence of stimulation (●).Vehicle control (DMSO, ▲). Data are mean±standard error 
of mean (SEM) from 6 independent experiments Significance is denoted as *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
The FL-4 F/F0 after 6mins in response to CRP-XL (1μg/ml) was abrogated from 1.69±0.07 to 
1.07±0.04 upon pre-treatment with 2-APB (p<0.0001, Figure 6.2A). This did not significantly differ 
from vehicle treatment (DMSO) in 2-APB treated, and untreated platelets (1.08±0.04 and 1.03±0.07, 
respectively, p>0.05, ns, Figure 6.2A).  
Upon U46619 stimulation (10µM), FL-4 F/F0 after 6mins was also abrogated from 1.58±0.04 
to 1.15±0.04 in 2-APB-treated platelets (p<0.05, Figure 6.2B). This also did not differ from the vehicle 
control 2-APB treated and untreated platelets (1.10±0.01, respectively p>0.05, ns, Figure 6.2B). 
FL-4 F/F0 following thrombin (1U/mL) stimulation for 6mins was also abrogated from 3.9±0.5 
to 1.2±0.1 in 2-ABP-pretreated platelets (p<0.0001,Figure 6.2C) compared to 1.1±0.1 for the vehicle 
control (p<0.0001, Figure 6.2C). The final FL-4 F/F0 induced by thrombin on 2-APB-pre-treated 
platelets also did not significantly differ to the vehicle control in 2-APB treated and untreated platelets 
(1.1±0.1 and 1.0±0.1 respectively, p>0.05, ns, Figure 6.2B). In demonstrating 2-APB-dependent 
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reductions in agonist-evoked FL-4 fluorescence, these data validate the use of 2-APB as an IP3R 
antagonist  
The data described above indicate that [Zn2+]i may be mobilised from the dense tubular system 
in a similar manner to Ca2+. Inhibition of IP3R did not completely abrogate agonist-induced increases 
in FZ-3 fluorescence. This is consistent with a more substantial role for redox-dependent mechanisms 
in Zn2+ release. The demonstration of two potential 2-APB and redox-sensitive release routes indicates 
that at least two mechanisms are responsible for regulating increases in [Zn2+]i. It is possible that both 
vesicular- and protein-based Zn2+ stores exist and are accessible upon agonist stimulation. Accessibility 
may be dependent on heterogeneous signalling. To investigate this, potential Zn2+-release 
mechanisms were investigated further. 
 
6.2.2 CK2 induces intracellular Zn2+ signalling via phosphorylation of 
the Zn2+ channel ZIP7 
The release of [Zn2+]i from 2-APB-sensitive stores was further investigated. Whilst it is well 
documented that IP3R mediates [Ca2+]i release from the DTS upon activation (Figure 1.10, Chapter 1), 
the release of Zn2+ from this store is yet to be determined. A similar mechanism to IP3R mediated 
[Ca2+]i release in platelets may also be apparent for [Zn2+]i,allowing co-release of Zn2+ with Ca2+ during 
activation. Whether Zn2+ release occurs via IP3R is unknown. Other potential candidates for mediating 
Zn2+ release from the DTS include the Zn2+ transporter ZIP7 which is present in the platelet proteome 
although its expression in platelets has yet to be confirmed (Burkhart et al., 2012).  
Phosphorylation of ZIP7 as demonstrated in nucleated cells (such as breast cancer cells) is 
required to enable activation to drive Zn2+ release from intracellular stores (Taylor et al., 2008). 
Phosphorylation is mediated by protein kinase CK2 (CK2) which phosphorylates Ser275/276. Platelet CK2 
activity has been implicated in thrombus formation, and also in mediating platelet interactions with 
platelets and other vascular cells types (Ampofo et al., 2015). Thus a potential mechanism for Zn2+ 
release may involve phosphorylation of ZIP7 by CK2. Experiments were performed to investigate the 
expression of ZIP7, and the roles of CK2 and ZIP7 in mediating [Zn2+]i release upon agonist stimulation. 
The role of ZIP7 in this agonist-induced [Zn2+]i elevation was initially assessed by examining 
changes in the phosphorylation state of ZIP7. Due to there being no specific, commercially available 
ZIP7 inhibitors, pharmacological investigation of ZIP7 activity is not possible. Therefore CK2 was 
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targetted to assess ZIP7 activity. The widely used specific inhibitor of CK2, CX-4945 was employed to 
assess the role of CK2 in ZIP7 phosphorylation in platelets. As previous work determined that 10µM 
was sufficient to inhibit CK2 activity in platelets, a similar concentration was used here (Ampofo et al., 
2015). 
Western blotting of platelet lysates with anti-phospho-ZIP7 antibodies revealed a protein at 
48kDa, consistent in size with phosphorylated ZIP7. Upon stimulation of platelets with CRP-XL 
(1µg/mL), the intensity of this band increase, in a manner consistent with increased 
phosphorylation. CRP-XL-mediated ZIP7 phosphorylation was significantly higher than vehicle 
treatment (0.40±0.05 and 0.16±0.01 respectively, p<0.01, Figure 6.3). 
This phosphorylation was significantly reduced in 2-APB treated platelets (from 0.40±0.05 to 
0.18±0.02 , p<0.01, Figure 6.3A). Interestingly, U46619 treatment did not result in significant increases 
in ZIP7 phosphorylation, indicating that U46619-induced [Zn2+]i elevation does not result in ZIP7 
activation. The level of phosphorylation induced by the U46619 (10μΜ) in the presence and absence 
of 2-APB (10μΜ) was 0.15±0.03  and 0.12±0.01, respectively (p>0.05, ns, Figure 6.3A). This data 
correlates CRP-XL induced [Zn2+]i increases with ZIP7 activity, and a reliance on IP3R signalling.  
 
Figure 6.3. ZIP7 phosphorylation occurs in response to platelet stimulation with CRP-XL, but not U46619, which is 
abrogated by CX-4945. Representative Western blots and quantification showing changes in ZIP7 phosphorylation in 
untreated platelets (A) or in CX-4945 pre-treatment platelets (B), following stimulation for 15mins with CRP-XL (1μg/ml) 
(U46619 (10µM)or the vehicle (DMSO) in the absence and presence of 2-APB (30μΜ). CRP-XL induced significant increases 
in ZIP7 phosphorylation which was abrogated with CX-4945 (10μM) pre-treatment. B-actin was used as a loading control. 
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The level of B-actin did not vary with drug treatment (not shown). Blots and quantification are representative and 
means±SEM of 4 experiments. Significance is denoted as *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
The level of ZIP7 phosphorylation in response to CRP-XL (1μg/ml) was abrogated from 
0.40±0.05 to 0.08±0.01 in CX-4945 pre-treated platelets (p<0.01, Figure 6.3A-B). This did not differ to 
that induced by the vehicle control (0.07±0.01 ,p>0.05, ns, Figure 6.3B). Furthermore, no ZIP7 
phosphorylation was observed in CX-4945 pre-treatment platelets relative to vehicle treatment 
(Figure 6.3B) 
These data demonstrate that agonist-evoked activation mediates the phosphorylation of ZIP7 
in platelets. CRP-XL, but not U46619 induced significant levels of phosphorylation. This correlates with 
the observation that CRP-XL induces significantly higher [Zn2+]i elevations than U46619 (Chapter 3). 
Thus the greater level of [Zn2+]i increase following CRP-XL activation may be attributable to ZIP7 
activation and subsequent [Zn2+]i release from intracellular stores.  
Further experiments were performed to assess the role of ZIP7 activation on agonist-mediated 
[Zn2+]i elevation. CX-4945 was again employed to modulate ZIP7 activity. [Zn2+]i fluctuations in FZ-3-
loaded platelets were measured using fluorometry. Pretreatment of washed platelet suspensions with 
CX-4945 (10μM) significantly reduced increases in FZ-3 fluorescence induced by CRP-XL (1μg/ml, 
Figure 6.4A). FZ-3 F/F0 values after 6mins in response to stimulation by CRP-XL (1μg/ml) were reduced 
from 2.2±0.2 to 1.40±0.03 upon pre-treatment with CX-4945 (10µM, p<0.0001, Figure 6.4A). 
Interestingly, in a similar manner to 2-APB pre-treatmentwith CX-4945 did not completely abrogate 
increases in CRP-XL-induced FZ-3 fluorescence. The FZ-3 F/F0 in response to CRP-XL was higher than 
the vehicle control (1.0±0.1, p<0.01, Figure 6.4A). No significant differences in FZ-3 fluctuations were 
shown in CX-4945 treated or untreated platelets following U46619 (10μΜ) stimulation. Respective FZ-
3 fluorescence values were 1.57±0.02, and 1.51±0.06 respectively (p>0.05, ns, Figure 6.4B). These FZ-
3 F/F0 values were significantly higher than that induced by the vehicle controls (in the presence and 
absence of CX-4945) which were 1.01±0.01 and 1.0±0.01 respectively (p<0.0001. Figure 6.4B). Thus, 
TP signalling may not mediate [Zn2+]i elevation via ZIP7.  
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Figure 6.4. CX-4945 treatment inhibits agonist evoked increases in FZ-3 fluorescence. Fluozin-3 (FZ-3)-labelled washed 
human platelets were stimulated by 1μg/ml of CRP-XL (A) or 10μM U46619 1(B) following pre-treatment  with vehicle (DMSO, 
○, CX-4945 (10µM, ■), or without agonist stimulation (DMSO, ▲), or with CX-4945 pretreatment in the absence of agonist 
stimulation (▼). [Zn2+]i fluctuations were recorded over 6 minutes using fluorometry. CX-4945 treatment inhibited CRP-XL 
evoked increases in FZ-3 fluorescence but did not influence U46619 induced increases in FZ-3 fluorescence. Results are 
representative and means±SEM of 6 experiments. Significance is denoted as **** (p<0.00010, *** (p<0.001), ** (p<0.01) or 
* (p<0.05). 
 
These data are consistent with data described in Figure 6.3, and both correlate CK2 with CRP-
XL-mediated ZIP7 phosphorylation and subsequent increases in Zn2+ fluorescence. U46619 treatment 
did not increase ZIP7 phosphorylation (Figure 6.3) and was unresponsive to CX-4945 suggesting that 
U46619 mediated Zn2+ elevations occurs via a different mechanism, and are not mediated by canonical 
membrane store release. Other interpretations are possible. For example,as mentioned earlier the 
increase in [Zn2+]i (measured by FZ-3 increases) following U46619 is modest compared to CRP-XL (as 
shown in Chapter 3, and in Figure 6.4 above). Thus CRP-XL, but not U46619, induced [Zn2+]i elevation 
may be attributable to ZIP7 mediated store release. This may explain the lower [Zn2+]i increase in 
response to U46619 stimulation. 
Further experiments were performed to investigate the influence of increased [Ca2+]i on ZIP7 
phosphorylation and CK2 activity. Pre-treatment of washed platelet suspensions with CX-4945 (10μM, 
CK2 inhibitor) had no influence on the agonist-induced [Ca2+]i release in Fluo-4 (FL-4) loaded platelets. 
The FL-4 F/F0 induced by CRP-XL (1μg/ml) after 6 mins were 1.97±0.10 and 1.91±0.05 in untreated and 
CX-4945-treated platelets respectively. These values did not significantly differ from each other but 
were significantly higher than the vehicle control (1.0±0.1, p<0.0001, Figure 6.5A). FL-4 F/F0 after 6 
170 
 
mins in response to U46619 (10μM) was 1.34±0.02, and 1.40±0.03 respectively in untreated and CX-
4945-treated platelets. Again these values did not significantly differ from each other but were 
significantly higher than the vehicle control (1.0±0.1, p<0.0001, Figure 6.5B).  
 
 
Figure 6.5. CX-4945 treatment does not effect agonist-evoked increases in FL-4 fluorescence. Fluo-4 (FL-4)-labelled washed 
human platelets stimulated by 1μg/ml of CRP-XL (A) or 10μM U46619 (B) following pretreatment with vehicle (DMSO, ○), 
CX-4945 (10μM , ■), or without agonist stimulation (DMSO, ▲), or with CX-4945 pretreatment in the absence of agonist 
stimulation (▼). [Ca2+]i fluctuations was recorded over six minutes using fluorometry. Results are representative and 
means±SEM of 6 experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
These data indicate that whilst ZIP7 activation by CK2 influences agonist-evoked [Zn2+]i 
increases, it does not influence [Ca2+]i elevation. This suggests a difference between the mechanisms 
responsible for Zn2+ and Ca2+ handling in response to agonist stimulation in platelets. Furthermore, 
this data from this section also suggests that ZIP7 mediated [Zn2+]i elevation from the DTS may be 
dependent in IP3R induced [Ca2+]i elevation since inhibition of IP3R inhibited ZIP7 activity (Figure 6.3). 
Therefore store mediated [Zn2+]i is dependant on store mediated [Ca2+]i release. However, [Ca2+]i 
elevation via IP3R activation may be independent of ZIP7 induced [Zn2+]i elevation since inhibition of 
ZIP7 activity did not influence agonist-evoked [Ca2+]i elevation.  
The interplay between Ca2+ and Zn2+, both of which are elevated upon agonist-evoked 
activation, remains a complex subject to explore.The work carried out in the following section aimed 
to investigate the influence of these cations on each other in terms of signalling. 
 B 
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6.2.3 Intracellular Zn2+ signalling is independent of Ca2+ signalling 
Experiments to assess changes in [Zn2+]i described herein were carried out in a Ca2-free 
environment. It is possible that extracellular Ca2+ is able to influence intracellular mechanisms that 
regulate fluctuations in [Zn2+]i. For example, in a Ca2+-free environment store-operated Ca2+ entry 
(SOCE) is reduced. Furthermore, storage of platelets in a Ca2+-free environment may result in depletion 
of Ca2+ from intracellular stores. This would reduce Ca2+ signalling upon platelet activation, possibly 
enabling a greater potential for Zn2+ to act as the major mediator in the activatory signalling pathways.  
To explore the influence of extracellular Ca2+ on agonist or ionophore avoked Zn2+ -mediated 
platelet activation, measurements of [Zn2+]i fluctuations were acquired in the presence of 
physiological levels (2mM) of extracellular Ca2+. 2mM extracellular Ca2+ did not influence the changes 
in FZ-3 fluorescence following stimulation with CRP-XL or U46619 (Figure 6.6A, C). FZ-3 F/F0 in response 
to CRP-XL (1μg/mL) after 6mins in the absence and presence of 2mM extracellular Ca2+ were 2.2±0.1 
and 1.81±0.20, respectively (p>0.05, ns, Figure 6.6A, C). FZ-3 F/F0 in response to U46619 (10μM) 
stimulation for 6mins, in the presence absence of 2mM Ca2+ was 1.34±0.20 and 1.30±0.03, respectively 
(p>0.05, ns, Figure 6.6A, C). As expected, extracellular Ca2+ also had no influence on thrombin-induced 
FZ-3 fluctuations, as thrombin stimulation was previously shown to not result in FZ-3 responses (Figure 
6.6A, C). 
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Figure 6.6. Agonist or ionophore evoked increases of FZ-3 in the presence of 2mM CaCl2. Fluozin-3 (FZ-3) loaded washed 
platelets were stimulated with platelet agonists in the absence (A) or presence (C) of extracellular Ca2+ (2mM calcium 
chloride, CaCl2). CRP-XL (1µg/mL, ○), U46619 (10µM, ▲), Thrombin (1U/mL, ■), vehicle control (DMSO) ●. Fluozin-3 (FZ-3) 
loaded washed platelets were stimulated with ionophores in the absence (B) or presence (D) of 2mM CaCl2 ; Clioquinol (○, 
300µM), Pyrithione, (■, 300µM), A23187 (▲, 300µM), or vehicle control (DMSO) ● . Changes in FZ-3 fluorescence were 
monitored. Data are mean±SEM of 5 independent experiments. Significance is denoted as **** (p<0.0001), *** (p<0.001), 
** (p<0.01) or * (p<0.05).  
 
Extracellular 2mM CaCl2 also did not significantly influence ionophore-induced increases in FZ-
3 fluorescence. FZ-3 F/F0 after 6mins in response to Cq (300μΜ), Py (300μM) or A23187 (300μM) in 
CaCl2-free medium were 6.7±0.3, 4.1±0.2 and 2.2±0.2, respectively (Figure 6.6B), whereas in the 
presence of 2mM CaCl2 (Figure 6.6B) these were 6.10±0.70, 4.32±0.40 and 2.30±0.30, respectively 
(p>0.05, ns, Figure 6.6B, D). therefore, ionophore evoked Zn2+ signalling is not influenced by 
exogenous Ca2+. Conversely, A23187 evoked FZ-3 increase was apparent after 30s of stimulation 
before reaching a plateau in the presence of 2mM CaCl2, whereas in the absence of CaCl2 fluctuations 
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in FZ-3 were only apparent towards the end of the experiment. Although the end point FZ-3 
fluorescence values in response to A23187 did not differ in relation to Ca2+ concentration these data 
show that the presence of exogenous Ca2+ results in increases in FZ-3 at an earlier stage in response 
to A23187. This may be due to the coordination of Zn2+ by A23187. 
Published work has shown that exogenous Zn2+ is able to mediate platelet activation (Taylor 
and Pugh, 2016; Watson et al., 2016). High concentrations of extracellular Zn2+ (300µM) directly 
activates platelets, whilst lower concentrations (30µM) are subactivatory. In order to investigate 
whether agonist stimulation potentiates Zn2+-entry into platelets, experiments were performed in the 
presence of sub-activatory concentrations of Zn2+ (Watson et al., 2016). The comparison between 
exogenous Ca2+ or exogenous Zn2+ on [Zn2+]i elevations was of interest to study the potential interplay 
between these cations.  
Supplementation with 30μM ZnSO4 elevated CRP-XL or U46619-mediated Fz-3 fluorescence 
above levels that were achieved in the absence of extracellular Zn2+. Interestingly, stimulation with 
thrombin in the presence of 30µM Zn2+ also increased Fz-3 fluorescence, indicating that thrombin-
mediated simulation results in increased penetrance of extracellular Zn2+ into the platelet cytosol. This 
activation-dependent Zn2+ entry mirrors Ca2+-entry as a result of activation-dependent gating of TRP 
channels (ROCE, receptor-operated Ca2+ entry) on the platelet surface and store-operated Ca2+ entry 
(SOCE, Figure 1.10). F/F0 in response to thrombin (1U/ml) after 6 mins of stimulation was significantly 
increased from 0.9±0.3 to 1.7±0.1 upon supplementation with 30μM ZnSO4 (p<0.0001, Figure 6.7A, C). 
The F/F0 in response to U46619 (10μM) after 6 mins of stimulation was significantly increased from 
1.4±0.1 to 2.1±0.2 upon supplementation with 30μM ZnSO4 (p<0.01, Figure 6.7B). The F/F0 in response 
to CRP-XL (1μg/ml) after 6mins in the presence and absence of exogenous Zn2+ was 2.7±0.2 and 
4.2±0.3 (p<0.01, Figure 6.7A, C)).  
 These data indicate that activation by all agonists tested results in entry of Zn2+ from the 
extracellular medium to contribute to increases in [Zn2+]i. This may indicate a conserved mechanism 
which regulates Ca2+ entry channels. It is possible that these include canonical Ca2+ channels, through 
which Zn2+ has previously been shown to be conducted (for example TRP channels). Further work 
would be required to confirm the mechanism. 
Supplementation with 30μM of ZnSO4 resulted in faster increases in FZ-3 fluorescence induced 
by the Zn2+ ionophores relatively to non-supplemented platelets. Cq-induced FZ-3 fluorescence in the 
first 30s of treatment, with a plateau being reached at an earlier stage compared to non-
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supplemented platelets. The FZ-3 F/F0 in response to Cq with 30μM of ZnSO4 present after 30s was 
7.3± 1.0 which was significantly higher than when no exogenous Zn2+ was present (1.4±0.3, p<0.0001 
Figure 6.7B, D). These data support the proposed mechanism of Cq as an ionophore, as the increased 
availability of Zn in the media enables increased Cq mediated-Zn2+ entry followed by equilibration. 
However, the endpoint fluorescence induced by Cq in the presence and absence of extracellular Zn2+ 
did not significantly differ. After 6 mins, FZ-3 F/F0 induced by Cq (300μΜ), after 6.2±0.7 whereas upon 
supplementation 30μM of ZnSO4 was 7.9±1.0 (p>0.05, ns, Figure 6.7B, D). This may be due to an 
equilibrium state of Zn2+ reached within platelets; thus no further increases in FZ-3 fluorescence were 
observed.  
Conversely, FZ-3 fluorescence induced by Py did however significantly increase upon ZnSO4 
(30μM) supplementation. After 6 mins, FZ-3 F/F0 in response to Py (300μM) was significantly increased 
from 3.7±0.3 to 7.6±0.6 (p<0.01, Figure 4.1B, Figure 6.7B). These data provide further validation of the 
mechanism of Py as a suitable ionophore, as Py was able to mediate Zn2+ entry into the platelets.  
Supplementation of Zn2+ also resulted in a significant increase in A23187 induced FZ-3 
fluorescence in comparison to when no exogenous Zn2+ was present. This may be due to the potential 
for A23187 to act as a Zn2+ ionophore (in addition to being a Ca2+ ionophore), resulting in more Zn2+ 
being transported into the platelets. Conversely, increased [Ca2+]i as a result of A23817 treatment may 
regulate cation entry channels on the platelet surface to mediate further Zn2+ entry. The FZ-3 F/F0 
following 6 mins of treatment with A23187 (300μM) was significantly increased from 1.7±0.2 to 
2.7±0.3 (p<0.05, Figure 6.7B, D).  
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Figure 6.7. Agonist or ionophore evoked increases of FZ-3 are influenced by subactivatory levels of extracellular Zn2+. 
Fluozin-3 (FZ-3)-loaded washed platelets suspended in CFT buffer supplemented with 30μΜ ZnSO4 were stimulated with 
platelet agonists in the absence (A) or presence (C) of extracellular Zn (30μΜ ZnSO4); CRP-XL (1µg/mL, ○), U46619 (10µM, 
▲), Thrombin (1U/mL, ■),Vehicle control (DMSO) ●. FZ-3-loaded washed platelets suspended in CFT buffer supplemented 
with 30μΜ ZnSO4 were stimulated with ionophores in the absence (B) or presence (D) of extracellular Zn2+ (30μΜ ZnSO4) ; 
Clioquinol (○, 300µM), Pyrithione, (■, 300µM), A23187 (▲, 300µM), Vehicle control (DMSO) ● during which changes in Zn2+ 
fluorescence were monitored. Data are mean±SEM of 5 independent experiments. Significance is denoted as **** 
(p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05).  
 
Further experiments were carried out to assess the influence of extracellular Ca2+ on [Ca2+]i 
fluctuations evoked by the agonists and ionophores. This work served as a positive control to assess if 
extracellular Ca2+ entry is being mediated by agonist into the platelets, which has been demonstrated 
in the literature (Brüne and Ullrich, 1991; Lang et al., 2013; Pozzan et al., 1988; Xia et al., 2015).  
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 As expected agonist-mediated [Ca2+]i elevation was increased throughout the experiment in 
the presence of extracellular 2mM CaCl2, as a consequence of store-operated calcium entry (SOCE) as 
well as activation-dependent gating of TRP channels such as TPC6 (Figure 1.10). The FL-4 F/F0 in 
response to CRP-XL (1μg/ml), U46619 (10μM) or Thrombin (1U/ml) after 6mins increased from 
1.7±0.3, 1.5±0.1 and 3.9±0.3, respectively to 4.42±0.57, 2.90±0.34 and 6.21±0.80, upon 
supplementation with 2mM CaCl2 (p<0.01, Figure 6.8A, C).Thus these findings are consistent with 
SOCE as described previously in the literature, and validate the approach used to investigate Zn2+-
operated store entry here (Authi, 2007; Hassock et al., 2002; Lang et al., 2013; Varga-Szabo et al., 
2009; Xia et al., 2015). 
2mM CaCl2 did not significantly influence ionophore-induced Ca2+ release. The FL-4 F/F0 
induced by Cq (300μΜ), Py (300μM) or A23187 (300μM) were 1.7±0.2, 1.47±0.10 and 6.9±0.9, 
respectively (Figure 6.8B). These values did not the significantly differ values upon supplementation 
of 2mM CaCl2, where the FL-4 F/F0 induced by Cq (300μΜ), Py (300μM) or A23187 (300μM) was 
1.52±0.10, 1.41±0.20, 7.80±0.73, respectively (p>0.05, ns, Figure 6.8B, D). 
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Figure 6.8. Agonist but not ionophore evoked increases of FL-4 are increased in the presence of extracellular 2mM CaCl2. 
Fluo-4 (FL-4) loaded washed platelets were stimulated with platelet agonists in the absence (A) or presence (C) of 
extracellular Ca2+ (2mM CaCl2); CRP-XL (1µg/mL, ○), U46619 (10µM, ▲), Thrombin (1U/mL, ■), or vehicle control (DMSO) 
●. Fluo-4 (FL-4) loaded washed platelets were stimulated with ionophores the absence (B) or presence (D) of 2mM CaCl2 ; 
Clioquinol (○, 300µM), Pyrithione, (■, 300µM), A23187 (▲, 300µM), or vehicle control (DMSO) ● during which changes in 
FL-4 fluorescence were monitored. Data are mean±SEM (n=5) independent experiments. Significance is denoted as **** 
(p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05).  
The absence of A23187-mediated increases in FL-4 fluorescence in the presence of 
extracellular CaCl2 could reflect saturation of the FL-4 probe with Ca2+. Under such circumstances, 
CaCl2 supplementation may have had a negligible effect on and increases in fluorescence of this probe. 
Interestingly exogenous Ca2+ did not have any significant influence on the low elevation of FL-4 
fluorescence induced by the Zn2+ ionophores. This further indicated the specificity of the Zn2+ 
ionophores Cq and Py for Zn2+ as these Zn2+ ionophores did not act as Ca2+ carriers in these experiments 
since no increase in FL-4 fluorescence was observed with exogenous Ca2+ supplementation.  
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Fluctuations in [Ca2+]i in the presence of extracellular Zn2+ were assessed to determine 
whether Zn2+ entry into platelets was able to regulate Ca2+ homeostasis. 
 
Figure 6.9. Agonist or ionophore evoked increases of FL-4 are not influenced upon supplementation with sub-activatory 
levels of exogenous Zn2+. Fluo-4 (FL-4) loaded washed platelets were stimulated with platelet agonists in the absence (A) or 
presence (C) of extracellular ZnSO4; CRP-XL (1µg/mL, ○), U46619 (10µM, ▲), Thrombin (1U/mL, ■), or vehicle control (DMSO) 
●. Fluo-4 (FL-4) loaded washed platelets were stimulated with, ionophores the absence (B) or presence (D) of 30μM ZnSO4 ; 
Clioquinol (○, 300µM), Pyrithione, (■, 300µM), A23187 (▲, 300µM), or vehicle control (DMSO) ● during which changes in 
FL-4 fluorescence were monitored. Data are mean ± SEM of 5 independent experiments. Significance is denoted as **** 
(p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05).  
 
Supplementation with 30μM of ZnSO4 did not significantly affect agonist-evoked FL-4 
fluorescence levels. The FL-4 F/F0 induced by CRP-XL (1μg/ml), U46619 (10μM), or thrombin (1U/ml) 
after 6mins in the presence of 30μM ZnSO4 were 3.2±0.6, 4.2±0.5 and 2.2±0.4 respectively (Figure 
6.9A). These did not significantly differ to results obtained in the absence of extracellular Zn2+, where 
the final F/F0 evoked by CRP-XL (1μg/ml), U46619 (10μM), or thrombin (1U/ml) were 3.1±0.6, 2.1±0.6 
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and 4.4±0.4 (p>0.05, ns, Figure 6.9A, C). This data shows that exogenous Zn2+ does not influence 
agonist-mediated elevations of [Ca2+]i. 
 Supplementation with 30μM ZnSO4 did not influence ionophore-induced increases in Ca2+ 
fluorescence. The FL-4 F/F0 after 6 mins in response to Cq (300μΜ), Py (300μM) or A23187 (300μM) 
in the presence of 30μM ZnSO4 were 1.42±0.10, 1.40±0.10, 6.10±1.04 and 1.10±0.10, respectively 
(Figure 6.9B). This compared to 1.5±0.1, 1.4±0.1 and 5.5±0.8, respectively on unsupplemented 
platelets does not differ (p>0.05, ns, Figure 6.9B, D)  
These experiments demonstrate that agonist-evoked increases in Zn2+ signalling occur in the 
presence of exogenous Ca2+, as agonist evoked Zn2+ was not influenced upon application of exogenous 
Ca2+ at physiological. This is an important observation, as it further indicates that platelet activity in 
response to Zn2+ reagents is not an artefact of Ca2+-dependent processes. 
6.2.4 Store-Operated Zn2+ Entry (SOZE) enables Zn2+ entry into platelets 
The mechanisms that mediate [Ca2+]i elevations in platelets are well documented. SOCE is a 
major mechanism employed by platelets to enable entry of Ca2+ into the platelets and to replenish 
Ca2+ stores that are depleted upon platelet activation [Ca2+]i elevation upon stimulation is crucial for 
platelet activity. It was hypothesised that similar mechanisms may be available to regulate [Zn2+]i 
mobilisation from stores in platelets. In a similar manner to Ca2+ entry during SOCE, potential Zn2+ 
stores may also require Zn2+ entry into the platelets to increase [Zn2+]i regulating activatory events, or 
alternatively replenishment of store Zn2+ which may be depleted following platelet activation. Recent 
work by Watson et al., 2016,  found that Zn2+ gains entry into platelets from the extracellular medium. 
However, the mechanisms which enable Zn2+ entry into platelets is yet to be identified. Furthermore, 
the work described in section 6.2.3 showed that supplementation of exogenous Zn2+ resulted in 
increased FZ-3 upon agonist stimulation (Figure 6.8). Interestingly, thrombin treatment also resulted 
in increases in FZ-3 fluorescence, indicating that thrombin stimulation activates Zn2+ entry pathways. 
This novel finding is suggestive of a similar process to SOCE (Figure 1.10), in which store depletion 
results in Zn2+ entry (termed Store-Operated Zn2+ Entry, SOZE). Further work was carried out this 
section to test the hypothesis that SOZE operates as an activatory process in platelets. 
Thapsigargin (TG) is widely used to investigate Ca2+ influx and the SOCE process in platelets. 
TG inhibits Ca2+ uptake into the Ca2+ stores by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ 
ATPase (SERCA) which pumps Ca2+ back into the DTS (Brüne and Ullrich, 1991; Islam and Berggren, 
1993). As it blocks SERCA without playing an inhibitory effect on the plasma membrane calcium 
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ATPase (PMCA), TG treatment effectively results in the depletion of the DTS, therefore, evoking SOCE 
via STIM1 and ORAI1 (Islam and Berggren, 1993; Lang et al., 2013; Pozzan et al., 1988; Xia et al., 2015). 
FZ-3- or FL-4-loaded platelets were assessed in real time using flow cytometry (section 2.10, 
Chapter 2) over a 6 min time period in the presence of exogenous Zn2+ (30μM ZnSO4) or Ca2+ (2mM 
CaCl2). Application of TG (1μM) resulted in significant increases in FZ-3 fluorescence when exogenous 
Zn2+ was present, compared to experiments conducted in the presence of exogenous Ca2+ or in the 
absence of cations (via treatment with the potent cation chelator EGTA, (2mM) Figure 6.11). The peak 
F/F0 upon addition of TG (1μM) in the presence of exogenous Zn2+ was 3.1±0.3 which was significantly 
higher than the vehicle control (EGTA treatment, 1.1±0.1) or in the presence of exogenous Ca2+ 
(1.2±0.1, p<0.0001, Figure 6.10B). Exogenous Ca2+ did not significantly effect TG-evoked fluctuations 
of FZ-3, providing further evidence of the specificity of FZ-3 to Zn2+.  
 
Figure 6.10. Thapsigargin treatment results in increases in FZ-3 fluorescence in the presence of extracellular Zn2+. 
Fluorescence changes in Fluozin-3 (FZ-3) loaded washed human platelets were observed for 30s prior to treatment with 
thapsigargin (TG, (1μM). Experiments were performed in the absence of cations (2mM EGTA, control), in buffer containing 
30μM ZnSO4, or in buffer containing 2mM CaCl2. Representative peak traces are shown (A), and the fluorescent peaks are 
quantified (B), , Control (2mM EGTA), ,30μM extracellular ZnSO4, ,2mM extracellular CaCl2. TG treatment induced a 
significant increase in FZ-3 fluorescence, consistent with store-operated Zn2+ entry. Significance is denoted as **** 
(p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). Data are representative of 6 independent experiments. 
 
Similar experiments were performed to assess FL-4 fluctuations in response to TG treatment 
in the presence of exogenous cations. TG treatment resulted in greater FL-4 fluorescence compared 
to either the vehicle control or Zn2+ supplementation. The peak FL-4 F/F0 induced upon the addition of 
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TG (1μM) in the presence of exogenous Ca2+ was 5.4±0.5 which was significantly higher the vehicle 
control (1.2±0.2), or in the presence of exogenous Zn2+ (1.7±0.4, p<0.0001, Figure 6.11B).  
 
 
Figure 6.11. Thapsigargin treatment results in increases in FL-4 fluorescence in the presence of extracellular Ca2+. 
Fluorescence changes in Fluo-4 (FL-4) labelled washed human platelets were observed for 30s prior to treatment TG (1μM). 
Experiments were performed in the absence of cations (2mM EGTA), in buffer containing 30μM ZnSO4, or in buffer containing 
2mM CaCl2. Representative peak traces are shown (A) and Fluorescent peaks were quantified (B), , Control (2mM EGTA), 
,30μM extracellular ZnSO4, ,2mM extracellular CaCl2. TG treatment induced a significant increase in Fluo-4 fluorescence, 
which is consistent with SOCE. Significance is denoted as *** (p<0.001), ** (p<0.01) or * (p<0.05). Data are a representative 
of 6 independent experiments. 
These experiments provide the first description of SOZE as a phenomenon in platelets. Whilst 
considerable work needs to be done to test this hypothesis further, it is possible that SOZE contributes 
to platelet activation at sites of vascular injury or plaque rupture, where exogenous Zn2+ is increased. 
Whilst the work described in this section has diverged from the main aims of this thesis, these data 
provide a platform to further investigate in future projects. 
 
6.3 Discussion 
Work described in previous chapters demonstrated that [Zn2+]i is elevated upon agonist 
stimulation to mediate platelet processes. This is indicative of behaviour as a secondary messenger in 
a similar manner to Ca2+. As both intracellular Zn2+ and Ca2+ are elevated upon activation, the possibility 
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exists that these two cations may work in synergy during platelet activation. The work in this chapter 
aimed to further the relationship between Zn2+ and Ca2+ in platelets. 
Initial experiments demonstrated that agonist-evoked [Zn2+]i increases are sensitive to 
inhibition of IP3R, suggesting that Zn2+ is mobilised from the Ca2+ store (DTS) (Figure 6.1). This indicates 
that the DTS may contain Zn2+ which is co-released with Ca2+, contributing to the elevation of [Zn2+]i. 
IP3R inhibition did not completely abolish the agonist-evoked increases in [Zn2+]i whereas redox 
modulation did. This implies that elevation of [Zn2+] was primarily mediated by redox modulation and 
that release from stores such as the DTS may be a secondary source of [Zn2+]i required for large 
increases in [Zn2+]i to regulate activatory processes. 
 Further experiments were performed to assess [Ca2+]i fluctuations in response to IP3R 
inhibition to assess the validity of the inhibitor used. As expected, agonist-evoked [Ca2+] elevation was 
abrogated upon 2-APB pre-treatment validating this inhibitor and confirming that agonist-evoked Ca2+ 
increases occur downstream of IP3R activity (including direct release from stores and SOCE). A further 
complication of the interpretation of these data is that 2-APB has also been shown to inhibit TRP 
channels in addition to IP3R. TRP channels present on the external membrane of platelets and act to 
enable cation entry upon activation. As most experiments described here were performed in a cation-
free buffer, the action of TRP channels is not likely to have been significant (Authi, 2007; Hassock et 
al., 2002).  
The release of [Zn2+]i from 2-APB-sensitive stores was further assessed. The Zn2+ transporter 
ZIP7 mediates Zn2+ release in a similar manner to PLC/IP3R mediated Ca2+ and also associates with the 
membranes of Ca2+ stores (in a similar manner to IP3R) in MCF-7 breast cancer cells (Hogstrand et al., 
2013; Taylor et al., 2008). ZIP7 is present in the platelet proteome and may act as a Zn2+ release 
channel in a similar manner as IP3R for Ca2+. (Burkhart et al., 2012). CRP-XL stimulation resulted in 
increased phosphorylation of ZIP7, consistent with increased activity of the transporter. This 
correlates well with the data showing that CRP-XL stimulation results in the highest elevation of [Zn2+]I 
compared to other agonists. Interestingly U46619 stimulation did not result in phosphorylation of ZIP7 
even though U46619 induces elevation of [Zn2+]i., However, the increase in [Zn2+]i induced by U46619 
was less than that induced by CRP-XL, which could explain the reduction in phosphorylation. 
Alternatively, this may indicate heterogeneous response mechanisms. For example, GpVI signalling 
may regulate the release of Zn2+ from stores in conjunction with release from redox-sensitive proteins, 
whereas U46619 induced [Zn2+]i elevation may solely be induced upon redox modulation.  
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Pharmacological inhibitors of ZIP7 are not currently available. However, ZIP7 activity has been 
shown to be regulated by CK2 (Taylor et al., 2012). Targetting CK2 was therefore performed as a 
strategy to investigate agonist-evoked changes to ZIP7 activity. In platelets, CK2 is involved in 
mediating platelet-platelet interactions leading to thrombus formation, and also in by mediating 
platelet interactions other cells types in the vasculature (Ampofo et al., 2015). Inhibition of CK2 results 
in a reduction in expression of key adhesion molecules on platelets and endothelial cells such as αIIbβ3,  
CD62P, VWF and other vascular cell adhesions molecules (Ampofo et al., 2015). Reduced CK2 activity 
also inhibits the conversion of fibrinogen to fibrin during the coagulation cascade (Ampofo et al., 2015; 
Ryu and Kim, 2013). In this chapter Inhibition of CK2 significantly reduced CRP-XL-mediated ZIP7 
phosphorylation, confirming that ZIP7 phosphorylation and subsequent activity is downstream of CK2 
activity. Inhibition of CK2 also resulted in the inhibition of agonist-evoked FZ-3 fluorescence further 
indicating a mechanistic relationship between CK2, ZIP7 leading to [Zn2+]i increases. This data suggest 
that ZIP7 is involved in the elevation of [Zn2+]i in a manner similar to that of IP3R. These ideas are still 
in their infancy and require further experimental validation, but could represent a mechanism by 
which platelets become activated. 
Further experiments showed that [Zn2+]i elevation is independent of exogenous physiological 
levels of Ca2+, as exogenous Ca2+ had no significant influence on agonist and ionophore evoked [Zn2+]i 
elevation (section 6.2.3). Therefore, Ca2+ and Zn2+ can induce platelet activation independently, and 
Zn2+ signalling is not biased by an absence of extracellular Ca2+.  
Interestingly exogenous Zn2+ resulted in increases in FZ-3 fluorescence in response to agonists 
and in particular thrombin which does not mediate FZ-3 fluctuations (Chapter 3). Therefore these 
findings are suggestive of a process mirroring ROCE and SOCE (Figure 1.10) , where agonist stimulation 
results in entry of Zn2+ via TRP channels (activation-dependent gated on the platelet surface) and store-
operated entry of Zn2+ following the depletion from the DTS. Further experiments showed that TG 
stimulation results in increases in [Zn2+]i in the presence of extracellular Zn2+, indicating that store 
depletion opens Zn2+-channels in the platelet membrane permitting Zn2+ entry. TG initiates SOCE by 
blocking the replenishment of the DTS (via the SERCA pumps, Figure 1.10). These findings indicate that 
SOCE also evoked a Zn2+ entry response, however, the exact mechanism by which Zn2+ entry occurs is 
yet to be confirmed. Depletion of cations from the DTS may evoke entry of Zn2+ in a similar manner to 
Ca2+. Thus STIM1 and ORAI1 may be involved in enabling store-operated Zn2+ entry.Whilst this is yet 
to be investigated in platelets, STIM1 which is the Ca2+ sensor molecule binds to Ca2+ via its EF-hand 
domain. Interestingly as described earlier in this chapter, Zn2+ may also bind to EF-hand domains as 
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illustrated in other proteins consisting of this motif (Baudier et al., 1986; Mills and Johnson, 1985; 
Nakayama and Kretsinger, 1994; Schäfer et al., 2000; Schumacher et al., 2004; Y. Wang et al., 2014; 
Warren et al., 2007b). During the SOCE process, when Ca2+ is released from the DTS via the IP3R, Ca2+ 
dissociates from STIM1 which results in the redistribution of STIM1 to the plasma membrane where 
it interacts with ORAI1 (a Ca2+ channel on the membrane which evokes Ca2+ entry upon interaction 
with STIM1) (Hodeify et al., 2015; Lang et al., 2013; Nonato et al., 2016; Varga-Szabo et al., 2009). In 
this similar manner, Zn2+ may also be bound to STIM1 which may dissociate from STIM1 upon DTS 
induced Zn2+ release, thus resulting in STIM1/ORAI1 interactions which may mediate Zn2+ entry in 
addition to Ca2+, although this has not been studied yet and is still very speculative. A more likely 
explanation could be upon the SOCE process the ORAI1 channels may also be permeable to Zn2+, thus 
enabling the entry of extracellular Zn2+ in addition to Ca2+. However the permeability of ORAI1 for Zn2+ 
has not been shown yet.This is an area which warrants investigation and would provide evidence to 
elucidate this store-operates Zn2+ entry process. A speculative schematic (Figure 6.12) is shown below 
illustrating this potential mechanism termed as Store-Operated Zn2+ Entry (SOZE).  
 
Figure 6.12. Schematic model of store-operated Zn2+ entry in platelets. Agonist-induced stimulation results in 
phospholipase C (PLC) mediated IP3R activation on the Zn2+ store (hypothesised to be the dense tubular system, DTS). IP3R 
may contribute to intracellular Zn2+ ([Zn2+]i elevation which may involve ZIP7 activity. ZIP7 is activated by protein kinase CK2 
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via phosphorylation which is activated upon GpVI stimulation. Following depletion of the DTS , cation entry is evoked in a 
manner analogous to store operates Ca2+ entry (SOCE) termes as store-operated Zn2+ entry (SOZE). This would result in Zn2+ 
entry from the extracellular space via ORAI1 channels which may be permeable to Zn2+ (unconfirmed). TRP channel (TRPC) 
may also evoke Zn2+ in a manner analogous to receptor operatedd Ca2+ entry  (ROCE) termed as receptor-operated Zn2+ entry 
(ROZE). SOZE and ROZE may replenish the Zn2+ store and also elevate the [Zn2+]i concentration.  
6.3.1 Conclusion 
This chapter provided the first reports demonstrating a novel mechanism by which [Zn2+]i may 
be elevated in addition to the redox-sensitive mechanism (Chapter 3). ZIP7 may be associated with 
IP3R on the DTS, in a manner which is yet to be studied. The association of ZIP7 and IP3R may evoke 
the co-release of both Ca2+ and Zn2+ from the DTS via the IP3R and ZIP7 respectively. Depletion of the 
DTS may also evoke SOZE in a similar manner to SOCE. Furthermore, Zn2+ signalling was independent 
of Ca2+ which suggested that these two cations may be co-released but modulate platelet function 
independently of each other. The work carried out in this chapter has provided preliminary novel 
findings, and provides a platform for a much in-depth investigation into the findings of this chapter.  
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Chapter 7  
7.0 Discussion and Future work 
7.1 Discussion 
The role of Zn2+ as a secondary signalling molecule has received limited research interest, 
possibly owing to Zn2+ being overlooked in favour of Ca2+ which is present at much higher 
concentrations in cells (Faure et al., 1995; Matiaa sa et al., 2010; Woodier et al., 2015). Furthermore 
many cation ionophores, fluorophores and chelators that have been widely used to investigate Ca2+ 
signalling (including in platelet research), have higher affinities for Zn2+ than Ca2+. Therefore, any 
conclusions drawn from the use of these reagents may be attributable to Zn2+. Thus, the importance 
of Zn2+ has likely been underestimated in platelets. The work described in this thesis provides initial 
evidence to indicate that Zn2+ plays an important role in platelet physiology. Experiments described 
herein are the first to show agonist-evoked increases of [Zn2+]i in platelets, resulting in activation-
related responses, in a manner consistent with a secondary messenger. The primary aim of this thesis 
was to investigate the influence of increased Zn2+ on platelet activation using Zn2+-specific ionophores. 
During the course of this work, further aims were developed to investigate agonist-evoked increases 
in [Zn2+]i, and to investigate the mechanisms of release. 
 
Receptor-specific signalling leads to Zn2+ responses 
In Chapter 3, it was shown that [Zn2+]i elevation occurred in response to agonist stimulation. 
These were the first reports illustrating that there are mobilizable Zn2+ stores in platelets that are 
accessible upon agonist stimulation. These findings implicate Zn2+ as a modulator of in platelet activity, 
consistent with observations from previous studies using exogenous Zn2+ as an agonist (Watson et al., 
2016). Elevations of [Zn2+]i in platelets occurred following stimulation of GpVI and TP, but not PAR 
stimulation (Figure 3.1), indicating that [Zn2+]i elevation is regulated via differing signalling pathways.  
 
Differences in Zn2+ handling as a result of GpVI or PAR stimulation 
Signalling downstream of GpVI results in a tyrosine phosphorylation signalling cascade of 
platelet proteins involving Syk and LAT, which leads to the activation of PLCγ2 and intracellular Ca2+ 
mobilisation (Dunster et al., 2015; Gibbins et al., 1998; Judd et al., 2002; Nieswandt and Watson, 
2003). This process was observed in experiments described in Chapter 3, which illustrated [Ca2+]i 
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increases following GpVI stimulation. Increases in Zn2+ as a result of GpVI stimulation may indicate 
conserved cation release pathways that mediate both [Zn2+]i and [Ca2+]i release.  
Whilst PAR stimulation resulted in [Ca2+]i increase, it did not have an effect on [Zn2+]i. 
Engagement of PARs, therefore, initiates a different signalling cascade than that induced by GpVI. 
Current understanding is that PAR induced signalling culminates in the activation of PLCβ, leading to 
Ca2- mobilisation from the DTS. These findings suggested that, unlike Ca2+, the elevation of [Zn2+]i is 
independent of PAR and may therefore be attributable to a different signalling pathway. PAR 
stimulation via thrombin induced a larger [Ca2+]i elevation than GpVI (Figure 3.2). It is possible that 
large [Ca2+]i increases induced upon thrombin treatment negatively regulate [Zn2+]i elevation. This may 
occur due to both Ca2+ and Zn2+ competing for similar signalling pathways, for example as both of these 
cations able to bind to similar motifs (such as the EF-hand domain) in signalling proteins such as 
calmodulin (Mills and Johnson, 1985; Schumacher et al., 2004; Warren et al., 2007b). Thus, greater 
elevation of [Ca2+]i induced by thrombin (PAR stimulation) relative to that induced by CRP-XL (GpVI 
stimulation) may be evoking Ca2+ to outcompete Zn2+ and perhaps negatively regulate Zn2+ signalling. 
These findings also suggest that GpVI signalling could be linked to a specific Zn2+ response which does 
not involve Ca2+ which is yet to be identified.   
TP but not PAR evoked increases in [Zn2+]i. This observation is difficult to reconcile, as both 
receptors engage similar signalling pathways which couple to Gα12/13 and Gαq. In the same manner, 
as PAR induced signalling, TP evoked signalling also results in the activation of PLCβ, leading to Ca2- 
mobilisation from the DTS. This scheme was confirmed in experiments described in Chapter 3, which 
showed Ca2+ release in response to U46619 and thrombin and validates the observation of 
heterogeneous Zn2+ responses to different agonists. Due to the similar signalling pathways evoked by 
TP and PAR stimulation, it is difficult to currently provide speculation as to why the Zn2+ response 
evoked upon stimulation of these GPCR’s differ. However, the work from this thesis suggests that 
there are likely to be differential mechanisms that are differentially regulated by Zn2+ upon TP and 
PAR stimulation, suggestive of a specific Zn2+ response independent of PAR signalling.  
These findings provided the first reports suggesting a novel GpVI or TP dependant signalling 
pathway which mediates [Zn2+]i elevation. This potential novel signalling pathway warrants further 
investigation and provides a new platform to assess the platelet physiology, which in turn would 
contribute to the development of antiplatelet therapies.  
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The mechanism of agonist-evoked intracellular Zn2+ release 
 Modulation of the platelet redox state regulated [Zn2+]i fluctuations in a similar manner to 
that seen in nucleated cells (Krezel et al., 2007; Li et al., 2016b). Whilst ROS is commonly associated 
with oxidative stress and cellular damage, by modulating protein thiols via oxidation such as catalytic 
cysteines in protein tyrosine phosphatases, it has also been shown to act as a secondary messenger 
(Chen et al., 2009; Wu et al., 2005). ROS evoked [Zn2+]i elevation is known to occur in neurons, where 
it is tightly regulated via redox-sensitive proteins such as metallothionines (MTs) (Hardyman et al., 
2016). MTs play a major role in the hemostasis of Zn2+, and under reducing conditions readily 
sequester Zn2+ (Stork and Li, 2016). Thus, the elevation of ROS may have major implications for Zn2+ 
activity in cells, for example in neurons where excessive free Zn2+ as a result of increases in ROS can 
evoke neurotoxicity. The role of ROS in modulating [Zn2+]i is likely to be translated into platelets, as 
redox-sensitive proteins such as MTs, which have found to be present in platelets, may be responsive 
to changes in redox and regulate [Zn2+]i in platelets.  
Changes in redox states occur in response to fluctuations in ROS, where increases in ROS result 
in oxidative stress (Ferroni et al., 2012; Freedman, 2008; Sies, 2014). Antioxidants such as superoxide 
dismutase (SOD) and catalase (CAT) were used to regulate ROS levels and maintain reducing 
conditions (Beckman et al., 1988; Machtay et al., 2006; Pandya et al., 2013; Tainer et al., 1983). GpVI- 
or TP- dependent stimulation resulted in increases of [Zn2+]i that were sensitive to the platelet redox 
state. Agonist-induced [Zn2+]i elevations were abrogated upon antioxidant treatment and were 
increased upon H2O2 application. Published data show that binding of Zn2+ to thiols on proteins such 
as MTs is redox-sensitive, and Zn2+ liberation is mediated from the thiol containing proteins upon 
redox modulation resulting in the elevation of free Zn2+ (Andrews, 2001; Hardyman et al., 2016; Krężel 
and Maret, 2017b). Therefore, redox-sensitive Zn2+ binding proteins may act as a storage mechanism 
for Zn2+ in platelets. In contrast, agonist-induced increases in [Ca2+]i were not influenced by changes in 
redox states, indicating that Zn2+ and Ca2+ liberation may be regulated differently in platelets. As the 
DTS is the primary Ca2+ store which is mobilised upon activation and is the primary mechanism for 
[Ca2+]i elevation, these data indicate that the DTS is not utilised as a Zn2+ store.  
Interestingly GpVI induced the greatest ROS increase in comparison to that evoked by 
thrombin and U46619. This is consistent with GpVI being more able to induce increases in [Zn2+]i, 
indicating that the two processes may be mechanistically linked. The generation of ROS via GpVI 
induced activation may evoke the liberation of Zn2+ from redox-sensitive proteins. As of yet, the role 
of Zn2+ in GpVI induced ROS generation is yet to be studied, however [Zn2+]i elevation upon GpVI 
stimulation may occur in response to ROS elevation.  
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GpVI-induced activation results in the generation of different ROS such as superoxide anions 
and hydrogen peroxides which contribute to evoking the full activatory response upon stimulation of 
GpVI (Krötz et al., 2002; Pignatelli et al., 1998). Generation of ROS upon GpVI activation occurs via the 
NADPH oxidase (NOX) pathway (Figure 1.8) which is mediated by the adaptor receptor TNF (tumour 
necrosis factor) adaptor receptor 4 (TRAF4) (Cangemi et al., 2014; Violi et al., 2015). TRAF4 is a binding 
partner of GpVI in human platelets (Arthur et al., 2011). TRAF4 associated proteins including Hic-5 and 
the NOX subunit p47phox interact with GpVI (Arthur et al., 2012, 2011). The NOX subunit p47phox 
generates ROS via the NOX Pathway (Figure 1.8), as p47phox activates the NOX pathway via 
phosphorylation. Thus the bridging between GpVI and the TRAF4/p47phox complex evokes GpVI-
induced ROS generation. Hic-5 which is part of the TRAF4/p47phox complex associates with the Src 
family tyrosine kinase Lyn, where it is constitutively bound to Lyn via the SH3 domain of Lyn. Lyn plays 
a key role in propagating GpVI signalling upon activation (Figure 1.3), suggesting a role for this ROS 
mediating complex in propagating GpVI signalling. In addition to this, previous work has shown that 
NOX mediated ROS formation initiates Syk activation (Syk activation occurs upon coming into close 
proximity with ITAM, which occurs following phosphorylation of ITAM by the Src family tyrosine 
kinases, Figure 1.3). Therefore, it can be suggested that ROS formation during bridging of the 
TRAF4/p47phox/Hic-5 complex mediates the activation of Src family tyrosine kinases, which then results 
in the activation of Syk. Therefore ROS may play a key regulatory role during GpVI signalling via a 
TRAF4 mediated pathway involving p47phox and Hic-5. Interestingly TRAF4 consists of Zn2+ finger 
domains which are involved in mediating interactions with other receptors although the full 
mechanisms and understanding of TRAF4 have still to be confirmed, particularly in platelets (Arthur 
et al., 2012; Glauner et al., 2002; Rousseau et al., 2011). Although the role of Zn2+ has yet to be 
confirmed in GpVI induced ROS activity, it can be suggested that Zn2+ may bind to the Zn2+ domains 
found in TRAF4 and potentially regulate this protein. A potential positive feedback mechanism 
involving Zn2+ and ROS may be in place as initially suggested in Chapter 4. This may involve GpVI 
evoking ROS formation which would then oxidise redox-sensitive proteins such as metallothioneins 
(MTs) that sequester Zn2+, resulting in the liberation of Zn 2+ from MTs (Figure 7.1). Labile Zn2+ may 
then bind to Zn2+ domain in TRAF4 which could then further induce GpVI evoked ROS formation. This 
mechanism is speculative and would require substantial work for confirmation. Furthermore, studies 
have shown that ROS can target and regulate the phosphatase SHP-2 which is a negative regulator of 
collagen-induced activation. Production of ROS via GpVI induced TRAF4 mediated pathway is able to 
induce oxidative inactivation of SHP-2, which enhances phosphorylation of Syk and other proteins in 
the LAT signalosome (Figure 1.3). Thus ROS elevation can also result in enhanced GpVI mediated 
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platelets activity (Jang et al., 2014). Interestingly Zn2+ has an IC50 of 1-2 μM for SHP-2, thus [Zn2+]i 
elevation upon agonist-evoked stimulation may regulate SHP-2 to also enhance GpVI induced 
activation (Dunster et al., 2015; Mazharian et al., 2013). Therefore, ROS and Zn2+ upon elevation can 
both mediate GpVI upregulation of tyrosine phosphorylation induced signal transduction via the 
inhibition of SHP-2. This proposed mechanism warrants further investigation and serves SHP-2 as a 
target to assess the role that Zn2+ along with ROS is having on this phosphatase during platelet 
activation.  
The NOX pathway also generates TxA2, following GpVI activation via the p38 MAPK signalling 
pathway (Figure 1.8), thus mediating further platelet activation via the TP receptor. Interestingly as 
described above TP stimulation also results in increases in ROS. Although this increase was modest, it 
is consistent with the modest increases in [Zn2+]i upon stimulation of this TxA2 receptor. The 
mechanism linking TP stimulation to ROS elevation is unclear, although previous studies have also 
shown that TP stimulation results in ROS elevation in platelets. This has been suggested to occur via 
the NOX pathway, as inhibition of NOX inhibited ROS elevation upon TP stimulation by U46619 
(Begonja et al., 2006, 2005; Tang et al., 2011; Violi and Pignatelli, 2014). The generation of ROS upon 
TP stimulation requires further work and may be a process which is mediated by Zn2+ as work in this 
thesis showed that chelation of [Zn2+]i via TPEN abolished U46619 evoked ROS increase. 
These findings suggested an interplay between Zn2+ and ROS, where increased Zn2+ evokes 
ROS increases and vice versa. This would demonstrate a mechanistic link between these two 
secondary messengers in platelets. The understanding of ROS activity in platelets is still however 
limited, thus requires further investigation to elucidate the ROS induced mechanism that is involved 
in platelet activation which may be primarily dependant on Zn2+ as the data suggests from this thesis. 
Figure 7.1 below presents a schematic of the ROS mediated mechanism that evoked [Zn2+]i upon 
agonist stimulation. 
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Figure 7.1. General schematic illustrating agonist-evoked intracellular Zn2+ elevation upon changes in redox states in 
platelets. Glycoprotein VI (GpVI) or thromboxane A2 receptor (TP) stimulation evokes elevation of reactive oxygen species 
(ROS). Stimulation of GpVI results in TRAF4 mediated ROS generation via the NADPH oxidase (NOX) pathway. The NOX 
pathway is activated by the NOX subunit p47phox which is associated with TRAF4 and interacts with GpVI. The NOX complex 
generates ROS. ROS elevation is able to mediate the PLCγ2/PKC/MAPKp38 signalling cascade resulting in PLA2 activation. PLA2 
is then able to induce the synthesis of thromboxane A2 (TXA2), where F2 isoprostane (F2-IsoP) can also form as a result of 
oxidation by peroxides. TxA2 and F2-IsoP can both bind to TP. Stimulation of TP also evokes ROS generation via the NOX 
pathway. Upon GpVI stimulation, the HIC-5 protein which is associated with TRAF4 is associated with the Src Kinase Lyn and 
propagates GpVI induced signalling. Elevation of ROS via the NOX pathway upon GpVI and stimulation results in the oxidation 
of metallothionines (MTs) which then liberate Zn2+ from its thiols. Therefore, resulting in increased intracellular Zn2+ 
concentrations. In a reducing environment, Zn2+ is sequestered by the MTs via reduction, thus reducing the intracellular Zn2+ 
concentration.  
192 
 
 
 Modest increases in ROS were observed upon thrombin stimulation, which was sensitive to 
TPEN-mediated chelation of Zn2+. Whilst these data indicate that fluctuations in ROS induced by 
thrombin were attributable to Zn2+, this is inconsistent with an absence in [Zn2+]i increases in response 
to thrombin. It is possible that obligate Zn2+-bound proteins are functionally implicated in ROS 
regulation. In this scheme, such proteins would not be influenced by changes in [Zn2+]i, but would be 
affected by Zn2+ chelation via TPEN. The nature of such proteins, and whether this mechanism occurs 
is currently speculative. Recent studies demonstrate that thrombin-evoked ROS increases are 
dependent on both PAR4 and the membrane protein GPIbα although the exact mechanism and the 
relationship between ROS and thrombin evoked activation is yet to be elucidated (Carrim et al., 2015).  
The findings from this thesis provide evidence to suggest the mechanism that evokes 
activatory increases in [Zn2+]i involves GpVI and TP-induced ROS increases within platelets, which 
culminate in the oxidation of Zn2+ sequestering redox-sensitive proteins, resulting in the release of Zn2+ 
into the cytosol. Confirmation of this scheme (illustrated in Figure 7.1) would require significant 
experimentation, such as examination of changes of the oxidation state of platelet MTs following 
agonist stimulation. Such experiments are interesting but beyond the scope of the current work. 
 
Investigation of the effects of increased [Zn2+]i on platelet activatory processes 
The influence of [Zn2+]i on the platelet activation was examined by using membrane permeable 
Zn2+-specific ionophores, Py and Cq, which have been widely used to model increases in [Zn2+]i in 
various cell types (Ding et al., 2005; Franklin et al., 2016; Kim et al., 1999, 1999; Rodríguez-Santiago et 
al., 2015; Schimmer et al., 2012; Seo et al., 2015). Cq and Py both induced significant increases in 
[Zn2+]i, where Cq was found to induce a greater elevation than Py (Figure 4.1), suggesting differences 
between these ionophores. Whilst these are yet to be investigated, one potential difference could be 
how these ionophores enter platelets, determining whether they could efficiently access Zn2+ stores 
Cq and Py differ structurally. Cq contains halogen groups (which are not present in Py) which increase 
lipophilicity enabling increases absorption in the cell as shown in neurons (Bush, 2003; Prachayasittikul 
et al., 2013). Thus Cq may be able to enter the cells more readily than Py and target storage sites. This 
may explain why Cq was able to induce a greater elevation of [Zn2+]i than Py. Both of these ionophores 
only resulted in increases in FZ-3 fluorescence and did not evoke any fluctuations in FL-4, thus 
demonstrating the specificity of these ionophores to Zn2+ and not Ca2+. In contrast, a non-specific 
effect was seen following application of the Ca2+ ionophore A23187. A23187 stimulation resulted in 
rapid increases [Ca2+]i, but also a modest increase in [Zn2+]i. This is not unexpected because A23187 
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has also previously shown to be able to bind to Zn2+, and therefore may not be as specific to Ca2+ as 
previously thought (Sakanashi et al., 2009). However, A23187 was able to evoke a greater effect in 
terms of platelet activation such as aggregation and granule release (discussed below) than Cq and Py, 
indicating the greater contribution of Ca2+ compared to Zn2+ in platelet activation. Experimental 
differentiation of the effects of the cations is difficult, as the role of Ca2+ cannot be solely assessed due 
to chelators such as BAPTA, which has a high affinity for Zn2+ than Ca2+. Therefore, chelating Ca2+ to 
determine if the effects seen were due to Ca2+ would also chelate Zn2+. Chelation of Zn2+ via the highly 
specific [Zn2+]i chelator TPEN would assess the role of Zn2+ and enable the effect of Ca2+ to be observed 
in the absence of Zn2+. However, the use of chelators may also result in the stripping of cations from 
proteins that are always bound to cations which may disrupt the effect seen. Thus, the development 
of methodologies to assess cation induced activity is required, which may involve the development of 
more specific probes and chelators which could target specific sites of interest.  
In contrast to agonist-induced [Zn2+]i elevation, ionophore-induced [Zn2+]i elevation was not 
redox-sensitive. Additionally, Zn2+ ionophore-induced [Zn2+]i elevation was far greater than that 
induced by the CRP-XL. This indicates that ionophores can access Zn2+ stores that are otherwise 
inaccessible to conventional agonists. Whilst the existence of an accessible Zn2+ store in platelets is yet 
to be confirmed, a number of potential storage mechanisms are known to exist. These include redox-
sensitive Zn2+ binding proteins and α-granules which are known to contain Zn2+ (Marx et al., 1993b). A 
potential drawback with the use of ionophores to model [Zn2+]i elevation is that the level of [Zn2+]i 
increases is higher than for conventional agonists. This suggests that ionophore use may not fully 
represent the physiological situation. Despite this, Zn2+ ionophores are a suitable tool to explore Zn2+-
dependent mechanisms and the functional role of Zn2+. 
The work described in Chapter 5 was designed to examine the functional role of increased 
[Zn2+]i in different aspects of platelet behaviour. Elevation of [Zn2+]i following ionophore stimulation 
induced upregulation of αIIbβ3, which is required for platelet aggregation (Bennett et al., 1999; Chari-
Turaga and Naik, 2011; Nieswandt et al., 2009). This correlates well with aggregation data which shows 
that elevation of [Zn2+]i evokes sub-maximal platelet aggregation (submaximal relative to the full aggregation 
evoked by agonist and a23187). Furthermore, this is consistent with data showing ionophore-induced 
aggregation was sensitive to the αIIbβ3 antagonist, GR144053 (Figures 5.1-2, 5.4).  
Interestingly Cq, but not Py was able to induce an aggregatory response. However, Py was still 
able to induce increases in PAC-1 binding which is consistent with αIIbβ3 upregulation. This finding is 
difficult to reconcile, as upregulation of αIIbβ3 is associated with platelet aggregation. Py was found to induce 
a lower increase in [Zn2+]i than Cq, which may not be enough to elicit a comparable response. This finding 
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indicates that high increases [Zn2+]i are required for platelet aggregation. Differences in effects of the Zn2+ 
ionophores warrants further investigation to determine the differences in the mechanism of these two Zn2+ 
ionophores; however, it is worth noting that neither ionophore was supplemented with exogenous Zn2+. 
A23187, which induced full platelet aggregation induced a reduction in PAC-1 binding in platelets that had 
been subjected to Zn2+ chelation with TPEN. This was again difficult to reconcile as chelation of [Zn2+]i had 
no influence on the aggregatory response evoked by A23817 (Figure 5.1). However, it is probable that TPEN 
may also be stripping of Zn2+ from proteins that Zn2+ would bind in an obligate manner (i.e. always bound), 
results in a loss of function of proteins that would be independent of [Zn2+]i fluctuations. Furthermore, Since 
A23187 also evoked a modest increase in [Zn2+]i in a similar manner to Py, it can also be suggested that low 
increases in [Zn2+]i may not elicit an aggregatory response but may potentiate this response instead. This 
was shown in previous work where low concentrations of exogenous Zn2+ potentiated agonist-evoked 
aggregatory responses (Watson et al., 2016). Further work carried out in Chapter 5 elucidated the role of 
[Zn2+]i in platelet aggregation which further coincided with the work by Watson et al., (2016), as chelation 
of [Zn2+]i reduced the level of PAC-1 binding induced by the conventional agonists (CRP-XL, U46619 and 
thrombin, Figure 5.12). Therefore, further outlining the importance that Zn2+ has on platelet aggregation, 
although the exact mechanism by which Zn2+ mediates platelet aggregation response is yet to be confirmed.  
 
Elevation of [Zn2+]i resulted in increases tyrosine phosphorylation of proteins, further indicating the 
potential of Zn2+ to modulate platelet behaviour. Tyrosine phosphorylation is a major signalling event in 
platelets, that can lead to full activation. Zn2+-dependent Increases in tyrosine phosphorylation may indicate 
Zn2+-dependent changes to the activatory state of phosphatases or kinases, some of which have previously 
been shown to be sensitive to Zn2+. For example, protein tyrosine phosphatases such as SHP-1 (Src homology 
2 (SH2) domain-containing tyrosine phosphatases) and SHP-2 have IC50 values of 93nM and 1-2μM 
respectively for Zn2+ thus may be modulated upon [Zn2+]i elevation. These phosphatases are known to be 
activated upon GpVI stimulation, where SHP-1 is a positive regulator of platelet activation via αIIbβ3 
activation, and SHP-2 negatively regulates platelet activation. Since GpVI has also been demonstrated 
to evoke increases in [Zn2+]i in this thesis, these phosphatases which are modulated upon GpVI 
stimulation may be as a result of increased [Zn2+]i. Therefore, it can be suggested that GpVI induced 
regulation of platelet activation may be mediated by Zn2+. Increases in redox dependant GpVI induced 
[Zn2+]i elevation may regulate SHP-2 thus resulting in enhanced GpVI induced activity. Furthermore, 
SHP-2 phosphatase was found to regulate GpVI signalling in a redox-sensitive manner (Jang et al., 
2014) as discussed above. Elevation of ROS upon GpVI stimulation may result in increased [Zn2+]i which 
may also regulate SHP-2 in addition to increased ROS. Thus the relationship between ROS and Zn2+ 
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upon elevation via GpVI stimulation could play a key role in further mediating GpVI induced signalling 
and platelet activation further. Further assessment would be required to determine the activity of 
these phosphatases in response to Zn2+ and provides a platform to assess a potential new regulatory 
signalling pathway in platelets. Kinases such as protein kinase C (PKC) and Ca2+/calmodulin dependent 
kinase II (CaMKII) have been shown to be influenced by Zn2+ (Csermely et al., 1988; Hubbard et al., 
1991b; Lengyel et al., 2000). However, whether this occurs in platelets is not known. It could be 
speculated that increases in Zn2+ could lead to the activation of PKC, (which plays a central role in 
platelets in mediating a wide range of activatory processes in platelets such as aggregation and granule 
release, (Yacoub et al., 2006),) and CaMKII which plays a significant role in Ca2+ signalling, Millon-
Frémillon et al., 2013; Vostal et al., 1991). This would result in increased platelet activity, suggesting a 
mechanism by which Zn2+ is able to evoke platelet activity. Thus, these findings provide initial reports 
demonstrating that these kinases may also be influenced in platelet activity which plays major roles 
in evoking platelet activation in response to increased [Zn2+]i. Further work is required to determine 
the role of Zn2+ in influencing kinases in additions to phosphatases, which may serve to elucidate novel 
mechanism in platelet physiology.  
 
Platelet shape change is mediated by cytoskeletal rearrangement in the initial steps of upon 
platelet activation. [Zn2+]i elevation via ionophore stimulation resulted in shape change, which could 
be inhibited by Cyt-D treatment, verifying the shape-changing response as biological and not a non-
specific chemical, response (Figure 5.5). Chelation of [Zn2+]i also inhibited the spreading of platelet 
spreading on fibrinogen, indicating a key role for [Zn2+]i in platelet shape change, which may be 
attributable to outside-in signalling (Figure 1.7). These data implicate Zn2+ in the functional regulation 
of cytoskeletal rearrangement. The extent and significance of the role of Zn2+ is currently unknown. It 
is possible that increases in [Zn2+]i are an absolute requirement for the initiation or propagation of 
shape change. However, specific targets of Zn2+ are as yet unknown. [Zn2+]i has been found play a 
major role in regulating cytoskeletal changes in nucleated cells (Perrin et al., 2017b; Rudolf et al., 
2008b). Chelation of [Zn2+]i using TPEN in HeLa and prostate cancer (PC)-3 cell lines suppresses the 
formation of filopodia and stress fibres as a result of actin rearrangement in repose to H2O2. H2O2 
stimulation results in the elevation of FZ-3 fluorescence, which is consistent with increases in [Zn2+]i, 
which was associated with activation of the TRP channel TRMP2 in these cell types (Li et al., 2016). 
Furthermore, in this study, application of the Zn2+ ionophore Py increased cell migration, which was 
inhibited upon TPEN pretreatment. This study confirms a role for Zn2+ in actin rearrangement that 
mediates filopodia and stress fibre formation and cellular migration. The mechanism by which Zn2+ 
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regulates cytoskeletal changes is yet to be confirmed. Cellular cytoskeletal arrangement involves Rho 
family GTPases such as RhoA. It is possible that Zn2+ may influence this process via interaction with 
these proteins, however again this yet to be studied and serves as a platform to assess the role of Zn2+ 
in cytoskeletal changes in these cells which have been shown play a major role thus far (Li et al., 
2016a).  
 Zn2+ has also been shown to regulate tubulin polymerisation in neurons, as incubation of 
neuronal cells in Zn2+ deficient media results in impaired transport of the transcription factor NFAT 
(nuclear factor of activated T cells) due to a loss of tubulin polymerisation (Mackenzie and Oteiza, 
2007; Perrin et al., 2017a). The mechanism by which Zn2+ regulates tubulin polymerisation in neurons 
is yet to be elucidated. However previous work in rodent neurons has shown the association of Zn2+ 
and tubulin and the ability of Zn2+ to stimulate tubulin polymerisation (Hesketh, 1982). These studies 
further illustrate the role that Zn2+ has on cytoskeletal rearrangement in cells. 
In Chapter 5 it was found that chelation of [Zn2+]i in mouse embryonic fibroblasts (MEF) 
resulted in a loss of attachment and cellular spreading. Zn2+ may be involved in regulating the affinity 
state of integrins in these cells since chelation of [Zn2+]i in MEF prevented adhesion. Inside out 
signalling evokes the activation of integrins which is essential for adhesion (Calderwood, 2004), thus 
[Zn2+]i may play a key role in regulating inside out activation of these MEF cells. This correlates with 
showing that TPEN also inhibits platelet adhesion and spreading, which suggested that Zn2+ may play 
a role in regulating integrins via the outside in and inside out signalling process in platelets (Figure 1.5-
6). These findings support published work from in nucleated cells illustrate the importance of Zn2+ in 
regulating cytoskeletal changes as Zn2+ has been shown to regulate a number of processes induced 
upon cytoskeletal rearrangement including filopodia and stress fibre formation, tubulin 
polymerisation, adhesion and spread and are suggestive of conserved mechanisms. Identification of a 
reported role of Zn2+ in regulating cytoskeletal rearrangement in nucleated cells further implicates a 
similar role for Zn2+ in platelets as shown in this thesis and discussed above. However, the mechanism 
by which Zn2+ mediates changes in the cytoskeletal in platelets is currently unknown, however, may 
involve the regulation of signalling process including Rho GTPases such as RhoA and integrins which 
are known to evoke actin rearrangement during cytoskeletal remodelling and adhesion in nucleated 
cells (Chauhan et al., 2011).   
One potential mechanism for Zn2+ induced cytoskeletal derangement in platelets involves the 
regulation of cytoskeletal proteins. Here, [Zn2+]i elevation was found to induce increased 
phosphorylation of MLC. MLC phosphorylation occurs in response to activated MLCK and is able to 
induce changes actin dynamics. Published work has shown that platelet shape change occurs in a Ca2+-
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dependent manner that involves activation of the Ca2+-binding protein calmodulin, which then enables 
activation of MLCK resulting in MLC phosphorylation (Kamiya et al., 2014; Shin et al., 2017). 
Additionally, platelet shape change involves the Rho-associated coiled-coil-containing kinases (ROCK) 
which regulate phosphorylation of MLC by inhibiting MLC phosphatases (MLC-P) (Paul et al., 1999). 
The data discussed in Chapter 5 indicates that [Zn2+]i-induced shape change occurs via a signalling 
pathway independent of calmodulin and was found to be mediated by a Ca2+-independent signalling 
pathway which involves Rho-associated coiled coil-containing kinases (Figure 5.16). This is an 
interesting finding because it indicates that Zn2+ is not simply substituting for Ca2+, for example, EF 
hands of calmodulin to regulated canonical downstream responses. The target of increased Zn2+ here 
is not known. The association of Zn2+ and ROCK serves as the major mechanism by which Zn2+ induced 
shape change occurs, however, the role for Zn2+ in ROCK signalling is yet to be confirmed. Although 
previous studies in endothelium cells have shown that ROCK consists of a Zn2+ binding motif (Bernal 
et al., 2011) suggests a potential role for Zn2+ in ROCK, as the binding of Zn2+ to this motif in ROCK may 
regulate the activity of ROCK. However, this relationship between Zn2+ and ROCK is still to be 
confirmed and warrants further investigation. 
 [Zn2+]i did not induce phosphorylation of VASP, which indicated that [Zn2+] signalling was 
independent of cyclic nucleotide-dependent kinases such as PKG or PKA which have previously been 
shown to regulate platelet shape change (Aburima et al., 2013). 
 
The elevation of [Zn2+]i induced externalisation of dense granules but not α-granules. This was 
apparent upon chelation of [Zn2+]i on experiments which measure granule release in response to 
conventional agonists. The signalling pathways that contribute to the differential release of α and 
dense granules are not fully understood. However, the work carried out this thesis provides a novel 
avenue which involves Zn2+ to further investigate the degranulation mechanisms (Golebiewska and 
Poole, 2015; Heijnen and Sluijs, 2015). Current understanding of signalling that evoked granule release 
in platelets involves several signalling events some of which include Ca2+ signalling, PKC dependent 
phosphorylation, integrin signalling, TxA2 generation and GTPase signalling. Granule release mediates 
enhanced platelet activation and also facilitates the recruitment of nearby platelets to the growing 
thrombus. All of these signalling pathways interlink during platelet activation and may potentially have 
Zn2+ implicated as a regulatory cation. The relationship between Zn2+ and Ca2+ is central to the work 
described in this thesis. The interplay between the two cations may have implications for intracellular 
signalling. For example, PKC, which is known to play a central role in platelet activation, is influenced 
by Zn2+ (Csermely et al., 1988). Therefore Zn2+ might be affecting platelet activity via direct PKC 
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activation. Integrin outside in and inside out signalling has also been suggested to be regulated by Zn2+. 
Redox-sensitive GpVI signalling which is mediated by Zn2+ is also involved in TxA2 generation (Figure 
7.1). Here, GTPase signalling in particular ROCK signalling during platelet shape change was shown to 
be regulated by Zn2+. Thus the potential regulatory role of Zn2+ in these signalling events suggests a 
potential regulatory role for Zn2+ inducing granule release. Further work is required to investigate each 
of these signalling events further to investigate the finding that [Zn2+]i elevation only evoked dense 
granule and not α- granule release. 
Differential regulation of cytoskeletal elements may serve as a mechanism to determine the 
[Zn2+]-dependent differential granule release. In vitro studies have shown that granule secretion is 
accompanied by centralisation of the granules which is driven by actin and myosin-driven contractile 
forces (Gerrard and White, 1976; Morgenstern et al., 1984). Since Zn2+ regulates cytoskeletal 
rearrangement in platelets, Zn2+-induced cytoskeletal rearrangement during platelet shape change 
may evoke centralisation of granules. This may explain the mechanism as to how Zn2+ mediated dense 
granule release but does not correlate with the absence of α granule release in response to Zn2+. 
Interestingly previous work shows that the exposure of high concentrations of actin-disrupting agents 
(cytochalasins) inhibit α-granule release in response to agonists whereas dense granule release is 
enhanced in response to agonists (Flaumenhaft et al., 2005). These findings illustrated that the platelet 
cytoskeleton serves as a regulator of granule release and since Zn2+ has been found to potentially play 
a regulatory role in cytoskeletal remodelling in this thesis, these findings from this previous study 
(Flaumenhaft et al., 2005) provide a mechanism by which [Zn2+]i elevation is inducing dense granule 
secretion but not α-granule secretion. Without knowing more about differential granule secretion in 
platelets, it is difficult to reconcile these observations, and further work is required. Interestingly 
whilst α granules have been shown to contain Zn2+ (Marx et al., 1993b),modulation of [Zn2+]i had no 
effect on α granule release. This is also difficult to reconcile but could highlight mechanistic differences 
in differential granule release. 
 [Zn2+]i elevations induce PS exposure, in a manner that is partially mediated by caspases. This 
is consistent with previous work which has shown that apoptosis which is measured by PS exposure is 
evoked by Zn2+ , particularly in nucleated cells such (Eron et al., 2018; Hamatake et al., 2000; Iitaka et 
al., 2001; Treves et al., 1994). Although the exact mechanism by which Zn2+ does this is yet to be 
confirmed, as Zn2+ regulates apoptosis in caspase independent and dependent manners, and remains 
an area with much scope to investigate (Hamatake et al., 2000; Zhang et al., 2014). Thus, these findings 
from previous work in nucleated cells, further strengthen a role for Zn2+ in inducing PS exposure in 
platelets, as illustrated by the findings in this thesis. This implicates a role for Zn2+ in mediating 
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initiation or propagation of the pro-coagulant pathway (Figure 1.1). Whilst the mechanism by which 
Zn2+ induced PS exposure in platelets is yet to be confirmed, a potential mechanism may involve the 
Ca2+ dependent scarambalase which has been identified as TMEM16F (transmembrane protein 16F) 
in platelets (Suzuki et al., 2013; van Kruchten et al., 2013; Yang et al., 2012). Scramblase facilitates the 
translocation of PS from the inner to the outer membrane in a Ca2+-dependent manner (Figure 1.7). 
The scramblase protein, TMEMF16 protein may also be sensitive to activation by other cations such 
as Zn2+. Furthermore, TMEMF proteins consist of a Ca2+ binding site which coordinates the activity of 
the protein (Brunner et al., 2014), which in the case of TMEMF16 would be PS exposure which. This 
binding site may also serve as a binding site for Zn2+, as Ca2+ binding bindings sites such as the EF-hand 
domain have also been shown to occupy Zn2+ for example in calmodulin (Mills and Johnson, 1985; 
Warren et al., 2007b). Therefore, Zn2+ may also occupy the Ca2+ binding site in TMEMF16, which 
provides a potential mechanism by which Zn2+ mediates PS exposure. Interestingly, TMEM16F behaves 
as a non-selective cation channel during lipid scrambling. Its mechanism of action may, therefore, 
relate to Zn2+ translocation (Yang et al., 2012).  
Whilst the mechanism by which TMEMF16 mediates PS exposure is still unclear, significant 
data are presented here to hypothesis an as yet unstudied role for Zn2+ in this process.  
 
The interplay between Zn2+ and Ca2+ during platelet activation 
Finally, the work described in Chapter 6 addressed the interplay between Zn2+ and Ca2+ 
signalling in platelets. The conclusions from this work are that Zn2+ signalling works independently of 
Ca2+, as exogenous Ca2+ at physiological levels had no influence on agonist-evoked [Zn2+]i increases. 
This demonstrates that these two cations may independently regulate platelet activity. This is an 
important observation, as it further indicates that platelet activity in response to Zn2+ reagents is not 
an artefact of Ca2+-dependent processes. Furthermore, data from Chapter 6 suggests that whilst Zn2+ 
is released from intracellular stores in a similar manner to Ca2+, it potentially involves ZIP7, perhaps 
working synergistically with IP3R on the DTS. A novel mechanism termed SOZE (Store-Operated Zn2+ 
Entry) was proposed from this work, as agonists were able to evoke Zn2+ entry upon activation (Figure 
6.12). In this scheme, reduction of Ca2+ stores following platelet activation results in the opening of 
cation channels on the platelet membrane surface (such as Orai or TRPC6). This leads to Zn2+ entry in 
a similar manner to Ca2+ entry. Zn2+ entering from the cytosol would then activate platelets in a similar 
manner to that previously shown with exogenously added Zn2+ (Watson et al., 2016). Whilst this is an 
intriguing possibility, further work is needed to confirm entry pathways, and to determine whether 
this system operates under conditions of physiological Ca2+. Furthermore, whether membrane Zn2+-
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permeable channels or transporters are activated upon agonist stimulation is not known, but remains 
a possibility during platelet activation. Another possibility is of receptor-operated Zn2+ entry (ROZE), 
which may work in a similar manner to receptor mediates Ca2+ entry (ROCE) which occurs following 
agonist stimulation and results in cation entry via TPC6 channels (Gamberucci et al., 2002; Hassock et 
al., 2002; Varga-Szabo et al., 2009)].  
 
 
7.1.1 Conclusion 
In conclusion, the experiments described herein provide the first evidence for agonist-evoked 
increases of [Zn2+]i in platelets, in a manner consistent with a secondary messenger. [Zn2+]i elevations 
in response to GpVI or TP stimulation were found to be sensitive to the platelet redox state, indicative 
of a role for redox in agonist-evoked Zn2+ signalling. Modelling of [Zn2+]i elevation using Zn2+-specific 
ionophores demonstrates several functional roles for [Zn2+]i in platelet activatory processes. [Zn2+]i 
signalling was found to mediate key activatory platelet responses such as shape change, αIIbβ3 
activation, dense granule release and PS exposure. The mechanism by which Zn2+ affects these platelet 
processes is yet to be determined, but modulation in the activity of Zn2+ binding enzymes could be one 
explanation. This work also provides the first evidence for SOZE upon agonist stimulation, which has 
been demonstrated to occur in a similar manner as SOCE in platelets.  
The work described in this thesis has provided evidence to suggest a novel regulatory role for 
labile [Zn2+]i during platelet activation. Figure 7.2 illustrates the speculative mechanism by which [Zn2+]i 
elevation mediates platelet activation. 
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Figure 7.2. Schematic illustrating agonist evoked intracellular Zn2+ and its role in mediating platelet behaviour. GpVI and 
thromboxane A2 receptor stimulation evoke reactive oxygen species (ROS) elevation. ROS elevation evokes oxidation of Zn2+ 
sequestered metallothioneins (MTs), resulting in the liberation of Zn2+ from the MTs and contributing to an increase in 
intracellular Zn2+ ([Zn2+]). GpVI stimulation also results in phospholipase C (PLC)-mediated activation of the inositol-1,4,5-
trisphosphate receptor (IP3R activation) which contributes to Zn2+ release (whether this is due to conducting Zn2+ from the 
DTS, or from secondary regulation of [Zn2+]i increases is not known. IP3R activity contributes to [Zn2+]i increases which may 
involve ZIP7. ZIP7 is also activated by the protein kinase CK2 via phosphorylation, which is activated upon GpVI stimulation 
via unknown mechanisms. Following store depletion (of Ca2+, and possibly also Zn2+), Zn2+ entry may occur from the 
extracellular space via the STIM1 which senses depletion of Zn2+ in the store, which then interacts with the cation channel, 
ORAI1 (Permeability of ORAI1 for Zn2+ has not been confirmed). This process is termed as store-operated Zn2+ entry (SOZE) 
and is analogous to store operates Ca2+ entry (SOCE). GpVI induced activation also evokes transient receptor channel (TRPC) 
mediated Zn2+ entry in a manner similar to receptor-operated Ca2+ entry (ROCE), termed as receptor-operated Zn2+ entry. 
SOZE and ROZE replenish Zn2+ stores and elevate [Zn2+]i. Elevated [Zn2+]i regulates activatory process in platelets such as 
shape change, αIIbβ3 upregulation, dense granule release and phosphatidylserine exposure. Whilst this is a speculative model, 
it provides testable hypotheses to better understand the role of Zn2+ in platelet activation. 
 
7.2 Future work 
The work described in this thesis provides a number of potential avenues to explore for future 
work. Primarily, all of the experiments described here were performed in vitro. To understand 
whether Zn2+ is a significant modulator of platelet behaviour, it would be necessary to perform in vivo 
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work. However, the conclusions reached here that indicate that Zn2+ is an important mediator of 
platelet activation are consistent with previous reports that have shown reduced platelet activity in 
humans and rodent with dietary Zn2+ deficiency. Further in vivo studies could result in data being 
translated clinically to potentially contribute to the development of antithrombotics (Makris et al., 
2013).  
 
Quantitation of [Zn2+]i concentrations 
Due to a lack of suitable, commercially available reagents, it was not possible to accurately 
use ratiometric probes to reliably convert the increases in Zn2+ fluorescence to concentrations. 
Development of more Zn2+ probes may enable the determination of the level of [Zn2+]i which would 
provide further information on the potential enzymes and thus processes that could be influenced by 
Zn2+.  
 
Zn2+ signalling is independent of PAR induced activation  
Whilst U46619-dependent activation resulted in [Zn2+]i fluctuations, PAR stimulation did not. 
This observation is difficult to reconcile, given that these receptors engage similar signalling pathways 
(Boknäs et al., 2014; Brass et al., 1993b; Chen et al., 2013; Zhou et al., 2017). Therefore, potential 
future work could aim to specifically target the signalling pathways of this agonist and try to 
differentiation and investigate the reasoning as to TP stimulation but not PAR stimulation results in 
[Zn2+]i elevation.  
 
Differences between the Zn2+ ionophores, clioquinol (Cq) and pyrithione (Py) 
The differences between the Zn2+ ionophores Cq and Py could be further investigated as these 
ionophores were found to have a difference in platelet activity even tho they share the same purpose 
and approximate affinities to Zn2+. The mechanism which attributes to [Zn2+]i mediated modulations 
in platelet process is a major avenue to explore as if determined could potentially provide novel 
insights into the platelet physiology. Thus understanding and further development of reagents such 
as Cq and Py is imperative for further assessment of the role of Zn2+ in platelet behaviour. 
 
Redox dependant Zn2+ signalling 
The role of redox-sensitive proteins in platelets warrants further investigated, given that data 
from this thesis strongly implicated redox-sensitive proteins as a storage mechanism for Zn2+. The 
expression and role of such proteins such as metallothioneins (MTs) have been shown in platelets. 
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MTs play an inhibitory role in platelet aggregation; however, its role in platelets is limited. Given that 
MTs are able to sequester Zn2+ (Hardyman et al., 2016; Krezel et al., 2007), MTs serve as a candidate 
to target to assess if Zn2+ storage in platelets is attributable to redox-sensitive proteins. 
Further work could also be carried out to investigate the role of Zn2+ in NOX-mediated ROS 
generation, particular following GpVI stimulation. Data described here show that GpVI evokes the 
greatest increases in [Zn2+]i. This correlates with the potency of GpVI in terms of ROS production, 
relative to other agonists (Freedman, 2008; Walsh et al., 2014). The role of [Zn2+]i in GpVI-induced ROS 
signalling via the NOX pathway is an interesting area to explore and would aid in further understanding 
the mechanistic link between GpVI induced [Zn2+]i and intracellular ROS elevation in platelets. Since 
changes in redox are determined by ROS fluctuations, assessment of the relationship between this 
mechanistic link serves as a novel platform to determine redox dependant Zn2+ signalling.   
The TRPM2 (transient receptor potential melastatin 2) which is expressed in platelets may be 
involved in evoking [Zn2+]i elevation in platelets in a redox dependent manner. TRPM2 is gated by ROS 
and is permeable to Zn2+ as shown in pancreatic β cells (Manna et al., 2015). This mechanism of action 
of TRPM2 may also be applicable in platelets. Exogenous ROS may mediate exogenous Zn2+ entry and 
serves as a novel mechanism in platelets. Thus this provides another area to explore to elucidate 
further Zn2+ signalling which may be redox dependent.  
 
The mobilisation of Zn2+ from intracellular stores 
Identification of ZIP7 on platelets permits the further investigation of this protein in platelet 
function. The role and location of ZIP7 could be investigated as inhibition of ZIP7 activity via the 
inhibition of protein kinase CK2 was found to reduce agonist-evoked increases in [Zn2+]i. The 
investigation of Zn2+ in the DTS could also be explored since experiments described here showed that 
inhibition of IP3R mediates Ca2+ mobilisation influenced ZIP7 activity. These findings are complex and 
difficult to understand, but allow the development of testable hypotheses. For example, the DTS may 
also contain Zn2+, and that it may be released from the DTS along with Ca2+ albeit by different 
mechanisms (ZIP7 and IP3R). Pharmacological limitations prevented direct inhibition of ZIP7 activity. 
Thus indirect activation had to be carried out by targeting the protein kinase CK2 which mediates ZIP7 
activity. However, inhibition of this kinase may also have an indirect effect on other processes in 
platelets which may complicate the conclusions reached. (Taylor et al., 2012, 2008). Thus the 
development of direct inhibitors of ZIP7 or knockout models of ZIP7 would provide further a way of 
further asses the role of ZIP7 and [Zn2+]i release.  
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Store-operated Zn2+ entry (SOZE) 
A major avenue of interest is the SOZE process which was proposed in chapter 6 as being 
analogous to SOCE. SOZE is a novel mechanism which may potentially be applicable in other cell types. 
SOCE involves STIM1 and ORAI1 which coordinate to detect store depletion and regulate Ca2+ entry 
(Guéguinou et al., 2016; Lang et al., 2013). The influence of Zn2+ on STIM1 and ORAI1 is yet to be 
studied but would be an easy initial target to test SOZE. 
Another potential scheme to consider is ROZE, which is analogous the process of ROCE, where 
DAG mediated TRPC6 entry of Ca2+ occurs (Varga-Szabo et al., 2009). TRPC6 is expressed in platelets 
and is to be permeable to both Zn2+ and Ca2+. Therefore assessment of TRPC6 via pharmacological 
inhibition or knock out model studies would serve as a way to investigate the role of this channel in 
mediating Zn2+ entry. Furthermore the TRMP7 (transient receptor potential melastatin 7) cation 
channel may also evoke Zn2+ entry in a similar manner to TRPC6, as TRPM7 has been found to be a 
channel to be highly permeable to Zn2+, even more so than Ca2+ in neurons (Inoue et al., 2010; 
Monteilh-Zoller et al., 2003). TRPM7 is expressed on platelet and megakaryocytes and has been 
implicated in the regulation of STIM1 activity (Leng et al., 2015; Mammadova-Bach et al., 2019). In 
previous studies, the deletion of the TRMP7 kinase in mice inhibits agonist-evoked [Ca2+]i mobilisation 
as a result of a reduction in STIM1 activity during SOCE (2018). STIM1 activity is regulated via 
phosphorylation of its serine residues (Kawasaki et al., 2010; Pozo-Guisado and Martin-Romero, 
2013). Thus TRPM7 kinase may be regulating STIM1 activity via phosphorylation of the serine residues 
of STIM1 , this may also apply to ORAI1 which is regulated in a similar manner to STIM1 (Kawasaki et 
al., 2010; Mammadova-Bach et al., 2019; Pozo-Guisado and Martin-Romero, 2013; Sanjeev K. et al., 
2018). The findings from these studies suggest a potential mechanism by which Zn2+ may be implicated 
in the store-operated entry which may involve TRPM7. The function of TRPM7, Zn2+ and store-
operated entry of cations are yet to be studied; however, TRP7 is another candidate in addition to 
ZIP7 that could be involved in mediating SOZE and is an area that warrants further investigation. 
 
The mechanism by which Zn2+ affects functional responses in platelets 
Here, canonical platelet functions, such as αIIbβ3 upregulation, shape change, dense granule 
release and PS exposure have been shown to be regulated by Zn2+. Whilst the experiments described here 
have started to unravel the mechanisms by which Zn2+ regulates this mechanism; more work is needed. 
In particular, the observation that Zn2+ differentially influences dense and alpha granule 
release provides an opportunity to better understand the differences in the regulation of 
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degranulation, which at present are poorly understood (Flaumenhaft, 2003; Golebiewska and Poole, 
2015; Heijnen and van der Sluijs, 2015).  
To summarise Zn2+ has been demonstrated to play a major role in platelets, and thus further 
understanding of the platelet physiology could be evoked by further investigation into the role that 
Zn2+ plays in platelets. 
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